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*Legislative Background 
The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This 
public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List and that pose the most significant potential 
threat to human health, as determined by ATSDR and the EPA.  The availability of the revised priority 
list of 275 hazardous substances was announced in the Federal Register on November 17, 1997 (62 FR 
61332). For prior versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 
FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 
43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 
48801); and February 28, 1994 (59 FR 9486).  Section 104(i)(3) of CERCLA, as amended, directs the 
Administrator of ATSDR to prepare a toxicological profile for each substance on the list. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of 
available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and 
assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of 
health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of 
exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in 
the clinical setting. Please refer to the Public Health Statement to identify 
general health effects observed following exposure. 
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
Section 3.7 Children’s Susceptibility 
Section 6.6 Exposures of Children 
Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center 
Phone:  1-888-42-ATSDR or 404-498-0110 Fax: 404-498-0057 
E-mail: atsdric@cdc.gov Internet:  http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials incident. 
Volumes I and II are planning guides to assist first responders and hospital emergency department 
personnel in planning for incidents that involve hazardous materials.  Volume III—Medical Management 
Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients 
exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341­
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or  NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 •  Phone: 202-347-4976 • 
FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 55 West Seegers Road, Arlington Heights, IL 
60005 • Phone: 847-818-1800 • FAX: 847-818-9266. 
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1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific minimal risk levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3.	 Data Needs Review. The Research Implementation Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 
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PEER REVIEW
 
A peer review panel was assembled for pentachlorophenol.  The panel consisted of the following 
members:
1. 	 Dr. Donald Morgan, Professor Emeritus in Preventive Medicine, University of Iowa Medical 
School, 1650 Koehler Drive NW, #247, Cedar Rapids, IA 52405; 
2. 	 Dr. Norman Rawlings, Professor of Veterinary Physiological Sciences, Department of Veterinary 
Biomedical Sciences, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4 
Canada; 
3. 	 Dr. Thomas Thompson, Manager of Environmental Sciences, Saskatchewan Health Provincial 
Laboratory, 3211 Albert Street, Regina, SK S4S 5W6 Canada; 
4.	 Dr. Loren Koller, Professor, College of Veterinary Medicine, Oregon State University, 105 
Magruder Hall, Corvallis, OR 97331-4802; 
5.	 Dr. Philip Leber, Goodyear Tire & Rubber Company, 1485 East Archwood Avenue, Akron, OH 
44306; 
6.	 Dr. John Lech, Professor, Pharmacology and Toxicology, Medical College of Wisconsin, 8701 
Watertown Park Road, Milwaukee, WI 53226; and 
7.	 Dr. Frederick Oehme, Professor, Comparative Toxicology Laboratories, 1800 Denison Avenue, 
Kansas State University, Manhattan, KS 66506-5606. 
These experts collectively have knowledge of pentachlorophenol's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1 PENTACHLOROPHENOL 
1. PUBLIC HEALTH STATEMENT
 
This public health statement tells you about pentachlorophenol and the effects of exposure.  
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Pentachlorophenol has been found in at least 313 of the 
1,585 current or former NPL sites.  However, the total number of NPL sites evaluated for this 
substance is not known. As more sites are evaluated, the sites at which pentachlorophenol is 
found may increase.  This information is important because exposure to this substance may harm 
you and because these sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to pentachlorophenol, many factors determine whether you’ll be harmed. 
These factors include the dose (how much), the duration (how long), and how you come in 
contact with it. You must also consider the other chemicals you’re exposed to and your age, sex, 
diet, family traits, lifestyle, and state of health. 
1.1 WHAT IS PENTACHLOROPHENOL? 
Pentachlorophenol is a synthetic substance, made from other chemicals, and does not occur 
naturally in the environment.  It is made by only one company in the United States.  At one time, 
it was one of the most widely used biocides in the United States.  Since 1984, the purchase and 
use of pentachlorophenol has been restricted to certified applicators. It is no longer available to 
the general public. Application of pentachlorophenol in the home as an herbicide and pesticide 
accounted for only 3% of its consumption in the 1970s.  Before use restrictions, 
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pentachlorophenol was widely used as a wood preservative. It is now used industrially as a 
wood preservative for power line poles, cross arms, fence posts, and the like.  
Pure pentachlorophenol exists as colorless crystals. It has a very sharp characteristic phenolic 
smell when hot but very little odor at room temperature.  Most people can begin to smell 
pentachlorophenol in water at less than 12 parts pentachlorophenol per million parts of water 
(ppm).  Impure pentachlorophenol (the form usually found at hazardous waste sites) is dark gray 
to brown and exists as dust, beads, or flakes. Pentachlorophenol can be found in two forms: 
pentachlorophenol itself or as the sodium salt of pentachlorophenol.  The sodium salt dissolves 
easily in water, but pentachlorophenol does not. These two forms have some different physical 
properties, but are expected to have similar toxic effects.  
Humans are generally exposed to technical-grade pentachlorophenol, which usually contains 
such toxic impurities as polychlorinated dibenzo-p-dioxins and dibenzofurans. Table 3-2 lists 
the impurities found in three different grades of pentachlorophenol. 
For more information on the physical and chemical properties of pentachlorophenol, see 
Chapter 4. For more information on its production, use, and disposal, see Chapter 5. 
1.2	 WHAT HAPPENS TO PENTACHLOROPHENOL WHEN IT ENTERS THE 
ENVIRONMENT? 
Pentachlorophenol is released to the air by evaporation from treated wood surfaces and factory 
(chemical manufacturing plants and wood preservation plants) waste disposal.  It enters surface 
water and groundwater from factories, wood-treatment facilities, and hazardous waste sites.  It 
also enters the soil as a result of spills, disposal at hazardous waste sites, and its use as a 
pesticide. The physical and chemical properties of the compound suggest that not much will 
evaporate into the atmosphere and that most of it will move with water and generally stick to soil 
particles. Movement of pentachlorophenol in soils depends on the soil's acidity.  The compound 
can be present in fish or other species used for food, as demonstrated by the ongoing food 
monitoring program of the Food and Drug Administration (FDA).  In air, soil, and surface water, 
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pentachlorophenol lasts for hours to days. The compound is broken down in soil and surface 
water by microorganisms, and in air and surface water by sunlight, to other compounds, some of 
which may be harmful to humans.  
More information on the releases, occurrence, and movement of pentachlorophenol in the 
environment can be found in Chapters 5 and 6.  
1.3 HOW MIGHT I BE EXPOSED TO PENTACHLOROPHENOL? 
In addition to workplace exposures, humans can be exposed to very low levels of pentachloro­
phenol through indoor and outdoor air, food, soil, and drinking water.  Exposure may also result 
from dermal contact with wood treated with preservatives that contain pentachlorophenol. 
Levels in the workplace, near certain hazardous waste sites, and near sites of accidental spills are 
usually higher than in the general environment.  
Exposure to pentachlorophenol by eating contaminated food is limited.  The average intake in 
food is estimated to be 0.0105 milligrams of pentachlorophenol for a 70 kg human.  Daily intake 
by drinking contaminated water is also low and is estimated to be about 0.021 mg for a 70 kg 
human.  In its survey of various population groups in 1986–1991, the ongoing food monitoring 
program of the FDA observed a substantial decrease in the daily intakes of pentachlorophenol. 
We do not have much information on the levels of pentachlorophenol in indoor and outdoor air, 
but the general population is estimated to breathe in about 0.063 mg/day.  People who work or 
live near pentachlorophenol sources are exposed to higher levels. A 1984 report cites the 
measured concentration of pentachlorophenol in the indoor air of pressure-treated log homes 
brushed with pentachlorophenol in the range of 0.5–10 parts per trillion (ppt, 1 ppt is 
1 million times less than 1 ppm) and in the air of industrially dipped, nonpressure-treated log 
homes at 34–104 ppt.  Levels of pentachlorophenol in the air at wood-treatment facilities and 
lumber mills are much higher, and workers exposed at these places are estimated to breathe in 
10.5–154.0 mg/day.  Workers who handle treated lumber can take in about 35.0 mg/day through 
the skin. 
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For more information on exposure to pentachlorophenol, see Chapter 6. 
1.4 HOW CAN PENTACHLOROPHENOL ENTER AND LEAVE MY BODY? 
Pentachlorophenol easily enters your body through your lungs when you breathe it, through your 
digestive tract after you eat contaminated food or water, or through your skin.  The most 
significant ways are through breathing and skin contact.  After a short exposure period, 
pentachlorophenol quickly leaves your body (studies in humans show that half the amount taken 
in is usually gone within 33 hours). It does not seem to build up in the body very much.  Most of 
the pentachlorophenol taken into your body does not break down, but instead leaves in your 
urine. Much smaller amounts leave in your feces.  Only a small amount escapes through your 
exhaled air. Some of the pentachlorophenol taken into your body is joined with other natural 
chemicals that make the pentachlorophenol less harmful.  The combined product can then leave 
your body more easily.  
Chapter 3 contains more information on how pentachlorophenol enters and leaves your body. 
1.5 HOW CAN PENTACHLOROPHENOL AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.  
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary.  Animal testing may 
also be used to identify health effects such as cancer or birth defects. Without laboratory 
animals, scientists would lose a basic method to get information needed to make wise decisions 
to protect public health. Scientists have the responsibility to treat research animals with care and 
compassion.  Laws today protect the welfare of research animals, and scientists must comply 
with strict animal care guidelines. 
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Some, but not all, of the harmful effects associated with exposure to pentachlorophenol are due 
to impurities present in commercial pentachlorophenol.  Short exposures to large amounts of 
pentachlorophenol in the workplace or through the misuse of products that contain it can cause 
harmful effects on the liver, kidneys, blood, lungs, nervous system, immune system, and 
gastrointestinal tract. Contact with pentachlorophenol (particularly in the form of a hot vapor) 
can irritate the skin, eyes, and mouth.  If large enough amounts enter the body, heat is produced 
by the cells in the body, causing an increase in body temperature.  The body temperature can 
increase to dangerous levels, causing injury to various organs and tissues and even death. This 
effect is the result of exposure to pentachlorophenol itself and not the impurities.  The lengths of 
exposure and the levels that cause harmful effects have not been well defined.  Long-term 
exposure to low levels such as those that occur in the workplace can cause damage to the liver, 
kidneys, blood, and nervous system.  Studies in animals also suggest that the endocrine system 
and immune system can also be damaged following long-term exposure to low levels of 
pentachlorophenol. All of these effects get worse as the level of exposure increases. 
Decreases in the number of newborn animals, harmful effects on reproductive organs of the 
mothers, decreases in the number of successful pregnancies, and increases in the length of 
pregnancy were observed in animals exposed to pentachlorophenol while they were pregnant. 
Harmful effects on reproductive organs of the females were also seen in animals exposed to 
pentachlorophenol while they were not pregnant.  We do not know if pentachlorophenol 
produces all of the same effects in humans that it causes in animals.  
An increased risk of cancer has been shown in some laboratory animals given large amounts of 
pentachlorophenol orally for a long time.  There is weak evidence that pentachlorophenol causes 
cancer in humans.  The International Agency for Research on Cancer (IARC) has determined 
that pentachlorophenol is possibly carcinogenic to humans, and the EPA has classified 
pentachlorophenol as a probable human carcinogen. 
Chapters 2 and 3 contain more information on the health effects linked with exposure to penta­
chlorophenol. 
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1.6 HOW CAN PENTACHLOROPHENOL AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans. 
Children might be exposed to pentachlorophenol by eating fish and other foods contaminated 
with the substance, by accidentally or intentionally eating soil or drinking water contaminated 
with the substance, or by drinking breast milk contaminated with the substance.  Tests have not 
been performed to measure pentachlorophenol in breast milk in the United States, although small 
amounts have been found in the milk of chemical workers in Eastern Europe.  Children might 
also be exposed to pentachlorophenol by breathing air in homes that contain wood that has been 
treated with the substance or by skin contact with contaminated soils or with the exposed surface 
of wood that has been treated with the substance. For most people, food is the most important 
source of intake of pentachlorophenol, and most of this intake is from root vegetables.  Based on 
analyses of foods representative of the diets of different age/gender population groups, daily 
intakes of pentachlorophenol from the diet, although low overall, are higher in infants and 
toddlers than in teenagers and adults. Daily intakes of pentachlorophenol from food have 
decreased over time.  
Newborn children who were accidentally exposed to diapers and bedding that were contaminated 
with pentachlorophenol had high fevers, a large amount of sweating, a hard time with breathing, 
and harmful effects on their nervous system and liver, and some died.  In the newborn animals of 
mothers that were given pentachlorophenol by mouth, slight changes were seen in the formation 
of bones and their weight was decreased at weaning. One study in animals showed that large 
amounts of pentachlorophenol taken by mouth can damage the testes, but it is unknown whether 
such large amounts affect the ability of animals to have babies.  The immune system was 
suppressed in family members, including children as young as 8 years old, who were exposed to 
pentachlorophenol while living in log homes.  Absorption of pentachlorophenol is expected by 
all routes of exposure, and the harmful effects of pentachlorophenol should be qualitatively 
similar over all routes of exposure; these effects might also occur in children exposed to low 
levels of pentachlorophenol by any route. There is not enough information to know whether 
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children under 18 years of age differ from adults in their sensitivity to the health effects of 
pentachlorophenol. One study in animals found that small amounts of pentachlorophenol may 
cross the placenta, and it is possible that it can reach and cross the placenta in humans. 
1.7	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 
PENTACHLOROPHENOL? 
If your doctor finds that you have been exposed to significant amounts of pentachlorophenol, ask 
whether your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate. 
Pentachlorophenol was a widely used pesticide and a wood preservative (utility poles) for a long 
time.  It is no longer present in any product you can buy today. It can be applied only by 
certified applicators. Although it is no longer commonly used, traces of pentachlorophenol are 
still found in small amounts in air, water, and soil.  It is also found at some hazardous waste 
sites. 
Up until 1980, you could buy pentachlorophenol-containing pesticides. Since then, it has been 
regulated and can only be used in a restricted number of places.  You may have old containers of 
pesticides in your attic, basement, or garage that contain pentachlorophenol.  Removing these old 
containers will reduce your family’s risk of exposure to pentachlorophenol.  You should dispose 
of these old containers in an appropriate manner through your county’s hazardous waste facility. 
Otherwise, place them out of reach of young children to prevent accidental exposures.  You 
should never store pesticides or household chemicals in containers that children would find 
attractive to eat or drink from, such as soda bottles.  
Your children may be exposed to pentachlorophenol if an unqualified person applies pesticides 
containing it around your home.  In some cases, the improper use of pesticides banned for use in 
homes has turned homes into hazardous waste sites.  Make sure that any person you hire is 
licensed and, if appropriate, certified to apply pesticides. Your state licenses each person who is 
qualified to apply pesticides according to EPA standards and further certifies each person who is 
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qualified to apply “restricted use” pesticides. Ask to see the license and certification. Also ask 
for the brand name of the pesticide, a Material Safety Data Sheet (MSDS), the name of the 
product’s active ingredient, and the EPA registration number.  Ask whether EPA has designated 
the pesticide “for restricted use” and what the approved uses are. This information is important 
if you or your family react to the product. 
Though pentachlorophenol has been found in some foods, its levels are low.  You can minimize 
the risk of your family’s exposure by peeling and thoroughly washing fruits and vegetables 
before cooking. 
Small children have a tendency to eat soil, and to put their hands and foreign objects in their 
mouths.  This could result in their exposure to pentachlorophenol that may be present in the soil 
and on objects. Children may be exposed to pentachlorophenol by absorption through the skin. 
Pentachlorophenol is known to be rapidly absorbed by the skin from the soil.  You should 
prevent children from putting their hands and foreign objects in their mouths and you should 
discourage your children from eating dirt.  Make sure they wash their hands frequently. Very 
low levels of pentachlorophenol have been detected in house and carpet dust. Keeping the house 
clean and free of dust will reduce your family’s exposure to pentachlorophenol.  
Pentachlorophenol was used for treating wood. It is no longer used for treating wood used in 
and around homes.  But it is still used for treating wood utility poles and railroad ties. If you live 
near a utility pole or railroad tracks, you should prevent your children from playing, climbing, or 
sitting on them especially in the hot summer months.  Old playground equipment may contain 
pentachlorophenol, and children may be exposed dermally when playing on it.  If you have old 
treated wood in or around your house, covering it with epoxy paint may reduce the risk of your 
family’s exposure to pentachlorophenol.  Wood treated with pentachlorophenol (e.g., railway 
ties) should not be used for landscaping, especially near gardens or private wells 
9 PENTACHLOROPHENOL 
1. PUBLIC HEALTH STATEMENT 
1.8	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO PENTACHLOROPHENOL? 
Pentachlorophenol and its products can be measured in the blood, urine, and tissues of exposed 
persons. Because urine and blood samples are easily collected, testing these fluids is the best 
way to find out whether a person has been exposed. Neither test is usually available at a doctor's 
office because both require the use of special equipment.  Although these tests can prove that a 
person has been exposed, they cannot be used to tell how severe any health effects might be. 
Because pentachlorophenol leaves the body fairly quickly, these tests are best for finding 
exposures that occurred within the last several days. Exposure at hazardous waste sites usually 
includes exposure to other organic compounds, such as hexachlorobenzene, that could break 
down into pentachlorophenol. On the other hand, measurement of blood and urine levels for 
pentachlorophenol and its products in groups of exposed people and nonexposed people is a 
good way to tell whether exposure to pentachlorophenol or members of the same chemical 
family occurred. 
Chapter 7 contains more information on tests for measuring pentachlorophenol in the body. 
1.9	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). 
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
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Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for pentachlorophenol include the 
following: 
The federal government has set regulatory standards and guidelines to protect workers from the 
possible health effects of pentachlorophenol in air. OSHA has set a legally enforceable limit of 
0.5 milligrams per cubic meter (mg/m3) in workroom air to protect workers during an 8-hour 
shift over a 40-hour work week. 
The federal government has also set regulatory standards and guidelines to protect the public 
from the possible health effects of pentachlorophenol in drinking water.  EPA decided that the 
amount in the drinking water should not be more than 0.022 milligram per liter (mg/L) and that 
any release of more than 10 pounds to the environment should be reported.  For short-term 
exposures, EPA decided that drinking water levels should not be more than 1.0 mg/L for 1 day or 
0.3 mg/L for 10 days.  EPA also estimates that for an average-weight adult, exposure to 
0.03 mg/kg/day will probably not cause any noncancer health effects.  EPA is now working to 
measure the levels of pentachlorophenol found at abandoned waste sites.  
For more information on criteria and standards for pentachlorophenol exposure, see Chapter 8. 
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1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road NE, Mailstop E-29 
Atlanta, GA 30333 
* Information line and technical assistance 
Phone: 1-888-42-ATSDR (1-888-422-8737)
 
Fax: 1-404-498-0057
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
* To order toxicological profiles, contact 
National Technical Information Service
 
5285 Port Royal Road
 
Springfield, VA 22161
 
Phone: (800) 553-6847 or (703) 605-6000
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2.1	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PENTACHLOROPHENOL 
IN THE UNITED STATES 
Pure pentachlorophenol exists as colorless crystals that are poorly soluble in water, but dissolve in 
organic solvents such as alcohol, ether, and benzene.  Typically, commercial grade pentachlorophenol is 
86% pure.  Contaminants generally consist of other polychlorinated phenols, polychlorinated dibenzo­
p-dioxins (CDDs), and polychlorinated dibenzofurans (CDFs), which are formed during the 
manufacturing process and can impart a darker color to the crystals.  To increase its water solubility, 
pentachlorophenol has often been manufactured and marketed as a sodium salt.  Pentachlorophenol was, 
in the past, one of the most heavily used pesticides in the United States, but is now regulated as a 
restricted-use pesticide and is no longer contained in wood preserving solutions or in insecticides or 
herbicides available for home and garden use.  Its use is restricted to the treatment of utility poles, railroad 
ties, and wharf pilings. Pentachlorophenol is found in all environmental media as a result of its past 
widespread use; current releases to the environment are more limited as a result of changing use patterns. 
In addition, a number of other environmental contaminants, including hexachlorobenzene, pentachloro­
benzene, pentachloronitrobenzene, and hexachlorocyclohexane isomers, are known to be metabolized to 
pentachlorophenol. 
Humans may be exposed to pentachlorophenol in occupational settings through inhalation of 
contaminated workplace air and dermal contact with the compound or with wood products treated with 
the compound.  General population exposure may occur through contact with contaminated 
environmental media, particularly in the vicinity of wood treatment facilities and hazardous waste sites. 
Important routes of exposure appear to be inhalation of contaminated air, inhalation exposure to 
pentachlorophenol that has volatilized from treated wood surfaces, ingestion of contaminated 
groundwater used as a source of drinking water, ingestion of contaminated food, and dermal contact with 
contaminated soils or wood products treated with the compound.  Children are likely to be exposed to 
pentachlorophenol by the same routes as adults.  In addition, small children are generally more likely than 
adults to have significant contact with soil and have less concern with hygiene than adults.  ATSDR 
believes that the primary route of human exposure to pentachlorophenol at hazardous waste sites is 
ingestion of contaminated media, and to a lesser extent, inhalation and dermal contact with contaminated 
media.  Pentachlorophenol has been identified in at least 313 of the 1,585 hazardous waste sites that have 
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been proposed for inclusion on the EPA National Priorities List (NPL).  However, the number of sites 
evaluated for pentachlorophenol is not known. 
2.2 SUMMARY OF HEALTH EFFECTS 
Adverse health effects have been observed in humans and experimental animals following short- and 
long-term exposure to pentachlorophenol by the inhalation, oral, and dermal exposure routes.  Reports of 
inhalation and/or dermal exposure in humans and oral exposure studies in animals make up the bulk of 
the available toxicity data.  The liver, thyroid, immune system, reproductive system, and the developing 
organism are the primary targets of pentachlorophenol toxicity.  Case reports of individuals acutely 
exposed to pentachlorophenol via inhalation and dermal contact and longer-term occupational exposure 
via inhalation and/or dermal contact identify a number of adverse health effects.  The observed effects 
include symptoms associated with uncoupling of oxidative phosphorylation (tachycardia, increased 
respiratory rate, labored breathing, profuse sweating, fever, metabolic acidosis), liver effects, and 
impaired immune function.  The lack of information on exposure characterization and the possible 
concomitant exposure to other chemicals in the studies reporting these effects somewhat clouds their 
interpretation. However, acute and longer-term oral studies in experimental animals provide support for 
these health effects. Since humans are generally exposed to technical-grade pentachlorophenol, which 
usually contains such toxic impurities as polychlorinated dibenzo-p-dioxins and dibenzofurans, some of 
the effects observed in humans (or the severity and dose-response characteristics of the effects) may be 
related, at least in part, to the presence of the impurities.  Animal studies with both technical-grade and 
purified pentachlorophenol have demonstrated that, within the ranges of doses tested, some of the toxic 
effects attributed to pentachlorophenol were actually due to the impurities.  Because human exposure is 
generally to technical-grade pentachlorophenol, studies on technical-grade pentachlorophenol are 
considered relevant. 
In addition to the liver, thyroid, immune, reproductive, and developmental effects, exposure to 
pentachlorophenol is also associated with carcinogenic, renal, and neurological effects.  The results of 
several epidemiology studies suggest that pentachlorophenol may be a human carcinogen.  This 
assessment is supported by the findings in chronic oral rodent studies of increased incidences of liver 
tumors (hemangiosarcomas, adenomas, and carcinomas) and adrenal gland pheochromocytomas in mice 
and mesotheliomas and nasal squamous cell carcinomas in rats.  No increases in gene mutations have 
been observed in a variety of in vivo or in vitro studies. Clastogenic effects have been observed in a 
number of in vitro studies. The EPA classifies pentachlorophenol in group B2 (probable human 
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carcinogen) and IARC classifies it in group 2B (possibly carcinogenic to humans).  Several studies have 
reported adverse health effects in children accidentally exposed to pentachlorophenol.  The observed 
effects were symptoms of oxidative phosphorylation uncoupling (high fever, profuse sweating, increased 
respiratory rate, labored breathing, tachycardia, hepatomegaly, and irritability) and death.  Thus, the 
effects observed in children are similar to those seen in adults.  However, the data are inadequate to assess 
whether children are more susceptible than adults to the toxicity of pentachlorophenol. 
Hepatic Effects. A number of case reports describe liver effects in individuals exposed to technical-
grade pentachlorophenol either occupationally or in the home via inhalation and/or dermal contact.  The 
types of hepatic effects noted in the case reports include enlarged liver, jaundice, centrilobular 
degeneration, and elevated serum biliary acid concentrations.  Liver enlargement was also observed in 
newborns exposed for a short time via contaminated diapers and bed linen in a hospital nursery.  In 
addition, elevated urinary porphyrin and delta-amino levulinic acid concentrations and elevated levels of 
serum alanine aminotransferase and aspartate aminotransferase have been reported in epidemiological 
studies. 
Animal studies have confirmed the identification of the liver as one of the primary targets of pentachloro­
phenol toxicity.  Increased liver weights, increased serum enzymes, and histological alterations 
(centrilobular hepatocellular hypertrophy and vacuolization, necrosis, degeneration, and periportal 
fibrosis) have been observed in rats and mice exposed to pure and technical-grade pentachlorophenol. 
Thyroid Effects. There are limited data on the effect of pentachlorophenol on thyroid function in 
humans.  An inverse relationship between triiodothyronine levels and blood pentachlorophenol levels was 
found in women with gynecological and/or endocrinological disorders; who lived in homes with wood 
ceilings and wood panels treated with a wood preservative containing pentachlorophenol.  However, the 
triiodothyronine levels were frequently within the normal range and it is likely that they were also 
exposed to other chemicals.  
In animal studies, decreases in circulating and free concentrations of triiodothyronine and thyroxine have 
been observed in rats and sheep orally exposed to pure or technical-grade pentachlorophenol for an 
intermediate duration and first and second generation mink exposed to pentachlorophenol (purity not 
reported) in a multigeneration study.  The chronic-duration oral MRL is based on alterations in thyroid 
hormone levels (see Section 2.3). 
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Developmental Effects. Developmental effects (congenital eye cataracts) have been observed in the 
children of male sawmill workers exposed to a mixture of sodium salts of pentachlorophenol and 
tetrachlorophenol; however, other chemicals, in particular CDDs, may have contributed to the occurrence 
of these effects. However, animal studies provide strong evidence that pentachlorophenol is a 
developmental toxicant following oral exposure.  Developmental effects are frequently observed at doses 
that cause decreases in maternal body weight gain.  However, decreases in fetal or pup body weight have 
been observed at doses that do not result in maternal toxicity.  Increases in fetal/neonatal mortality, and 
soft tissue and skeletal malformations/variation (subcutaneous edema, diaphragmatic hernia, dilation of 
kidneys, lumbar spurs, and delays in ossification), and decreases in offspring growth have been observed 
in rats and sheep. Pure pentachlorophenol appears to be slightly more developmentally toxic than 
technical-grade pentachlorophenol. The maternal dose of technical grade pentachlorophenol that would 
be lethal to 50% of embryos was over two times higher than for pure pentachlorophenol.  The acute-
duration oral MRL, see Section 2.3 for details, was based on the increased occurrence of delayed skull 
ossification in rats. 
Reproductive Effects. No studies were found that adequately assessed the reproductive toxicity of 
pentachlorophenol in humans.  A possible association between pentachlorophenol exposure and 
reproductive effects was found in women exposed to technical-grade pentachlorophenol from outgassing 
wood panels treated with a wood preservative containing pentachlorophenol; however, study limitations, 
particularly lack of exposure characterization and possible exposure to other chemicals, preclude using 
these study to establish a causal relationship.  A number of animal studies provide evidence that the 
reproductive system is a sensitive target of pentachlorophenol toxicity.  A decrease in fertility was 
observed in first generation rats administered pentachlorophenol by gavage in a two-generation study; no 
alterations in fertility were observed in the parental generation in this study.  In contrast, no effects on 
fertility were observed in another multigeneration study in which mink were exposed to lower doses of 
pentachlorophenol. Several other studies have reported alterations in reproductive tissues.  The observed 
effects include decreased testes weight and focal/multifocal mononuclear cell infiltrate in the epididymis 
in first generation rats, focal degeneration of the seminiferous tubules in sheep, and increased severity of 
uterine and oviduct cysts in sheep and mink.  Histological alterations were not observed in rats orally 
exposed to pure or technical-grade pentachlorophenol for an intermediate or chronic duration. 
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Immunological Effects. Immunological effects have been reported in humans exposed via 
inhalation and/or dermal contact with pentachlorophenol and in animals following oral exposure.  A 
number of immunological effects (e.g., activated T-cells, autoimmunity, immunosuppression, B-cell 
dysregulation) have been reported in families living in pentachlorophenol-treated log homes and male 
factory workers involved in brushing technical-grade pentachlorophenol onto wood strips.  A number of 
animal studies indicate that oral exposure to technical-grade pentachlorophenol affects a wide range of 
immune functions, such as humoral and cellular immunity, susceptibility to tumor induction, and 
complement activity.  However, studies that tested both technical-grade and pure pentachlorophenol 
provide strong evidence that the immune effects are related to the level of impurities in the technical-
grade product (e.g., CDDs and CDFs). There is some evidence that pure pentachlorophenol is an 
immunotoxicant in rats.  Enhanced mitogen-induced T- and B-lymphocyte blastogenesis and suppression 
of the antibody response against sheep red blood cells has been observed in rats orally exposed to pure 
pentachlorophenol (>99% pure with no detectable dioxin impurities) for 28 days.  However, studies in 
mice suggest that pure pentachlorophenol has relatively little immunotoxic activity. 
2.3 MINIMAL RISK LEVELS 
Inhalation MRLs 
Inhalation MRLs for acute, intermediate, or chronic exposure have not been derived.  While target organs 
have been identified in humans following inhalation exposure to technical-grade pentachlorophenol, the 
exposure levels at which these effects occur have not been quantified.  No data exist on the toxicity of 
pentachlorophenol following inhalation exposure in animals from which MRLs could be developed.  
Oral MRLs 
C For acute oral exposure, an MRL of 0.005 mg/kg/day has been derived for pentachlorophenol. 
This MRL is based on a developmental toxicity study in which groups of pregnant rats were administered 
pure or technical-grade pentachlorophenol in corn oil by gavage on gestational days 6–15.  At the lowest 
pure pentachlorophenol dose tested (5 mg/kg/day), a significant increase in the occurrence of delayed 
ossification of the skull was observed. At higher doses ($15 mg/kg/day), significant increases in the 
occurrence of subcutaneous edema, lumbar spurs, and skeletal anomalies in the ribs, sternebrae, and 
vertebrae were observed. Increased fetal resorptions and decreased fetal body weight were observed at 
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$30 mg/kg/day.  Decreases in maternal body weight gain were observed at $30 mg/kg/day.  Similar 
results were found in rats exposed to technical-grade pentachlorophenol.  However, increased fetal 
resorptions and skeletal anomalies were observed at $15 mg/kg/day.  The MRL was derived by dividing 
the lowest-observed-adverse-effect level (LOAEL) of 5 mg/kg/day pure pentachlorophenol by an 
uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for interspecies extrapolation, and 10 for human 
variability).  Similar developmental effects have been observed in another rat developmental toxicity 
study.  In this study, significant increases in the occurrence of resorptions, and soft tissue and skeletal 
malformations and variations, and decreases in fetal body weight were observed in the offspring of rats 
that were administered by gavage 80 mg/kg/day technical-grade (89% pure) pentachlorophenol on 
gestational days 6–15.  This study identified a no-observed-adverse-effect level (NOAEL) of 
30 mg/kg/day.  Intermediate-duration oral developmental toxicity studies in rats have also reported 
increased fetal/neonatal mortality, malformations and/or variations, and decreased growth. 
C  An intermediate-duration oral MRL of 0.001 mg/kg/day has been derived for pentachlorophenol. 
This MRL is based on a LOAEL of 1 mg/kg/day for reproductive effects in mink exposed to 
pentachlorophenol (purity not reported) in the diet for 3 weeks prior to mating and throughout gestation 
and lactation. At the only dose tested, 1 mg/kg/day, decreases in the proportion of mated females 
accepting a second mating and mink that whelped were observed.  No effect on the proportion of mink 
accepting the first mating or the proportion of mink with visible implantation sites were found.  An 
increase in the severity cystic uterine glands was also observed in the pentachlorophenol-exposed mink. 
The MRL was derived by dividing a LOAEL of 1 by an uncertainty factor of 1000 (10 for use of a 
LOAEL, 10 for interspecies extrapolation, and 10 for human variability). 
As discussed in the previous section, reproductive effects have also been observed in rats and sheep orally 
exposed to pentachlorophenol for intermediate or chronic durations, but the results have been 
inconsistent. Significant decreases in the number of rats mated and in the ratio of pregnant rats to number 
of rats in cohabitation were observed in a two-generation rat study.  The effects were observed in the first 
generation of rats exposed to 60 mg/kg/day, but not in the parental generation.  In contrast, no effects on 
fertility were observed in a multi-generation study in mink exposed to 1 mg/kg/day pentachlorophenol in 
the diet or in sheep or sheep offspring (only females were exposed) exposed to 1 mg/kg/day 
pentachlorophenol in the diet. Histological alterations in female reproductive tissues have also been 
observed in sheep; increased severity of oviductal intraepithelial cysts in sheep exposed to 2 mg/kg/day 
pentachlorophenol by gavage twice weekly for 43 days and lymphocyte infiltration into the endometrium 
  
19 PENTACHLOROPHENOL 
2. RELEVANCE TO PUBLIC HEALTH 
were observed in sheep exposed to 1 mg/kg/day pentachlorophenol in the diet for 5 weeks prior to mating 
and during pregnancy and lactation.  However, no histological alterations were observed in female mink 
exposed to 1 mg/kg/day pentachlorophenol in the diet in a multi-generation study. 
Liver and developmental effects also appear to be sensitive end points of pentachlorophenol following 
intermediate-duration oral exposure; the lowest adverse effect levels for these effects are 10-fold higher 
than the reproductive effects reported in mink.  Significant increases in relative liver weight and the 
occurrence of centrilobular hepatocellular hypertrophy have been reported in rats and mice exposed to 
<10 mg/kg/day pure or technical-grade pentachlorophenol.  At higher doses, hepatocyte degeneration and 
necrosis have been observed. Developmental effects (decreased pup body weight) have also been 
observed in rat offspring at 10–15 mg/kg/day.
C For chronic oral exposure, an MRL of 0.001 mg/kg/day has been derived for pentachlorophenol.  
This MRL was based on a LOAEL of 1 mg/kg/day (only dose tested) for significantly decreased serum 
thyroxine concentrations first generation males and both males and females of the second generation, and 
decreased relative thyroid weight second generation females when mink were administered pentachloro­
phenol of unspecified purity continuously in the diet in a multigeneration reproduction study.  Several 
studies support the identification of the thyroid gland as a sensitive target of pentachlorophenol toxicity. 
Oral gavage administration of pure pentachlorophenol to young adult female rats over a 28-day period at 
doses of 3 or 30 mg/kg produced decreases in circulating and free concentrations of the thyroid hormones 
triiodothyronine and thyroxine in serum, a decrease in serum thyroid stimulating hormone, decreases in 
intrathyroidal levels of  triiodothyronine and thyroxine, a decrease in the thyroxine:triiodothyronine ratio 
in serum, and a reduction in thyroidal hormone stores.  Technical-grade pentachlorophenol, tested only at 
a dose of 3 mg/kg, produced the same effects, except for the reduction in free triiodothyronine in serum 
(data for free serum thyroxine were not reported).  A decrease in maternal serum thyroxine concentration 
throughout pregnancy and lactation and a significant increase in maternal thyroid gland follicle size were 
found in female sheep administered 1 mg/kg/day pentachlorophenol (purity not indicated) in the diet 
5 weeks prior to mating and throughout pregnancy and lactation until 2 weeks after weaning of the lambs. 
Additionally, increased thyroxine levels were observed in their ewe and ram lambs that also received 
postnatal exposure to pentachlorophenol. The chronic-duration MRL was derived by dividing the 
LOAEL of 1 mg/kg/day by an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for interspecies 
extrapolation, and 10 for human variability). 
Dermal MRLs 
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Appropriate methodology does not currently exist to develop MRLs for dermal exposure.  This is most 
often because of the difficulty in identifying reliable, absorbed doses from most dermal studies.  The 
paucity of dermal studies is in part due to the difficulty in constructing animal models which limit 
exposure exclusively to the dermal route.  An approach to deriving dermal MRLs from oral or inhalation 
data through route-to-route extrapolation is currently being evaluated for potential use by the agency. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of pentachloro­
phenol. It contains descriptions and evaluations of toxicological studies and epidemiological 
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic 
data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or 
lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 
studies. LOAELS have been classified into "less serious" or "serious" effects.  "Serious" effects are those 
that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory 
distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction 
or death, or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
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major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of pentachloro­
phenol are indicated in Table 3-1 and Figure 3-1. Because cancer effects could occur at lower exposure 
levels, Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 
1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for pentachlorophenol.  An MRL is defined as an estimate of daily human exposure to a substance 
that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified 
duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target 
organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of 
exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. 
MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral 
routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990a), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
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A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
Since humans are generally exposed to technical-grade pentachlorophenol, which usually contains such 
toxic impurities as polychlorinated dibenzo-p-dioxins and dibenzofurans (see Table 3-2), some of the 
effects observed in humans (or the severity and dose-response characteristics of the effects) may be 
related, at least in part, to the presence of the impurities.  Animal studies with both technical-grade and 
purified pentachlorophenol have demonstrated that, within the ranges of doses tested, some of the toxic 
effects attributed to pentachlorophenol were actually due to the impurities.  Because human exposure is 
generally to technical-grade pentachlorophenol and because ATSDR's intent is to protect human health, 
studies on both technical-grade and purified pentachlorophenol preparations are reviewed, and special 
reference is made to those adverse effects seen in humans that are believed to be a result of the 
contaminants. 
3.2.1 Inhalation Exposure 
Only limited data were available on the inhalation toxicity of pentachlorophenol in humans.  Most of the 
information available for humans comes from cases of acute poisoning following home use of penta­
chlorophenol-containing products such as wood preservatives or herbicides in the garden (home and 
garden use of pentachlorophenol is no longer approved by EPA), and following occupational exposure in 
agricultural and wood-treatment industries.  Many of these poisoning incidences involved inhalation and 
dermal exposure to pentachlorophenol.  Below is a discussion of the case reports and studies in which 
inhalation is the primary route of exposure; the remaining studies are discussed in Section 3.2.3, Dermal 
Exposure. Exposure concentrations and duration, as well as information on other exposures and 
contaminants present in technical-grade pentachlorophenol, are often not available in these studies.  Thus, 
no studies were considered suitable for presentation in a table describing significant levels of inhalation 
exposure to pentachlorophenol. 
3.2.1.1 Death 
Data on the lethality of pentachlorophenol in humans is limited to a case report of a man who died 
following 3 weeks of daily occupational exposure to pentachlorophenol dust (purity not reported) (Gray 
et al. 1985). 
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Death has been reported in experimental animals following acute inhalation of sodium pentachloro­
phenate aerosol. The reported LC50 (45 minutes) for rats is 14 mg/m3 (11.7 mg/kg) (Hoben et al. 1976b). 
3.2.1.2 Systemic Effects 
No studies were located regarding any systemic effects in animals after inhalation exposure to penta­
chlorophenol. No studies were located regarding cardiovascular, gastrointestinal, musculoskeletal, or 
renal effects in humans after inhalation exposure to pentachlorophenol.  It should be noted that many of 
the systemic effects observed following occupational exposure which are discussed below resulted from 
uses of pentachlorophenol that are no longer accepted and that the pentachlorophenol used in these 
instances had a composition (e.g., presence of more impurities) different from the pentachlorophenol that 
is currently used.  
Respiratory Effects. In humans, chronic high-dose occupational exposure to pentachlorophenol 
causes inflammation of the upper respiratory tract and bronchitis (Baader and Bauer 1951; Klemmer et al. 
1980). The purity of pentachlorophenol in these cases was not specified, and inhalation of pentachloro­
phenol contaminants (chlorinated dibenzo-p-dioxins and dibenzofurans) and other compounds (such as 
dieldrin, chromium, fluorine, arsenic, copper, boron, and tin compounds) present in workplace air was 
likely and may have contributed to the respiratory response observed.  Furthermore, the inflammation 
observed may have also been the result of physical irritation from the inhalation of particulate matter. 
Hematological Effects. In a chronic occupational study, increased numbers of immature leukocytes 
and basophils were observed in workers exposed to technical-grade pentachlorophenol; however, these 
parameters were still within normal limits (Klemmer et al. 1980). 
Hepatic Effects. In an epidemiology study of male and female pentachlorophenol-production 
workers, higher urinary excretion of coproporphyrins, compared with unexposed controls, was associated 
with workers with chloracne involved in the production of pentachlorophenol (Hryhorczuk et al. 1998). 
In another epidemiology study, Cheng et al. (1993) found elevated urinary porphyrin and delta-amino 
levulinic acid concentrations among male workers who produced technical-grade pentachlorophenol, but 
there were no differences in these parameters between the workers with chloracne and those without.  
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Endocrine Effects. In a brief report, Gerhard et al. (1991) noted that elevated blood levels of penta­
chlorophenol (>25 µg/L) and/or lindane (>100 ng/L) were found in 22 of 90 women with histories of 
habitual abortion, unexplained infertility, menstrual disorders, or the onset of menopause.  Exposure 
duration was 4.6–10 years, and exposure occurred via offgassing (from wooden ceiling and wall panels 
and from carpets and leather upholstery treated with wood preservatives) as well as via dermal contact 
with these treated materials.  Pentachlorophenol blood levels were highest in the women with infertility 
(mean=73 µg/L) and lower in those with menstrual dysfunction (42 µg/L).  Seventeen of the 22 women 
also exhibited adrenocortical insufficiency, and 6 of these women had thyroid dysfunction as assessed by 
measurement of thyroid stimulating hormone releasing hormone (no further details were provided). 
Conclusions cannot be drawn from these data because a control group was not used and statistical 
analyses were not performed.  Gerhard et al. (1998) also examined several endocrine end points among 
89 women with repeated miscarriages.  An inverse correlation was found between triiodothyronine levels 
and pentachlorophenol levels. It should be noted that this is a preliminary study; study design limitations 
include lack of a matched control group, lack of control for other confounding factors, only 15% of the 
women had pentachlorophenol levels that were above the reference level of 25 µg/L, no information was 
provided on possible sources of exposure to pentachlorophenol, and elevated levels of other chlorinated 
hydrocarbons (e.g., PCBs, DDT) were also present in some of the women.  In a third study by Gerhard et 
al. (1999) of a group of women with gynecological and/or endocrinological disorders, a decrease in 
triiodothyronine levels were found in women with elevated pentachlorophenol serum levels (median level 
of 3.59 µg/L); although the levels were lower than levels found in age-, geographical region-, and 
condition-matched controls, the mean and median triiodothyronine levels were within the normal range. 
An euthyroid goiter was also observed in 50% of these subjects as compared to 30% in the controls. 
Other statistically significant alterations in endocrine hormones included an increase in adrenocortico­
tropic hormone (ACTH)-stimulated cortisol levels and decreases in follicle stimulating hormone, 
testosterone, hydroepiandrosterone, hydroepiandrosterone sulfate, 17-hydroxypregnenolone, and 
17-hydroxyprogesterone levels.  As with the triiodothyronine levels, the hormone levels were within the 
normal range.  The source of pentachlorophenol was wood ceilings that were treated with wood 
preservatives; it is likely that these women were also exposed to other chemicals in the wood 
preservative. 
No studies were located regarding endocrine effects in animals after inhalation exposure to pentachloro­
phenol. 
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Dermal Effects. Occupationally-exposed workers at a wood-treatment plant exhibited a statistically 
significant increase in low-grade inflammation of skin and subcutaneous tissue, and severe eruptions of 
the skin. However, it is possible these symptoms resulted from exposure to contaminants in pentachloro­
phenol (chlorinated dibenzo-p-dioxins, dibenzofurans) and other materials such as dieldrin, chromium, 
fluorine, arsenic, copper, boron, and tin compounds (Baader and Bauer 1951; Klemmer et al. 1980). 
Hosenfeld et al. (1986) reported the presence of skin abnormalities (type not specified) in some residents 
of log homes treated with pentachlorophenol (purity not indicated).  
Numerous occupational exposure studies have reported chloracne, characterized by extensive cysts and 
pus forming abscesses on the face, chest, abdomen, and proximal part of the extremities in sodium 
pentachlorophenate (Seghal and Ghorpade 1983) and pentachlorophenol (Cheng et al. 1993; Hryhorczuk 
et al. 1998; O’Malley et al. 1990) production workers.  It is likely that these workers were also exposed to 
chlorinated dibenzo-p-dioxins and dibenzofurans, which are known to induce chloracne in humans. 
Ocular Effects. Inflammation of the conjunctival membrane of the eyes was observed in workers 
exposed to technical-grade pentachlorophenol at a wood treatment plant (Klemmer et al. 1980). 
3.2.1.3 Immunological and Lymphoreticular Effects 
In an epidemiologic study, McConnachie and Zahalsky (1991) evaluated 18 lymphocyte phenotype 
frequencies, proliferative responses of peripheral lymphocytes to mitogens and allogenic stimulator 
lymphocytes, serum immunoglobulin levels, and autoantibody levels in 38 people ages 8–60 (21 males) 
and 9–60 (17 females) from 10 families who had been exposed to pentachlorophenol (purity not 
indicated) in their pentachlorophenol-treated log homes for periods of 1–13 years.  Fifteen of the 
individuals were children ages 8–18. The mean serum concentration of pentachlorophenol in the 
individuals who still lived in log homes at the time of the study was 884 µg/L; this was higher than the 
mean of 420 µg/L found in another study of people living in log homes and a mean level of 40 µg/L 
reported for members of the general public with no known exposure to pentachlorophenol (Cline et al. 
1989). Comparison of the pentachlorophenol-exposed individuals with controls indicated that the 
exposed individuals had activated T-cells, autoimmunity, immunosuppression, and B-cell dysregulation. 
T-cell activation was indicated by statistically-significant increases of more than 50% in the proportion of 
lymphocytes with T-cell activation markers, as detected by monoclonal antibodies, in pentachlorophenol­
exposed individuals compared with controls.  Autoantibodies were detected in 8 of 38 pentachlorophenol­
exposed subjects, and there was increased expression of a monoclonal-antibody-detected marker 
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associated with autoimmunity in the pentachlorophenol-exposed group.  Functional immunosuppression 
was indicated by statistically-significant decreases of 24–41% in the proliferative response of peripheral 
lymphocytes of pentachlorophenol-exposed individuals, compared with controls, to three different 
mitogens and to allogeneic stimulation in mixed-lymphocyte culture.  A statistically-significant increase 
in natural killer cell function was also reported in pentachlorophenol-exposed women compared with 
women of the control group.  This study is limited by the absence of reported serum pentachlorophenol 
concentrations in members of the control group and the lack of control for potential confounders such as 
smoking, hypertension, and alcohol use.  Gerhard et al. (1991) reported “immunological disorders” (no 
further details were given) in 15 of 22 women attending a clinic for reproductive and/or endocrinological 
disorders. The women were exposed to pentachlorophenol by the outgassing of wood products in the 
home. 
No studies were located regarding immunological effects in animals after inhalation exposure to penta­
chlorophenol. 
3.2.1.4 Neurological Effects 
There are limited data on the neurotoxicity of inhaled pentachlorophenol in humans.  Signs of central 
nervous system toxicity (lethargy and tachypnea) and cerebral edema with focal swelling of the myelin 
sheath was observed in a worker exposed to pentachlorophenol dust (Gray et al. 1985).  It is likely that 
these effects were secondary to hyperthermia, which resulted from pentachlorophenol-induced 
uncoupling of oxidative phosphorylation. 
A study by Peper et al. (1999) examined neurotoxicity in individuals exposed to wood preserving 
chemicals used to treat wood ceilings and wood paneling.  An increase in subjective symptoms (increased 
fatigue, distractability, attenuated motivation, and depressed mood) and impaired performance on several 
objective tests of neurobehavioral performance (paired-associated learning with a distracting condition, 
verbal memory test with distraction, visual short term memory, and incidental learning of visual objects) 
were observed in 15 women with elevated pentachlorophenol (mean of 43.6 µg/L) and γ-hexachloro­
cyclohexane (0.085 µg/L) blood levels, as compared to a sex-, age-, education-, and intelligence-matched 
control group. Additionally, the results of the reading speed, naming speed, paired associated learning, 
and visual short-term memory tests were significantly associated with pentachlorophenol blood levels. 
Although this study provides some suggestive evidence of the neurotoxic potential of pentachlorophenol, 
 28 PENTACHLOROPHENOL 
3. HEALTH EFFECTS 
interpretation of the results is complicated by co-exposure to high levels of γ-hexachlorocyclohexane 
(lindane) and other solvents and the small number of subjects.  
A reduction in median motor nerve conduction velocity was seen in male pentachlorophenol production 
workers, as compared to matched controls (Cheng et al. 1993).  However, the reduction was only 
statistically significant in the subgroup of pentachlorophenol workers in the trichlorobenzene tank area 
where the highest levels of chlorinated dibenzo-p-dioxins (CDDs) were also found. In contrast, Triebeg 
et al. (1987) did not find significant alterations in motor or sensory nerve conduction velocities in the 
ulnar and/or median nerve in workers exposed to low levels (0.0003–0.18 mg/m3) of technical-grade 
pentachlorophenol. 
In a case-control study of patients with Parkinson’s disease, Seidler et al. (1996) found significant 
associations of Parkinson’s disease with long-term (>15 years) exposure to wood paneling in the home, 
contact with wood preservatives in free time, and contact with wood preservatives at work.  However, the 
association of Parkinson’s disease with exposure to pentachlorophenol is uncertain because the patients 
were more likely than control subjects to have used organochlorines and alkylated phosphates/ 
carbamates, and the patients reported more frequent exposure to heavy metals, solvents, exhaust fumes, 
and carbon monoxide than the control group. 
No studies were located regarding neurological effects in animals following inhalation exposure to penta­
chlorophenol. 
3.2.1.5 Reproductive Effects 
In a brief report, Gerhard et al. (1991) noted that elevated blood levels of pentachlorophenol (>25 µg/L) 
and/or lindane (>100 ng/L) were found in 22 of 90 women with histories of habitual abortion, 
unexplained infertility, menstrual disorders, or the onset of menopause.  However, a causal relationship 
between pentachlorophenol exposure and the effects is uncertain because of concurrent exposures to other 
chemicals, the absence of matched controls, and lack of control for other confounding factors.  Gerhard et 
al. (1999) also examined a group of 65 women with gynecological and/or endocrinological alterations and 
elevated serum pentachlorophenol levels (median level was 35.9 µg/L).  Statistically significant decreases 
in follicle stimulating hormone and testosterone levels were found, as compared to age-, geographical-, 
region-, and condition-matched controls.  Although the hormone levels were lower than in the control 
group, they were within the normal range of values.  The women were exposed to pentachlorophenol via 
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outgassing of wood ceilings treated with wood preservatives. It is likely that the women were also 
exposed to other components of the wood preservatives. 
No studies were located regarding reproductive effects in animals following inhalation exposure to penta­
chlorophenol. 
3.2.1.6 Developmental Effects 
Information on the developmental toxicity of pentachlorophenol in humans is limited to a study of male 
sawmill workers exposed to CDD-contaminated chlorophenate (a mixture of the sodium salts of 
pentachlorophenol and tetrachlorophenol) (Dimich-Ward et al. 1996).  A significant correlation between 
presumed exposure to chlorophenate and an increased incidence of congenital eye cataracts were 
observed in the workers’ children.  Because there were no data on exposure level, exposure to 
chlorophenate was estimated by 10 experienced workers based on each cohort member’s job title. 
No studies were located regarding developmental effects in animals after inhalation exposure to penta­
chlorophenol. 
3.2.1.7 Cancer 
Case reports suggest a possible association between cancer (Hodgkin's disease, soft tissue sarcoma, and 
acute leukemia) and occupational exposure to technical-grade pentachlorophenol (Fingerhut et al. 1984; 
Greene et al. 1978; Roberts 1983). These studies are limited by confounding factors such as concurrent 
exposure to other potentially carcinogenic chemicals, small sample size, follow-up periods too short to 
detect an excess cancer risk, mortality due to competing causes of death, and brief exposure periods.  
Several epidemiological studies found no association between inhalation of pentachlorophenol (purity not 
stated) in any form and cancer in humans (Gilbert et al. 1990; Jäppinen et al. 1989; Johnson et al. 1990; 
Robinson et al. 1985). For example, workers exposed to wood treating chemicals between the years of 
1960 and 1981 were evaluated for health-related problems.  Eighty-eight wood treaters having exposures 
of 0.33–26.3 years, with a median of 6.5 years, were compared to 58 matched controls.  No adverse 
health effects or increased incidence of mortality from exposure were detected even though the urinary 
pentachlorophenol excretion levels were clearly increased (174 ppb versus 35 ppb) (Gilbert et al. 1990). 
However, IRIS (1999) indicated that the study of Gilbert et al. (1990) cannot be used as evidence of no 
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effect of the exposures based on their evaluation of various aspects of the experimental design and 
conduct. 
Johnson et al. (1990) found no association between soft tissue sarcoma and exposure to chlorophenols in 
a meta-analysis of deaths due to cancer in 15 cohort studies published 1979–1987.  However, each of the 
individual studies had a low power to detect elevated risk estimates (Johnson et al. 1990).  Because of the 
nature of the analysis performed by Johnson et al. (1990) (deaths due to cancer), their study excluded 
analysis of two studies, which had only incidence data, that found an association between exposure to 
technical-grade pentachlorophenol and soft tissue sarcoma (Eriksson et al. 1981; Hardell and Sandstrom 
1979). In a recent study, in which all data collection and coding were blinded as to cases or controls, 
Eriksson et al. (1990) found an association between soft tissue sarcoma and high-grade exposure (1 week 
or more continuously or at least 1 month totally over the years) to technical-grade pentachlorophenol. 
Compared with the high-grade pentachlorophenol association, a slightly stronger association was found 
for chlorophenols exposure and a weaker association was found for exposure to phenoxyacetic acids.  In a 
meta-analysis of four of their previous case-control studies, Hardell et al. (1995) found a significant 
association between soft tissue sarcoma and exposure to pentachlorophenol (purity not specified).  An 
increase in the occurrence of soft tissue sarcoma was also found in workers reporting exposure to 
phenoxyacetic acids or chlorophenols.  Hoppin et al. (1998) found a significant association in men aged 
30–60 years between soft tissue sarcoma risk and ever having high-intensity chlorophenol exposure. 
However, their findings were also consistent with an association to some other component of cutting oils. 
Seventeen percent of the jobs rated as high intensity involved wood preservation, whereas 82% involved 
cutting oils. Due to the limited nature of the exposure information in this study, potential for dioxin 
exposure could not be evaluated. 
Hardell et al. (1994) also reported a significant association, in men of various professions, between non­
Hodgkin’s lymphoma and high-grade exposure (1 week or more continuously or at least 1 month in total 
over the years) to pentachlorophenol (purity not specified).  Compared with the high-grade pentachloro­
phenol association, a slightly stronger association was found for high-grade exposure to chlorophenols. 
Hertzman et al. (1997) reported a borderline positive association between an increasing incidence of non­
Hodgkin’s lymphoma and increasing chlorophenate exposure among sawmill workers.  The trend 
approached statistical significance. 
Ramlow et al. (1996) reported a significant association between death from kidney cancer and increasing 
exposure to technical-grade pentachlorophenol but indicated that the finding must be considered 
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preliminary because of the small number of cases, lack of control for confounders, and absence of 
information concerning other occupational exposures. 
No studies were located regarding cancer in animals after inhalation exposure to pentachlorophenol. 
3.2.2 Oral Exposure 
Only two reports were found in the literature concerning adverse effects in humans of ingestion of penta­
chlorophenol (Cretney 1976; Haley 1977).  However, pentachlorophenol (particularly the technical-
grade) has been shown to affect several organ systems in experimental animals.  Target organs or systems 
of oral pentachlorophenol-induced toxicity in experimental animals include liver, kidney, central nervous 
system, endocrine system, immune system, and reproductive system; the developing organism is also a 
sensitive target of pentachlorophenol toxicity.  Hematologic, cardiovascular, and respiratory effects have 
also been noted following oral administration of pentachlorophenol in experimental animals.  Oral 
administration of pentachlorophenol also produced developmental effects in animals and cancer in rats 
and mice. 
Some of the effects of pentachlorophenol may be due, at least in part, to the uncoupling of oxidative 
phosphorylation by pentachlorophenol (see Section 3.5), which leads to hyperthermia and related effects. 
Some effects may also result from chlorinated dibenzo-p-dioxin and other impurities in technical-grade 
pentachlorophenol. The adverse effect of pure pentachlorophenol on thyroid homeostasis and the 
induction of oxidative deoxyribonucleic acid (DNA) damage by oral exposure to pentachlorophenol may 
also contribute to its spectrum of toxic effects. 
3.2.2.1 Death 
One case report that described a suicide from pentachlorophenol ingestion was found in the reviewed 
literature, but the amount of pentachlorophenol ingested was not specified (Cretney 1976).  The lowest 
human lethal dose for pentachlorophenol (purity not specified) is estimated to be 1 gram (approximately 
17.0 mg/kg) (Driesbach 1980).  
Pentachlorophenol may cause death in experimental animals following ingestion.  Death usually is a 
result of hyperthermia.  There does not appear to be much difference in doses that cause death across 
species. The LD50 values were 80–120 mg/kg in rats (St. Omer and Gadusek 1987) and 117–177 mg/kg 
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in mice (Borzelleca et al. 1985; Renner et al. 1986).  Preweaned and adult rats have been reported to have 
lower oral LD50 values for technical-grade pentachlorophenol than juvenile rats (25–50 days old) (St. 
Omer and Gadusek 1987).  The ranges of LD50 values in preweaned, juvenile, and adult rats were 50–180, 
220–230, and 80–120 mg/kg, respectively.  The lethality of pentachlorophenol was greatly enhanced 
when it was administered in a fuel oil or corn oil vehicle (Deichmann et al. 1942).  Absorption of 
chemicals such as pentachlorophenol that have substantial lipid solubility across skin and mucous 
membranes is increased by the presence of hydrocarbon or corn oil solvents.  The greater toxicity of 
pentachlorophenol when dissolved in these vehicles may be due partly or entirely to more efficient 
absorption of pure pentachlorophenol. 
Deaths were also seen in a 30-day oral range-finding study in mice (NTP 1989), a 28-day oral range-
finding study in rats with highly purified pentachlorophenol (Chhabra et al. 1999; NTP 1999), and a 
6-month oral study in mice (NTP 1989).  At the highest dietary concentration tested (12,500 ppm) in the 
30-day study in mice (NTP 1989), incidences of deaths were higher in animals fed pure pentachloro­
phenol (98.6% pure with <0.0002% chlorinated dibenzo-p-dioxins and dibenzofurans) and the purified 
EC-7 pentachlorophenol preparation (90% pure with <0.0002% chlorinated dibenzo-p-dioxins and 
dibenzofurans) than in animals fed technical-grade pentachlorophenol (90% pure with 0.18% chlorinated 
dibenzo-p-dioxins and dibenzofurans). 
All reliable LD50 values from acute duration studies and NOAELs/LOAELs for death in longer-duration 
studies are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.2 Systemic Effects 
No studies were located regarding gastrointestinal, musculoskeletal, dermal, or ocular effects in humans 
or animals after oral exposure to pentachlorophenol. 
The highest NOAEL values and all reliable LOAEL values from each reliable study for systemic effects 
in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects. The National Toxicology Program (NTP) conducted a 6-month dietary range-
finding study (NTP 1989) with 3 different preparations of pentachlorophenol (technical-grade, Dowicide 
EC-7, and pure) in B6C3F1 mice (see analysis in Table 3-2).  Increased incidences of nasal mucosal 
metaplasia/goblet cell hyperplasia, compared with controls, were seen in female mice that received 
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Table 3-2. Results of Analyses of Impurities Present in the Pentachlorophenol Used in National Toxicology
 
Program (NTP) Feeding Studies and the Types of Tumors They Induce a,b
 
Impurity Technical grade Dowicide EC-7c Pure Tumor type Species 
Dichlorophenol – – – No data 
Trichlorophenold 100 ppm 70 ppm 100 ppm Liver, leukemiase , Rat, mouse 
lymphomas 
Tetrachlorophenol 38,000 ppm 94,000 ppm 14,000 ppm Not carcinogenic Rat, mouse 
Hexachlorobenzene 50 ppm 65 ppm 10 ppm Liver Rat, hamster, 
mouse 
Thyroid/ Parathyroid Rat 
Adrenal Rat 
Kidney Rat 
Lymphosarcomas Mouse 
Tetrachlorodibenzodioxin – <0.04 ppm <0.08 ppm Liver, thyroid Rat, mouse (both 
tumor types) 
Hexachlorodibenzodioxin 10.1 ppm 0.19 ppm <1 ppm Liver Rat, mouse 
Heptachlorodibenzodioxin 296 ppm 0.53 ppm – No data 
Octachlorodibenzodioxin 1,386 ppm 0.69 ppm <1 ppm No data 
Pentachlorodibenzofuran 1.4 ppm – – No data 
Hexachlorodibenzofuran 9.9 ppm 0.13 ppm – No data 
Heptachlorodibenzofuran 88 ppm 0.15 ppm – No data 
Octachlorodibenzofuran 43 ppm – – No data 
Heptachlorohydroxydiphenyl ether 500 ppmf – 100 ppm No data 
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Table 3-2. Results of Analyses of Impurities Present in the Pentachlorophenol Used in National Toxicology
 
Program (NTP) Feeding Studies and the Types of Tumors They Induce a,b (continued)
 
Impurity Technical grade Dowicide EC-7c Pure Tumor type Species 
Octachlorohydroxydiphenyl ether 19,100 ppm – 900 ppm No data 
Nanochlorohydroxydiphenyl ether 35,600 ppm – 2,100 ppm No data 
Hexachlorohydroxydibenzofuran 1,600 ppm – 1,100 ppm No data 
Heptachlorohydroxydibenzofuran 4,700 ppm – 2,200 ppm No data 
aSamples were dissolved in benzene, placed on a deactivated alumina column, and eluted with benzene.  Further separation was carried out with a basic
 
aluminum oxide column; elution was with methylene chloride in hexane.  Identification was performed by gas chromatography with an SP2100 capillary
 
column/mass spectrometry; quantitation was by comparison with spiked samples analyzed by gas chromatography with an SP1240 DA column.

bDerived from NTP 1989
 
cFour unidentified impurities with concentrations of 0.14, 0.057, 0.045, and 0.035 ppm were also detected.

dIdentified as the 2,3,6-isomer; another isomer was believed to be present but was not identified.
 
eData are for 2,4,6-isomer.
 
fIncludes oxtachlorodiphenyl ether
 
– = not detected; EC-7 = Dow Company chemical name 
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dietary doses of $64 mg/kg/day EC-7 (90% pure) and $67 mg/kg/day pure pentachlorophenol, but were 
not observed in the female mice exposed to 209 mg/kg/day technical-grade pentachlorophenol (which 
contains relatively high concentrations of chlorinated dibenzo-p-dioxins and dibenzofurans). The female 
mice appeared to be more sensitive to the nasal effects than the male mice.  The LOAELs for nasal lesions 
were 148 and 381 mg/kg/day in the EC-7 and pure pentachlorophenol groups, respectively.
Cardiovascular Effects. One report describing effects of ingestion of pentachlorophenol in humans 
was found in the literature (Haley 1977).  In this case, an adult male intentionally ingested an estimated 
4–8 ounces of weed killer that contained 12% pentachlorophenol, 1.5% other chlorinated phenols, 
82% aromatic hydrocarbons, and 4.5% inert ingredients.  Clinical signs observed upon subsequent 
hospital admission included tachycardia.  This effect is possibly the result of pentachlorophenol's ability 
to uncouple oxidative phosphorylation, leading to hyperthermia. 
One early report described the occurrence of extensive vascular damage and heart failure in rats, rabbits, 
guinea pigs, and dogs following a single oral administration (dose not specified) of pentachlorophenol of 
unidentified purity (Deichmann et al. 1942). 
Hematological Effects. No studies were located regarding hematological effects in humans after 
oral exposure to pentachlorophenol. 
Various hematologic changes of questionable biological significance have been reported in animal 
studies. A depression in number of erythrocytes, a decrease in hemoglobin level, and a decrease in 
packed cell volume were observed in rats fed technical-grade pentachlorophenol for 90 days but not in 
those fed purified pentachlorophenol (Johnson et al. 1973).  However, a decrease in white blood cell 
count was observed in pigs administered purified pentachlorophenol for 30 days (Greichus et al. 1979). 
Conflicting findings over time were reported in rats fed a purified pentachlorophenol preparation, which 
contained no tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) and <0.03% of the other chlorinated dibenzo­
p-dioxins, for 12 weeks (Knudsen et al. 1974). Increased hemoglobin and hematocrit were observed after 
6 weeks of treatment, followed by a decrease in hemoglobin and erythrocytes at study termination. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure to 
pentachlorophenol. 
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The liver is a target organ for pentachlorophenol-induced toxicity in experimental animals.  Evidence of 
biochemical (alterations in hepatic enzyme activities), and gross (increased liver weight), and 
histopathological (hypertrophy, vacuolization, hyperplasia, fibrosis, necrosis, and degeneration) effects is 
seen following acute, intermediate, and chronic oral exposure to pentachlorophenol in rodents.  At low 
dosages, the observed liver effects are characteristic of enzyme induction.  Increases in liver weight and 
hepatocellular hypertrophy and vacuolization have been observed in mice exposed to 41 mg/kg/day pure 
pentachlorophenol for 2 weeks (Umemura et al. 1996), in rats exposed to 1–40 mg/kg/day pure or 
technical-grade pentachlorophenol for an intermediate duration (Argus 1997/Bernard et al. 2001c; 
Blakley et al. 1998; Kimbrough and Linder 1978; Knudsen et al. 1974; Nishimura et al. 1982; NTP 
1999), in mice exposed to 9 mg/kg/day pure or technical-grade pentachlorophenol for 4–12 weeks 
(Kerkvliet et al. 1982; Umemura et al. 1996), and in pigs exposed to 10 mg/kg/day pure 
pentachlorophenol for 30 days (Greichus et al. 1979). 
The severity of the liver damage increased with increasing exposure concentrations.  Intermediate-
duration exposure to doses of 7–48 mg/kg/day pure or technical-grade pentachlorophenol resulted in 
necrosis, periportal fibrosis, and hepatocellular degeneration in rats (Argus 1997/Bernard et al. 2001c; 
Kimbrough and Linder 1978; NTP 1989) and multifocal necrosis and hepatocellular degeneration in mice 
exposed to 67–105 mg/kg/day pure or technical-grade pentachlorophenol (Kerkvliet et al. 1982; NTP 
1989). Hepatocellular degeneration was observed in rats exposed to 10–60 mg/kg/day pure 
pentachlorophenol in the diet for 52 or 104 weeks (NTP 1999).  The biochemical changes consisted of 
increases in the serum levels of alanine and aspartate aminotransferase at 40 and 67 mg/kg/day pure or 
technical-grade pentachlorophenol in rats (Nishimura et al. 1980) and mice (NTP 1989), respectively.
The results of the Kimbrough and Linder (1978) study suggests that the impurities found in technical-
grade pentachlorophenol may influence its toxicity.  The liver effects observed in this study included 
centrilobular hepatocyte hypertrophy at 1 mg/kg/day, periportal fibrosis at 7 mg/kg/day, and periportal 
fibrosis and bile duct proliferation at 48 mg/kg/day in rats exposed to technical-grade pentachlorophenol 
in the diet for 8 months.  In contrast, minimal liver effects (centrilobular hepatocyte hypertrophy) were 
observed at the highest tested dose (32 mg/kg/day) of pure pentachlorophenol.  It is possible that the 
tetrachlorophenol, hexachloro-p-dibenzodioxin, heptachloro-p-dibenzodioxin, octachloro-p-dibenzo­
dioxin, hexachlorodibenzofuran, pentachlorodibenzofuran, and tetrachlorodibenzofuran present in the 
technical-grade pentachlorophenol influenced its hepatotoxicity.  However, other studies that compared 
the hepatotoxicity of pure and technical-grade pentachlorophenol did not find differences in potency or 
the type of liver effects (Kerkvliet et al. 1982; NTP 1989). 
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Renal Effects. No studies were located regarding renal effects in humans after oral exposure to penta­
chlorophenol. 
There is evidence of mild-to-moderate renal toxicity in experimental animals as a result of long-term oral 
administration of pentachlorophenol.  The most frequently reported toxic effects seen in kidneys of 
rodents include increased organ weight and altered enzyme levels.  Histopathologic effects are rarely 
seen. The possibility that impurities in pentachlorophenol may be responsible for the adverse effects 
observed is likely.  Furthermore, some of the data discussed below have many inconsistencies. 
Purified pentachlorophenol (2 mg/kg/day, only dose tested, >99% pure with no detectable dioxin 
impurities) induced a small but significant increase in relative kidney weight in rats exposed twice weekly 
for 28 days (Blakley et al. 1998). 
When similar doses of technical-grade and purified pentachlorophenol (>99% pure) were fed to rats for 
8 months, the pure compound induced a slight, non-dose-related increase in kidney weight in males, 
whereas the technical-grade compound did not alter kidney weight in either sex (Kimbrough and Linder 
1978). When similar doses of technical-grade and pure pentachlorophenol (no detectable chlorinated 
dibenzo-p-dioxins) were fed to rats for 3 months, increased kidney weight was reported at 
10–30 mg/kg/day of the technical-grade preparation, but only at the 30 mg/kg/day dose of the pure penta­
chlorophenol (Johnson et al. 1973). In neither study were renal histopathological changes observed to 
accompany organ weight changes.  Thus, the biological significance of these observations with regard to 
long-term toxicity is not known.  
Increased kidney weight and urine specific gravity and a dose-related incidence of kidney discoloration 
were observed in rats fed 1–30 mg/kg/day of Dowicide EC-7 (a purified pentachlorophenol containing 
<0.0002% chlorinated dibenzo-p-dioxins and dibenzofurans) for 24 months (Schwetz et al. 1978). 
Pigmentation per se is not considered an adverse effect. Biochemical changes indicative of renal toxicity 
have also been reported in pentachlorophenol-treated animals.  For example, after 15 days of oral 
exposure to purified pentachlorophenol at 10 or 15 mg/kg/day, young pigs exhibited statistically 
significant increased levels of blood urea nitrogen, but this effect was no longer significant after 30 days 
of treatment (Greichus et al. 1979).  Proximal tubular alkaline phosphatase activity was decreased after 
1 month of twice-weekly gavage doses (40–160 mg/kg/day) of 90% pure pentachlorophenol (sodium salt; 
impurities not identified) administered to rats, but this effect was no longer evident after 3 months of 
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treatment (Nishimura et al. 1980).  The biological significance of these apparently transient renal effects 
with regard to long-term toxicity is not known. 
Endocrine Effects. No studies were located regarding endocrine effects in humans after oral 
exposure to pentachlorophenol. 
Significant alterations in thyroid hormone levels have been observed in several intermediate- and chronic-
duration animal studies.  Oral gavage administration of pure pentachlorophenol to young adult female rats 
over a 28-day period at a dose of 30 mg/kg produced decreases in circulating and free concentrations of 
the thyroid hormones triiodothyronine and thyroxine in serum, a decrease in serum thyroid stimulating 
hormone, decreases in intrathyroidal levels of triiodothyronine and thyroxine, a decrease in the ratio of 
serum thyroxine to triiodothyronine, and a reduction in thyroidal hormone stores.  Decreases in 
circulating and free thyroxine were also observed at 3 mg/kg/day.  Technical-grade pentachlorophenol, 
tested only at a dose of 3 mg/kg,  produced the same effects as 30 mg/kg of pure pentachlorophenol 
except the reduction in free T3 in serum (data for free serum T4 were not reported).  Technical-grade 
pentachlorophenol, in addition, produced an increase in thyroid epithelial-cell height (Jekat et al. 1994). 
In a multigeneration study in mink, significant decreases in serum thyroxine levels were observed in the 
F1 males and the F2 males and females exposed to 1 mg/kg/day pentachlorophenol (purity not reported) 
(Beard and Rawlings 1998). A decrease in relative thyroid weight was also observed in the F2 female 
mink.  This LOAEL of 1 mg/kg/day was used to derive a chronic-duration oral MRL of 0.001 mg/kg/day, 
as described in the footnote in Table 3-1. 
Alterations in thyroid hormone levels were also observed in a series of studies in sheep.  A significant 
decrease in thyroxine levels was observed in female sheep administered 2 mg/kg/day pure 
pentachlorophenol by gavage twice weekly for 36 days (Rawlings et al. 1998).  Exposure of female sheep 
to 1 mg/kg/day pentachlorophenol (purity not reported) for 5 weeks premating and throughout gestation 
and lactation, resulted in significant decreases in serum thyroxine levels in the mothers (Beard et al. 
1999b), in the ram lambs that were also exposed for 20 weeks post weaning (Beard et al. 1999a), and in 
the ewe lambs also exposed for 67 weeks post weaning (Beard and Rawlings 1999).  No alterations in 
thyroid stimulating hormone levels or the response to thyroid releasing hormone were observed in the 
female offspring.  However, in response to thyroid stimulating hormone, there were reductions in the 
magnitude and duration of the thyroxine response and in the maximum triiodothyronine level and net 
triiodothyronine increase. 
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There are limited data on the toxicity of pentachlorophenol to other endocrine tissues.  A significant 
increase in mean serum insulin concentrations was seen in sheep receiving twice weekly gavage doses of 
2 mg/kg/day (Rawlings et al. 1998).  No alterations in cortisol levels were observed in ram lambs (Beard 
et al. 1999a). 
Body Weight Effects. Significant ($10%) decreases in body weight gain were observed in several 
studies where both technical-grade and pure pentachlorophenol were administered orally for intermediate 
or chronic durations to rats or mice (Chhabra et al. 1999; Kimbrough and Linder 1978; Nishimura et al. 
1980; NTP 1989, 1999; Welsh et al. 1987). Suppression of body weight gain by oral administration of 
pentachlorophenol was also reported in maternal animals, fetuses, and neonates. 
Metabolic Effects. There are limited data on the metabolic toxicity of pentachlorophenol.  Nishimura 
et al. (1980) reported significant increases in blood glucose levels and decreases in hepatic glycogen 
levels in rats administered 40 mg/kg/day technical-grade sodium pentachlorophenate by gavage twice 
weekly for 1 to 3 months. 
Other Systemic Effects. In the intermediate-duration studies conducted by NTP (1989), granular 
eosinophilic pigment was observed in the epithelial cells of the urinary bladder of rats exposed to 
technical-grade pentachlorophenol, EC-7 (90% pure), and pure pentachlorophenol; the increase in 
pigment was not accompanied by inflammation.  
3.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans following oral exposure to penta­
chlorophenol. 
Evidence for pentachlorophenol-induced alterations in immune function was obtained from studies 
conducted in experimental animals.  The available data indicate that, at doses of 0.5–100 mg/kg/day, 
pentachlorophenol affects a wide range of immune functions, such as humoral and cellular immunity, 
susceptibility to tumor induction, and complement activity.  Detailed studies in mice indicate that the 
majority of the immunotoxic effects of pentachlorophenol appear to be related to the level of impurities in 
the technical-grade product (e.g., polychlorinated dibenzo-p-dioxins and dibenzofurans) (Kerkvliet et al. 
1982, 1985a; NTP 1989; White and Anderson 1985).  However, a recent study in rats provides evidence 
that pure pentachlorophenol (>99% with no detectable dioxin impurities) can affect immune function 
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(Blakley et al. 1998).  Studies that compared effects of technical-grade to pure pentachlorophenol are 
reviewed below in an attempt to illustrate immunotoxic effects attributable to pentachlorophenol. 
Female B6C3F1 mice exposed daily to 10–100 mg/kg of technical-grade pentachlorophenol by gavage for 
2 weeks exhibited a dose-related suppression of in vivo antibody response (IgM plaque-forming cells 
[PFC]) to sheep red blood cells (SRBC) when mice were immunized during exposure (Holsapple et al. 
1987). This response was not seen following exposure to purified pentachlorophenol at a dose of 
100 mg/kg.  It was further observed that spleen cells from mice treated with technical-grade pentachloro­
phenol could still produce antibodies following in vitro immunization, indicating that the suppression 
seen following in vivo immunization was not due to a direct effect on antibody-forming cells. 
Purified pentachlorophenol (>99% pure with no detectable dioxin impurities) administered to male F344 
rats twice weekly for 28 days at a dose of 2 mg/kg/treatment significantly enhanced mitogen-induced T-
and B-lymphocyte blastogenesis and significantly suppressed the antibody response against injected 
sheep red blood cells when the response was expressed per viable spleen cell (Blakley et al. 1998). 
In 6-month dietary range-finding studies (NTP 1989) with 3 different preparations of pentachlorophenol 
(technical-grade, Dowicide EC-7, or pure) in B6C3F1 mice (see Table 3-2), the antibody response to 
sheep red blood cell injection was decreased at doses of technical-grade pentachlorophenol 
$48 mg/kg/day in males but was not affected in males by dosing with Dowicide EC-7 or pure penta­
chlorophenol. Antibody response data were not reported for females.  In the same studies, significant 
increases in relative spleen weight were not seen in dosed females, but were seen in males at doses of 
376 mg/kg/day technical-grade pentachlorophenol, $49 mg/kg/day Dowicide EC-7, and $225 mg/kg/day 
pure pentachlorophenol. 
Effects of dietary administration of both technical-grade and purified pentachlorophenol for 10–12 weeks 
on the ability of male B6C3F1 mice to resist syngeneic tumor growth, an indication of an organism's state 
of immunosurveillance, were studied (Kerkvliet et al. 1982).  Technical-grade preparation induced a 
significant dose-independent enhancement of susceptibility to methylcholanthrene-induced sarcoma 
1412 tumor growth, whereas the purified preparation had no effect on this parameter.  In another test of 
immunocompetence, treated mice were studied for their ability to resist secondary tumor growth induced 
by Maloney sarcoma virus (MSV).  After exposure to technical-grade pentachlorophenol, animals were 
inoculated with MSV, which resulted in transient subcutaneous injection-site tumors.  Upon subsequent 
challenge with MSV-transformed tumor cells, a significant increase in mortality and secondary tumor 
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susceptibility was seen in animals treated with technical-grade pentachlorophenol but not in animals 
administered purified pentachlorophenol.  This result suggests a detrimental effect of components of the 
technical-grade pentachlorophenol on both primary and secondary T-cell-dependent cytotoxic immune 
response. An increase in secondary splenic tumors was seen in animals treated with both grades of penta­
chlorophenol at a dose of 25 mg/kg/day.  This was interpreted as a more sensitive indicator of 
immunocompetence suppression by purified pentachlorophenol.  In a third test designed to evaluate 
macrophage competence, resistance to encephalomyocarditis virus (EMCV) was also studied in mice 
treated with both grades of pentachlorophenol. No effect was seen on susceptibility of either group of 
animals to EMCV-induced mortality.  The investigators concluded that immunomodulatory effects 
observed with pentachlorophenol were due primarily, but not exclusively, to contaminants present in the 
technical-grade preparation. 
To further investigate the role of these impurities in immunotoxicity induced by technical-grade penta­
chlorophenol, the antibody (IgM) response to an SRBC challenge in C57BL/6 mice given single oral 
doses of both grades of pentachlorophenol was studied (Kerkvliet et al. 1985a).  In agreement with results 
seen by Holsapple et al. (1987), technical-grade pentachlorophenol induced a dose-related suppression of 
this response at a dose of 30 mg/kg/day whereas purified pentachlorophenol did not.  Co-administration 
of heptachloro-p-dibenzodioxin (HpCDD), one of the most prevalent chlorinated dibenzo-p-dioxin 
impurities in technical-grade pentachlorophenol, with pure pentachlorophenol resulted in an immuno­
suppressive response that was similar in magnitude to that seen with technical-grade pentachlorophenol or 
HpCDD alone. These results provide good evidence that impurities (particularly HpCDD) are responsible 
for some of the immunotoxic effects attributed to technical-grade pentachlorophenol.  Results from the 
next series of experiments conducted by these investigators further supported this hypothesis.  Technical-
grade pentachlorophenol was fed to both C57BL/6 mice and DBA/2 mice for 6 weeks (Kerkvliet et al. 
1985a). The former strain has a high-affinity aryl hydrocarbon (Ah) receptor and the latter a low-affinity 
Ah receptor. The ability of chlorinated dibenzo-p-dioxin and dibenzofuran congeners (that are present as 
impurities in pentachlorophenol) to bind to this receptor correlates with their toxicity and their ability to 
induce P1-450 monooxygenase activity.  Antibody response to SRBC was suppressed by 28% (p#0.01) 
and 72% (p#0.01) in the 2 groups of C57BL/6 mice with different levels of technical-grade pentachloro­
phenol, as opposed to 0 and 45% (p>0.01) in corresponding groups of D2 mice.  Based on these results, 
the authors concluded that the immunosuppressive effect of technical-grade pentachlorophenol was 
probably mediated by contaminant chlorinated dibenzo-p-dioxins and dibenzofurans via interaction with 
the Ah receptor. 
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In a study designed to evaluate effects of dietary exposure to technical-grade pentachlorophenol on T-cell, 
macrophage, and natural killer cell activity, C57BL/6 mice were administered technical-grade penta­
chlorophenol for 8 weeks prior to conducting a number of in vitro immunofunction tests (Kerkvliet et al. 
1985b). They found that T-cell and macrophage-mediated (cell-mediated) immunocompetence is 
relatively resistant to perturbation by technical-grade pentachlorophenol.  The only statistically significant 
change seen was a reduction in lymphoproliferative response in mixed lymphocyte culture.  This finding 
contrasts with marked effects that technical-grade pentachlorophenol has on antibody-mediated 
immunity. 
The complement component of the immune system in mice has also been found to be affected by 
exposure to technical-grade pentachlorophenol, but not Dowicide EC-7, a preparation of 90% penta­
chlorophenol that contains reduced levels of chlorinated dibenzo-p-dioxins and dibenzofurans (see 
Table 3-2) (White and Anderson 1985). In this study, technical-grade pentachlorophenol inhibited 
functional activity of all aspects of complement in a dose-dependent manner.  This suppression was still 
seen up to 30 days after termination of treatment. 
The highest NOAEL values and all LOAEL values from each reliable study for immunological effects in 
each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.4 Neurological Effects 
One report describing effects of ingestion of pentachlorophenol in humans was found in the literature 
(Haley 1977).  In this case, an adult male intentionally ingested an estimated 4–8 ounces of weed killer 
that contained 12% pentachlorophenol, 1.5% other chlorinated phenols, 82% aromatic petroleums, and 
4.5% inert ingredients.  Clinical signs observed upon subsequent hospital admission included pyrexia, 
diaphoresis, hyperkinesis, muscle twitching, tremors, epigastric tenderness, leg pain, tachypnea, and 
tachycardia.  These neurologic symptoms may be the result of pentachlorophenol's ability to uncouple 
oxidative phosphorylation (including the resultant increase in body temperature, tachycardia, and 
tachypnea) rather than a direct toxic effect of pentachlorophenol on the central or peripheral nervous 
systems. 
Results from animal studies demonstrate that the central nervous system is adversely affected by penta­
chlorophenol, possibly as a result of hyperthermia induced by uncoupling of oxidative phosphorylation. 
At the neurochemical level, transient changes in activity of some brain enzymes and decreased glial 
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glutathione levels were seen in rats administered technical-grade pentachlorophenol in drinking water for 
14 weeks (Savolainen and Pekari 1979). These findings suggest another biochemical component to 
technical-grade pentachlorophenol neurotoxicity.  The possibility and extent of the role of technical-grade 
contaminants in producing these effects are not known, although the study authors concluded that the 
neurochemical changes were most likely associated with the body burden of chlorophenols.  Inhibition of 
the uptake of thyroxine into the cerebrospinal fluid, as demonstrated in rats following intraperitoneal 
injection of pentachlorophenol is another possible component of pentachlorophenol neurotoxicity. 
Degenerative changes in 10% of the Types A and B fibers consisting of breaks in the myelin sheath of 
sciatic nerves and a variable loss of neurotubules, neurofilaments, and other axoplasmic components were 
observed in male rats administered 38 mg/kg/day pentachlorophenol (purity not reported) in drinking 
water for 90 days or 114 mg/kg/day for 120 days.  Type C fibers were unaffected.  These changes were 
more marked in the rats receiving the higher dose.  No effects were observed in rats exposed to 
11.4 mg/kg/day for 60 days or 38 mg/kg/day for 60 days.  While these results suggest that pentachloro­
phenol can cause neurotoxic changes in the morphology of peripheral nerves, since the purity of the 
pentachlorophenol tested was not specified, it is not possible to determine whether these changes were 
due to pentachlorophenol itself or impurities present in technical-grade pentachlorophenol.  Other 
limitations associated with this study include a lack of protocol details (e.g., number of animals per 
group) and a lack of quantitative incidence data (Villena et al. 1992). 
The NTP (1989) conducted a 6-month dietary range-finding study with three different preparations of 
pentachlorophenol (technical-grade, Dowicide EC-7, or pure [see composition in Table 3-2]) in 
B6C3F1 mice.  Neurobehavioral studies were conducted during exposure weeks 5 and 26.  No penta­
chlorophenol-related neurobehavioral effects were observed at 5 weeks except for animals administered 
technical-grade pentachlorophenol, which showed a dose-dependent decrease in motor activity and 
rotarod performance.  In contrast, exposure to all 3 pentachlorophenol preparations caused dose-related 
increases in both motor activity and startle response in female mice at 26 weeks, whereas only technical-
grade pentachlorophenol caused these effects in male mice.  NTP (1989) did not provide actual dose-
response data. 
The LOAEL for neurological effects in rats following intermediate exposure is recorded in Table 3-1 and 
plotted in Figure 3-1. 
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3.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to pentachloro­
phenol. 
A number of animal studies have examined the reproductive toxicity of pentachlorophenol.  The available 
data suggest that long-term exposure to pentachlorophenol can decrease fertility, although the mechanism 
does not appear to be through histological damage to reproductive tissue.  In a two-generation study, 
decreased fertility (significant decreases in the number of rats mated and in the ratio of pregnant rats to 
the number of rats in cohabitation) was observed in the first generation of rats exposed to 60 mg/kg/day 
pentachlorophenol (purity not reported) administered by gavage (Argus 1997/Bernard et al. 2001c).  No 
alterations in fertility were observed in the F1 generation exposed to 10 or 30 mg/kg/day or in the parental 
generation. The only other reproductive effects observed in this study were a significant decrease in 
testicular spermatid count, decreases in absolute testes weight and the ratio of testes weight to brain 
weight, and focal/multifocal mononuclear cell infiltrate in the epididymis in the F1 rats administered 
30 or 60 mg/kg/day.  However, no alterations in the average number of motile or nonmotile sperm, 
epididymal or testicular sperm counts, or sperm morphology were observed in either generation.  No 
alterations in reproductive tissues were observed in the female rats.  Significant increases in the average 
day of preputial separation and vaginal patency were observed in the F1 generation, suggesting that in 
utero exposure to pentachlorophenol disrupted the normal development of the reproductive system.  No 
adverse reproductive effects were observed in another multigeneration study in which mink were fed a 
diet containing 1 mg/kg/day pentachlorophenol (purity not reported) (Beard and Rawlings 1998).  A 
single-generation mink study also conducted by this group reported significant decreases in the 
proportion of mated females accepting a second mating and the proportion of mink that whelped, 
although no effect on the proportion of mink that accepted the first mating or the proportion of mink with 
visible implantation sites were found (Beard et al. 1997).  In both studies, the minks were exposed to 
1 mg/kg/day pentachlorophenol (purity not reported) in the diet for 3 weeks prior to mating. 
Additionally, no significant alterations in mating response, ovulation rate, follicle and corpus luteum size, 
gestation length, pregnancy rate, lambing rate, and lamb birth rate were observed in sheep exposed to 
1 mg/kg/day pentachlorophenol in the diet for 5 weeks premating and throughout the gestation and 
lactation periods (Beard et al. 1999b). No effect on fertility was observed in the offspring of these sheep, 
later mated to unexposed males (Beard and Rawlings 1999). 
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Several reproductive toxicity and nonreproductive toxicity studies have reported histological alterations 
in reproductive tissues. The observed effects include focal degeneration of the seminiferous tubules and 
decreased sperm density in the epididymis body (but not in caput or cauda epididymis) in sheep exposed 
to 1 mg/kg/day pentachlorophenol (purity not reported) in the diet during gestation, lactation, and for 
20-weeks postnatally (Beard et al. 1999a), minimal to marked germinal epithelial degeneration and lack 
of spermatozoa in the seminiferous tubules of rats exposed to 270 mg/kg/day pure pentachlorophenol in 
the diet for 28 days (effects may have been secondary to poor condition of animals) (Chhabra et al. 1999; 
NTP 1999), increased severity of cystic uterine glands in mink exposed to 1 mg/kg/day pentachloro­
phenol (purity not reported) prior to mating and during gestation and lactation periods (Beard et al. 1997), 
increased severity of oviductal intraepithelial cysts in sheep administered 2 mg/kg/day pure pentachloro­
phenol by gavage twice weekly for 43 days (Rawlings et al. 1998), and lymphocyte infiltration into the 
endometrium in sheep exposed to 1 mg/kg/day pentachlorophenol (purity not reported) in the diet for 
5 weeks premating and during the gestation and lactation periods (Beard et al. 1999b).  No histological 
alterations in reproductive tissues were observed in male or female rats chronically exposed to 
30 mg/kg/day pure pentachlorophenol in the diet for 2 years (Chhabra et al. 1999; NTP 1999). 
Additionally, no alterations in reproductive hormones (estradiol, testosterone, progesterone, follicle 
stimulating hormone, and/or luteinizing hormone levels) have been observed in mink (Beard et al. 1997) 
or sheep (Beard et al. 1999a). The LOAEL of 1 mg/kg/day for decreases in the proportion of females 
accepting a second mating and the number of mink that whelped and the increased severity of cystic 
uterine glands identified in the single-generation mink study was used to derive an intermediate-duration 
oral MRL of 0.001 mg/kg/day, as described in the footnote in Table 3-1. 
3.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to pentachloro­
phenol. 
A number of animal studies have examined the developmental toxicity of pentachlorophenol and provide 
evidence that gestational exposure can result in fetal/neonatal mortality, malformation/variations, 
decreased growth, and possibly functional deficits in rats and sheep.  No developmental effects have been 
observed in rabbits administered up to 30 mg/kg/day 88–89% pure pentachlorophenol by gavage on 
gestational days 6–18 (Argus 1993a/Bernard et al. 2001c).  Significant increases in postimplantation 
resorptions or embryo lethality were observed in rats administered 30 mg/kg/day pure pentachlorophenol 
or 15 mg/kg/day technical-grade (88.4% pure) pentachlorophenol by gavage on gestational days 
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6–15 (Schwetz et al. 1974), in rats administered 80 mg/kg/day 89% pure pentachlorophenol by gavage on 
gestational days 6–15 (Argus 1993b/Bernard et al. 2001b), and in the offspring of rats exposed to 
46 mg/kg/day pure pentachlorophenol in the diet during mating and gestation (Welsh et al. 1987).  A 
decrease in litter size and decreases in neonatal survival were observed in offspring of rats exposed for 
77 days prior to gestation and throughout the gestation and lactation periods to 30 mg/kg/day 90.4% pure 
pentachlorophenol in the diet (Schwetz et al. 1978), in rats exposed to 48 mg/kg/day 85.5% pure 
pentachlorophenol in the diet for 10 weeks prior to mating and throughout gestation and lactation (Exon 
and Koller 1982), and in F1 and F2 rat pups exposed to 60 mg/kg/day pentachlorophenol (purity not 
specified) (Argus 1997/Bernard et al. 2001c). Schwetz et al. (1974) reported marked changes in the sex 
ratio of rats exposed to pentachlorophenol; the majority of surviving rats were males.  The ratios were 
3.6 and 4.9 in the rats administered 50 mg/kg/day technical-grade pentachlorophenol and 30 mg/kg/day 
pure pentachlorophenol, respectively, as compared to respective control values of 1.0 and 1.1.  Other 
developmental toxicity studies have not found alterations in sex ratio (Argus 1993b/Bernard et al. 2001b, 
Argus 1997/Bernard et al. 2001c). 
The occurrence of malformations and variations has been reported in a small number of studies.  Soft 
tissue (subcutaneous edema) and skeletal (lumbar spurs) anomalies were observed in the offsprings of rats 
exposed by gavage $15 mg/kg/day of technical-grade (88.4%) pentachlorophenol (Schwetz et al. 1974) 
and skeletal (variations in vertebral, sternal, and pelvic ossification, increased rib pairs, delays in sternal 
forelimb and hindlimb ossification) and soft tissue (diaphragmatic hernia, slight to moderate dilation of 
the kidneys) malformations and variations have been observed in rat offspring administered 
80 mg/kg/day, but not 30 mg/kg/day, 89% pure pentachlorophenol on gestational days 6–15 (Argus 
1993b/Bernard et al. 2001b). 
Decreases in growth have been reported in a number of developmental toxicity studies.  Statistically 
significant decreases in fetal body weights were observed in the offspring of rats administered pure or 
technical-grade pentachlorophenol by gavage at doses of $30 mg/kg/day (Argus 1993b/Bernard et al. 
2001b; Courtney et al. 1976; Larsen et al. 1975; Schwetz et al. 1974).  Decreases in pup weight have been 
observed in the offspring of rats administered 14 mg/kg/day 99% pure pentachlorophenol in the diet 
(Welsh et al. 1987), rats in a two-generation study administered 10 mg/kg/day pentachlorophenol (purity 
not specified) in the diet (Argus 1997/Bernard et al. 2001c), and in sheep fed 1 mg/kg/day 
pentachlorophenol (purity not reported) in the diet (Beard et al. 1999b). 
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There is some limited evidence that gestational/lactational exposure to pentachlorophenol may impair the 
development of the reproductive system.  Significant increases in the average day of vaginal patency in 
F1 females exposed to 60 mg/kg/day and preputial separation in F1 males exposed to 60 mg/kg/day 
(Argus 1997/Bernard et al. 2001c). Decreased fertility was also observed in the F1 generation. 
Schwetz et al. (1974) examined the differences in the developmental toxicity between pure and technical-
grade pentachlorophenol. The pure pentachlorophenol was slightly more toxic than the technical-grade 
pentachlorophenol in terms of maternal body weight gain, fetal resorptions, fetal body weight, and 
occurrence of fetal anomalies.  The study authors estimated that the maternal dose that would be lethal to 
one half of the embryos was 16 mg/kg/day pure pentachlorophenol versus 44 mg/kg/day for technical-
grade pentachlorophenol. 
In many of the oral developmental toxicity studies, decreases in maternal body weight were observed at 
the same doses as the developmental effects in rats (Argus 1993b/Bernard et al. 2001b; Courtney et al. 
1976; Schwetz et al. 1974). However, in other rat studies (Argus 1997/Bernard et al. 2001c; Welsh et al. 
1987), the LOAEL for maternal toxicity was higher than the LOAEL for developmental effects 
(decreased fetal or pup body weight), suggesting that developmental toxicity can occur in the absence of 
maternal toxicity. 
The highest NOAEL values and all LOAEL values from each reliable study for developmental toxicity in 
each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.7 Cancer 
Lampi et al. (1992) demonstrated significantly elevated risk ratios, compared to reference populations, 
for non-Hodgkin’s lymphoma and soft tissue sarcoma among people who consumed fish from a lake 
contaminated with tri-, tetra-, and penta-chlorophenols and drank water from wells nearby.  For 
non-Hodgkin’s lymphoma, there was a significant association with fish consumption.  The population 
was not exposed to chlorinated dibenzodioxins or dibenzofurans. 
Carcinogenicity of orally administered pentachlorophenol has been tested in at least four studies using 
rats and mice (Inns et al. 1969; NCI 1968; NTP 1989, 1999 [data also reported by Chhabra et al. 1999]; 
Schwetz et al. 1978). The purity of pentachlorophenol in these studies varied; this is an important factor 
to consider because pentachlorophenol, during its production, is usually contaminated with chlorinated 
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dibenzo-p-dioxins, some of which are animal carcinogens. NTP (1989) tested both technical-grade penta­
chlorophenol (TG-Penta), a 90% pure composite mixture of 3 technical-grades of pentachlorophenol, and 
Dowicide EC-7, a mixture containing 90% pure pentachlorophenol and fewer chlorinated dibenzo­
p-dioxin impurities than TG-Penta (see Table 3-2).  NCI (1968) tested Dowicide EC-7 as well. Schwetz 
et al. (1978) tested Dowicide EC-7. NTP (1999) tested pure pentachlorophenol (approximately 99% with 
one impurity, tetrachlorophenol). 
NCI administered Dowicide EC-7 (0 or 17 mg/kg/day) in the diet of weanling B6C3F1 mice for 78 weeks 
(NCI 1968), while NTP (1989) administered Dowicide EC-7 (0, 18, 37, or 118 mg/kg/day) in the diet of 
B6C3F1 mice for 103 weeks.  No significant elevation in incidence of cancer occurred in the NCI study; 
however, in the NTP study, significant increases in incidence of tumors were observed.  Male mice 
displayed significant dose-related increases in the incidence of adrenal medulla pheochromocytomas 
(benign and malignant) and hepatocellular adenomas and carcinomas.  Female mice in the high-dose 
group displayed significant increases in incidences of hepatocellular adenoma and carcinoma, in 
pheochromocytomas (benign and malignant), and in hemangiosarcomas (spleen and liver).  The 
differences between the two studies were that NCI tested for a shorter period of time, used fewer animals 
per group, had higher mortality in the dose group leaving fewer animals to be at risk of developing 
tumors, and used only one dose that was one-sixth of the highest dose used in the NTP study, and, 
therefore, was probably not the maximum tolerated dose. 
NTP (1989) also tested TG-Penta, a composite mixture of three technical-grades of pentachlorophenol. 
This mixture contained a higher percentage of chlorinated dibenzo-p-dioxin contaminants than did the 
Dowicide EC-7 mixture (see Table 3-2).  Groups of male and female B6C3F1 mice were given diets that 
contained 0, 100, or 200 ppm TG-Penta (equivalent to 0, 18, or 35 mg/kg/day, respectively) or Dowicide 
EC-7 (as described above for 103 weeks). Survival was reduced in all groups, including controls, when 
compared to historical controls.  Male mice displayed a significant increase over the male control 
incidence in tumors of the adrenal medulla (benign and malignant pheochromocytomas combined) and 
liver (adenomas and carcinomas combined).  Treated female mice displayed a significant increase over 
female controls with regard to incidence of hemangiosarcomas of the spleen and liver.  Chlorinated 
dibenzo-p-dioxins were found in the TG-Penta mixture at a concentration of 0.17%, but the mixture 
contained no 2,3,7,8-TCDD. Chlorinated dibenzo-p-dioxin exposure has been associated with an 
increased incidence of liver tumors in treated mice but not with pheochromocytomas or hemangio­
sarcomas (NCI/NTP 1980).  Although this study is limited because of unusually low survival in the male 
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TG-Penta control group, the occurrence of rare hemangiosarcomas was considered a carcinogenic 
response due to pentachlorophenol exposure. 
In the NTP (1999) study, groups of male and female F344 rats were given diets that contained 0, 200, 
400, or 600 ppm pentachlorophenol (approximately 99% pure with one impurity, tetrachlorophenol) in 
the diet (equivalent to doses of 0, 10, 20, or 30 mg/kg/day) for 105 weeks.  A stop-exposure group was 
given a diet that contained 1,000 ppm pentachlorophenol for 52 weeks (equivalent to a dose of 
60 mg/kg/day) followed by a control diet through 105 weeks.  At 2 years, a significantly increased 
incidence of malignant mesothelioma originating from the tunica vaginalis was present in 60 mg/kg/day 
stop exposure group males compared with controls, and the incidence exceeded the historical control 
range. Nasal squamous cell carcinomas were present in one control male, three 10 mg/kg/day males, one 
20 mg/kg/day male, and five 60 mg/kg/day males at 2 years, and the incidence in 1,000-ppm males 
exceeded the historical control range. 
In an earlier study, Dowicide EC-7 was administered to rats at dietary levels of 0, 1, 3, 10, or 
30 mg/kg/day in males and females for 22 months and 24 months, respectively (Schwetz et al. 1978).  No 
significant increases in incidence of tumors were observed during this study.  The study was limited, 
however because a small number of animals was tested, no data on survival were provided to evaluate if 
enough animals survived for a long enough period of time to develop tumors, and it is not known if the 
maximum tolerated dose was attained. 
The NTP (1999) study in F344 rats showed some evidence that purified pentachlorophenol 
(approximately 99% with one impurity, tetrachlorophenol) is carcinogenic, producing mesotheliomas and 
nasal squamous cell carcinomas.  The most convincing evidence that 90% pure pentachlorophenol is 
carcinogenic to mice following ingestion comes from the NTP (1989) bioassay.  This study was generally 
well conducted, taking into account the lifetime of the study animal, that gross necropsy and 
histopathology were completed on all suitable animals, and that percentages of the maximum tolerated 
dose were administered to determine carcinogenic response.  It is limited because the unusually low 
survival of males in the TG-Penta control group left fewer control animals at long-term risk of developing 
tumors. 
EPA has classified pentachlorophenol as a Group B2 substance (probable human carcinogen) (IRIS 
2001). A cancer potency factor of 0.12 (mg/kg/day)-1 was calculated by IRIS (2001) based on the NTP 
(1989) data. This cancer potency factor translates to estimated upper-bound unit risk levels of 9x10-3, 
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9x10-4, 9x10-5, 9x10-6, and 9x10-7 mg/kg/day for cancer risks of 1 in 1,000, 1 in 10,000, 1 in 100,000, 1 in 
1 million and 1 in 10 million respectively (see Figure 3-1).  
The CELs for pentachlorophenol are recorded in Table 3-1 and plotted in Figure 3-1, and the estimated 
upper-bound human cancer risk levels are plotted in Figure 3-1. 
3.2.3 Dermal Exposure 
Data on the toxicity of pentachlorophenol in humans exposed via dermal contact come from a number of 
case reports and studies in individuals applying wood preservative products containing  pentachloro­
phenol, using pesticides containing sodium pentachlorophenate, or children exposed to pentachlorophenol 
used in the laundering of diapers and bedding. The primary route of exposure is believed to be dermal 
contact, although inhalation exposure also occurred.  Studies in which inhalation exposure was the 
primary route and dermal contact the secondary route are discussed in Section 3.2.1 Inhalation Exposure. 
No studies considered suitable for presentation in a table describing significant levels of dermal exposure 
to pentachlorophenol were found. 
3.2.3.1 Death 
In most instances, death in humans exposed to pentachlorophenol was a result of occupational exposure 
or use of pentachlorophenol-containing products in the home by individuals who did not employ proper 
precautionary measures.  All of these reports are limited in that the possibility of concurrent exposure to 
other potentially toxic substances in technical-grade pentachlorophenol and concurrent exposure to other 
toxic substances (e.g., lindane, dieldrin) cannot be excluded, and because the pentachlorophenol exposure 
level and duration cannot be quantified because appropriate measurements were not taken at the time. 
Deaths were also seen in human infants exposed to pentachlorophenol used in the laundering of diapers 
and bedding. Though the primary route of exposure in all of these studies was believed to be dermal, the 
probability that inhalation exposure also occurred must be considered.  It should be noted that 
occupational exposure to pentachlorophenol has been strictly limited not only by use patterns but by 
application procedures, and all household uses of pentachlorophenol have been banned.  Therefore, 
exposure to pentachlorophenol resulting in death as described in this section is currently improbable, with 
the exception of hazardous waste workers involved in the clean up of pentachlorophenol-containing 
ponds or soils. It should also be noted that the deaths discussed below resulted from the use of 
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formulations that likely had a different composition (e.g., presence of more impurities) than the penta­
chlorophenol that is currently used. 
In a case report, nine infants in a small nursery for newborns exhibited an illness characterized by high 
fever, profuse sweating, increased respiratory rate, labored breathing, tachycardia, hepatomegaly, 
irritability followed by lethargy, metabolic acidosis, proteinuria, increased blood urea nitrogen, and 
pneumonia or bronchiolitis (Smith et al. 1996).  Two of the infants died.  At autopsy, both infants showed 
fatty metamorphosis of the liver and one showed fatty vacuolar changes in the renal tubules.  The 
remaining infants recovered after exchange transfusions and transfer to another hospital.  The clinical 
findings and deaths were attributed to the use of pentachlorophenol in a mixture of synthetic phenolic 
derivatives in the hospital laundry as an antimildew agent.  Pentachlorophenol was found in freshly 
laundered diapers and in the serum and urine of the infants. 
Five cases of fatal blood dyscrasias were reported.  Reports followed exposures to technical-grade penta­
chlorophenol or pentachlorophenol of undefined purity for 1-month to 4-year periods—three as a result of 
industrial exposure and two from home use (Roberts 1963, 1981, 1990).  The cause of death in all cases 
was reported to be either aplastic anemia or red blood cell aplasia.  Clinical signs, chemistries, and 
postmortem findings revealed functional and degenerative changes in most organ systems.  Deaths 
attributed to pentachlorophenol were also reported in a male working as a wood preserver for 1 week 
(Bergner et al. 1965), 5 herbicide sprayers exposed once (Gordon 1956), and nine sawmill workers 
exposed for 3–30 days (Menon 1958).  Deaths reported by Gray et al. (1985), Bergner et al. (1965), and 
Menon (1958) were all due to hyperthermia that resulted from uncoupling of oxidative phosphorylation 
by pentachlorophenol.  Manifestations of overexposure were chiefly those associated with hyperthermia: 
flushing, intense thirst, sweating, weakness, and occasionally, muscle spasms.  Toxic effects seen in these 
fatalities will be discussed in sections dealing with specific organ toxicity.  Hyperthermia is the major 
factor leading to death following fatal pentachlorophenol exposure in humans. 
One report of death following dermal exposure in experimental animals was found in the reviewed 
literature (Deichmann et al. 1942).  Eight out of 20 rabbits administered dermal applications of 4% penta­
chlorophenol (purity not indicated) in fuel oil for 6–61 weeks died of unspecified causes.  The vehicle 
contained known toxic substances (e.g., polyaromatic hydrocarbons), which may have contributed to the 
lethal effects observed. 
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3.2.3.2 Systemic Effects 
Most of the literature reviewed concerning systemic effects of dermal exposure to pentachlorophenol in 
humans described case reports of individuals exposed either occupationally or in the home during misuse 
of pentachlorophenol-containing solutions as a result of failure to adhere to appropriate precautionary 
measures.  The predominant route of exposure in such cases is dermal, but the possibility of some 
inhalation exposure cannot be ruled out.  All of these reports are limited because the possibility of 
concurrent exposure to other potentially toxic substances in technical-grades of pentachlorophenol cannot 
be excluded, and because the pentachlorophenol exposure level and duration were not quantified.  Some 
of the effects observed may be secondary to hyperthermia generated by uncoupling of oxidative 
phosphorylation (see Section 2.5).  
No studies were located regarding cardiovascular, musculoskeletal, endocrine, or ocular effects in humans 
or respiratory, cardiovascular, gastrointestinal, musculoskeletal, hepatic, renal, endocrine, or ocular 
effects in animals after dermal exposure to pentachlorophenol. 
Respiratory Effects. In a case report, nine infants in a small nursery for newborns exhibited 
increased respiratory rate and labored breathing from exposure to pentachlorophenol in a mixture of 
synthetic phenolic derivatives in diapers and linens from the hospital laundry (Smith et al. 1996).  It is 
likely that these effects are secondary to hyperthermia rather than a direct effect on the respiratory tract. 
Gastrointestinal Effects. Except for anecdotal reports of abdominal pain, nausea, and vomiting in 
humans occupationally exposed to pentachlorophenol of undefined purity (Gordon 1956; Menon 1958), 
no studies were located regarding gastrointestinal effects in humans or animals following dermal 
exposure to pentachlorophenol. 
Hematological Effects. Incidents of fatal hematological disorders were found in case reports 
following exposure (level and duration not specified) to technical-grade pentachlorophenol or penta­
chlorophenol of undefined purity as a result of predominantly dermal exposure.  Thirteen cases of aplastic 
anemia, pure red blood cell aplasia, or severe pancytopenia with abnormal marrow have been reported in 
individuals using pentachlorophenol-containing wood preservative products, eight of which resulted in 
death (Roberts 1981, 1990). Aplastic anemia was also diagnosed in an individual using pentachloro­
phenol in the renovation of an old home (Rugman and Cosstick 1990).  A case of intravascular hemolysis 
was attributed to use of a insecticide containing pentachlorophenol (Hassan et al. 1985). 
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Hepatic Effects. Most of the studies reviewed concerning hepatic effects of dermal exposure to 
pentachlorophenol in humans described case reports of individuals exposed either occupationally or in the 
home following the use of pentachlorophenol-containing solutions by individuals who did not employ 
appropriate precautionary measures.  Information regarding pentachlorophenol-induced hepatic toxicity 
in humans following dermal exposure, discussed below, is subject to some doubt regarding the extent to 
which the adverse effects seen can be attributed to pure pentachlorophenol.  Hepatic enlargement has 
been observed in herbicide sprayers (Gordon 1956), and in neonates exposed for a short time via 
contaminated diapers and bed linen in a hospital nursery (Armstrong et al. 1969; Robson et al. 1969; 
Smith et al. 1996).  Autopsy findings in those affected individuals who died revealed fatty infiltration of 
the liver (in the neonates) and severe centrilobular congestion with hepatocellular fat accumulation (in the 
chemical worker).  Centrilobular degeneration was also observed in a liver specimen from a worker who 
dipped wood in a preservative that contained 4.1% pentachlorophenol every day for 1 week (Bergner et 
al. 1965). In an epidemiologic study of male factory workers who brushed technical-grade pentachloro­
phenol onto wood strips, sometimes without gloves, serum biliary acid concentrations were elevated in 
the high-exposure group, but not the low-exposure group, compared with controls.  Exposure was 
assessed by measurement of pentachlorophenol concentrations in plasma and urine (Colosio et al. 1993b). 
The presence of elevated concentrations of bile acids in serum is a sensitive indicator of liver dysfunction 
(Franco et al. 1986). Evidence of liver damage was seen in an epidemiologic study of adult males 
occupationally exposed to pentachlorophenol in wood-treatment plants or as farmers or pest control 
operators in Hawaii (Klemmer 1972).  This evidence consisted of elevated levels of serum alanine 
aminotransferase (ALT) and asparate aminotransferase (AST) following chronic, predominantly dermal 
exposure to technical-grade pentachlorophenol or pentachlorophenol of undefined purity.  Hyperthermia 
induced by pentachlorophenol may be a major factor leading to liver injury. 
Renal Effects. Four reports were found that described renal toxic effects following dermal exposure 
to pentachlorophenol in humans.  All involved either occupational exposure or accidental poisoning with 
the predominant route of exposure being dermal, but the possibility of inhalation exposure cannot be 
excluded. In one instance, a 3-year-old girl was exposed to pentachlorophenol of undefined composition 
via a pesticide-contaminated domestic water supply.  Transient disruption of acid-base equilibrium and 
metabolic balance as evidenced by acidosis, aminoaciduria, and ketonuria suggested the occurrence of 
renal dysfunction in this child (Chapman and Robson 1965).  In a case study of nine infants, metabolic 
acidosis, proteinuria, and increased blood urea nitrogen were found following exposure of the infants to 
pentachlorophenol of undefined composition in diapers and bedding at a hospital that used pentachloro­
phenol in the hospital laundry as an antimildew agent.  Fatty vacuolar changes in the renal tubules were 
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noted in one of the two infants that died (Smith et al. 1996).  An autopsy conducted on a worker who 
dipped wood in a preservative that contained 4.1% pentachlorophenol every day for 1 week revealed mild 
renal tubular degeneration (Bergner et al. 1965).  Finally, evidence for pentachlorophenol-induced 
impaired glomerular filtration and tubular function was reported in 18 workers employed at a wood-
treatment facility (Begley et al. 1977).  These findings consisted of depressed creatinine clearance and 
phosphorus reabsorption. Considerable improvement in these symptoms was seen following a 20-day 
absence from work.  These data suggest that the renal toxicant effects of technical-grade pentachloro­
phenol are reversible. The extent to which contaminants of technical-grade pentachlorophenol are 
responsible for the effects discussed above is not known.  Hyperthermia may also be a mechanism of 
renal injury in individuals that are acutely overexposed to pentachlorophenol. 
Dermal Effects. Transient localized redness and pain subsequent to immersion of the hands in a 0.4% 
pentachlorophenol solution for 10 minutes were exhibited by an adult male (Bevenue et al. 1967).  Two 
cases of pemphigus vulgaris and one of chronic urticaria (both examples of severe skin lesions) attributed 
to nonoccupational chronic pentachlorophenol exposure (i.e., via contact with wood treated with penta­
chlorophenol) have been described (Lambert et al. 1986).  The dermal effects discussed above may have 
resulted from impurities present in the pentachlorophenol resulting from the manufacturing process. 
Pentachlorophenol-induced toxic effects on the skin of experimental animals have also been reported.  A 
single application of pentachlorophenol of unspecified purity (1,111 mg/kg in 95% ethyl alcohol or 
150 mg/kg in pale paraffin oil) resulted in gross changes such as pronounced edema and inflammation 
leading to wrinkling, cracking, desquamation, and hair loss.  Microscopic changes observed include 
widespread foci of atrophy and necrosis, thinning and disappearance of upper skin layers, and 
hyperkeratinization and hypertrophy of hair follicles (Deichmann et al. 1942).  Single dermal applications 
of 250 mg/kg of a 10% aqueous solution of sodium pentachlorophenate of unspecified purity to rabbits 
did not result in dermal irritation.  Repeated application of lower doses of pentachlorophenol (40 mg/kg in 
mineral oil) to rabbits for 21 days induced no irritation, whereas daily application of 10–50 mg/kg of a 
4% solution of pentachlorophenol in fuel oil for 6–61 weeks resulted in pronounced dermal effects, and 
daily application of 63 mg/kg of an aqueous sodium pentachlorophenate solution for 32 days was without 
effect (Deichmann et al. 1942).  No evidence of histologic changes in the epidermis or pilosebaceous unit 
were noted after application of 0.036 mg of sodium pentachlorophenate of unspecified purity to a 
9 cm2 area of the dorsal skin of hairless dogs once daily for 7 days.  The toxic effects of dermal exposure 
to pentachlorophenol appear to be most severe following high-dose, acute exposure to pentachlorophenol 
in fuel oil. 
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Acne was observed in rabbits following application of technical-grade pentachlorophenol to the ear, but 
was not observed following application of pure pentachlorophenol (Johnson et al. 1973), suggesting that 
the effects were due to contaminants rather than the pentachlorophenol. 
3.2.3.3 Immunological and Lymphoreticular Effects 
Two cases of pemphigus vulgaris and one of chronic urticaria (skin diseases with an immunologic 
etiology) have been attributed to nonoccupational exposure to pentachlorophenol (Lambert et al. 1986). 
Alterations in immune function were reported in patients who had been exposed for more than 6 months 
to pentachlorophenol-containing pesticides (composition not defined) (Daniel et al. 1995) and workers 
who brushed technical-grade pentachlorophenol onto wood strips (Colosio et al. 1993b).  
No studies were located regarding immunological effects in animals following dermal exposure to penta­
chlorophenol. 
3.2.3.4 Neurological Effects 
Numerous signs of central nervous system toxicity have been reported in case reports of individuals 
exposed to high levels of pentachlorophenol via dermal contact and inhalation exposure.  The observed 
effects include intermittent delirium and convulsions (Chapman and Robson 1965) and irritability 
(Robson et al. 1969; Smith et al. 1996).  It is likely that these are effects secondary to hyperthermia due to 
pentachlorophenol-induced uncoupling of oxidative phosphorylation. 
No studies were located regarding neurological effects in animals following dermal exposure to penta­
chlorophenol. 
3.2.3.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans and animals following dermal exposure 
to pentachlorophenol. 
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3.2.3.6 Developmental Effects 
No studies were located regarding developmental effects in humans and animals following dermal 
exposure to pentachlorophenol. 
3.2.3.7 Cancer 
Epidemiological studies and case reports described in Section 3.2.1.7 (in which dermal exposure was also 
likely) provide evidence that exposure to pentachlorophenol may be associated with soft tissue sarcomas 
and non-Hodgkin’s lymphoma in humans. 
Only one study was located in which investigators topically administered pentachlorophenol to animals 
(Boutwell and Bosch 1959). These investigators applied a 20% solution of commercial grade penta­
chlorophenol in benzene to shaved dorsal skin of mice twice a week for 13 weeks.  Mice were previously 
treated with a dose of 0.3% dimethylbenzanthracene (DMBA) in benzene to induce skin cancer.  No 
increase in DMBA-induced skin tumors resulted from pentachlorophenol treatment.  This study was 
designed to determine if pentachlorophenol was a tumor promoter and was therefore severely limited in 
its ability to detect a carcinogenic effect caused by pentachlorophenol because of administration of an 
insufficient dose over a short treatment period.  However, based on results of this study, pentachloro­
phenol was inactive as a promotor of skin tumors in mice. 
3.2.4 Other Routes of Exposure 
Endocrine Effects. Studies in animals have shown that acute (single-dose, intraperitoneal injection) 
pentachlorophenol administration causes a marked, statistically significant decrease in serum total 
thyroxine levels in rats (van Raaij et al. 1991a).  This decrease peaked 6–24 hours after administration, 
and thyroxine levels slowly returned to control values within 96 hours after administration.  Further in 
vitro studies by these investigators revealed that the likely mechanism of action for this anti-thyroid effect 
was competition for serum protein thyroxine binding sites (van Raaij et al. 1991b).  
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3.3 GENOTOXIC EFFECTS 
Numerous in vivo and in vitro studies have assessed the genotoxic potential of pentachlorophenol, and the 
results of these studies are presented in Tables 3-3 and 3-4, respectively.  Three studies examined the 
clastogenic activity of pentachlorophenol in workers primarily exposed via inhalation.  A marginal 
increase in chromosomal aberrations was found in the lymphocytes of workers exposed to pentachloro­
phenol or its sodium salt (Bauchinger et al. 1982).  In contrast, studies by Wyllie et al. (1982) and 
Ziemson et al. (1987) did not find significant increases in the occurrence of chromosomal aberrations in 
their studies of workers. The occurrence of sister chromatid exchange was not increased in the 
lymphocytes of workers (Bauchinger et al. 1982; Ziemson et al. 1987).  No other human in vivo 
genotoxicity studies were located.  An increase in DNA adduct formation was observed in the liver of 
mice orally exposed to pentachlorophenol (Sai-Kato et al. 1995; Umemura et al. 1996), but not in the 
kidney or spleen (Sai-Kato et al. 1995), and positive results were seen in a coat color spot test in mouse 
embryos treated transplacentally with pentachlorophenol (Fahrig et al. 1978).  In other in vivo assays, no 
evidence of genotoxicity was observed; the assays included sex-linked recessive lethal mutations in 
Drosophila melanogaster (Fahrig 1974; Fahrig et al. 1978; Vogel and Chandler 1974), micronuclei 
formation in rats and mice (NTP 1999), and gene mutations and recombination in a mouse spot test 
(Fahrig and Steinkamp-Zucht 1996). 
No alterations in the occurrence of gene mutations (Andersen et al. 1972; Donnelly et al. 1998;Lemma 
and Ames 1975; Markiewicz et al. 1996; Moriya et al. 1983; NTP 1999; Simmon et al. 1977; Waters et al. 
1982) or DNA damage (Fahrig 1974; Waters et al. 1982) were observed in bacterial systems, with the 
exception of one study that reported positive activity in the rec assay using Bacillus subtilis (Waters et al. 
1982). In yeast, pentachlorophenol induced gene mutations (Fahrig 1974; Fahrig et al. 1978) and genetic 
recombination (Fahrig et al. 1978; Waters et al. 1982).  Weak clastogenic activity was observed in 
chromosomal aberration assays in human lymphocyte (Fahrig 1974) and in chromosomal aberration and 
sister chromatid exchange assays in Chinese hamster ovary cells (NTP 1999).  No significant increases in 
the occurrence of DNA damage (adduct formation or single-strand breaks) were seen in mammalian cells 
(Dalhaus et al. 1996; Ehrlich 1990; Wang and Lin 1995).  
A few studies were found regarding the genotoxic potential of pentachlorophenol metabolites. 
Tetrachloro-p-hydroquinone (TCHQ), (isomer not specified) but not tetrachlorocatechol, induced a dose-
related and significant mutagenic response in Chinese hamster V-79 cells in the absence of exogenous 
metabolic activation (Jansson and Jansson 1991).  The para isomer of TCHQ, but not the ortho isomer, 
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Table 3-3. Genotoxicity of Pentachlorophenol In Vivo 
Species (test system) End point	 Results Reference 
Drosophila melanogaster 
spermatocytes 
Human lymphocytes 
(occupational exposure) 
Human lymphocytes 
(occupational exposure) 
Human lymphocytes 
(occupational exposure) 
Human lymphocytes 
(occupational exposure) 
Human lymphocytes 
(occupational exposure) 
B6C3F1 mouse 
(oral exposure) 
Mouse bone marrow 
(intraperitoneal exposure) 
Rat bone marrow 
(intraperitoneal exposure) 
Mouse embryonic cells 
(transplacental exposure) 
Mouse/spot test 
Mouse/spot test 
Sex-linked recessive lethal mutation 
Chromosomal aberrations 
Chromosomal aberrations 
Chromosomal aberrations 
Sister chromatid exchange 
Sister chromatid exchange 
DNA adduct formation
Micronuclei 
Micronuclei 
Gene mutation 
Gene mutation 
Recombination 
–	 Fahrig 1974; Fahrig et al. 1978; Vogel and
 
Chandler 1974
 
(+) Bauchinger et al. 1982
 
–	 Wyllie et al. 1982
 
–	 Ziemsen et al. 1987
 
–	 Bauchinger et al. 1982
 
–	 Ziemsen et al. 1987
 
+	 Sai-Kato et al. 1995; Umemura et al. 1996
 
–	 NTP 1999
 
– NTP 1999
 
(+) Fahrig et al. 1978
 
–	 Fahrig and Steinkamp-Zucht 1996
 
–	 Fahrig and Steinkamp-Zucht 1996

 – = negative results; + = positive results; (+) = weakly positive results 
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Table 3-4. Genotoxicity of Pentachlorophenol and its Metabolites In Vitro 
Results 
Species (test system) End point 
With 
activation 
Without 
activation Reference 
Pentachlorophenol 
Prokaryotic organisms: 
Salmonella typhimurium Gene mutation –  – Donnelly et al. 1998; Markiewicz et al. 1996; 
Moriya et al. 1983; NTP 1999; Simmon et al. 
1977; Waters et al. 1982 
S. typhimurium /spot test Gene mutation NT  – Andersen et al. 1972; Lemma and Ames 1975 
S. typhimurium
(mouse host-mediated assay) 
Gene mutation –  NT Buselmaier et al. 1973 
Invertebrate animal cells: Moriya et al. 1983; Simmon et al. 1977; 
Waters et al. 1982 
E. coli /spot test 
Serratia marcescens /spot test 
Bacillus subtilis /rec- assay 
E. coli pol A 
Eukaryotic organisms: 
Fungi: 
Saccharomyces cerevisiae MP-1 
S. cerevisiae aAeZ 
S. cerevisiae MP-1/intergenic 
recombination 
Gene mutation 
DNA damage 
DNA damage 
DNA damage 
Gene mutation 
Recombination 
Recombination 
NT
NT
NT
NT
NT
NT
NT
 – 
– 
+ 
– 
+ 
+ 
– 
Waters et al. 1982 
Fahrig 1974 
Waters et al. 1982 
Waters et al. 1982 
Fahrig et al. 1978 
Fahrig 1974 
Fahrig et al. 1978 
S. cerevisiae MP-1/intergenic 
recombination 
Recombination NT  + Fahrig et al. 1978 
S. cerevisiae Recombination +  + Waters et al. 1982 
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Table 3-4. Genotoxicity of Pentachlorophenol and its Metabolites In Vitro (continued) 
Results 
With Without 
Species (test system) End point activation activation Reference 
Mammalian cells: 
Human lymphocytes Chromosomal 
aberrations 
NT (+) Fahrig 1974 
Chinese hamster ovary cells Chromosomal 
aberrations 
(+)  – NTP 1999 
Chinese hamster ovary cells DNA damage NT  – Ehrlich 1990 
Chinese hamster ovary cells Sister chromatid 
exchange 
– (+) NTP 1999 
Chinese hamster V79 cells DNA damage 
(8-OH-dG adduct) 
NT  – Dahlhaus et al. 1996 
Chinese hamster V79 cells DNA damage 
(single-strand breaks) 
NT  – Dahlhaus et al. 1996 
Mouse embryonic fibroblast cells DNA damage 
(single-strand breaks) 
(+)  – Wang and Lin 1995 
Tetrachloro-o-benzoquinone 
Mammalian cells: 
Chinese hamster V79 cells DNA damage 
(8-OH-dG adduct) 
NT  + Dahlhaus et al. 1996 
Chinese hamster V79 cells DNA damage 
(single-strand breaks) 
NT  – Dahlhaus et al. 1996 
Tetrachloro-p-benzoquinone 
Mammalian cells: 
Chinese hamster V79 cells DNA damage 
(8-OH-dG adduct) 
NT  + Dahlhaus et al. 1996 
Chinese hamster V79 cells DNA damage 
(single-strand breaks) 
NT  + Dahlhaus et al. 1996 
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Table 3-4. Genotoxicity of Pentachlorophenol and its Metabolites In Vitro (continued) 
Results 
Species (test system) End point 
With 
activation 
Without 
activation Reference 
Tetrachloro-o-hydroquinone 
Mammalian cells: 
Chinese hamster V79 cells 
Chinese hamster V79 cells 
Tetrachloro-p-hydroquinone 
Mammalian cells: 
DNA damage 
(8-OH-dG adduct) 
DNA damage 
(single-strand breaks) 
NT 
NT 
– 
– 
Dahlhaus et al. 1996 
Dahlhaus et al. 1996 
Chinese hamster ovary cells 
Chinese hamster V79 cells 
Chinese hamster V79 cells 
Tetrachlorohydroquinone 
Mammalian cells: 
DNA damage 
DNA damage 
(8-OH-dG adduct) 
DNA damage 
(single-strand breaks) 
NT 
NT 
NT 
+ 
+ 
+ 
Ehrlich 1990 
Dahlhaus et al. 1996 
Dahlhaus et al. 1996 
Chinese hamster V79 cells Gene mutation NT + Jansson and Jansson 1991 
– = negative result; + = positive result; (+) = weakly positive result; DNA = deoxyribonucleic acid; 8-OH-dG = 8-hydroxydeoxyguanosine; NT = not tested 
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induced DNA damage in Chinese hamster V79 cells as evidenced by DNA single-strand breaks and an 
increase in the amount of 8-hydroxydeoxyguanosine in DNA (Dahlhaus et al. 1996).  In the same study, 
the para isomer of tetrachlorobenzoquinone produced DNA single-strand breaks and an increase in the 
amount of 8-hydroxydeoxyguanosine in DNA, whereas the ortho isomer of this compound produced an 
increase in the amount of 8-hydroxydeoxyguanosine in DNA but did not produce DNA single-strand 
breaks (Dahlhaus et al. 1996). TCHQ was also found to exert a severe cytotoxic effect and cause marked 
DNA damage (i.e., single-strand breaks and/or alkali-labile sites) in Chinese hamster ovary cells; the 
parent compound was weakly cytotoxic but not genotoxic at comparable levels (Ehrlich 1990). 
3.4 TOXICOKINETICS 
Pentachlorophenol is efficiently absorbed following inhalation, oral, and dermal exposure.  Absorbed 
pentachlorophenol is distributed to the liver, lungs, kidneys, blood, fat tissues, and brain.  The binding of 
pentachlorophenol to plasma proteins plays a significant role in the distribution of pentachlorophenol 
(Braun et al. 1977; Gómez-Catalán et al. 1991).  Results from animal and human studies indicate that 
pentachlorophenol is not completely metabolized, as evidenced by a large portion of the administered 
dose being excreted in urine unchanged in all species studied.  Pentachlorophenol binds extensively to 
plasma proteins as discussed in Section 3.4.2.2.  Pentachlorophenol has a greater binding affinity for 
thyretin, a major thyroxine transport protein in the rat, than thyroxine itself (den Besten et al. 1991), and 
the binding of pentachlorophenol to thyretin is likely responsible for its adverse effect on thyroid 
homeostasis.  The available human and animal data indicate that metabolism of pentachlorophenol does 
occur in the liver, and the major pathways are conjugation to form the glucuronide and oxidative 
dechlorination to form tetrachlorohydroquinone (TCHQ).  However, recent studies in rats and mice 
following oral administration of pentachlorophenol (Lin et al. 1997; Waidyanatha et al. 1994, 1996) 
suggest that the metabolism of pentachlorophenol can also proceed through the quinols TCHQ and 
Cl4CAT via microsomal cytochrome P 450 enzymes and that these quinols can be oxidized via 
semiquinone intermediates (tetrachloro-1,2-semiquinone [Cl4-1,2-SQ] and tetrachloro-1,4-semiquinone 
[Cl4-1,4-SQ]) into the corresponding quinones (tetrachloro-1,2-benzoquinone [Cl4-1,2-BQ] and 
tetrachloro-1,4-benzoquinone [Cl4-1,4-BQ]).  Both the quinones and semiquinones are electrophilic and 
can bind to cellular macromolecules (Lin et al. 1997).  Horseradish peroxidase catalyzed the oxidation of 
pentachlorophenol to Cl4BQ in vitro via a phenoxyl radical intermediate (Samokyszyn et al. 1995).  The 
study authors suggest that this is a potential in vivo metabolic step that could be catalyzed by mammalian 
peroxidases, including prostaglandin H synthase, myeloperoxidase, salivary peroxidase, lactoperoxidase, 
or uterine peroxidase. 
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The primary route of pentachlorophenol elimination in all species studied, including humans, by all routes 
of exposure, is urine. Approximately 74 and 12% (total of 86%) of pentachlorophenol ingested by 
humans was eliminated as pentachlorophenol and its glucuronide conjugate, respectively (Braun et al. 
1979). In rodents, from 60– 83% of the administered oral dose is eliminated in the urine (Ahlborg et 
al. 1974; Braun et al. 1977; Larsen et al. 1972; Reigner et al. 1991); in monkeys, 45–75% of the 
administered oral dose is eliminated in the urine (Braun and Sauerhoff 1976) (see Section 3.4.4.2 for a 
discussion of the metabolites of pentachlorophenol excreted in each species).  Fecal elimination of penta­
chlorophenol and its metabolites accounted for 4% of the administered oral dose in humans, 4–34% of the 
administered oral dose in rodents, and 4–17% in monkeys.  Only trace amounts were eliminated in 
expired air. The pharmacokinetic profile of pentachlorophenol excretion following single doses is 
species- and possibly sex-dependent.  Elimination was rapid and biphasic in rats (Braun et al. 1977; 
Reigner et al. 1991) and slow and first-order in monkeys and humans following oral exposure (Braun and 
Sauerhoff 1976; Braun et al. 1979). Enterohepatic circulation and plasma protein binding influence the 
elimination kinetics of pentachlorophenol, but no data are available to assess whether the elimination 
kinetics of pentachlorophenol are dependent on its concentration in blood. 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
There are limited data on the absorption of inhaled pentachlorophenol in humans.  In an attempt to 
measure inhalation absorption of pentachlorophenol in humans, 2 volunteers were exposed to penta­
chlorophenol in an enclosed area for 45 minutes while they applied pentachlorophenol to wood with a 
brush (Casarett et al. 1969). Ambient pentachlorophenol concentrations in air were 0.230 and 
0.432 ng/m3. The extent of pentachlorophenol absorption in these 2 subjects was calculated to be 88 and 
76% of the total potential inhaled dose, based on measurements of respiratory rates during exposure, total 
urinary pentachlorophenol recovered for up to 1 week postexposure, and tidal volume estimates.  These 
data indicate that pentachlorophenol is readily absorbed through the lungs of humans.  These data are 
supported by the finding of increased plasma and urine pentachlorophenol levels in exposed workers 
(Casarett et al. 1969; Jones et al. 1986; Pekari et al. 1991) and in residents of log homes treated with 
pentachlorophenol (Cline et al. 1989; Hosenfeld et al. 1986). 
Pulmonary absorption of pentachlorophenol in rats has been demonstrated to occur readily; 70–75% of 
radioactivity from a single 20-minute inhalation exposure (at a concentration calculated by the authors to 
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be equivalent to 5.7 mg [14C]-pentachlorophenol/kg) was recovered in urine, plasma, liver, and lung by 
24 hours postexposure (Hoben et al. 1976c). 
3.4.1.2 Oral Exposure 
Results of studies in humans (Braun et al. 1979; Uhl et al. 1986) and animals (Ahlborg et al. 1974; Braun 
and Sauerhoff 1976; Braun et al. 1977; Meerman et al. 1983; Reigner et al. 1991) indicate that penta­
chlorophenol and its sodium salt are readily absorbed following oral administration.  Oral absorption of 
pentachlorophenol (as the sodium salt in water) in humans was determined to be first order, with peak 
blood levels of 0.248 µg/mL pentachlorophenol being achieved within 4 hours of ingestion of 0.1 mg 
sodium pentachlorophenate/kg by four healthy male volunteers (Braun et al. 1979).  The average half-life 
of absorption was calculated to be approximately 1.3 hours, indicating that oral absorption of penta­
chlorophenol in humans is rapid. 
Oral absorption of pentachlorophenol by rats and monkeys was compared following administration of 
single oral doses in corn oil of 10 mg [14C]-pentachlorophenol/kg (monkeys) (Braun and Sauerhoff 1976) 
and 10 or 100 mg [14C]-pentachlorophenol/kg (rats) (Braun et al. 1977).  In both species, absorption 
through the gastrointestinal tract was rapid; females in both species exhibited faster absorption than males 
as evidenced by different rate constants of absorption.  These rate constants were 1.95 hour-1 and 
1.52 hour-1 for male and female rats, respectively, and 0.215 hour-1 and 0.383 hour-1 for male and female 
monkeys, respectively.  The half-lives of absorption were 3.64 and 1.81 hours, for male and female 
monkeys, respectively.  Peak blood levels of approximately 60 µg pentachlorophenol/g plasma were 
achieved in both sexes of rat within 4–6 hours, and peak plasma levels of 10–30 µg pentachlorophenol/g 
plasma were reached by 12–24 hours in both sexes of monkey.  Absorption of pentachlorophenol through 
the gastrointestinal tract was extensive in both species following administration of a single dose of 
[14C]-pentachlorophenol as evidenced by more than 90% recovery of radioactivity in urine, feces, expired 
air, tissues, and carcass. 
Similar results were obtained in another study in rats using a lower dose (2.5 mg/kg) of pentachloro­
phenol (Reigner et al. 1991). Peak plasma concentrations (7.3±2.8 µg/mL) were achieved between 
1.5 and 2 hours after administration.  Absorption appeared to be first order and fit a one-compartment 
model in three of five animals tested.  Half-life of absorption varied between 0.25 and 1.50 hours. Based 
on the results of this study, the authors concluded that pentachlorophenol is virtually completely absorbed 
after oral administration in rats.  These same investigators studied the pharmacokinetics of pentachloro­
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phenol in B6C3F1 mice following the administration of a single gavage dose of 15 mg/kg (Reigner et al. 
1992b). Peak plasma concentrations (28±7 µg/mL) were achieved between 1.5 and 2 hours after 
administration.  Half-life of elimination from the blood averaged 5.8±0.6 hours.  Based on the results of 
this study, the study authors concluded that pentachlorophenol is virtually completely absorbed after oral 
administration in mice.  
Absorption of pentachlorophenol (>99%) from the gastrointestinal tract of F344 rats after gavage doses of 
9.5 or 38 mg/kg in an aqueous methylcellosolve vehicle was first order, with an absorption half-life of 
about 1.3 hours. The absorption rate of pentachlorophenol, determined after administration of 302 or 
1,010 ppm concentrations in the diet (approximately 21 or 64 mg/kg), was comparable to that obtained 
from aqueous methylcellosolve gavage formulations, but the bioavailability of pentachlorophenol 
administered in the diet (52% at 302 ppm and 30% at 1,010 ppm) was markedly lower than the 
bioavailability of pentachlorophenol administered by gavage (100% at 9.5 mg/kg and 86% at 38 mg/kg). 
Following gavage administration of a single dose of 9.5 or 38 mg/kg pentachlorophenol to the male rats, 
peak plasma concentrations of pentachlorophenol appeared in 2–4 hours and the concentration was dose-
dependent. In males administered pentachlorophenol in the diet for 5 days, diurnal variation was seen in 
the serum concentration of pentachlorophenol, with increases during the 12-hour dark period and 
decreases during the 12-hour light period (Yuan et al. 1994). 
The extent of absorption of pentachlorophenol or sodium pentachlorophenate from the gastrointestinal 
tract was studied in rats allowed free access to drinking water that contained a 1.4 millimolar (mM) 
solution of sodium pentachlorophenate (288 mg/L) or food that contained 350 ppm pentachlorophenol or 
sodium pentachlorophenate (Meerman et al. 1983).  Based on analysis of pentachlorophenol plasma 
concentrations over a 24-hour period and comparison with parameters obtained after intravenous 
administration, the study authors concluded that absorption of pentachlorophenol and sodium penta­
chlorophenate under these conditions was essentially complete.  
3.4.1.3 Dermal Exposure 
Using human abdominal skin (dermis and epidermis) obtained at autopsy, it has been demonstrated that 
62% of pentachlorophenol in diesel oil solution penetrated skin in vitro, while only 16% of an aqueous 
solution of sodium pentachlorophenate penetrated skin (Hortsman et al. 1989).  Thus, it appears that 
pentachlorophenol is absorbed to a much greater extent in an oily solution than in an aqueous solution 
following dermal exposure in humans.  The only other available information on dermal absorption of 
 84 PENTACHLOROPHENOL 
3. HEALTH EFFECTS 
pentachlorophenol and its salts by humans comes from occupational case studies in which elevated levels 
of pentachlorophenol have been detected in urine and plasma of workers who handle pentachlorophenol­
treated wood and/or do not wear adequate personal protective gear when working in areas where penta­
chlorophenol is being sprayed (Jones et al. 1986).  In addition, numerous case reports describe occurrence 
of severe toxicity and/or death in individuals whose exposure to pentachlorophenol is presumed to be 
predominantly via the dermal route (Gray et al. 1985; Robson et al. 1969; Smith et al. 1996; Wood et al. 
1983). 
Animal studies support the human findings that pentachlorophenol is absorbed across the skin.  In a 
Rhesus monkey study, pentachlorophenol was well absorbed following percutaneous application in soil 
or in acetone (Wester et al. 1993). Under the conditions of this study (0.7 µg/cm2 in soil and 0.8 µg/cm2 
in acetone of 14C-pentachlorophenol applied for 24 hours to abdominal skin), 24.4±6.4% of the applied 
dose in soil and 29.2±5.8% of the applied dose in acetone were absorbed.  In an in vivo swine model, 
40 µg/cm2 [14C-UL]-pentachlorophenol was applied occlusively or nonocclusively in a soil-based mixture 
to a clipped abdominal site of 8–10-week-old female pigs (Qiao et al. 1997).  By 408 hours after dosing, 
total radiolabel absorption was 29.08% under nonocclusive conditions and 100.72% under occlusive 
conditions. When antibiotics (neomycin sulfate, bacitracin, and polymyxin B) were codosed with 
occlusively applied [14C-UL]-pentachlorophenol, total radiolabel absorption by 408 hours was 86.21%. 
The antibiotics were selected to provide a combined wide spectrum of antimicrobial and antifungal 
activity.  If it assumed that the antibiotics had no direct effect on the dermal absorption of pentachloro­
phenol, then the inhibition of dermal absorption by the antibiotics suggests that degradation of penta­
chlorophenol by skin microorganisms may play a role in dermal absorption.  The percentage of applied 
dose present in blood or plasma reached maxima at approximately 96 hours under occlusive conditions 
(with or without antibiotics) and 144 hours under nonocclusive conditions.  These results indicate that 
pentachlorophenol is readily absorbed following dermal exposure and is bioavailable from soil.  
3.4.2 Distribution 
There are limited data on the distribution of pentachlorophenol in humans.  The distribution of 
background levels of pentachlorophenol were measured in the urine and tissues collected during the 
autopsy of 21 humans (Grimm et al. 1981).  The highest concentrations of pentachlorophenol were found 
in the liver (0.067 µg/g), kidneys (0.043 µg/g), brain (0.047 µg/g), spleen (0.019 µg/g), and body fat 
(0.013 µg/g).  The median pentachlorophenol levels in the urine and blood were 0.0044 and 0.033 µg/mL, 
respectively.  Low levels of pentachlorophenol were found in human breast milk from West Germany 
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(Gebefugi and Korte 1983) and Slovakia (Veningerova et al. 1996).  The source of pentachlorophenol 
was not specified. It is possible that the pentachlorophenol in breast milk was not due to pentachloro­
phenol exposure, but rather to exposure to other industrial chemical (e.g., hexachlorobenzene, 
hexachlorocyclohexane), which are metabolized to pentachlorophenol.  Since pentachlorophenol was 
detected in 64% of urine samples gathered from 1,000 human adults living in the United States (Hill et al. 
1995), it is likely that pentachlorophenol is present in breast milk in U.S. citizens.  Because pentachloro­
phenol is a metabolite of a number of environmental contaminants, it is not known if the pentachloro­
phenol present in the urine, breast milk, or tissues resulted from exposure to pentachlorophenol.  The 
discussion of experimental animal studies follows.  
3.4.2.1 Inhalation Exposure 
Information regarding distribution of pentachlorophenol following inhalation exposure in animals is 
limited.  Distribution of pentachlorophenol was evaluated following single and multiple (five) 20-minute 
inhalation exposures to concentrations calculated by the authors to be equivalent to a dose of 5.7 mg 
pentachlorophenol/kg body weight by measuring concentrations of pentachlorophenol in liver, lungs, 
blood, and urine only (Hoben et al. 1976c).  Rapid distribution away from the site of exposure was 
apparent after a single exposure since only 1.8% of the administered dose was present in lungs 
immediately after exposure.  By 24 hours postexposure, approximately 55% of the administered dose was 
recovered in urine, 7% in plasma, 9% in liver, and 0.7% in lung.  These data indicate that pentachloro­
phenol was cleared rapidly, and only small amounts accumulated in the tissue samples studied.  Repeated-
exposure experiments support the observation that pentachlorophenol does not accumulate in rats 
following inhalation exposure. By 24 hours after the last (fifth) exposure, 70% of the administered dose 
was recovered in urine, 5% in plasma, 4% in liver, and 0.3% in lung.  It is not clear from these data where 
pentachlorophenol was distributed immediately following exposure, but high levels in urine suggest that 
pentachlorophenol was cleared rapidly and did not reach an appreciable body burden following repeated 
exposure. Binding of pentachlorophenol to plasma proteins influences its distribution (see 
Section 3.4.2.2). Binding of pentachlorophenol to plasma proteins varies linearly with increasing dose 
following inhalation exposure (Hoben et al. 1976d). No studies were located regarding distribution of 
pentachlorophenol in animals following long-term inhalation exposure. 
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3.4.2.2 Oral Exposure 
Distribution studies in rats conducted 9 days after oral administration of a single dose of 10 mg 
[14C]-pentachlorophenol/kg body weight in corn oil demonstrated that the highest levels of radioactivity 
are found in liver and kidneys and lower levels are found in brain and fat tissue.  Radioactivity was also 
detected in lungs, testes, ovaries, heart, and adrenal glands.  Levels of radioactivity were uniformly higher 
in plasma and tissues of females as compared to males, though the distribution pattern was qualitatively 
the same (Braun et al. 1977).  A similar distribution pattern was observed by Larsen et al. (1972) in rats 
40 hours after gavage administration of 37–41 mg [14C]-pentachlorophenol/kg body weight in corn oil. 
Larsen et al. (1975) administered a single oral dose of 60 mg/kg pentachloro[U-14C]phenol (99.54% 
radiochemical purity) to 14 rats on day 15 of gestation.  Groups of 2 rats were sacrificed at 2, 4, 8, 12, 16, 
24, and 32 hours after dosing, and the distribution of administered dose was determined in blood serum, 
placentas, and fetuses. Tissue distributions, expressed as the percentage of administered dose per gram 
tissue, were 0.88% in blood serum, 0.20% in placentas, and 0.05% in fetuses at 2 hours after dosing. 
Peak amounts occurred in serum at 8 hours (1.12%), in placentas at 12 hours (0.28%), and in fetuses at 
12 hours (0.08%).  By 32 hours after dosing, percentages of administered dose were 0.43% in serum, 
0.08% in placentas, and 0.04% in fetuses. The chemical nature of the radioactivity present in serum, 
placentas, and fetuses was not investigated. Since the administered pentachlorophenol did not have 100% 
radiochemical purity, it is possible that some of the radioactive material distributed in the fetuses was due 
to radioactive impurities. 
Following gavage administration of a single dose of 9.5 or 38 mg/kg pentachlorophenol (>99%) to male 
F344 rats, peak plasma concentrations of pentachlorophenol appeared in 2–4 hours and the concentration 
was dose dependent. In male F344 administered pentachlorophenol at 302 or 1,010 ppm concentrations 
in the diet (approximately 21 or 64 mg/kg) for 5 days, diurnal variation was seen in the serum 
concentration of pentachlorophenol, with increases during the 12-hour dark period and decreases during 
the 12-hour light period (Yuan et al. 1994). 
At the end of the 2-year dietary bioassay of pentachlorophenol (approximately 99% with one impurity, 
tetrachlorophenol) in F-344 rats (NTP 1999), mean plasma concentrations of pentachlorophenol were 
approximately proportional to pentachlorophenol concentrations in the feed, and plasma concentrations in 
females were higher than those in males.  Plasma concentration of pentachlorophenol were 24, 44, and 
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67 µg/mL in females and 17, 36, and 53 µg/mL in males at dietary concentrations of 200, 400, and 
600 ppm, respectively. 
Distribution of [14C]-pentachlorophenol was measured in 2 monkeys 360 hours after oral administration 
of a single dose of 10 mg [14C]-pentachlorophenol/kg body weight.  Approximately 11% of administered 
radiolabel was found in the body at the time of analysis; 80% of this activity was in the liver and in the 
large and small intestines.  These data suggest that the monkey differs from the rat with regard to 
distribution of orally absorbed pentachlorophenol.  There appears to be extensive biliary secretion and 
enterohepatic circulation of pentachlorophenol in the monkey as evidenced by the long half-life of penta­
chlorophenol in the body of monkeys and the fact that most of the radiolabel still present in the body 
360 hours after administration was in the liver and large and small intestines (Braun and Sauerhoff 1976). 
Binding of pentachlorophenol to plasma proteins plays a significant role in the distribution of penta­
chlorophenol. Tissue/plasma ratios and renal clearance rates following oral administration of penta­
chlorophenol were much lower than would be predicted, based on the octanol/water partition coefficient 
and glomerular filtration rate (Braun et al. 1977).  This could be explained by extensive binding of penta­
chlorophenol to plasma proteins.  The authors subsequently demonstrated using an in vitro diafiltration 
technique that 95% of pentachlorophenol in plasma is protein bound (Braun et al. 1977).  In another 
experiment in rats, 97.1±2.0% of the administered dose of pentachlorophenol was found bound to plasma 
proteins as compared to plasma lipoproteins (Gómez-Catalán et al. 1991).  Protein binding may result in 
lower levels being distributed to tissues (i.e., liver and kidney) for metabolism and excretion and 
increased retention in the body. 
3.4.2.3 Dermal Exposure 
The distribution of radiolabelled pentachlorophenol was examined in female pigs following occlusive 
application of 40 µg/cm2 [14C-UL]-pentachlorophenol (Qiao et al. 1997).  The distribution of radiolabel 
17 days after dosing was as follows (highest to lowest): liver, lung, ovary, gall bladder, kidney, spleen, 
uterus, urinary bladder, heart, diaphragm, and brain.  A large amount of the label was retained in the 
body, approximately 50–67% of the absorbed label was present in the tissues 17 days after exposure. 
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3.4.2.4 Other Routes of Exposure 
Distribution of radioactivity in mice following intraperitoneal and subcutaneous administration of single 
doses of [14C]-pentachlorophenol has been reported (Jakobson and Yllner 1971).  Only 0.4–6% of the 
administered dose was found in tissues 96 hours after intraperitoneal injection of 14.8–37.2 mg 
[14C]-pentachlorophenol/kg body weight.  The highest concentrations of radiolabel were found in the gall 
bladder, liver, stomach wall, and gastrointestinal contents, indicating the occurrence of biliary secretion of 
pentachlorophenol. Lesser amounts of radiolabel were found in the kidneys, heart, and brain.  A similar 
distribution pattern was observed after subcutaneous administration of 50 mg [14C]-pentachlorophenol/kg 
body weight.  The concentration of radiolabel in the liver remained high 1 week after dosing.  These data 
are similar to those obtained after oral administration of pentachlorophenol. 
Dose- and time-dependent uptake of pentachlorophenol (purity not stated) into the cerebrospinal fluid of 
rats was demonstrated following single intraperitoneal injections of pentachlorophenol into rats at doses 
up to 17 mg/kg.  Since similar doses of pentachlorophenol also significantly decreased the uptake of 
radiolabeled T4 into cerebrospinal fluid, the study authors suggested that pentachlorophenol may interact 
with the T4 binding site of transthyretin and compete with T4 for uptake into cerebrospinal fluid (van 
Raaij et al. 1994). This is a plausible explanation since the affinity of pentachlorophenol for the T4 
binding site on transthyretin is 2.5-fold greater than that of T4 itself (den Besten et al. 1991). 
Based on plasma concentrations and clearance rates, the volume of distribution of pentachlorophenol was 
estimated to be relatively small and approximately correspond to the volume of distribution of albumin 
and volume of extracellular fluid following intravenous injection of a single dose of 2.5 mg/kg to rats 
(Reigner et al. 1991). Similar results were obtained in mice (Reigner et al. 1992b).  Following 
intravenous administration of 5 mg/kg pentachlorophenol (>99% purity) into rats, plasma concentrations 
tended to be slightly higher in males than in females during the first 12 hours.  The volume of distribution 
was 0.13±0.006 L/kg in males and 0.19±0.04 L/kg in females, but the difference was not statistically 
significant (Yuan et al. 1994). 
Reigner et al. (1993) investigated the binding of radiolabeled pentachlorophenol to serum proteins in vitro 
using ultrafiltration. The percent unbound pentachlorophenol in serum was 1.37 in mice, 0.85 in rats, 
0.67 in monkeys, 0.53 in humans, and 0.43 in cows.  These percentages correlated inversely with the total 
protein levels in the same serum samples.  Percent unbound pentachlorophenol also correlated inversely 
with serum albumin concentrations with the exception of the cow, which had a lower albumin 
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concentration than humans.  These data suggest that the distribution of pentachlorophenol may be 
restricted due to extensive plasma protein binding. 
3.4.3 Metabolism 
Results from animal and human studies indicate that pentachlorophenol is not extensively metabolized, as 
evidenced by a large portion of the administered dose being excreted in urine unchanged in all species 
studied. Extensive plasma protein binding of pentachlorophenol discussed in Section 3.3.2.2 may 
account for the low degree of metabolism because protein-bound material is not readily distributed to 
tissues. However, available human and animal data indicate that metabolism of pentachlorophenol does 
occur in the liver, and the major pathways are conjugation to form glucuronide and oxidative 
dechlorination to form TCHQ.  A summary of possible metabolic pathways for pentachlorophenol is 
presented in Figure 3-2. 
UDP-glucuronosyl transferase and sulfotransferases are involved in phase II metabolism of pentachloro­
phenol. Both of these enzymes are thought to be developmentally regulated (Leeder and Kearns 1997). 
Although the ontogeny of UDP-glucuronosyl transferase is isoform-specific, the adult level of activity 
seems to be achieved in humans by 6–18 months of age (Leeder and Kearns 1997).  Ontogeny for the 
sulfotransferases seems to be more rapid than that for UDP-glucuronosyl transferase, and the activity for 
some isoforms of sulfotransferase may exceed adult levels during infancy and early childhood (Leeder 
and Kearns 1997). 
Mehmood et al. (1996) has provided evidence that human cytochrome P450 3A4 may metabolize penta­
chlorophenol to TCHQ in phase I metabolism of pentachlorophenol; however, the initial purity of the 
pentachlorophenol used in this study was not indicated.  In humans, this enzyme has low activity in the 
first month of life, with approach toward adult levels by 6–12 months of postnatal age; adult activity may 
be exceeded between 1–4 years of age and then activity progressively declines, reaching adult levels at 
the conclusion of puberty (Leeder and Kearns 1997).  By Western immunoblotting using monoclonal 
antibodies to identify the different P 450 isozymes, pure pentachlorophenol (>99%)was identified as an 
inducer of cytochrome P450 3A7 in studies in cultured rat hepatocytes, quail hepatocytes, and human 
hepatoma (Hep G2) cells (Dubois et al. 1996).  In humans, functional activity of cytochrome P450 3A7 in 
the fetus is approximately 30–75% of adult levels (Leeder and Kearns 1997). 
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Figure 3-2. Proposed Metabolic Scheme for Pentachlorophenol 
PCP = pentachlorohenol; PCP-Glu = pentachlorophenol-β-glucuronide; PCP-S = pentachlorophenylsulfate;
 
TCHQ = tetrachloro-p-hydroquinone; TCP-Glu = tetrachlorophenol-β-glucuronide; TCP-S = tetrachlorophenylsulfate;
 
TCQ = tetrachloroquinone; Tri CHQ = trichloro-p-hydroquinone; Tri CP-Glu = trichlorophenyl-β-glucuronide;
 
Tri CP-S = trichlorophenylsulfate; Tri CQ = trichloro-p-quinone
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3.4.3.1 Inhalation Exposure 
Ahlborg et al. (1974) analyzed urine from 2 workers employed as spraymen 24 hours after exposure to 
sodium pentachlorophenate that was presumably via the inhalation route.  Both unchanged pentachloro­
phenol and TCHQ were identified (relative proportions were not specified), but no mention was made 
regarding the possible presence of glucuronide conjugates.  Thus, at least oxidative dechlorination of 
pentachlorophenol occurs in humans exposed via inhalation.  In rats, 70–75% of inhaled pentachloro­
phenol is excreted unchanged in urine following a single exposure (Hoben et al. 1976a). 
3.4.3.2 Oral Exposure 
Oral administration of small doses of pentachlorophenol (0.02–0.31 mg pentachlorophenol/kg) of $99% 
purity to volunteers resulted in excretion of unchanged pentachlorophenol (78% of administered dose) 
and pentachlorophenol glucuronide (12% of the administered dose) in urine and feces (Braun et al. 1979; 
Uhl et al. 1986). No TCHQ was identified. 
Studies in rats indicate that both metabolic pathways described above were operative following oral 
administration of pentachlorophenol, but most of the administered dose was excreted unchanged (Ahlborg 
et al. 1974; Braun et al. 1977; Renner 1989; Renner and Hopfer 1990).  The following urinary metabolites 
were recovered and identified by gas chromatography from female Sprague-Dawley rats dosed with 
pentachlorophenol (>99% pure) for 28 days:  2,3,4,5-tetrachlorophenol; 2,3,4,6-tetrachlorophenol; 
2,3,5,6-tetrachlorophenol; tetrachlorocatechol (Cl4CAT); trichloro-1,4-benzenediol; tetrachloro­
1,4-benzenediol; tetrachlororesorcinol; trichlorohydroquinone; TCHQ; and traces of trichloro­
1,4-benzoquinone and tetrachloro-1,4-benzoquinone.  The major metabolite was TCHQ, which was 
excreted mainly as a glucuronide conjugate (Renner and Hopfer 1990).  Based on the urinary metabolites 
identified, the study authors concluded that the main metabolic pathway for pentachlorophenol in the rat 
was pentachlorophenol to 2,3,5,6-tetrachlorophenol to TCHQ, with a minor pathway being pentachloro­
phenol to 2,3,4,6- and 2,3,4,5-tetrachlorophenol to trichlorohydroquinone.  Pentachlorophenol 
(conjugated with glucuronic acid and unconjugated) and TCHQ (conjugated with glucuronic acid and 
unconjugated) were recovered from urine and quantified by high-performance liquid chromatography and 
confirmed by using capillary gas chromatography from female Sprague-Dawley rats dosed with penta­
chlorophenol (>99% pure) for 28 days (Renner and Hopfer 1990).  Unconjugated pentachlorophenol 
accounted for 36–58% of pentachlorophenol recovered, and 10–19% of the TCHQ excreted was 
unconjugated. Concentrations of both pentachlorophenol and TCHQ in urine fell to negligible amounts 
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within one week after cessation of treatment.  The study authors concluded that conjugation of penta­
chlorophenol with glucuronide and the metabolism of pentachlorophenol to TCHQ in rats results in more 
rapid excretion than in species that excrete unchanged pentachlorophenol (e.g., monkey) (see discussion 
below). 
In other studies in rats, 48% of the 100 mg [14C]-pentachlorophenol/kg administered orally to rats was 
recovered as unchanged pentachlorophenol in urine, 10% was TCHQ, and 6% was pentachlorophenol­
glucuronide. No TCHQ-glucuronide was detected (Braun et al. 1977).  Similar results were obtained in 
rats and mice when a single dose of 25 mg [14C]-pentachlorophenol was administered by gavage, except 
that TCHQ conjugates (not positively identified as glucuronides) were identified in urine (Ahlborg et al. 
1974). These investigators found that 41–43% of the administered radiolabel was recovered in the urine 
as unchanged pentachlorophenol in rats and mice, 5% as TCHQ in rats, and 24% as TCHQ in mice.  An 
unspecified proportion of radioactivity was found in urine as conjugated pentachlorophenol and TCHQ, 
but it could not be determined whether these were glucuronide conjugates.  Other investigators have 
reported results in rats that differ from those of Braun et al. (1977).  Approximately 60% of a 2.5 mg/kg 
dose of pentachlorophenol was recovered in the urine of Sprague-Dawley rats after 72 hours, mostly as 
conjugated pentachlorophenol and TCHQ, with only 5.3±0.2% of the dose recovered as unchanged penta­
chlorophenol (Reigner et al. 1991). Treatment of urine with sulfuric acid indicated that sulfate conjugates 
of pentachlorophenol and TCHQ accounted for about 90% of conjugated pentachlorophenol and TCHQ 
(glucuronide conjugates reported by Braun et al. [1977]).  Metabolites and unchanged pentachlorophenol 
in feces accounted for 10% of the administered dose. 
It has been demonstrated that the monkey differs from the rat and mouse in that virtually all radioactivity 
recovered in urine following oral administration of 10 mg [14C]-pentachlorophenol/kg was associated with 
pentachlorophenol; no TCHQ or glucuronide conjugates were identified (Braun and Sauerhoff 1976). 
These data suggest that pentachlorophenol is not metabolized to any great degree by the monkey. 
Binding of pentachlorophenol to specific components of liver cells or differential distribution of penta­
chlorophenol to different cellular organelles can affect its metabolic fate or that of other xenobiotics and 
ultimately regulate the manifestation of toxic effects.  Arrhenius et al. (1977) administered a single dose 
of gas-chromatographically pure pentachlorophenol (40 mg/kg) by stomach tube to rats, killed them 
16 hours later, separated subcellular fractions, and determined that the relative concentration of penta­
chlorophenol in microsomes was 6 times greater than in mitochondria.  Since maximum effects on 
inhibition of microsomal detoxification processes (requiring electron transport from flavin to cytochrome) 
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occur at a pentachlorophenol concentration (100 µM) that is 4 times greater than the concentration of 
pentachlorophenol required to cause maximum inhibition of oxidative phosphorylation in mitochondria 
(25 µM), Arrhenius et al. (1977) suggested that inhibition of mitochondrial oxidative phosphorylation and 
inhibition of microsomal detoxification by pentachlorophenol might be equally important.  The 
possibility that the presence of pentachlorophenol in microsomes allows this substance to inhibit its own 
metabolism provides a possible explanation for the relative lack of pentachlorophenol metabolism seen in 
all species studied. Another possible explanation is that extensive plasma binding of pentachlorophenol 
limits distribution of pentachlorophenol to the liver for subsequent biotransformation.  In either case, any 
perturbation that increases the level of free circulating pentachlorophenol may result in enhanced toxicity 
as well as an increased rate of biotransformation and elimination.  For individuals living in close 
proximity to areas of potentially high pentachlorophenol exposure, concomitant exposure to chemicals or 
intentional ingestion of drugs that compete with pentachlorophenol for protein binding may enhance 
pentachlorophenol-induced toxicity. 
3.4.3.3 Dermal Exposure 
No studies were located regarding metabolism in humans or animals after dermal exposure to penta­
chlorophenol. 
3.4.3.4 Other Routes of Exposure 
Results of studies in rats and mice indicate that metabolism of pentachlorophenol following 
intraperitoneal injection is similar to that observed following oral exposure (Ahlborg et al. 1978; 
Jakobson and Yllner 1971). In vitro studies in both human and rat liver homogenates clearly demonstrate 
that pentachlorophenol is converted to TCHQ (Juhl et al. 1985).  Using a genetic construct in which 
human cytochrome P450 3A4 is expressed in Saccharomyces cerevisiae strain AH22, Mehmood et al. 
(1996) demonstrated that human cytochrome P450 3A4 may metabolize pentachlorophenol to TCHQ; 
however, the initial purity of the pentachlorophenol used in this study was not indicated.  By Western 
immunoblotting using monoclonal antibodies to identify the different P 450 isozymes, pure pentachloro­
phenol (>99%) was identified as an inducer of cytochrome P450 3A7 in studies in cultured rat 
hepatocytes, quail hepatocytes, and human hepatoma (Hep G2) cells (Dubois et al. 1996). 
Since studies with rat liver microsomes using 19F nuclear magnetic resonance have demonstrated the 
cytochrome P450-dependent oxidation of pentafluorophenol to tetrafluorobenzoquinone (den Besten et al. 
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1993), it can be speculated that cytochrome P450 may also catalyze the oxidation of pentachlorophenol to 
tetrachlorobenzoquinone. 
Horseradish peroxidase catalyzed the oxidation of pentachlorophenol to Cl4BQ in vitro via a phenoxyl 
radical intermediate (Samokyszyn et al. 1995).  The study authors suggest that this is a potential in vivo 
metabolic step that could be catalyzed by mammalian peroxidases, including prostaglandin H synthase, 
myeloperoxidase, salivary peroxidase, lactoperoxidase, or uterine peroxidase. 
The rate of pentachlorophenol-glucuronide conjugation in human liver microsomes is reported to be 
one-third of that found in rat liver microsomes (Lilienblum 1985), although phenobarbital-enhanced 
dechlorination of pentachlorophenol, phenobarbital, and 3-methylcholanthrene (another microsomal 
enzyme inducer) had little effect on the conjugation reaction in rat liver microsomes (Ahlborg et 
al. 1978). This indicated that the extent of glucuronide conjugation was governed by factors other than 
phenobarbital- and 3-methylcholanthrene-inducible microsomal enzyme activity. 
It has been proposed that accumulation of pentachlorophenol by lipid-containing tissues seen in vitro is 
due to conjugation with fatty acids (Leighty and Fentiman 1982).  These investigators reported that penta­
chlorophenol conjugated with palmitic acid in an in vitro rat liver coenzyme A fortified microsomal 
system.  This ester is also found in human fat (Ansari et al. 1985).  The mechanism by which the 
palmitoyl-pentachlorophenol is formed in human fat has yet to be determined.  The presence of this ester 
in human fat demonstrates that xenobiotics such as pentachlorophenol can be made more lipophilic and 
stored in the fat of humans rather than excreted by the kidneys, thereby providing a potential reservoir of 
toxin that could be released at a later time.  
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
The available information regarding pentachlorophenol excretion following inhalation exposure in 
humans comes predominantly from occupational case studies.  Data obtained by Bevenue et al. (1967) 
from measuring urinary levels of pentachlorophenol in residents of Honolulu (some with a history of 
occupational exposure to pentachlorophenol) indicated that elimination was biphasic, with urinary penta­
chlorophenol levels decreasing approximately 35% per day in the first 2 days.  Urinary levels of penta­
chlorophenol measured in wood-treatment workers prior to, during, and after vacation implied a urinary 
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half-life of elimination of 19–20 days following inhalation exposure (Begley et al. 1977).  A 10-day half-
life of pentachlorophenol excretion in urine was estimated from urinary levels of pentachlorophenol 
measured in a tannery worker 1 day after the last day of work-related pentachlorophenol exposure and 
during a subsequent holiday period (Barbieri et al. 1995).  The results of studies conducted by Casarett et 
al. (1969) in occupationally exposed humans suggest that pentachlorophenol excretion kinetics differ 
between single high-level and chronic low-level exposure.  Urinary half-lives of approximately 10 hours 
were displayed by 2 subjects following a 45-minute inhalation exposure resulting from painting 
household materials in an enclosed area, whereas urine pentachlorophenol levels in exposed workers 
decreased only by 60–80% when the workers were absent from work for up to 18 days.  The authors 
hypothesized that slower elimination of pentachlorophenol in the chronic situation may be the result of 
the establishment of an equilibrium between lung, plasma proteins, urine, and tissue depots.  
A group of 7 sawmill workers (6 males and 1 female) exposed to a sodium chlorophenolate wood-
preserving product containing 3% pentachlorophenol were monitored for serum and urinary 
concentrations of pentachlorophenol (as well as other chlorophenols) throughout a wood-treatment season 
of approximately 7 months and an additional 171 days after the termination of exposure for the season 
(Pekari et al. 1991). Maximal pentachlorophenol urine concentrations after the period of exposure were 
0.2–0.9 µmol/L.  Approximately 76% of the pentachlorophenol in urine was conjugated.  The elimination 
rate constant in these workers using a one-compartment model was 0.044±0.018/day with a 
corresponding half-life of 16 days for pentachlorophenol.  The minimal urinary clearance for pentachloro­
phenol was 0.2 mL/minute and varied with urine flow.  The study authors noted that the relatively high 
concentrations of pentachlorophenol found in the serum (23%) as compared to the low percentage of 
pentachlorophenol in the technical product (3%) indicates that pentachlorophenol accumulates in the 
serum, in accordance with its relatively long half-time (16 days as compared to 18 hours and 4.2 days for 
tri- and tetrachlorophenol, respectively).  Breathing zone measurements of concentration of airborne 
contamination compared to quantitative urine measurements would greatly improve the quality of the 
study. 
Excretion of pentachlorophenol following inhalation exposure in animals has not been well documented. 
The elimination half-life of pentachlorophenol following a single 20-minute inhalation exposure to 
5.7 mg [14C]-pentachlorophenol/kg was 24 hours (Hoben et al. 1976c).  Pentachlorophenol does not 
undergo appreciable biotransformation as most of the inhaled dose was found to be eliminated unchanged 
in the urine. The authors of this study also reported that repeated (five) exposures increased urinary 
output of pentachlorophenol. These results are not inconsistent with those of Casarett et al. (1969). 
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Elimination of many toxicants from high body burdens follows first-order kinetics initially, but the 
pattern of elimination becomes much more complex as lower body burdens are attained.  Accumulation 
with repeated exposure will occur if rate of absorption exceeds rate of elimination, irrespective of 
excretion kinetics or tissue storage. 
3.4.4.2 Oral Exposure 
Studies investigating excretion of pentachlorophenol by humans following ingestion of 0.016–0.31 mg 
pentachlorophenol/kg have yielded conflicting results.  Uhl et al. (1986) found that pentachlorophenol 
was excreted slowly, displaying an elimination half-life in both blood and urine of 14 days and a renal 
clearance of 0.07 mL/minute following ingestion of 0.016–0.31 mg pentachlorophenol/kg in ethanol by 
volunteers. The authors concluded that slow elimination could be attributed to extensive plasma protein 
binding and tubular reabsorption. 
When Braun et al. (1979) studied excretion kinetics of pentachlorophenol (as the sodium salt) in 
volunteers who ingested 0.1 mg pentachlorophenol/kg, they found that the half-life of elimination was 
30.2 hours from plasma and 33.1 hours from urine for pentachlorophenol, and 12.7 hours from urine for 
the glucuronide conjugate. Approximately 74% of the administered dose was eliminated in urine as 
pentachlorophenol and 12% as pentachlorophenol-glucuronide within 168 hours postingestion, and 4% 
was recovered as pentachlorophenol and pentachlorophenol-glucuronide in feces.  These investigators 
concluded that pentachlorophenol elimination in humans followed first-order kinetics with enterohepatic 
recirculation following oral exposure. One possible explanation for the different half-lives observed in 
the Uhl et al. (1986) and the Braun et al. (1979) studies is the different dosing procedures employed. 
Subjects in the Uhl et al. (1986) study were reported to have ingested pentachlorophenol "without 
restriction of diet," while Braun et al. (1979) reported that "food was withheld 8 hours before and 1 hour 
after ingestion of the dose." Dispersion in gut contents may have slowed absorption in the Uhl et al. 
(1986) subjects, while absorption of the full dose occurred over a much shorter interval in the Braun et al. 
(1979) subjects, thus accounting for the different half-lives observed.  Other explanations for the 
differences observed between the two studies include the fact that sodium pentachlorophenate was used 
for the Braun et al. (1979) study and pentachlorophenol in ethanol was used for the Uhl et al. (1986) 
study, and the vehicle used in the Uhl et al. (1986) study (ethanol) may have altered the solubility of 
pentachlorophenol. 
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Elimination of pentachlorophenol in rats following oral exposure was shown to be rapid and biphasic, 
with urine being the major route of excretion (Braun et al. 1977).  The authors of this study reported that 
within 8–9 days, 80% of the radioactivity from the single oral administration of 10 mg [14C]-pentachloro­
phenol/kg to rats was recovered in urine and 19% in feces; 64% was detected in urine and 34% in feces 
following single oral administration of 100 mg [14C]-pentachlorophenol/kg.  Elimination half-lives were 
17 and 13 hours for the first phase and 40 and 30 hours for the second phase in low-dose males and 
females, respectively.  Ninety percent of the radioactivity was eliminated in the first phase.  High-dose 
males exhibited elimination half-lives of 13 and 121 hours for the first and second phases, respectively.
High-dose females exhibited first-order kinetics with a half-life of 27 hours.  No explanation was offered 
for the difference in kinetics seen in high-dose females.  These data indicate that: (1) the rate of 
elimination in the slow phase only and the relative distribution of radioactivity in feces varied linearly 
with increasing dose, (2) females eliminated pentachlorophenol faster than males, and (3) plasma binding 
and hepatic retention could account for the prolonged second phase of elimination. 
Different results were reported in rats administered single doses of 37–41 mg [14C]-pentachlorophenol/kg 
(Larsen et al. 1972). While the half-lives of rapid phases of elimination were comparable, Larsen et 
al. (1972) reported a half-life of 102 days for the second phase.  However, these data are questionable 
because Larsen et al. (1972) did not obtain 100% recovery in urine and assumed that fecal excretion was 
constant. Therefore, they only reported a total fecal excretion value after 10 days. 
Results similar to those obtained by Braun et al. (1977) were reported by Reigner et al. (1991, 1992b) 
with respect to urinary and fecal elimination of pentachlorophenol following single-dose exposure in rats 
and mice.  In the Reigner et al. studies, 8–10% of the administered dose (2.5 and 15 mg/kg, respectively, 
for rats and mice) of pentachlorophenol was recovered in the feces.  Therefore, biliary excretion must 
play some role in elimination of pentachlorophenol. 
Elimination of pentachlorophenol by monkeys was slow and followed first-order kinetics.  Braun and 
Sauerhoff (1976) orally administered single doses of 10 mg [14C]-pentachlorophenol/kg to monkeys and 
monitored excretion of radioactivity for up to 360 hours after administration.  They found that 10–20% of 
administered radioactivity was steadily excreted in the feces, attesting to a relatively high degree of 
biliary secretion.  Urinary pentachlorophenol accounted for 70–80% of the administered radiolabel.  The 
half-life of elimination was 40.8 hours in males and 92.4 hours in females.  The long half-life was 
attributed to enterohepatic circulation with subsequent biliary secretion. 
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The role of enterohepatic circulation and biliary secretion in pentachlorophenol elimination in monkeys 
was further investigated by measuring the relative extent of excretion of pentachlorophenol in urine, 
feces, and bile before and after administration of cholestyramine, a substance that binds phenols (Ballhorn 
et al. 1981; Rozman et al. 1982).  The cholestyramine was administered in the diet 24 hours after 
pentachlorophenol exposure. At 30 mg/kg/day, control excretion was 92.3% in urine and 7.7% in feces. 
Following cholestyramine administration, excretion was 12.1% renal and 86.9% fecal.  At 50 mg/kg/day, 
control excretion was 79.9% renal and 20.1% fecal.  Following cholestyramine administration, excretion 
was 15.4% renal and 84.6% fecal. Total excretion was also increased by cholestyramine administration. 
Total recovery of administered dose over a 6-day period increased from 26 to 45% at the low dose and 
from 15 to 31% at the high dose (Ballhorn et al. 1981). 
In a follow-up study, cholestyramine treatment reduced urinary excretion of pentachlorophenol from 
35 to 5% of the administered dose and increased fecal excretion from 3 to 54% of the administered dose. 
The increase in fecal excretion induced by cholestyramine exceeded the decrease in urinary excretion. 
Total excretion increased by 40%.  Seventy percent was excreted in bile during the control period, and 
52% was excreted in bile after cholestyramine treatment (Rozman et al. 1982), suggesting that 
cholestyramine treatment also enhanced the excretion of pentachlorophenol across the intestinal wall. 
The following conclusions can be drawn from these studies: 
• In untreated monkeys, oral absorption of pentachlorophenol was followed by elimination via bile 
into the duodenum, reabsorption in the small intestine, and enterohepatic circulation and 
excretion, predominantly via the kidney. 
• Cholestyramine, which binds phenols, interrupted enterohepatic circulation by binding penta­
chlorophenol and/or its metabolites, resulting in predominantly fecal excretion. 
• Total excretion was increased after cholestyramine treatment, suggesting that it reduced the half-
life of pentachlorophenol in the monkey by enhancing its elimination from the body. 
• Cholestyramine increased elimination of pentachlorophenol by sequestering it from enterohepatic 
circulation and increasing its excretion across the intestinal wall. 
3.4.4.3 Dermal Exposure 
No studies were located regarding excretion in humans after dermal exposure to pentachlorophenol. 
In an in vivo swine model, 40 µg/cm2 [14C-UL]-pentachlorophenol was applied occlusively or 
nonocclusively in a soil-based mixture to a clipped abdominal site of 8–10-week-old female pigs (Qiao et 
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al. 1997). As an additional dosing protocol, antibiotics (neomycin sulfate, bacitracin, and polymyxin B, 
selected to provide a combined wide spectrum of antimicrobial and antifungal activity) were codosed with 
occlusively-applied [14C-UL]-pentachlorophenol to determine if inhibition of dermal microbial activity 
would influence absorption and disposition. Only one-third to one-half of the absorbed dose was almost 
equally excreted through urinary and fecal routes at constant rates over the 408-hour study period.  In 
general, both the urinary and fecal excretion rates were faster for occlusive than for nonocclusive 
conditions. At 408 hours, the excretion data indicated that occlusion significantly increased the urinary 
(4x) and fecal (2.5x) excretion. Codosing of antibiotics with occlusive pentachlorophenol application 
significantly decreased urinary and fecal excretion.  Based on the excretion curves, the urinary excretion 
rates were 0.35, 1.29, and 0.65% dose/day for nonocclusive, occlusive, and occlusive-antibiotic 
conditions, respectively, and the fecal excretion rates were 0.47, 1.24, and 0.82% dose/day for 
nonocclusive, occlusive, and occlusive-antibiotic conditions, respectively.
3.4.4.4 Other Routes of Exposure 
Kinetics of elimination of pentachlorophenol in rats following a single intravenous injection (Reigner et 
al. 1991) differ from those reported by Braun et al. (1977) following oral exposure.  In the Reigner et al. 
(1991) study, the clearance rate of pentachlorophenol from plasma was 0.026±0.003 L/hour/kg. 
Elimination of pentachlorophenol from plasma was biphasic and fit a two-compartment model, with the 
half-life for the first phase being 0.67±0.46 hours and the half-life for the second phase being 
7.11±0.87 hours. Most of the pentachlorophenol was eliminated during the second phase.  However, 
routes of excretion and main metabolites recovered in urine and feces were similar to those seen by these 
same investigators after oral administration (Reigner et al. 1991).  The study authors proposed that 
specificity of the analytical methodology is one possible explanation for the difference in elimination 
kinetics seen between their study and the study by Braun et al. (1977), who, instead of taking multiple 
blood samples from the same animal, killed two animals at different times to get the kinetic profile.  Use 
of pooled data such as this may have provided inaccurate data for modeling. 
Following intravenous administration of 5 mg/kg pentachlorophenol (>99% purity) into rats, the 
estimated mean terminal elimination half-life of pentachlorophenol was 5.6±0.37 hours in males and 
9.5±4.2 hours in females, but the difference was not significant (Yuan et al. 1994). 
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3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
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many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-3 shows a conceptualized representation of a PBPK model. 
No PBPK modeling studies were located for pentachlorophenol. 
3.5 MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms 
Pentachlorophenol is a nonpolar, lipophilic substance.  While the exact mechanism of absorption is not 
known, it can be assumed that because of its lipophilicity it can easily cross cell membranes and be 
absorbed in lungs, gastrointestinal tract, and skin.  Toxicokinetic studies in animals and humans 
demonstrate this to be the case (see Section 3.4.1).  
Binding of pentachlorophenol to plasma proteins plays a role in the distribution of pentachlorophenol.  It 
has been demonstrated, using an in vitro diafiltration technique (Braun et al. 1977), that 95% of the penta­
chlorophenol in plasma is protein bound.  Extensive plasma protein binding of pentachlorophenol may 
account for the low degree of metabolism seen with this compound (most pentachlorophenol is excreted 
unchanged) because protein-bound material is not readily distributed to tissues where it can be 
metabolized.  van Raaij et al. (1994) demonstrated a dose- and time-dependent uptake of pentachloro­
phenol into the cerebrospinal fluid of rats following single intraperitoneal injections.  Since similar doses 
of pentachlorophenol also significantly decreased the uptake of radiolabeled T4 into cerebrospinal fluid, 
the study authors suggested that pentachlorophenol may interact with the T4 binding site of transthyretin 
and compete with T4 for uptake into cerebrospinal fluid (van Raaij et al. 1994).  This is a plausible 
explanation since the affinity of pentachlorophenol for the T4 binding site on transthyretin is 2.5-fold 
greater than that of T4 itself (den Besten et al. 1991). 
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Figure 3-3. Conceptual Representation of a Physiologically Based
 
Pharmacokinetic (PBPK) Model for a Hypothetical 

Chemical Substance
 
Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by 
inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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3.5.2 Mechanisms of Toxicity 
It is widely believed that pentachlorophenol exerts its toxic effects, at least in part, by uncoupling 
mitochondrial oxidative phosphorylation, thereby causing accelerated aerobic metabolism and increased 
heat production. Pentachlorophenol has been found to bind to purified rat liver mitochondrial protein. 
This may induce conformational changes in enzymes involved in oxidative phosphorylation (Weinbach 
and Garbus 1965). The pattern of pentachlorophenol-induced toxicity often seen in humans and animals 
supports this proposed mechanism of action.  A young worker who died following 3 weeks of exposure to 
pentachlorophenol dust in a chemical plant was found to have cerebral edema and fatty degeneration of 
liver and lungs at necropsy (Gray et al. 1985).  The study authors concluded that these clinical findings 
are consistent with a hypermetabolic state resulting from a derangement of aerobic metabolism and 
characterized by hyperthermia, which can lead to tachycardia, tachypnea, hyperemia, diaphoresis, and 
metabolic acidosis.  This is usually followed by death and rapid, profound rigor mortis.  Toxicity 
resulting from uncoupling of oxidative phosphorylation was generally seen prior to death in animals 
acutely exposed to pentachlorophenol.  These included accelerated respiration, hyperemia, cardiac and 
muscular collapse, asphyxial convulsions, death, and rapid rigor mortis (St. Omer and Gadusek 1987). 
The ultrastructural changes observed in mitochondria from liver cells of rats treated with technical-grade 
pentachlorophenol for 15 days are consistent with uncoupling of oxidative phosphorylation (Fleischer et 
al. 1980). 
The cell membrane is apparently a possible site of action for pentachlorophenol.  Lipid bilayers of 
purified and total cell membranes have been reported to destabilize following sublethal pentachlorophenol 
treatment (Duxbury and Thompson 1987).  This was evidenced by a 50% decrease in bulk lipid fluidity 
attributable to disruption of the bilayer by pentachlorophenol.  These authors also found that pentachloro­
phenol partitions into the hydrophobic interior of the bilayer.  Other membrane changes observed by these 
investigators included a decrease in phospholipid phosphate levels that they believe was a result of a 
selective chemical effect on phospholipase C.  However, the authors concluded that this was only a 
sublethal effect since the cells remained viable. 
In another investigation of the physicochemical basis of pentachlorophenol membrane effects, membrane 
toxicity was associated with the pentachlorophenol-induced change in hydrogen ion permeability of the 
membrane lipid matrix (Smejtek 1987).  The onset of toxic effects was correlated with the loss of 
membrane electrical resistance and a measurable amount of pentachlorophenol binding to the membrane. 
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Studies described above indicate that pentachlorophenol can disrupt membrane structure and function. 
These effects could conceivably occur throughout the body and could therefore explain the wide range of 
toxic effects associated with pentachlorophenol, including the uncoupling of oxidative phosphorylation. 
Oral and intraperitoneal administration of pentachlorophenol to animals causes adverse effects on thyroid 
homeostasis (e.g., decreased serum thyroxine) and on the thyroid gland (Beard and Rawlings 1998; Beard 
et al. 1999b; Jekat et al. 1994; van Raaij et al. 1991a). These effects may occur during gestation, 
pregnancy, and lactation (Beard and Rawlings 1998; Beard et al. 1999b).  Further in vitro studies by van 
Raaij et al. (1991b) revealed that the likely mechanism of action for this anti-thyroid effect of penta­
chlorophenol was competition for serum protein thyroxine binding sites.  van Raaij et al. (1994) 
subsequently demonstrated a dose- and time-dependent uptake of pentachlorophenol into the 
cerebrospinal fluid of rats following single intraperitoneal injections.  Since similar doses of pentachloro­
phenol also significantly decreased the uptake of radiolabeled T4 into cerebrospinal fluid, the study 
authors suggested that pentachlorophenol may interact with the T4 binding site of transthyretin and 
compete with T4 for uptake into cerebrospinal fluid (van Raaij et al. 1994).  This is a plausible 
explanation since the affinity of pentachlorophenol for the T4 binding site on transthyretin is 2.5-fold 
greater than that of T4 itself (den Besten et al. 1991). 
Such effects on thyroid parameters, combined with the activity of pentachlorophenol as a potent inhibitor 
of oxidative phosphorylation (Weinbach 1954), may be expected to have general adverse effects on basal 
metabolic rate and many critical processes including development, reproduction, nervous system function, 
and the specific functioning of endocrine and other organs. 
In addition, the effects of pentachlorophenol on thyroid homeostasis and the availability of T4 to the 
central nervous system may have adverse effects on development of the nervous system.  Deficiencies in 
thyroxine during prenatal and postnatal life can cause decrements in intellectual function in children 
(Bargagna et al. 1997; Birrell et al. 1983; Kooistra et al. 1994), and hypothyroidism in animals leads to 
disorders in structural and functional development of the brain (Gould et al. 1990; Neveu and Arenas 
1996; Stein et al. 1991; Vega-Nunez et al. 1995). However, testing has not been performed on animals 
exposed to pentachlorophenol, either prenatally or postnatally, to examine the potential for the anti-
thyroid effects of pentachlorophenol to produce adverse effects on neurobehavior. 
Recent studies in rats and mice involved the characterization of chlorinated protein adducts arising from 
pentachlorophenol metabolism following oral administration of pentachlorophenol (Lin et al. 1997; 
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Waidyanatha et al. 1994, 1996).  Results from these studies and previously summarized studies suggest 
that the metabolism of pentachlorophenol can proceed through the quinols TCHQ and Cl4CAT via 
microsomal cytochrome P 450 enzymes and that these quinols can be oxidized via semiquinone 
intermediates (tetrachloro-1,2-semiquinone [Cl4-1,2-SQ] and tetrachloro-1,4-semiquinone [Cl4-1,4-SQ]) 
into the corresponding quinones (tetrachloro-1,2-benzoquinone [Cl4-1,2-BQ] and tetrachloro-1,4-benzo­
quinone [Cl4-1,4-BQ]).  Both the quinones and semiquinones are electrophilic and can bind to cellular 
macromolecules (Lin et al. 1997).  The redox cycling associated with oxidation of TCHQ and reduction 
of Cl4-1,4-BQ generates oxygen radicals that caused an increase in 8-hydroxy-2-deoxyguanosine levels in 
liver DNA in mice that had been fed pentachlorophenol (Sai-Kato et al. 1995; Umemura et al. 1996) or 
TCHQ (Dahlhaus et al. 1994) in the diet for up to 4 weeks.  It is possible that the formation of such 
adducts is involved in the induction of hepatic neoplasms in mice (NTP 1989).  Lin et al. (1997) 
measured levels of chlorinated protein adducts arising from pentachlorophenol metabolism in the livers of 
mice and rats administered pentachlorophenol in the diet for up to 4 weeks.  After aggregation of the 
estimated contributions of all quinone species derived from pentachlorophenol metabolism, mice had a 
four-fold greater dose to liver nuclei than rats, whereas rats had a three-fold greater dose to liver cytosol 
than mice.  The increased nuclear dose to mouse liver compared to that of the rat suggests that the mouse 
is at greater risk to hepatic DNA damage from pentachlorophenol-derived quinones.  Using a model to 
predict quinone and semiquinone production, Lin et al. (1999) estimated that at low doses of 
pentachlorophenol, the production of semiquinone adducts was proportionally greater in rats than mice; in 
mice, direct oxidation to quinones and the production of quinone adducts is favored in mice exposed to 
low doses of pentachlorophenol. These data suggest that both the types and amounts of adducts differ in 
rats and mice, which may account for the occurrence of liver tumors in mice but not in rats in bioassays 
conducted by NTP (1989, 1999). 
In an epidemiologic study of male factory workers who brushed pentachlorophenol onto wood strips, 
sometimes without gloves, serum biliary acid concentrations were elevated in the high-exposure group, 
but not the low-exposure group, compared with controls (Colosio et al. 1993b).  This effect may have 
been caused in part by the impurities in the pentachlorophenol.  The presence of elevated concentrations 
of bile acids in serum is a sensitive indicator of liver dysfunction (Franco et al. 1986).  Since bile acids 
are essential for lipid transport, are the major products of cholesterol metabolism, and regulate the 
transcription of genes that control cholesterol homeostasis (Makishima et al. 1999; Parks et al. 1999), the 
elevation of serum bile acids by exposure to high levels of pentachlorophenol may have some effect on 
biochemical pathways involved in cholesterol metabolism and homeostasis.  
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3.5.3 Animal-to-Human Extrapolations 
Reigner et al. (1993) investigated the binding of radiolabeled pentachlorophenol to serum proteins in 
vitro, found that the percentage of unbound pentachlorophenol in serum was 1.37 in mice, 0.85 in rats, 
0.67 in monkeys, 0.53 in humans, and 0.43 in cows and found that these percentages correlated inversely 
with the total protein levels in the same serum samples.  These investigators, assuming that pentachloro­
phenol itself is responsible for carcinogenicity in mice, developed a new method for interspecies 
extrapolation in which the interspecies differences in clearance and serum protein binding of pentachloro­
phenol were taken into account in interspecies scaling.  Several pharmacokinetic parameters, including 
volume of distribution, unbound volume of distribution, clearance, unbound clearance, and unbound 
clearance time maximum life potential, were scaled to body weight.  The method produced estimates of 
equivalent human doses of pentachlorophenol (derived from experimental doses in mice that caused 
increased tumor incidences in the NTP [1989] 2-year bioassay) that are up to four times smaller than 
those obtained using body surface area. 
3.6 ENDOCRINE DISRUPTION 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones, or otherwise 
interfere with the normal function of the endocrine system.  Chemicals with this type of activity are most 
commonly referred to as endocrine disruptors.  Some scientists believe that chemicals with the ability to 
disrupt the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. 
Others believe that endocrine disrupting chemicals do not pose a significant health risk, particularly in 
light of the fact that hormone mimics exist in the natural environment.  Examples of natural hormone 
mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These 
compounds are derived from plants and are similar in structure and action as endogenous estrogen.  While 
there is some controversy over the public health significance of endocrine disrupting chemicals, it is 
agreed that the potential exists for these compounds to affect the synthesis, secretion, transport, binding, 
action, or elimination of natural hormones in the body that are responsible for the  maintenance of 
homeostasis, reproduction, development, and/or behavior (EPA 1997).  As a result, endocrine disruptors 
may play a role in the disruption of sexual function, immune suppression, and neurobehavioral function. 
Endocrine disruption is also thought to be involved in the induction of breast, testicular, and prostate 
cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
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Several studies have documented effects of pentachlorophenol on thyroid homeostasis (Beard and 
Rawlings 1998, 1999; Beard et al. 1999a, 1999b; Jekat et al. 1994; van Raaij et al. 1991a).  These effects 
include decreased serum thyroxine concentration (Beard and Rawlings 1998, 1999; Beard et al. 1999a, 
1999b; Jekat et al. 1994; van Raaij et al. 1991a), decreased thyroxine and triiodothyronine response to 
thyroid stimulating hormone (Beard and Rawling 1999), and decreased uptake of thyroxine into 
cerebrospinal fluid (van Raaij et al. 1994); these effects may be linked with a demonstrated competition 
of pentachlorophenol with the thyroxine binding site on transthyretin, a major thyroxine transport protein 
(den Besten et al. 1991). 
Developmental toxicity studies provide some limited evidence that pentachlorophenol has the ability to 
disrupt endocrine function. A marked increase in the sex ratio (most female fetuses did not survive) was 
observed in the offspring of rats administered pure or technical-grade pentachlorophenol on gestational 
days 6–15 (Schwetz et al. 1974).  However, the finding was not confirmed in other developmental 
toxicity studies (Argus 1993b/Bernard et al. 2001b, Argus 1997/Bernard et al. 2001c).  In a 
multigeneration study in rats, significant increases in the average day of vaginal patency and preputial 
separation were observed in the F1 offspring exposed to an unspecified purity pentachlorophenol (Argus 
1997/Bernard et al. 2001c). 
In an in vitro test system, pure pentachlorophenol inhibited the activity of the human progesterone 
receptor. Tran et al. (1996) transformed a yeast strain with an expression plasmid for the human 
progesterone (hPR) receptor and a reporter containing two progesterone response elements.  In the 
resulting yeast strain, hPR-PRE, beta-galactosidase activity was measured as an indicator of stimulation 
of the hPR signaling pathway.  When the signaling pathway was stimulated by progesterone, 1 µM penta­
chlorophenol (99% pure) significantly inhibited hPR activity.  Competitive binding studies indicated that 
pentachlorophenol effectively competed with a radiolabeled synthetic progestin for binding to hPR. 
Investigation of the interaction of pentachlorophenol with the progesterone-signaling pathway in animals 
might be another avenue for future research. 
In rainbow trout hepatocytes, pentachlorophenol inhibited the induction of the estrogen receptor by 
estradiol and inhibited the induction of vitellogenin messenger RNA by estradiol (Flouriot et al. 1995).  In 
short-term, whole-embryo assays using Xenopus laevis, pentachlorophenol significantly decreased the 
rates of tail resorption in metamorphs studied from day 50 (stage 60) to day 64 (stage 66) of development 
(Fort and Stover 1997). 
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3.7 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. 
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
109 PENTACHLOROPHENOL 
3. HEALTH EFFECTS 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility while others may 
decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
There have been several reports of children accidentally exposed to pentachlorophenol; the children were 
predominantly exposed via dermal contact and, to a lesser extent, by the inhalation route.  The observed 
health effects include symptoms of hyperthermia (high fever, profuse sweating, increased respiratory rate, 
labored breathing, tachycardia, hepatomegaly, and irritability) due to the uncoupling of oxidative 
phosphorylation and death in newborn infants following dermal contact with diapers and bedding washed 
in an antimildew agent containing pentachlorophenol (Robson et al. 1969; Smith et al. 1996) and in a 
child exposed to bath water contaminated with pentachlorophenol (Chapman and Robson 1965).  The 
Chapman and Robson (1965) report provides suggestive evidence that young children may be more 
susceptible to the toxicity of pentachlorophenol than adults.  All members of the child’s family bathed in 
the contaminated bath water over a 13-day period; however, the only symptoms reported in the other 
family members were nasal stuffiness and swollen, painful eyes.  A study by McConnachie and Zahalsky 
(1991) also reported health effects in children. Alterations in immunological parameters were observed in 
individuals living in log homes treated with a wood preservative containing pentachlorophenol.  Fifteen 
of the 38 subjects were children aged 8–18. This study cannot be used to assess whether children would 
be more susceptible to the toxicity of pentachlorophenol because no comparisons across age groups were 
made.  In addition to these health effects, hematological disorders (Cheng et al. 1993; Hryhorczuk et al. 
1998; Klemmer et al. 1980; Roberts et al. 1981, 1990; Rugman and Cosstick 1991) and liver (Armstrong 
et al. 1969; Bergner et al. 1965; Colosio et al. 1993b; Gordon 1956; Robson et al. 1969; Smith et al. 
1996) effects have been observed in adults exposed to pentachlorophenol, and these are likely targets in 
children. An animal study that compared LD50 values provides evidence that infants may be more 
susceptible than children. Lower LD50 values were found in preweaning animals, as compared to juvenile 
rats (25–50 days); however, the LD50 value in adult rats was similar to the value for preweaning rats (St. 
Omer and Gadusek 1987).  
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There is some limited evidence that the developmental process in humans is altered by paternal exposure 
to pentachlorophenol. An increased risk of congenital eye cataracts was observed in the children of men 
presumably exposed to CDD-contaminated chlorophenate (Dimich-Ward et al. 1996); however, as 
discussed in Section 3.2.1.5, deficiencies in the study design limits interpretation of these results.  Studies 
of potential developmental effects of pentachlorophenol in animals indicate that the developing organism 
is a sensitive target of toxicity.  Fetal/neonatal mortality (Argus 1993b/Bernard et al. 2001b, Argus 1997/ 
Bernard et al. 2001c; Schwetz et al. 1974; Welsh et al. 1987), malformations/anomalies (Argus 1993b/ 
Bernard et al. 2001b; Schwetz et al. 1974), decreased growth (Argus 1993b/Bernard et al. 2001b; Beard et 
al. 1999b; Courtney et al. 1976; Larsen et al. 1975; Schwetz et al. 1974; Welsh et al. 1987), and possibly 
impaired development of the reproductive system (Argus 1997/Bernard et al. 2001c) have been observed 
in rats and sheep following gestational exposure. In most of these studies, the developmental effects 
occurred at maternally toxic doses; however, decreases in fetal body weight gain have been observed at 
doses that were not associated with maternal toxicity (Argus 1997/Bernard et al. 2001c; Welsh et al. 
1987). A number of studies in rats (Jekat et al. 1994) and sheep (Beard and Rawlings 1998; Beard et al. 
1999a, 1999b) have demonstrated that exposure to pentachlorophenol can result in decreased serum 
thyroxine and triiodothyronine levels.  Deficiencies in thyroxine during prenatal and postnatal life can 
cause decrements in intellectual function in children (Bargagna et al. 1997; Birrell et al. 1983; Kooistra et 
al. 1994). It is not known if this will also occur following exposure to pentachlorophenol, and neuro­
behavioral testing has not been performed on animals exposed to pentachlorophenol either prenatally or 
postnatally.  Such testing might be an avenue for future research. 
There is no information regarding pharmacokinetics of pentachlorophenol in children or regarding 
nutritional factors that may influence absorption of pentachlorophenol.  There are no PBPK models for 
pentachlorophenol. Mehmood et al. (1996) has provided evidence that human cytochrome P450 3A4 
may metabolize pentachlorophenol to TCHQ in phase I metabolism of pentachlorophenol; however, the 
purity of the pentachlorophenol used in this study was not indicated.  In humans, this enzyme has low 
activity in the first month of life, with approach toward adult levels by 6–12 months of postnatal age; 
adult activity may be exceeded between 1–4 years of age and then activity progressively declines, 
reaching adult levels at the conclusion of puberty (Leeder and Kearns 1997).  By Western 
immunoblotting using monoclonal antibodies to identify the different P 450 isozymes, pure pentachloro­
phenol (>99%) was identified as an inducer of cytochrome P450 3A7 in studies in cultured rat 
hepatocytes, quail hepatocytes, and human hepatoma (Hep G2) cells (Dubois et al. 1996).  In humans, 
functional activity of cytochrome P450 3A7 in the fetus is approximately 30–75% of adult levels (Leeder 
and Kearns 1997). UDP-glucuronosyl transferase and sulfotransferases are involved in phase II 
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metabolism of pentachlorophenol.  Both of these enzymes are thought to be developmentally regulated 
(Leeder and Kearns 1997). Although the ontogeny of UDP-glucuronosyl transferase is isoform-specific, 
the adult level of activity seems to be achieved in humans by 6–18 months of age (Leeder and Kearns 
1997). Ontogeny for the sulfotransferases seems to be more rapid than that for UDP-glucuronosyl 
transferase, and the activity for some isoforms of sulfotransferase may exceed adult levels during infancy 
and early childhood (Leeder and Kearns 1997).  Larsen et al. (1975) provided evidence that pentachloro­
phenol (0.05–0.08% of an oral dose administered on day 15 of gestation) may cross the placenta; the 
chemical nature of the radioactive material present in the fetuses was not investigated. 
Low levels of pentachlorophenol were found in human breast milk of women living in Germany or 
Slovakia (Gebefugi and Korte 1983; Veningerova et al. 1996).  It is likely that pentachlorophenol will 
also be present in the breast milk of women living in the United States, particularly since pentachloro­
phenol has been detected in more than half of the urine samples of adults living in the United States (Hill 
et al. 1995). However, it is not known if the pentachlorophenol present in the breast milk or urine 
samples resulted from exposure to pentachlorophenol or to other industrial chemicals that are metabolized 
to pentachlorophenol. 
There is no reason to suspect the mechanism of action of pentachlorophenol is different in children. 
There are no specific biomarkers of exposure or effect for pentachlorophenol that have been validated in 
children or adults exposed as children. No studies were located regarding interactions of pentachloro­
phenol with other chemicals in children. 
There are no pediatric-specific methods for reducing peak absorption or reducing body burden following 
exposure to pentachlorophenol. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
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molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to pentachlorophenol are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by pentachlorophenol are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic 
or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in 
the biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10. “Populations That Are Unusually Susceptible”. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Pentachlorophenol 
Since pentachlorophenol is excreted in the urine largely unchanged (Ahlborg et al. 1974; Braun et al. 
1979; Larsen et al. 1972; Reigner et al. 1991) and since it can be easily detected and quantified in the 
urine at concentrations as low as <1 ppb (Chou and Bailey 1986; Drummond et al. 1982; Edgerton et al. 
1979; EPA 1980b; Holler et al. 1989; NIOSH 1984b; Pekari and Aitio 1982; Rick et al. 1982; Siqueina 
and Fernicola 1981), pentachlorophenol in the urine is a useful biomarker of exposure.  In addition, 
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pentachlorophenol can be easily detected and quantified in blood serum at concentrations as low as 
<1 ppb (Bevenue et al. 1968; EPA 1980b; Needham et al. 1981; NIOSH 1984b) and adipose tissue 
(Kuehl and Dougherty 1980; Needham et al. 1981; Ohe 1979; Shafik 1973).  It has been demonstrated 
that pentachlorophenol is present in human adipose tissue as an ester of palmitic acid (Ansari et al. 1985). 
The detection limit for pentachlorophenol in adipose tissue is approximately 5 ppb (Kuehl and Dougherty 
1980; Ohe 1979; Shafik 1973). However, measuring pentachlorophenol in body fluids and tissues is not a 
specific biomarker for pentachlorophenol exposure because other compounds to which exposure may 
occur (e.g., hexachlorobenzene and lindane) may be metabolized to pentachlorophenol in the body.  In 
addition, the available data do not permit the establishment of a quantitative relationship between levels 
of pentachlorophenol in the environment and levels in human fluids or tissues.  However, it has been 
reported that repeated workday exposure to pentachlorophenol at a concentration of 0.5 mg/m3 has 
resulted in a maximum steady state level of pentachlorophenol in plasma of about 0.5 mg/L (Wood et al. 
1983). Based on samples taken prior to 1989, background levels of up to 0.1 ppm pentachlorophenol 
could be found in blood and urine of members of the general population who had no recognized exposure 
to pentachlorophenol (Cranmer and Freal 1970; EPA 1989b; Hill et al. 1989; Kutz et al. 1978). 
TCHQ, a major urinary metabolite of pentachlorophenol, has potential use as an indicator of exposure to 
pentachlorophenol. It has been demonstrated that pentachlorophenol is converted to TCHQ by human 
microsomal enzymes (Juhl et al. 1985).  In human and animal studies, TCHQ has been identified as the 
major urinary metabolite of pentachlorophenol (Ahlborg et al. 1974; Braun et al. 1977; Reigner et al. 
1991; Renner 1989). However, the presence of TCHQ in the urine is not specific to pentachlorophenol 
and would also be present following exposure to chemicals that are metabolized to pentachlorophenol. 
The presence of elevated levels of 8-hydroxydeoxyguanosine in the liver may serve as a nonspecific 
marker of oxidative DNA damage by pentachlorophenol.  Administration of pentachlorophenol (98.6% 
pure) to mice in the diet for up to 4 weeks produced oxidative damage to hepatic nuclear DNA as 
evidenced by an increase in the amount of 8-hydroxydeoxyguanosine in DNA (Sai Kato et al. 1995; 
Umemura et al. 1996).  A single oral dose of pentachlorophenol (98.6% pure) produced an increase in the 
amount of 8-hydroxydeoxyguanosine in liver DNA but not in kidney or spleen DNA (Sai-Kato et al. 
1995). 
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3.8.2 Biomarkers Used to Characterize Effects Caused by Pentachlorophenol 
Two of the major target organs for both humans and animals exposed to pentachlorophenol are liver and 
kidney.  Clinical manifestations of hepatic and renal toxicity include elevated serum ALT and AST levels 
for toxicity to the liver (Armstrong et al. 1969; Bergner et al. 1965; Gordon 1956; Gray et al. 1985; 
Klemmer 1972; Robson et al. 1969) and increased enzyme levels, increased blood urea nitrogen, and loss 
of proximal tubular alkaline phosphatase activity for toxicity to the kidney (Greichus et al. 1979; 
Kimbrough and Linder 1978; Nishimura et al. 1980).  Indices of changes in hepatic oxidative 
phosphorylation may also be useful as biomarkers for pentachlorophenol-induced liver changes (Ellinger 
et al. 1991). These effects are not specific for exposure to pentachlorophenol and have been associated 
with exposure to other compounds such as some chlorinated hydrocarbons.  Therefore, the major use of 
these biomarkers is restricted to comparisons between work groups exposed to the chemical in the 
workplace and control subjects. Other data indicate that contaminants in the commercial grade product 
may play an important role in these observed hepatotoxic effects.  
Human case reports of pentachlorophenol exposure suggest that the central nervous system appears to be 
a target of pentachlorophenol exposure (Chapman and Robson 1965; Gray et al. 1985; Haley 1977; 
Robson et al. 1969). As discussed in Section 3.2.2.4, the neurologic syndrome observed following 
exposure to pentachlorophenol is possibly the direct result of hyperthermia generated by uncoupling of 
mitochondrial oxidative phosphorylation rather than a direct effect on the nervous system.  The 
neurological syndrome observed following exposure to pentachlorophenol can be manifested by lethargy, 
tachypnea, tachycardia, intermittent delirium, convulsions, cerebral edema, focal swelling of the myelin 
sheath, and respiratory distress (Chapman and Robson 1965; Gray et al. 1985).  However, these 
symptoms are not specific for pentachlorophenol exposure.  
In general, there is no simple relationship between nonfatal health effects and levels of pentachlorophenol 
detected in serum and urine.  Serum levels of pentachlorophenol ranging from 23 to 162 mg/L (ppm) have 
been reported in cases of fatal overexposure to pentachlorophenol.  Serum levels of pentachlorophenol 
below 1.3 mg/L have not been associated with any adverse health effects (Cline et al. 1989; Klemmer et 
al. 1980). 
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3.9 INTERACTIONS WITH OTHER CHEMICALS 
No studies were located regarding the direct toxic interactions of pentachlorophenol with other chemicals 
in humans, including children, or animals.  No interactions between pentachlorophenol contaminants and 
the pure pentachlorophenol component of technical-grade pentachlorophenol have been demonstrated in 
some tests of immunotoxicity (Kerkvliet et al. 1985a). 
Pentachlorophenol may alter the toxicities of other compounds through its inductive action on 
microsomal metabolic enzymes (Vizethum and Goerz 1979).  While this inductive effect has not 
specifically been demonstrated to alter the toxicity of other compounds, these types of alterations in 
enzyme activity may influence metabolism and toxicity of many compounds.  Pentachlorophenol inhibits 
cytosolic sulfotransferases (Mulder and Scholtens 1977).  Compounds such as n-hydroxy-2-acetyl­
aminofluorene, which are activated by the formation of a sulfate ester, are considerably less toxic in 
animals pretreated with pentachlorophenol (Meerman et al. 1980).  Pentachlorophenol, an inhibitor of 
arylsulfotransferase, significantly decreased 2-acetylaminofluorene-induced DNA damage in rat 
hepatocytes in vitro. In vivo, pentachlorophenol alone induced a significant increase in unscheduled liver 
DNA synthesis, but also caused a significant decrease in 2-acetylaminofluorene-induced unscheduled 
liver DNA synthesis (Monteith 1992). 
Male rats were given pentachlorophenol (91.6%) daily by gavage at a dose of 20 mg/kg.  At 1, 2, 4, and 
5 weeks, the animals were given a single gavage dose of 2,6-dinitrotoluene, and urine was collected for 
24 hours and tested for mutagenicity in Salmonella typhimurium strain TA98. A statistically-significant 
increase in revertants at week 5 in pentachlorophenol-treated animals, compared with controls that did not 
receive pentachlorophenol, suggested that pentachlorophenol caused an increase in the excretion of 
mutagenic metabolites of 2,6-dinitrotoluene.  A slight, but statistically-significant, decrease in 
nitroreductase activity in the small intestine was also reported in the pentachlorophenol-treated rats 
compared with controls (Chadwick et al. 1993). 
Since pentachlorophenol is metabolized to a small extent by hepatic microsomal enzymes, chemicals that 
alter the activity of these enzymes can modify metabolism, and subsequently, the toxicity of pentachloro­
phenol (see discussion above). For example, phenobarbital, a microsomal enzyme inducer, increases 
biotransformation of pentachlorophenol to TCHQ thereby reducing the level of pentachlorophenol in the 
body (Ahlborg et al. 1978). 
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A great deal of pentachlorophenol is bound to plasma proteins (Braun et al. 1977).  Other agents that also 
have a high affinity for protein bonds (e.g., anticoagulants such as warfarin) could compete with and 
displace pentachlorophenol from proteins.  This action could then result in a higher level of free-
circulating pentachlorophenol that can be metabolized, or excreted, and/or induce toxic effects.  However, 
this hypothesis has not been experimentally confirmed. 
Various agents have been used in experimental animals to try to decrease the toxicity of pentachloro­
phenol. Cholestyramine is known to bind phenols (Reiman and Walton 1970) and to enhance fecal 
elimination of chlordecone (Kepone) in rats and humans (Boylan et al. 1977).  Rozman et al. (1982) 
found that cholestyramine enhances excretion of pentachlorophenol in Rhesus monkeys and recommends 
that its use be considered in cases of human pentachlorophenol overexposure.  
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to pentachlorophenol than will 
most persons exposed to the same level of pentachlorophenol in the environment.  Reasons may include 
genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette 
smoke).  These parameters result in reduced detoxification or excretion of pentachlorophenol, or 
compromised function of organs affected by pentachlorophenol.  Populations who are at greater risk due 
to their unusually high exposure to pentachlorophenol are discussed in Section 6.7, Populations With 
Potentially High Exposures. 
Groups possibly at greater-than-average risk of suffering from the toxic effects of pentachlorophenol 
include persons laboring in hot environments, persons with an inability or decreased ability to disperse 
body heat, geriatric and pediatric subpopulations, pregnant women, and those that are malnourished or 
consume an unbalanced diet.  People with impaired liver and kidney function are likely to be susceptible 
to the toxic effects of any chemical/product that is metabolized and/or excreted by these organs, and 
therefore, may be unusually susceptible to the toxic effects of pentachlorophenol. 
Persons laboring in hot environments are unusually susceptible to the acute toxic effects of pentachloro­
phenol. One of the principal effects of pentachlorophenol is hyperthermia induced by the uncoupling of 
oxidative phosphorylation.  The manifestations of overexposure to pentachlorophenol, particularly in 
persons laboring in a hot environment, are usually those associated with hyperthermia:  flushing, intense 
thirst, sweating, weakness and, occasionally, muscle spasms.  Persons working in hot environments are 
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unable to disperse excess body heat, resulting in potentially life-threatening hyperthermia.  For example, 
occupational deaths reported by Bergner et al. (1965), Gray et al. (1985), and Menon (1958) were all due 
to hyperthermia, and the symptoms of hyperthermia described above were exhibited by affected workers 
prior to death. 
There is some evidence that young children are more susceptible than older children or adults to the toxic 
effects of pentachlorophenol often associated with the uncoupling of oxidative phosphorylation.  In a 
study by Chapman and Robson (1965), signs of hyperthermia (resulting from the uncoupling of oxidative 
phosphorylation) were observed in a 3-year old child exposed to pentachlorophenol in contaminated bath 
water. However, no signs of hyperthermia were observed in older children or adults in the family. 
Preweaning and adult rats have been reported to have lower oral LD50s for technical-grade pentachloro­
phenol than juvenile rats (25–50 days old) (St. Omer and Gadusek 1987); similar differences in sensitivity 
are possible in humans.  
Age-related differences in the frequency or severity of toxic effects from pentachlorophenol exposure 
may arise from developmental regulation of cytochrome P-450s, which are involved in phase I 
metabolism of pentachlorophenol, and sulfotransferases and UDP-glucuronosyl transferase, which are 
involved in phase II metabolism of pentachlorophenol (see Section 3.7). 
Oral and intraperitoneal administration of pentachlorophenol to animals causes adverse effects on thyroid 
homeostasis (e.g., decreased serum thyroxine) and on the thyroid gland, and such effects may occur 
during gestation, pregnancy, and lactation.  Pentachlorophenol also significantly decreased the uptake of 
radiolabeled thyroid hormone into cerebrospinal fluid (see Section 3.7).  These effects of pentachloro­
phenol on the thyroid gland, thyroid homeostasis, and the availability of thyroid hormone to the central 
nervous system may have adverse effects on development of the nervous system.  Deficiencies in 
thyroxine during prenatal and postnatal life can cause decrements in intellectual function in children 
(Bargagna et al. 1997; Birrell et al. 1983; Kooistra et al. 1994), and hypothyroidism in animals leads to 
disorders in structural and functional development of the brain (Gould et al. 1990; Neveu and Arenas 
1996; Stein et al. 1991; Vega-Nunez et al. 1995). 
Individuals with liver or kidney disease may be unusually susceptible to the toxic effects of pentachloro­
phenol. In certain fatal human cases, the victim was found to have renal insufficiency (Hayes 1982). 
Experiments have shown that rabbits made nephrotic experimentally were much more susceptible to the 
toxic effects of pentachlorophenol than were normal rabbits (Hayes 1982).  Individuals exposed to other 
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chemicals that bind to plasma proteins (e.g., anticoagulants such as warfarin) may be at greater risk of 
suffering from pentachlorophenol-induced toxicity as well. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to pentachlorophenol. However, because some of the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment of exposures to pentachlorophenol. 
When specific exposures have occurred, poison control centers and medical toxicologists should be 
consulted for medical advice.  The following texts provide specific information about treatment following 
exposures to pentachlorophenol: 
Ballhorn L, Rozman T, Rozman K, et al.  1981. Cholestryamine enhances fecal elimination of 
pentachlorophenol in Rhesus monkeys.  Chemosphere 10:877-888. 
EPA. 1989b. Recognition and management of pesticide poisonings.  4th ed. Washington, DC: U.S. 
Environmental Protection Agency.  EPA-540/9-88-001. 
Goodman AG, Rall TW, Nies AS, et al.  1990. Goodman & Gilman’s the pharmacological basis of 
therapeutics. 8th ed. New York, NY: Pergamon Press, 1635. 
Rozman T, Ballhorn L, Rozman K, et al.  1982. Effect of cholestyramine on the disposition of 
pentachlorophenol in Rhesus monkeys.  J Toxicol Environ Health 10:277-283. 
3.11.1 Reducing Peak Absorption Following Exposure 
Means of limiting absorption of phenols include washing exposed skin and eyes and removing 
contaminated clothing in the case of dermal exposure, and inducing emesis, performing gastric lavage, 
and administering activated charcoal and a cathartic in the case of oral exposure (EPA 1989b).  Emesis is 
induced only if the patient is fully alert and the pentachlorophenol has not been ingested in a solvent so 
that there is no chance that the stomach contents may be aspirated.  If the patient is unconscious or 
vomiting cannot be induced, intubation, aspiration, and lavage of the stomach are suggested (EPA 
1989b). 
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3.11.2 Reducing Body Burden 
Various agents have been used in experimental animals to try to decrease the toxicity of pentachloro­
phenol by reducing body burden.  Cholestyramine is known to bind phenols (Reiman and Walton 1970) 
and to enhance fecal elimination of chlordecone (Kepone) in rats and humans (Boylan et al. 1977).  In 
studies performed on Rhesus monkeys, oral administration of cholestyramine enhanced fecal excretion of 
pentachlorophenol by interrupting enterohepatic circulation of pentachlorophenol and/or its metabolites 
(Ballhorn et al. 1981; Rozman et al. 1982).  Thus cholestyramine administration may be an effective 
means of reducing the body burden of pentachlorophenol in humans (Goodman et al. 1990); it should be 
noted that testing would be required to determine whether or not cholestyramine treatment would be 
effective for humans.  Hemodialysis and forced diuresis may not be effective means of reducing body 
burden of phenolic substances, and hemoperfusion has not been sufficiently tested as a means of 
accelerating elimination of phenols (EPA 1989b). 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects 
The naturally occurring antioxidants ellagic acid, epigallocatechin gallate, and vitamin C provided partial 
protection from pentachlorophenol-induced oxidative damage to liver DNA during daily oral 
administration of pentachlorophenol at 60 mg/kg/day for 5 days to male B6C3F1 mice (Sai-Kato et al. 
1995). Since these antioxidants are protective of animals, they may reduce toxic effects in humans. 
3.12 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of pentachlorophenol is available.  Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of pentachlorophenol. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
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that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Pentachlorophenol 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
pentachlorophenol are summarized in Figure 3-4.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of pentachlorophenol.  Each dot in the figure indicates that one 
or more studies provide information associated with that particular effect.  The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (ATSDR 1989), is substance-specific 
information necessary to conduct comprehensive public health assessments.  Generally, ATSDR defines a 
data gap more broadly as any substance-specific information missing from the scientific literature. 
Much of the literature reviewed concerning the health effects of pentachlorophenol in humans described 
case reports of individuals exposed occupationally, in log homes treated with pentachlorophenol as a 
preservative, or in the home following misuse of pentachlorophenol-containing solutions.  The 
predominant route of exposure in such cases is often dermal, but the possibility of some degree of 
inhalation exposure cannot be ruled out.  Therefore, Figure 3-4 reflects that information exists for both 
inhalation and dermal routes of exposure.  However, all of these reports are limited because of the 
possibility of concurrent exposure to other potentially toxic substances, present as either contaminants in 
technical-grade pentachlorophenol (i.e., chlorinated dibenzo-p-dioxins and dibenzofurans), as other 
components in pentachlorophenol-containing mixtures (i.e., pesticides and herbicides), or simply other 
compounds also in the environment.  Additionally, duration and level of exposure to pentachlorophenol 
generally cannot be quantified from information presented in these anecdotal reports. 
The database for health effects of pentachlorophenol following ingestion in experimental animals is 
substantial. However, as can be seen in Figure 3-4, very little information is available on the effects of 
inhalation and dermal exposure to pentachlorophenol in animals.  Furthermore, the health effects 
associated with acute and intermediate exposure durations are more fully characterized than those 
associated with chronic exposure. Genotoxicity data on pentachlorophenol are available from both in 
vitro and in vivo studies. Finally, when evaluating much of the data on health effects of pentachloro­
phenol, the toxicity of its impurities (which may themselves present a hazard at disposal sites) must be 
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Figure 3-4. Existing Information on Health Effects of Pentachlorophenol 
    
122 PENTACHLOROPHENOL 
3. HEALTH EFFECTS 
taken into account. However, it is now clear that pure pentachlorophenol is toxic to several organs and 
systems in rats and mice and is oncogenic in mice. 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Information on the acute toxicity of pentachlorophenol in humans 
comes from a number of case reports involving home use of pentachlorophenol-containing products, such 
as wood preservatives or herbicides in the garden (Gordon 1956; Hassan et al. 1985) and from a series of 
reports of newborn infants exposed to pentachlorophenol from diapers and linens treated with an 
antimildew agent (Armstrong et al. 1969; Robson et al. 1969; Smith et al. 1996).  In many of the cases, it 
is likely that the individuals were primarily exposed to technical-grade pentachlorophenol via dermal 
contact, although there may have also been some inhalation exposure.  There are also cases of individuals 
ingesting pentachlorophenol (Cretney 1976; Dreisbach 1980; Haley 1977).  In general, no information on 
exposure concentration, duration of exposure, exposure to other chemicals, or the impurities present in the 
technical-grade pentachlorophenol is available. A number of health effects were consistently observed in 
these individuals, including death, symptoms of hyperthermia generated by uncoupling of oxidative 
phosphorylation (e.g., tachycardia, increased respiratory rate, labored breathing, profuse sweating, fever, 
metabolic acidosis), hemolytic anemia, hepatic enlargement, and dermal toxicity (irritation and 
chloracne). 
The only available inhalation study in animals (Hoben et al. 1979b) reported death, but did not examine 
other end points. The lack of exposure information in the human studies and the inadequate animal study 
precluded deriving an acute-duration inhalation MRL.  Additional inhalation studies are needed to 
characterize target organs and establish exposure-response relationships. 
Most of the available information on the acute toxicity of pentachlorophenol in animals comes from oral 
exposure studies. A number of adverse effects were observed in oral exposure studies including death 
(Borzelleca et al. 1985; Deichmann et al. 1942; Renner et al. 1986; St. Omer and Gadusek 1987), 
cardiovascular effects (extensive vascular damage and heart failure) (Deichmann et al. 1942), 
hepatotoxicity (increased relative liver weight) (Nishimura et al. 1982), impaired immune function 
(Holsapple et al. 1987; Kerkvliet et al. 1985a; White and Anderson 1985), reproductive toxicity (Schwetz 
et al. 1974), and developmental toxicity (Schwetz et al. 1974).  The developing fetus was identified as the 
most sensitive target in rats following acute gavage exposure to pure pentachlorophenol (Schwetz et al. 
1974). The observed effects included delayed ossification at the lowest dose tested (5 mg/kg/day 
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administered on gestational days 6–15) and skeletal anomalies, decreased fetal body weights, increased 
male:female sex ratio, and increased resorptions at higher doses.  The Schwetz et al. (1974) study is the 
basis for an acute-duration oral MRL of 0.005 mg/kg/day. 
Pentachlorophenol is well absorbed through the skin, and is expected to produce effects in the same 
tissues affected by exposure via other routes.  Human reports describe numerous systemic effects in 
individuals predominantly exposed through dermal contact.  Skin irritation was reported in a dermal study 
in rabbits (Deichmann et al. 1942).  Additional studies via dermal exposure would be useful in 
determining target organs and dose-response relationships following acute-duration exposures. 
Intermediate-Duration Exposure. There is limited information on the toxicity of 
pentachlorophenol in humans following intermediate-duration exposure.  Case reports of individuals 
exposed either occupationally or in the home during misuse of pentachlorophenol-containing solutions as 
a result of failure to adhere to appropriate precautionary measures provide some information on the 
toxicity of pentachlorophenol in humans.  The observed effects include hematological alterations (aplastic 
anemia), hyperthermia (due to uncoupling of oxidative phosphorylation), hepatic enlargement, and 
impaired immune function (Daniel et al. 1995; Gray et al. 1985; Roberts 1963, 1981, 1990; Rugman and 
Cosstick 1990). Dermal contact is probably the primary exposure route in these cases, although the 
possibility of inhalation exposure cannot be ruled out.  The interpretation of the reports is limited by the 
small number of subjects and the lack of information on exposure concentration, route, and duration, 
concomitant exposure to other chemicals, and description of impurities present in the commercial- or 
technical-grade pentachlorophenol. No studies were located that examined the toxicity of 
pentachlorophenol in humans following intermediate-duration oral exposure. 
No inhalation studies in animals were located.  An intermediate-duration inhalation MRL was not derived 
due to the lack of human and/or animal data.  A 90-day inhalation study is necessary to identify sensitive 
end points and dose-response relationships. 
Information on the toxicity of pentachlorophenol in animals following intermediate-duration exposure 
primarily comes from oral exposure studies.  The results of these studies suggest that the reproductive 
system is the most sensitive target of toxicity following intermediate-duration exposure.  An increase in 
the severity of cystic uterine glands and decreases in the proportion of female mink accepting a second 
mating and the number of mink that whelped have been observed in a single-generation mink study 
(Beard et al. 1997). Other sensitive end points include the liver (increased liver weight, centrilobular 
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hepatocyte hypertrophy and vacuolation, hepatocellular degeneration, and periportal fibrosis) (Blakley et 
al. 1998; Greichus et al. 1979; Johnson et al. 1973; Kerkvliet et al. 1982; Kimbrough and Linder 1978; 
Knudsen et al. 1974; Nishimura et al. 1980; Umemura et al. 1996), endocrine system (decreased 
thyroxine levels, increased thyroid gland follicle size) (Beard et al. 1999; Rawlings et al. 1998), immune 
system (Blakley et al. 1998; Kerkvliet et al. 1982, 1985a, 1985b; NTP 1989), and the developing fetus 
(decreased litter size, decreased fetal body weights, embryo lethality) (Argus 1997/Bernard et al. 2001c; 
Beard et al. 1999; Welsh et al. 1987). The studies in sheep suggest that the thyroid system is a sensitive 
target of pentachlorophenol toxicity.  Additional studies are needed in conventional laboratory species to 
confirm the sensitivity of this organ and to evaluate the relevance of the effect to human health; other 
endocrine tissues should also be examined for potential effects.  The LOAEL identified for reproductive 
effects in mink was used to derive an intermediate-duration oral MRL.  Additional studies are needed to 
better define dose-response relationships and to identify no adverse effect levels. 
Information on the dermal toxicity of pentachlorophenol in animals is limited to a study that reported 
death and dermal irritation in rabbits following application of pentachlorophenol in fuel oil; the vehicle 
may have contributed to the observed effects (Deichmann et al. 1942).  Studies examining systemic end 
points following dermal exposure would be useful to establish thresholds. 
Chronic-Duration Exposure and Cancer. Occupational exposure studies and reports of families 
living in log homes that were treated with pentachlorophenol provide information on the chronic toxicity 
of pentachlorophenol in humans.  The reported effects include inflammation of the upper respiratory tract 
and bronchitis (Baader and Bauer 1951; Klemmer et al. 1980), reduced glomerular filtration rate and 
tubular function (Begley et al. 1977), hepatic effects (increased levels of biliary acid concentrations, 
urinary porphyrin, and serum alanine and aspartate transaminases) (Cheng et al. 1993; Colosio et al. 
1993a; Hryhorczuk et al. 1998; Klemmer 1972), and impaired immune function (McConnchie and 
Zahalsky 1991).  It is likely that the individuals were exposed via inhalation and dermal contact.  In 
general, the epidemiology studies involved exposure to technical-grade or undefined purity pentachloro­
phenol; therefore, other chemicals may have contributed to these effects.  Little information on exposure 
concentrations is available. No chronic oral human studies were located. 
Chronic-duration animals studies are only available for the oral route.  Liver effects (hepatocyte cystic 
degeneration, hepatodiaphragmatic nodules) (Chhabra et al. 1999; NTP 1999; Schwetz et al. 1978) and 
effects on the thyroid (decreased serum thyroxine and decreased relative thyroid weight) (Beard and 
Rawlings 1998, 1999; Beard et al. 1999a) were reported in these studies.  A chronic-duration oral MRL of 
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0.001 mg/kg/day was calculated based on a LOAEL of 1 mg/kg/day for significantly decreased serum 
thyroxine concentrations in males of the first generation and males and females of the second generation, 
and decreased relative thyroid weight in females of the second generation when mink were administered 
pentachlorophenol of unspecified purity continuously in the diet in a multigeneration reproduction study 
(Beard and Rawlings 1998). A chronic-duration inhalation MRL was not developed because 
concentrations that cause toxic effects in humans were not quantified and no animal studies were 
identified. Chronic inhalation studies are necessary for establishing exposure-response relationships and 
identifying sensitive targets of toxicity.  No dermal animal studies were identified; chronic dermal 
exposure studies would be useful for identifying sensitive targets of the toxicity and establishing 
exposure-response relationships. 
Epidemiology studies have not provided a firm association between pentachlorophenol exposure and an 
increased risk of cancer. Several occupational studies reported no association between inhalation of 
pentachlorophenol in any form and cancer in humans (Gilbert et al. 1990; Jappinen et al. 1989; Johnson et 
al. 1990; Robinson et al. 1985). However, each of the individual studies had a low power to detect 
elevated risk estimates.  In contrast, other occupational studies reported an association between 
pentachlorophenol exposure and soft tissue sarcoma (Eriksson et al. 1990; Hardell et al. 1995; Hoppin et 
al. 1998; Lampi et al. 1992) or non-Hodgkin’s lymphoma (Hardell et al. 1994; Hertzman et al. 1997; 
Lampi et al. 1992).  Many of these studies also reported significant associations between increased cancer 
risk and exposure to other chemicals (e.g., other chlorophenols, phenoxyacetic acids, cutting oil 
components).  Additional follow-up of pentachlorophenol-exposed cohorts using epidemiological 
methods and study designs of sufficient power and discrimination to distinguish effects of 
pentachlorophenol from effects attributable to other possible causes would be useful for assessing the 
carcinogenic potential of pentachlorophenol in humans.  Sufficient information exists from animal studies 
to support the conclusion that pentachlorophenol may cause cancer in humans.  Significant increases in 
the incidence of hemangiosarcomas, liver adenomas and carcinomas, and adrenal gland 
pheochromocytomas were observed in mice (NTP 1989), and mesotheliomas and nasal squamous cell 
carcinomas were observed in rats orally exposed to pure pentachlorophenol (Chhabra et al. 1999; NTP 
1999). No information is available on the carcinogenic potential following inhalation or dermal exposure; 
chronic bioassays by these routes would be useful in determining whether pentachlorophenol induces 
cancer of the respiratory tract and skin, respectively.
The suggestive human data and the positive carcinogenicity results from animal bioassays (Chhabra et al. 
1999; NTP 1989, 1999), along with genotoxicity data suggesting that pentachlorophenol is clastogenic, 
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provide sufficient evidence to suggest that pentachlorophenol may be a human carcinogen.  The 
International Agency for Research on Cancer (IARC 1999) has placed pentachlorophenol in group 2B 
(possibly carcinogenic to humans).  EPA classified pentachlorophenol as a group B2 carcinogen 
(probable human carcinogen) (IRIS 2001). 
Genotoxicity. The available genotoxicity data indicate that pentachlorophenol may have genotoxic 
potential. Two studies investigated the genotoxicity of pentachlorophenol in humans; both of these are 
inadequate because of the small number of subjects studied (Bauchinger et al. 1982; Wyllie et al. 1975). 
The observed effects included a small increase in the frequency of dicentrics and acentrics, but no 
increases in sister chromatid exchange, and an increase in chromosome aberrations.  In general, in vitro 
and in vivo studies have not reported evidence of genotoxicity.  Pentachlorophenol did not induce gene 
mutations in Salmonella typhimurium (Donnelly et al. 1998; Markiewicz et al. 1996; NTP 1999; Simmon 
et al. 1977; Waters et al. 1982) or Escherichia coli (Anderson et al. 1972; Lemma and Ames 1975; 
Moriya et al. 1983; Simmon et al. 1977; Waters et al. 1982); or DNA damage in E. coli (Fahrig 1974), 
Bacillus subtilis (Waters et al. 1982), Chinese hamster ovary cells (Ehrlich 1990), Chinese hamster V79 
cells (Dahlhaus et al. 1996), or mouse embryonic fibroblast cells (Wang and Lin 1995).  Several in vitro 
studies suggest that pentachlorophenol has clastogenic activity (Fahrig 1974; NTP 1999).  Increases in the 
occurrence of chromosomal aberrations in human lymphocytes and Chinese hamster ovary cells and sister 
chromatid exchange in Chinese hamster ovary cells have occurred (NTP 1999).  In Saccharomyces 
cerevisiae assays for recombination, positive and negative results have been found (Fahrig 1974; Fahrig et 
al. 1978; Waters et al. 1982), and positive results were found for induction of gene mutations (Fahrig et 
al. 1978). In in vivo studies, negative results have been found for gene mutations in a mouse spot test 
assay (Fahrig and Steinkamp-Zucht 1996), sex-linked recessive lethal mutations in Drosophila 
melanogaster (Sai-Kato et al. 1995; Umemura et al. 1996), and micronuclei occurrence in mouse and rat 
bone marrow (NTP 1999).  Given the availability of a number of genetic toxicology studies, there is no 
apparent need for additional genotoxicity testing at this time. 
Reproductive Toxicity. The possible association between pentachlorophenol exposure and 
reproductive effects in women has been investigated by Gerhard et al. (1991).  Elevated blood levels of 
pentachlorophenol were found in women with histories of reproductive effects (e.g., habitual abortions, 
unexplained infertility, menstrual disorders).  However, a causal relationship cannot be established due to 
limitations such as the lack of information on the exposure route and exposure to other chemicals (e.g., 
increased levels of PCBs were detected in the blood).  In addition, matched controls were not used and 
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other confounding factors were not controlled. No other human studies examined reproductive end 
points. 
Adverse reproductive effects were observed in animals following oral exposure to technical-grade and 
pure pentachlorophenol. In a two-generation reproductive toxicity study in rats, decreased fertility was 
observed the first generation exposed to 60 mg/kg/day pentachlorophenol (purity not reported) (Argus 
1997/Bernard et al. 2001c). Decreased frequency of second mating, decreased birth rate for the second 
mating, and increased severity of cystic uterine gland were observed in mink exposed to 1 mg/kg/day 
(Beard et al. 1997). In contrast, no reproductive effects were observed in a multigeneration study in mink 
using the same dietary concentration (Beard and Rawlings 1998).  No effect on fertility was observed in 
sheep exposed to 1 mg/kg/day prior to mating and throughout gestation and lactation (Beard et al. 1999b). 
No animal studies examined the reproductive toxicity of pentachlorophenol following inhalation or 
dermal exposure; studies by the inhalation and dermal routes would be valuable in establishing an 
exposure-response relationship for these exposure routes.  The intermediate-duration oral MRL is based 
on a LOAEL for reproductive effects observed in the single-generation mink study (Beard et al. 1997). 
Developmental Toxicity. An increased risk of congenital eye cataracts was observed in the children 
of male sawmill workers presumably exposed to CDD-contaminated mixtures of the sodium salts of 
pentachlorophenol and tetrachlorophenol (chlorophenate) (Dimich-Ward et al. 1996).  Interpretation of 
the study results is limited because exposure levels were not measured and a surrogate for chlorophenate 
exposure was used. No other human developmental toxicity studies were located. 
A number of animal studies reported developmental effects following oral exposure to pure or technical-
grade pentachlorophenol. The observed effects included fetal/neonatal mortality (Argus 1993b/Bernard 
et al. 2001b, Argus 1997/Bernard et al. 2001c; Schwetz et al. 1974; Welsh et al. 1987), 
malformations/anomalies (Argus 1993b/Bernard et al. 2001b; Schwetz et al. 1974), and decreased growth 
(Argus 1993b/Bernard et al. 2001b; Beard et al. 1993b; Courtney et al. 1976; Larsen et al. 1975; Schwetz 
et al. 1974; Welsh et al. 1987). A threshold for developmental toxicity has not been identified.  A 
comparison between the adverse effects levels for developmental effects with those for systemic, immune, 
and reproductive effects, suggests that the fetus/neonate is a sensitive target for pentachlorophenol.  Note 
that the acute duration oral MRL is based on a LOAEL for developmental effects (Schwetz et al. 1974). 
A common limitation of these developmental toxicity studies is that only one dose level was tested in 
most of these studies.  Additional studies using a range of doses would be useful for establishing the 
threshold for developmental toxicity.  Additionally, several oral studies provide evidence that the thyroid 
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gland is sensitive to the toxicity of pentachlorophenol (Beard and Rawlings 1998; Beard et al. 1999; Jekat 
et al. 1994; Rawlings et al. 1998). It is not known whether this would also be a sensitive target in the 
developing organism.  Developmental studies that assessed thyroid function and tested for potential 
neurobehavioral and neuropathological effects would be useful since deficiencies in thyroxine during 
prenatal and postnatal periods can cause decrements in intellectual function in children (Bargagna et al. 
1997; Birrell et al. 1983; Kooistra et al. 1994). The available developmental toxicity studies involve 
maternal exposure; no studies have examined the potential developmental effect of paternal exposure.  No 
animal inhalation or dermal developmental toxicity studies are available for pentachlorophenol.  Studies 
by these exposure routes would be useful for establishing dose-response relationships. 
Immunotoxicity. Several human studies provide suggestive evidence that pentachlorophenol is an 
immunotoxicant.  Impaired mitogen-induced lymphocyte stimulation was observed in individuals 
exposed to pentachlorophenol-containing pesticides (Daniel et al. 1995); T-cell activation, autoimmunity, 
immunosuppression, and B-cell dysregulation were observed in family members living in pentachloro­
phenol-treated log homes (McConnachie and Zahalsky 1991); and decreased proliferative response to a 
mitogen was observed in factory workers exposed to high levels of pentachlorophenol (Colosio et al. 
1993b). Oral studies in animals provide strong evidence that technical-grade pentachlorophenol is an 
immunotoxicant, although none of the identified studies performed a complete immunotoxicity battery. 
Humoral and cellular immunity (Holsapple et al. 1987; Kerkvliet et al. 1985a; NTP 1989), susceptibility 
to tumor induction (Kerkvliet et al. 1982), and complement activity (White and Anderson 1985) have 
been adversely affected following oral exposure. Studies that tested both technical-grade and pure 
pentachlorophenol provide strong evidence that the immune effects are related to the level of impurities in 
the technical-grade product (e.g., CDDs, CDFs). Support for the immunotoxicity of pure pentachloro­
phenol is less conclusive, with some rat and mouse studies reporting altered immune function (Blakley et 
al. 1998; Kerkvliet et al. 1982) and other studies reporting no effects (Kerkvliet et al. 1985a; NTP 1989). 
No studies that tested the immunotoxicity of pentachlorophenol following inhalation or dermal exposure 
were located. The available data suggest that the immune system may be a sensitive target of toxicity 
following oral exposure to technical-grade pentachlorophenol and possibly pure pentachlorophenol. 
Neurotoxicity. In a number of case reports, neurological effects have been described in individuals 
likely exposed via inhalation and dermal contact.  The symptoms of central nervous system neurotoxicity 
include intermittent delirium, fever, convulsions, profuse sweating, and increased respiratory rate and 
labored breathing (Chapman and Robson 1965; Robson et al. 1969; Smith et al. 1996).  Similar 
neurological symptoms were reported in an individual intentionally ingesting a weed killer containing 
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12% pentachlorophenol (Haley 1977).  These effects are probably due to hyperthermia resulting from 
uncoupling of oxidative phosphorylation, rather than to a direct effect on the central nervous system. 
Neurological effects have also been observed in animals ingesting pentachlorophenol.  Although a study 
examining a complete neurotoxicology battery of tests has not been identified, the available oral exposure 
data provide evidence that pentachlorophenol is a neurotoxicant at high doses.  Oral exposure to relatively 
high doses of technical-grade or pure pentachlorophenol resulted in impaired motor activity and startle 
response in mice exposed to pentachlorophenol for 26 weeks, but not after 5 weeks (NTP 1989). 
Degenerative changes in the sciatic nerve myelin sheath were observed in rats administered 
pentachlorophenol of unspecified purity (Villena et al. 1992).  No neurological studies involving 
inhalation or dermal exposure to pentachlorophenol were identified. 
Epidemiological and Human Dosimetry Studies. A number of studies have reported adverse 
health effects in humans following short- or long-term exposure to pentachlorophenol.  The short-term 
data comes from case reports involving home use of pentachlorophenol-containing products such as wood 
preservative or herbicides in the garden (Gordon 1956; Hassan et al. 1985) or a series of reports of 
newborn infants exposed to pentachlorophenol from diapers and linens treated with an antimildew agent 
(Robson et al. 1969; Smith et al. 1996).  Long-term toxicity information comes from families living in log 
homes that were treated with pentachlorophenol (McConnachi and Zahalsky 1991) and occupational 
exposure in agricultural and wood-treatment industries (Baader and Bauer 1951; Cheng et al. 1993; 
Colosio et al. 1993b; Hryhorczuk et al. 1998; Klemmer et al. 1980).  As discussed previously, these 
studies are limited by incomplete exposure characterization.  In general, information on exposure 
concentrations, exposure route, duration of exposure, possible concomitant exposure to other chemicals, 
and impurities present in technical-grade pentachlorophenol are not available.  In most cases, exposure 
was by the inhalation and dermal routes.  The consistently observed effects include death (Cretny 1976; 
Dreisbach 1980; Gordon 1956; Roberts 1981, 1990; Rugman and Cosstick 1990), inflammation of the 
upper respiratory tract and bronchitis (following inhalation exposure) (ACGIH 1991; Baader and Bauer 
1951; Klemmer et al. 1980), symptoms of hyperthermia generated by uncoupling of oxidative 
phosphorylation (e.g., tachycardia, increased respiratory rate, labored breathing, profuse sweating, fever, 
metabolic acidosis) (Bergner et al. 1965; Gordon 1956; Gray et al. 1985; Haley 1977; Hassan et al. 1985; 
Menon 1958; Robson et al. 1969; Smith et al. 1996), hemolytic anemia (Hassan et al. 1985; Roberts 1981, 
1990; Rugman and Cosstick 1990), hepatic enlargement (Bergner et al. 1965; Cheng et al. 1993; Colosio 
et al. 1993b; Gordon 1956; Hassan et al. 1985; Hryhorczuk et al. 1998; Smith et al. 1996), impaired 
immune function (Colosio et al. 1993b; Daniel et al. 1995; McConnachi and Zahalsky 1991), and dermal 
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toxicity (irritation and chloracne) (Baader and Bauer 1951; Hosenfeld et al. 1986; Klemmer et al. 1980; 
Lambert et al. 1986; O’Malley et al. 1990).  
Additionally, several epidemiology studies have examined the carcinogenic potential of pentachloro­
phenol. These data are inconclusive with some studies reporting no association between cancer risk and 
exposure to pentachlorophenol (Gilbert et al. 1990; Jappinen et al. 1989; Johnson et al. 1990; Robinson et 
al. 1985) and other studies indicating a significant risk of soft tissue sarcoma (Eriksson et al. 1990; 
Hardell et al. 1995; Hoppin et al. 1998; Lampi et al. 1992) or non-Hodgkin’s lymphoma (Hardell et al. 
1994; Hertzman et al. 1997; Lampi et al. 1992).  Hepatotoxicity (Blakley et al. 1998; Chhabra et al. 1999; 
Greichus et al. 1979; Johnson et al. 1973; Kerkvliet et al. 1982; Kimbrough and Linder 1978; Knudsen et 
al. 1974; Nishimura et al. 1982; NTP 1999; Schwetz et al. 1978; Umemura et al. 1996), impaired immune 
function (Blakley et al. 1998; Holsapple et al. 1987; Kerkvliet et al. 1982, 1985a, 1985b; NTP 1989; 
White and Anderson 1985), and increased incidence of malignant tumors (Chhabra et al. 1999; NTP 
1989, 1999) have also been reported in animal studies involving oral exposure.  A number of other 
sensitive end points for animals, including thyroid toxicity, reproductive toxicity, and developmental 
toxicity, have not been fully investigated in humans.  Additional epidemiological studies that provide 
sufficient information for exposure characterization and examine a number of systemic end points would 
be useful for establishing sensitive targets of toxicity in humans and dose-response relationship data. 
Biomarkers of Exposure and Effect.
Exposure. Pentachlorophenol is excreted in the urine largely unchanged (Ahlborg et al. 1974; Braun et 
al. 1979; Larsen et al. 1972) and can easily be detected and quantified in the urine at concentrations as 
low as <1 ppb (Chou and Bailey 1986; Drummond et al. 1982; Edgerton et al. 1979; EPA 1980a; Holler 
et al. 1989; NIOSH 1984b; Pekari and Aitio 1982; Rick et al. 1982; Siqueina and Fernicola 1981).  Thus, 
measurement of pentachlorophenol in the urine is a useful biomarker of exposure.  In addition, 
pentachlorophenol can be easily detected and quantified in blood serum at concentrations as low as 
<1 ppb (Bevenue et al. 1968; EPA 1980a; Needham et al. 1981; NIOSH 1984b) and adipose tissue (Kuehl 
and Dougherty 1980; Needham et al. 1981; Ohe 1979; Shafik 1973).  However, measuring pentachloro­
phenol in body fluids and tissues is not a specific biomarker for pentachlorophenol exposure because 
other compounds to which exposure may occur (e.g., hexachlorobenzene and lindane) may be 
metabolized to pentachlorophenol in the body.  In addition, the available data do not permit the 
establishment of a quantitative relationship between levels of pentachlorophenol in the environment and 
levels in human fluids or tissues.  Additionally, a major pentachlorophenol urinary metabolite, TCHQ, 
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has potential use as an indicator of exposure to pentachlorophenol (Ahlborg et al. 1974; Braun et al. 1977; 
Juhl et al. 1985; Reigner et al. 1991; Renner 1989), although this biomarker is not specific for penta­
chlorophenol. Additional studies are needed to establish a relationship between exposure level and 
urinary concentration of TCHQ. 
Effect. The liver is a target organ for both humans and animals exposed to pentachlorophenol.  Clinical 
manifestations of hepatic and renal toxicity include elevated serum ALT and AST levels for toxicity to 
the liver (Armstrong et al. 1969; Bergner et al. 1965; Gordon 1956; Gray et al. 1985; Klemmer 1972; 
Robson et al. 1969). Indices of changes in hepatic oxidative phosphorylation may also be useful as 
biomarkers for pentachlorophenol-induced liver changes (Ellinger et al. 1991).  These effects are not 
specific for exposure to pentachlorophenol and have been associated with exposure to other compounds, 
such as some chlorinated hydrocarbons.  Therefore, the major use of these biomarkers is restricted to 
comparisons in which pentachlorophenol-exposed and control groups can be identified (e.g., between 
workers exposed to chemical in the workplace and control subjects).  Oral exposure of animals to 
pentachlorophenol induces a decrease of thyroxine levels in serum (Beard et al. 1999b; Jekat et al. 1994; 
Rawlings 1998). Comparison of the levels of thyroxine in control and pentachlorophenol-exposed 
populations could also serve as a nonspecific biomarker of pentachlorophenol effect.  In general, there is 
no simple relationship between nonfatal health effects and levels of pentachlorophenol detected in serum 
and urine. Development of additional, more sensitive biomarkers that are specific for pentachlorophenol 
effects would be useful in monitoring populations at high risk. 
Absorption, Distribution, Metabolism, and Excretion. The absorption, distribution, 
metabolism, and excretion of pentachlorophenol have been investigated in humans and animals. 
Evidence for absorption of pentachlorophenol by humans after exposure by the inhalation and dermal 
routes is provided by the observation of elevated urine and plasma levels in workers (Casarett et al. 1969; 
Jones et al. 1986; Pekari et al. 1991) and residents of log homes treated with pentachlorophenol (Cline et 
al. 1989; Hosenfeld et al. 1986). A study of two humans exposed to pentachlorophenol vapors for 
45 minutes provides evidence that it is well absorbed (Casarett et al. 1969).  Similarly, human studies also 
indicate that pentachlorophenol is readily absorbed following oral exposure (Braun et al. 1979; Uhl et al. 
1986). The results of inhalation (Hoben et al. 1976c) and oral (Ahlborg et al. 1974; Braun and Sauehoff 
1976; Braun et al. 1977; Meerman et al. 1983; Reigner et al. 1991) exposure studies in animals confirm 
the results of the human studies that pentachlorophenol is well absorbed following inhalation or oral 
exposure.  In vivo animal studies (Qiao et al. 1997; Wester et al. 1993) are sufficient to characterize the 
extent of absorption of pentachlorophenol in soil. However, additional animal studies would be useful for 
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determining the absorption efficiency of an aqueous solution of pentachlorophenol and neat 
pentachlorophenol. 
No human studies examined the distribution of pentachlorophenol following inhalation, oral, or dermal 
exposure. The distribution of pentachlorophenol following inhalation (Hoben et al. 1976c), oral (Braun et 
al. 1977; Gómez-Catalán et al. 1991; Larsen et al. 1975), or dermal (Qiao et al. 1997) exposure has been 
characterized in acute-duration studies in animals.  Long-term studies examining distribution would be 
useful to determine if there are any duration-related differences in distribution.  Pentachlorophenol has 
been found in human breast milk from German and Slovakian women (Gebefugi and Korte 1983; 
Veningerova et al. 1996). 
Results from human and animal studies indicate that pentachlorophenol is not extensively metabolized, as 
evidenced by a large portion of the administered dose being excreted in urine unchanged in humans 
exposed by the inhalation (Ahlborg et al. 1974) and oral (Braun et al. 1979; Uhl et al. 1986) routes and in 
animals exposed to pentachlorophenol by the inhalation (Hoben et al. 1976a) and oral (Ahlborg et al. 
1974; Braun et al. 1977; Renner 1989; Renner and Hopfer 1990) routes.  The major metabolite is 
tetrachloro-p-hydroquinone (TCHQ) in humans exposed to pentachlorophenol by the inhalation route 
(Ahlborg et al. 1974) and in animals exposed to pentachlorophenol by the oral route (Ahlborg et al. 1974; 
Braun et al. 1977; Reigner et al. 1991; Renner and Hopfer 1990).  Additional studies of metabolites 
formed in humans after exposure to pentachlorophenol by the dermal and oral routes and in animals after 
exposure to pentachlorophenol by the inhalation and dermal routes would be useful.  The available human 
and animal data indicate that metabolism of pentachlorophenol occurs in the liver, and the major 
pathways are glucuronide conjugation and oxidative dechlorination to form TCHQ.  However, recent 
studies in rats and mice following oral administration of pentachlorophenol (Lin et al. 1997; Waidyanatha 
et al. 1994, 1996) suggest that the metabolism of pentachlorophenol can also proceed through the quinols, 
TCHQ, and tetrachlorocatechol, via microsomal cytochrome P 450 enzymes, and that these quinols can 
be oxidized via semiquinone intermediates.  Both the quinones and semiquinones are electrophilic and 
can bind to cellular macromolecules (Lin et al. 1997).  Additional studies in animals to determine if 
chlorinated quinones and semiquinones are produced following inhalation and dermal exposures to 
pentachlorophenol would be useful. Studies in animals by the inhalation, oral, or dermal routes to 
examine the potential role of peroxidases in pentachlorophenol metabolism would also be useful. 
Additional studies examining the metabolism of pentachlorophenol following inhalation and dermal 
exposure would be useful for determining if there are route-specific differences in metabolism.
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No information was found on the relative amounts of excreted pentachlorophenol and its metabolites in 
urine and feces after humans or animals were exposed to pentachlorophenol by inhalation. 
Approximately 74 and 12% (total of 86%) of pentachlorophenol ingested by humans was eliminated in 
the urine as pentachlorophenol and its glucuronide conjugate, respectively (Braun et al. 1979).  In 
rodents, from 60–83% of the administered oral dose is eliminated in the urine (Ahlborg et al. 1974; Braun 
et al. 1977; Larsen et al. 1972; Reigner et al. 1991); in monkeys, 45–75% of the administered oral dose is 
eliminated in the urine (Braun and Sauerhoff 1976).  Fecal elimination of pentachlorophenol and its 
metabolites accounted for 4% of the administered oral dose in humans (Braun et al. 1979), 8–34% of the 
administered oral dose in rodents (Braun et al. 1977; Larsen et al. 1972; Reigner et al. 1991, 1992), and 
3–20% in monkeys (Ballhorn et al. 1981; Braun and Sauerhoff 1976; Rozman et al. 1982).  Only trace 
amounts were eliminated in expired air.  Excretion data in animals indicate that the kinetics of penta­
chlorophenol elimination in humans following oral exposure is similar to that seen in monkeys in that 
they are first order (Braun and Sauerhoff 1976; Braun et al. 1979); additional studies examining potential 
species differences would be useful. No studies were located regarding excretion in humans after dermal 
exposure to pentachlorophenol. After application of radioactively-labeled pentachlorophenol in a soil-
based mixture to the skin of swine, one-third to one-half of the absorbed dose was almost equally 
excreted through urinary and fecal routes (Qiao et al. 1997).  Additional studies on routes of elimination 
of pentachlorophenol following exposures of animals by the dermal and inhalation routes would be 
useful. Two animal studies (Braun and Sauerhoff 1978; Braun et al. 1974) found an apparent difference 
in elimination kinetics between males and females.  Additional studies examining potential sex-related 
differences would be useful. 
Comparative Toxicokinetics. A series of studies conducted by Braun and associates (Braun and 
Sauerhoff 1976; Braun et al. 1977, 1979) suggest that there are toxicokinetic differences between humans, 
monkeys, and rats.  The results of these studies suggest that the excretion of pentachlorophenol follows a 
linear, one-compartment model in humans and monkeys.  In contrast, excretion in the rats was biphasic 
(two-compartment model).  However, other pharmacological properties, such as maximum plasma 
concentration, absorption rate constant, volume of distribution, steady-state concentration, and the 
excretion of glucuronide conjugates were similar for humans and rats, but not for humans and monkeys. 
These data suggest that the rat may be a better model for humans than the monkey.  Additional studies are 
needed to further evaluate species differences in the toxicokinetics of pentachlorophenol and to identify 
the most appropriate model for humans. 
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Methods for Reducing Toxic Effects. Pentachlorophenol can be absorbed through inhalation, 
oral, or dermal routes.  Methods are available for reducing absorption following oral and dermal exposure 
to pentachlorophenol; however, since gastrointestinal absorption of pentachlorophenol in humans is rapid 
(Braun et al. 1979), these methods (washing skin and eyes, emesis, lavage, activated charcoal, and 
catharisis) (EPA 1989, 1989b) are useful only immediately following exposure to the chemical.  Based on 
animal studies, cholestyramine administration is recommended in cases of human pentachlorophenol 
overexposure to enhance elimination of pentachlorophenol (Goodman et al. 1990); however, its use in 
humans has not been sufficiently tested.  Data on cholestyramine administration, hemoperfusion, and 
administration of sedatives and antipyretics as treatment methods would be useful. 
The mechanism of toxicity of pentachlorophenol is not clear.  Although pentachlorophenol has been 
shown to uncouple oxidative phosphorylation, affect thyroid homeostasis, and produce oxidative damage 
to DNA, the extent to which these effects contribute to toxicity in the various organs and systems affected 
by pentachlorophenol is not clear.  It is possible that these effects contribute to the toxicity spectrum seen 
in some organs, but are secondary unrelated to toxic effects seen in other organs.  Therefore, additional 
studies on the relative contributions of these effects (uncoupling of oxidative phosphorylation, 
disturbances in thyroid homeostasis, and oxidative damage to DNA) to pentachlorophenol toxicity and 
examination of other potential mechanisms of toxicity (e.g., interactions with specific cell or tissue 
receptors) would be useful steps toward identifying methods that may reduce the toxic effects of 
pentachlorophenol. 
Children’s Susceptibility. Adverse effects on the nervous system, liver, kidneys, and respiratory 
system, and some deaths were associated with exposure of newborn children to pentachlorophenol in 
diapers and bedding (Smith et al. 1996), and suppression of the immune system was seen in older children 
exposed to pentachlorophenol (McConnachie and Zahalsky 1991).  Additional studies to confirm and 
expand these findings would be useful. In animals, pentachlorophenol also causes a decrease in serum 
thyroxine levels, adverse effects on thyroid homeostasis, and inhibition of the uptake of thyroid hormone 
into the central nervous system.  Long-term epidemiological studies of possible health effects in large 
cohorts of individuals who were exposed to pentachlorophenol as children would be useful, particularly 
with regard to reproductive function, the immune system, neurobehavioral testing, and cancer.  
Oral exposure studies in animals provide evidence that pentachlorophenol is a developmental toxicant. 
Gestational exposure to pentachlorophenol has resulted in decreased fetal and neonatal survival (Schwetz 
et al. 1978), decreased fetal and neonatal body weight (Argus 1993b/Bernard et al. 2001b, Argus 1997/ 
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Bernard et al. 2001c; Beard et al. 1999b; Courtney et al. 1976; Larsen et al. 1975; Schwetz et al. 1978; 
Welsh et al. 1987), increased male:female sex ratio (Schwetz et al. 1974), delayed ossification (Schwetz 
et al. 1974), and skeletal anomalies (Schwetz et al. 1974, 1978).  There is some suggestive evidence that 
effects on the thyroid can lead to neurological deficiencies in the offspring; a neurodevelopmental toxicity 
study is needed to assess this potentially sensitive end point.  
There are no studies to indicate whether the pharmacokinetics and metabolism of pentachlorophenol in 
children are different from those in adults, and there are no PBPK models for pentachlorophenol. 
However, given the large number of potential reactive metabolites that can be formed from pentachloro­
phenol and the different levels of active metabolites among rodent species (Lin et al. 1997), well-
conducted studies on potential pharmacokinetic and metabolic differences between children and adults 
would be useful. A rationale for such studies is that UDP-glucuronosyl transferase and sulfotransferases, 
which are involved in phase II metabolism of pentachlorophenol, and two of the cytochrome P-450s, 
which are involved in the phase I metabolism of pentachlorophenol, are all thought to be developmentally 
regulated (Leeder and Kearns 1997). The need for a PBPK model for pentachlorophenol is not apparent 
at this time.  There are some data to show that radiolabeled pentachlorophenol may cross the placenta of 
animals and enter the developing fetus (Larsen et al. 1975), and can be present in human breast milk 
(Gebefugi and Korte 1983; Veningerova et al. 1996).  However, studies to confirm that pentachloro­
phenol crosses the placenta into developing fetuses and to characterize levels of pentachlorophenol in 
human breast milk in the United States would be useful.  There are no studies to evaluate whether the 
mechanism of action of pentachlorophenol is different in children, but there is no apparent reason to 
suspect that it would be different. However, studies to determine whether children have a different 
susceptibility to health effects from pentachlorophenol than adults would be useful, starting with studies 
that compare immature animals to adult animals.  
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 
Exposures of Children. 
3.12.3 Ongoing Studies 
Information on the ongoing studies cited in this section was obtained from FEDRIP (2001). 
Dr. I. Hertz-Picciotto at the University of North Carolina is assessing the feasibility of self-administered 
devices for collection of breath, urine, tap water, and indoor air monitoring samples in studies of penta­
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chlorophenol; generating data on background variability of body burdens and protein adducts from 
exposures to pentachlorophenol; and determining factors that influence such variability, including point 
sources of contamination and workplace, in addition to background factors such as sociodemographic, 
geographic, lifestyle, and home characteristics. 
Dr. S. M. Rappaport of the University of North Carolina at Chapel Hill is investigating the development 
and application of biomarkers of exposure to pentachlorophenol, including the levels of the parent 
compound in blood, exhaled air, and urine, and the levels of adducts with hemoglobin and serum 
albumin. 
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4.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of pentachlorophenol is located in Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of pentachlorophenol is located in Table 4-2. 
ClCl 
Cl Cl 
Cl 
ClCl 
Cl Cl 
Cl 
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Table 4-1. Chemical Identity of Pentachlorophenol and Pentachlorophenatea 
Characteristic Pentachlorophenol Sodium pentachlorophenate 
Synonym(s) 
Registered trade name(s)
 For 37% aqueous solutiona
 For polymeric formb 
Chemical formula 
Chemical structure 
Identification numbers: 
CAS Registry 
NIOSH RTECS 
EPA Hazardous Waste 
OHM/TADS 
DOT/UN/NA/IMCO 
HSDB 
NCI 
PCP; penchlorol; penta;
 
pentachlorophenate; 2,3,4,5,6­
pentachlorophenolb
 
Chlon; Dowicide 7; Dowicide
 
EC-7; Dura Treet II; EP 30;
 
Fungifen: 

Grundier Arbezol; Lauxtol;
 
Liroprem; Penta Concentrate;
 
Penta Ready; Penta WR;
 
Permasan; Santophen 20;
 
Woodtreatb
 
C6HCl5O 
OH 
87-86-5 
SM6300000 
U242; FO27 
7216842 
NA 2020 
894 
C54933; C55378; C56655 
Pentachlorophenol sodium; 
pentachlorophenol sodium salt: 
pentachlorophenoxy sodium: 
pentaphenate 
Dow Dormant Fungicide; Dowicide 
G; Dowicide 
G-St; Mystox D; Napclor-G; 
Santobrite; Sapco25 Weedbeads 
C6Cl5ONa 
O Na
+ 
131-52-2 
SM6490000 
No data 
No data 
UN 2567; IMO6.1 
761 
No data 
aAll information obtained from HSDB 2001 except where noted.
bRTECS 1991 
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
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Table 4-2. Physical and Chemical Properties of Pentachlorophenol 
and Sodium Pentachlorophenatea 
Sodium 
Property Pentachlorophenol pentachlorophenate 
Molecular weight 266.35 288.34 
Color Colorless or white (pure); dark gray to White or tan 
brown (crude product) 
Physical state Crystalline solid (pure); pellets or powder Flakes or powder 
(crude product)b 
Melting point 190 EC No data 
Boiling point 309–310 EC (decomposes) No data 
Density 1.978 g/mL at 22 EC/4 EC No data 
Odor Phenolic; very pungent (only when hot) No data 
Odor threshold: 
Water 0.857 mg/L at 30 EC; No data 
12.0 mg/L at 60 EC b,c 
Solubility: 
Water 14 mg/L at 20 EC 330,000 mg/L at 25 EC 
Organic solvent(s) Very soluble in alcohol and ether; soluble Soluble in acetone and 
in benzene; slightly soluble in cold ethanol 
petroleum etherd 
Partition coefficients: 
Log Kow 5.01b No data 
Log Koc 4.5e No data 
Vapor pressure at 25 EC 0.00011 mmHgf No data 
Photolysis t1/2 = 48 hg t1/2 = 0.70 hh 
Henry's law constant at 25 EC  3.4x10-6 atm-m3/moli No data 
Autoignition temperature No data No data 
Flashpoint No data No data 
Flammability limits at 25 EC No data No data 
Incompatibilities No data No data 
Conversion factors (25 EC) No data No data 
Explosive limits No data No data 
aAll information obtained from HSDB 2001 unless otherwise noted. 
bVerschueren 1983 
cHoak 1957 
dBudavari et al. 1989 
eSchellenberg et al. 1984
fEPA 1979e 
gWong and Crosby 1981
hPignatello et al. 1983
iLyman et al. 1982 
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5.1 PRODUCTION 
Vulcan Chemicals, a division of Vulcan Materials Company (Wichita, Kansas), is the only current 
domestic manufacturer of pentachlorophenol (SRI 1998).  Pentachlorophenol is produced by the stepwise 
chlorination of phenols in the presence of catalysts (anhydrous aluminum chloride or ferric chloride). 
Outside of the United States, it is also produced by the alkaline hydrolysis of hexachlorobenzene. 
Typically, commercial grade pentachlorophenol is 86% pure.  Contaminants generally consist of other 
polychlorinated phenols, polychlorinated dibenzo-p-dioxins, and polychlorinated dibenzofurans, which 
are formed during the manufacturing process (see Table 3-2).  Pentachlorophenol has also been marketed 
in the past as a water-soluble sodium salt, a 5% emulsifiable concentrate, or a 3–40% solution in 
formulation with other chlorophenols, methylene bisthiocyanate, or copper naphthenate (IARC 1979). 
Production volumes for 1983–1986 were as follows:  45 million pounds in 1983; 42 million pounds in 
1984; 38 million pounds in 1985; and 32 million pounds in 1986 (Mannsville 1987).  About 24 million 
pounds were manufactured in 1987 by Vulcan Materials (HSDB 2001).  More recent production data are 
not available. For further information on facilities in the United States that manufacture or process 
pentachlorophenol, refer to Table 5-1. Table 5-1 is derived from Toxics Release Inventory (TRI) data 
and reports only those facilities that release pentachlorophenol. 
5.2 IMPORT/EXPORT 
The U.S. consumption of pentachlorophenol for 1986 was reported to be 28 million pounds (CMR 1987). 
In 1982, 121,000 pounds of pentachlorophenol were imported to the United States (328,000 pounds were 
imported in 1980).  In 1985, 3 million pounds of pentachlorophenol were exported, and in 1986, 2 million 
pounds were exported (Mannsville 1987).  More recent data on the import/export volumes of pentachloro­
phenol are not available. 
5.3 USE 
Pentachlorophenol was one of the most widely used biocides in the United States.  It was registered for 
use by EPA as an insecticide (termiticide), fungicide, herbicide, molluscicide, algicide, disinfectant, and 
as an ingredient in antifouling paint (Cirelli 1978a), but it has been a restricted-use pesticide since July 
1984 (CELDS 1992; EPA 1984a). The principal use of pentachlorophenol is as a wood preservative 
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Table 5-1. Facilities that Produce, Process, or Use Pentachlorophenol 
Number of Minimum amount on Maximum amount on 
Statea facilities site in poundsb site in poundsb Activities and usesc 
AL 2 10,000 999,999 9 
AR 2 1,000 999,999 9, 13 
CA 1 100 999 13 
GA 1 10,000 99,999 9 
ID 1 10,000 99,999 13 
IL 1 1,000 9,999 13 
KY 1 10,000 99,999 13 
LA 2 10,000 999,999 9 
MD 1 10,000 99,999 1, 5 
MN 1 10,000 99,999 8 
MO 1 100,000 999,999 9 
MS 4 10,000 9,999,999 9, 12 
NC 2 10,000 999,999 8, 9 
NE 1 10,000 99,999 9 
NJ 1 1,000 9,999 13 
NV 1 10,000 99,999 9 
OH 1 1,000 9,999 13 
OR 3 10,000 99,999 9, 12, 13 
SC 2 10,000 999,999 9, 13 
SD 1 100,000 999,999 9 
TX 2 1,000 99,999 13 
UT 2 1,000 99,999 13 
Source: TRI99 2001 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 10. Repackaging 
2. Import 7. Reactant 11. Chemical Processing Aid 
3. Onsite use/processing 8. Formulation Component 12. Manufacturing Aid 
4. Sale/Distribution 9. Article Component 13. Ancillary/Other Uses 
5. Byproduct 
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(registered by EPA for power-line poles, cross arms, fence posts, and the like).  The treatment of wood for 
utility poles represents 80% of the U.S. consumption of pentachlorophenol (CMR 1987).  However, 
pentachlorophenol is no longer contained in wood preserving solutions or insecticides and herbicides 
available for home and garden use since it is a restricted-use pesticide.  Pentachlorophenol is used for the 
formulation of fungicidal and insecticidal solutions and for incorporation into other manufactured 
pesticide products. These nonwood uses account for no more than 2% of U.S. pentachlorophenol 
consumption (Mannsville 1987).  This wide spectrum of uses was partially attributed to the solubilities of 
the nonpolar pentachlorophenol in organic solvents, and the sodium salt in water.  
5.4 DISPOSAL 
After treatment with sodium bicarbonate or a sand-soda ash mixture, pentachlorophenol can be 
incinerated. Incineration of pentachlorophenol is one of the most important sources of polychlorinated 
dibenzo-p-dioxins and dibenzofurans, so care must be taken during this process (Karasek and Dickson 
1987). Pentachlorophenol has been designated as a hazardous substance, a hazardous pollutant, a toxic 
pollutant, and a hazardous waste by EPA.  Disposal of pentachlorophenol is subject to EPA restrictions 
(EPA 1991, 1992). 
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6.1 OVERVIEW 
Pentachlorophenol has been one of the most heavily used pesticides in the United States.  The compound 
is found in all environmental media (air, soil, and water) as a result of its past widespread use.  In 
addition, a number of other chemicals, including hexachlorobenzene, pentachlorobenzene, and benzene 
hexachloride isomers, are known to be metabolized to pentachlorophenol.  Current releases of 
pentachlorophenol to the environment are more limited as a result of decreasing volumes used, changing 
use patterns (e.g., phase-out of slimicide use in water cooling towers), and waste treatment practices (e.g., 
closing of on-site evaporation ponds at wood-treatment facilities).  Pentachlorophenol is currently 
regulated as a restricted-use pesticide. 
Pentachlorophenol is stable to hydrolysis and oxidation, but the compound is rapidly photolyzed by 
sunlight and can be metabolized by microorganisms, animals, and plants.  Adsorption to soils and 
sediments is more likely to occur under acidic conditions than under neutral or basic conditions.  The 
compound has been found to bioaccumulate to modest levels (e.g., bioconcentration factors of <1,000), 
but food chain biomagnification has not been observed.  In recent decades, pentachlorophenol has been 
widely detected in human urine, blood, and adipose tissue among members of the general population. 
Human exposure to pentachlorophenol is believed to occur via inhalation of indoor and workplace air, 
ingestion of contaminated water and food, and direct dermal contact with pentachlorophenol-treated wood 
products. Since pentachlorophenol is no longer used in the treatment of wood products used in new 
residences and agricultural buildings, future indoor air exposure to this compound from these sources is 
likely to be minimal. 
Pentachlorophenol has been identified in at least 313 of the 1,585 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2001).  However, the number 
of sites evaluated for pentachlorophenol is not known.  The frequency of these sites can be seen in 
Figure 6-1. Of these sites, 312 are located within the United States and 1 is located in the Commonwealth 
of Puerto Rico (not shown). 
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Figure 6-1. Frequency of NPL Sites with Pentachlorophenol Contamination 
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6.2 RELEASES TO THE ENVIRONMENT 
Pentachlorophenol is ubiquitously distributed in the environment.  It has been detected in surface waters 
and sediments, rainwater, drinking water, aquatic organisms, soils, and food, as well as in human milk, 
adipose tissue, and urine. The compound has been identified in at least 313 of the 1,585 hazardous waste 
sites on the NPL (HazDat 2001). 
The majority of pentachlorophenol annual releases during production and use are to the atmosphere 
(about 1.4 million pounds [620 metric tons]) from wood preservation plants and cooling towers, and to 
land (about 1.9 million pounds [890 metric tons]) from wood preservation and domestic use as a 
preservative. Pentachlorophenol is also released into the aquatic environment, especially in runoff waters 
and wood-treatment plant effluents.  Based on the available information, discharges to water, both direct 
and through municipal waste water treatment facilities, were estimated to be about 26,000 pounds 
(12 metric tons) and 11,000 pounds (5 metric tons), respectively (EPA 1980f).  It should be noted, 
however, that much of these data, and data discussed in the following sections, were collected before 
pentachlorophenol became a restricted-use pesticide.  Current releases are more limited, as indicated by 
the releases reported to the Toxics Release Inventory (TRI).  However, total current environmental 
releases may be higher than the TRI estimates because only certain types of facilities are required to 
report; the list of facilities is not exhaustive. 
The TRI data should be used with caution because only certain types of facilities are required to report. 
This is not an exhaustive list. 
6.2.1 Air 
Pentachlorophenol is released directly into the atmosphere via volatilization from treated wood products. 
Evaporation of pentachlorophenol-treated industrial process waters from cooling towers was an additional 
source of historical atmospheric releases of the compound.  Historical atmospheric releases included those 
from cooling towers, where pentachlorophenol and its sodium salt were used as slimicides in cooling 
tower waters. However, pentachlorophenol and its salt are no longer commonly used for this purpose 
(Vulcan Chemicals 1989) since the early 1980s, when its use was restricted (EPA 1984b). 
Emissions during production are considered to be relatively insignificant in volume, and are 
geographically restricted to the Vulcan Materials facility in Wichita, Kansas (SRI 1998).  Physical 
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removal mechanisms, such as wet deposition, are important processes that decrease pentachlorophenol 
concentrations in the atmosphere. 
Pentachlorophenol has historically been estimated to volatilize from the surface of pentachlorophenol­
treated wood products at an estimated rate of 760,000 pounds (344 metric tons) annually, or roughly 2% 
of the total amount of preservative applied.  These estimates are representative of usage of the compound 
in those applications in the 1970s (EPA 1980f). 
As much as 500,000 pounds annually (228 metric tons) of pentachlorophenol, used in cooling tower 
waters as an anti-fouling agent, have been released to the atmosphere through volatilization with heated 
water and steam in the past (EPA 1980f).  However, pentachlorophenol is no longer commonly used for 
this purpose (Vulcan Chemicals 1989). 
According to the TRI, an estimated total of 1,306 pounds of pentachlorophenol, amounting to 1.3% of the 
total environmental release, was discharged to the atmosphere from manufacturing and processing 
facilities in the United States in 1999 (TRI99 2001) (Table 6-1).  The TRI data should be used with 
caution because only certain types of facilities are required to report.  This is not an exhaustive list. 
Volatilization from treated wood poles and other outdoor-use wood also occurs; 30–80% of the 
pentachlorophenol applied to coniferous wood by dip or brush treatments may be lost by volatilization 
within 12 months (Bunce and Nakai 1989).  Ingram et al. (1986) reported increased volatilization of 
pentachlorophenol from treated wood with increased temperature; similar results with temperature change 
were seen with each of numerous solvent systems utilized for application of the compound.  Volatilization 
of pentachlorophenol was dependent on the carrier solvents and the wood coatings utilized; maximum 
volatilization occurred when methylene chloride or 100% mineral spirits were used as carrier solvents, 
while the minimum volatilization occurred with the use of the cosolvent WC-144. 
Pentachlorophenol may be formed during the incineration of chlorine-containing waste material.  Heeb et 
al. (1995) found that pentachlorophenol constituted 8% of polychlorinated phenols formed in the flue gas 
and 10% of the stack gas during the incineration of chlorine-containing waste material.  It may also be 
released in stack emissions as a result of pyrolysis of polyvinyl chlorides (Blankenship et al. 1994).   
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Pentachlorophenol 
Reported amounts released in pounds per yeara 
Number Total on and 
Stateb 
of 
facilities Airc Water 
Underground 
injection Land 
Total on-site 
released 
Total off-site 
releasee 
off-site 
release 
AL 7 459 813 No data 0 1,272 331 1,603 
AR 2 250 5 No data No data 255 115 370 
CA 2 5 No data No data No data 5 No data 5 
FL 1 No data No data No data 2,000 2,000 No data 2,000 
GA 2 13 5 No data No data 18 122 140 
ID 1 5 No data No data 43,000 43,005 No data 43,005 
IL 1 2 No data No data 0 2 74 76 
KY 1 10 No data No data 0 10 250 260 
LA 2 8 34 No data No data 42 23 65 
MD 1 No data No data No data No data No data No data No data 
MN 1 1 No data No data No data 1 No data 1 
MO 1 255 0 No data No data 255 1 256 
MS 4 10 112 No data 0 122 15 137 
NC 2 3 3 No data No data 6 1,480 1,486 
NE 1 255 No data No data No data 255 No data 255 
NJ 1 2 0 No data 0 2 15 17 
NV 1 2 No data No data No data 2 No data 2 
OH 1 2 1 No data No data 3 5 8 
OR 4 16 251 No data 26,793 27,060 14,654 41,714 
SC 2 6 0 No data 11,911 11,917 8 11,925 
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Pentachlorophenol 
(continued) 
Reported amounts released in pounds per yeara 
Number Total on and 
Stateb 
of 
facilities Airc Water 
Underground 
injection Land 
Total on-site 
released 
Total off-site 
releasee 
off-site 
release 
SD 1 1 53 No data No data 54 160 214 
TX 2 0 0 5 No data 5 No data 5 
UT 2 1 No data No data 15,133 15,134 255 15,389 
WA 4 No data No data No data No data No data No data No data 
Total 47 1,306 1,277 5 98,837 101,425 17,508 118,933 
Source:  TRI99 2001 
aData in TRI are maximum amounts released by each facility.

bPost office state abbreviations are used.
 
cThe sum of fugitive and stack releases are included in releases to air by a given facility.

dThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
eTotal amount of chemical transferred off-site, including to publicly owned treatment works (POTW).
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6.2.2 Water 
Pentachlorophenol releases to surface water occur through direct discharge and direct entry from 
numerous nonpoint sources, including treated wood.  In addition, pentachlorophenol is transported to 
surface waters from the atmosphere by wet deposition, and from soil by runoff and leaching. 
Approximately 90% of wood-treatment plants evaporate their waste water and, consequently, have no 
direct discharge to surface waters. The remainder of the plants discharge to municipal waste water 
treatment facilities.  Total annual pentachlorophenol releases to municipal waste water treatment facilities 
were estimated to be 12,000 pounds (5.3 metric tons) (EPA 1980g). 
About 2 metric tons of pentachlorophenol used as a biocide in cooling tower waters were estimated to 
have been discharged to surface waters in 1978 (EPA 1979a).  In addition, industries such as leather 
tanning and textile factories may have released up to 4,400 pounds (2 metric tons) and 12,000 pounds 
(5.5 metric tons) of pentachlorophenol, respectively, in their waste water discharges to surface waters on 
an annual basis in the 1970s (EPA 1980f). Pentachlorophenol is no longer used in these applications 
(Weinberg 1997). 
Chlorination of phenolic compounds during water treatment has been reported to produce detectable 
levels of pentachlorophenol (Detrick 1977; Smith et al. 1976).  In addition, common pesticides such as 
lindane, hexachlorobenzene, pentachlorobenzene, and pentachloronitrobenzene are known to be 
metabolized to pentachlorophenol by plants, animals, and/or microorganisms, but the contribution of the 
metabolism of these pesticides to environmental levels of pentachlorophenol is unknown (Dougherty 
1978). 
According to the TRI, an estimated total of 1,277 pounds of pentachlorophenol, amounting to 1.25% of 
the total environmental release, was discharged to water from manufacturing and processing facilities in 
the United States in 1999 (TRI99 2001) (Table 6-1). The TRI data should be used with caution because 
only certain types of facilities are required to report.  This is not an exhaustive list. 
6.2.3 Soil 
Pentachlorophenol is released to soils as a result of its past use as a herbicide, leaching from treated wood 
products, atmospheric deposition in precipitation (such as rain and snow), spills at industrial facilities 
using pentachlorophenol, and at hazardous waste sites. 
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Most of the pentachlorophenol removed from effluent streams by waste water treatment processes is 
adsorbed to sludge solids. Sludges from wood preservation industries historically have been estimated to 
contain up to 31,500 pounds (14.3 metric tons) of pentachlorophenol annually.  Pentachlorophenol in 
solid wastes from wood-treatment facility evaporation ponds was estimated to total an additional 
133,000 pounds (60.2 metric tons) annually in the 1970s (EPA 1980f).  However, most wood-treatment 
facilities have closed, or are in the process of closing, on-site evaporation ponds (Vulcan Chemicals 
1989). 
According to the TRI, an estimated total of 98,837 pounds of pentachlorophenol, amounting to 97.5% of 
the total environmental release, was discharged to soil from manufacturing and processing facilities in the 
United States in 1999 (TRI99 2001) (Table 6-1). The TRI data should be used with caution because only 
certain types of facilities are required to report.  This is not an exhaustive list. 
6.3 ENVIRONMENTAL FATE 
Pentachlorophenol released into the atmosphere from treated wood can be transported back to surface 
waters and soils via wet and dry deposition.  Atmospheric pentachlorophenol is transformed via 
photolysis; the compound may slowly undergo free radical oxidation with an estimated half-life of 
approximately 2 months.  
In surface waters, pentachlorophenol undergoes biotransformation and photolysis, and is adsorbed to 
sediments.  Hydrolysis, oxidation, and volatilization do not significantly affect surface water 
concentrations. 
In soils and sediments, pentachlorophenol is metabolized by acclimated microbes, under both aerobic and 
anaerobic conditions, or is adsorbed. Pentachlorophenol may also be methylated to form 
pentachloroanisole, a more lipid soluble compound. Adsorption of pentachlorophenol in soils is pH 
dependent. The compound has a pKa value of 4.7 and consequently exists in the ionic forms at 
environmentally relevant pH values.  For example, at pH 4.7, pentachlorophenol is 50% ionized, whereas 
at pH 6.7, the compound is about 99% ionized (Crosby 1981).  Adsorption decreases in neutral and basic 
soils and is strongest in acidic soils. Therefore, the compound is most mobile in neutral-to-basic mineral 
soils and least mobile in acidic organic soils.  Volatilization and photolysis do not appear to be important 
transport and transformation processes for pentachlorophenol in soils. 
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6.3.1 Transport and Partitioning 
A Henry’s law constant of 2.75x10-6 atm m3/mol has been reported for pentachlorophenol; the value for 
the salt or ionic form of this compound is expected to be much less.  Therefore, volatilization of the 
solvated anionic form from an aqueous system is not considered to be a significant transport mechanism 
under ambient conditions.  Pignatello et al. (1983) reported that volatilization loss of pentachlorophenol 
as vapor and aerosol from treated river water in outdoor manufactured channels was #0.006% of the 
initial test concentration. Volatilization of pentachlorophenol from soil is also not expected to be a major 
transport pathway.  Kilzer et al. (1979) determined the volatilization rates of pentachlorophenol from 
water and three soil types under laboratory conditions.  The volatilization rates (expressed as percentage 
of applied pentachlorophenol per mL evaporated water) from water, sand, loam, and humus were 2.57, 
0.13, 0.31, and 0.10%, respectively, in the first hour after application of 50 µg/L pentachlorophenol. 
During the second hour, the volatilization rates were 2.11, 0.12, 0.15, and 0.12%, respectively.
Pentachlorophenol is volatilized from treated wood surfaces.  Walls in a closed room treated with 
pentachlorophenol released the chemical into the air, with concentrations reaching 1 ng/m3 on the 
first day after treatment and 160 ng/m3 on the fourth day (Gebefugi et al. 1976). 
The adsorption or mobility of pentachlorophenol in soils is controlled primarily by soil pH.  The amount 
of pentachlorophenol adsorbed at a given pH increases with increasing organic content of the soil (Chang 
and Choi 1974). Pentachlorophenol is adsorbed to soil or sediment under acidic conditions, but the 
compound is mobile under neutral or alkaline conditions (Kuwatsuka and Igarashi 1975).  Maximum 
adsorption has been reported at soil pH values of 4.6–5.1, with no adsorption above pH 6.8 (Choi and 
Aomine 1974).  
Schellenberg et al. (1984) investigated the adsorption of chlorinated phenols to natural sediments and 
aquifer materials.  These authors demonstrated that adsorption of pentachlorophenol was highly 
dependent on the organic content of the adsorbent. An average Koc of 32,900 was measured for penta­
chlorophenol in lake sediment, river sediment, and aquifer materials.  
However, normalized partition coefficients (i.e., Koc) do not accurately predict adsorption for ionizable 
compounds such as pentachlorophenol since its adsorption does not increase linearly with increasing 
concentration (Christodoulatos et al. 1994). The use of the equation to normalize partition coefficients is 
not valid in such cases. Davis et al. (1994) investigated the retardation of pentachlorophenol in 
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groundwater at a former wood treating facility.  Data were not well represented by the Freundlich or 
Langmuir isotherms.  The authors observed that retardation of the compound in the aquifer was greater at 
lower concentrations (<40 µg/L) than at higher ones (>1000 or 10,000 µg/L), indicating that 
pentachlorophenol will move at rates closer to that of the groundwater when present at higher 
concentrations (>10,000 µg/L).  The authors stated that the results indicated that at the lower 
concentrations found at plume peripheries, pentachlorophenol would be attenuated and then biodegraded, 
while at higher concentrations such as at the source, the compound would be mobile.  
Pentachlorophenol is applied to wood as a liquid formulation composed of pentachlorophenol dissolved 
in hydrocarbon diluents such as oils, kerosene, or mineral spirits.  The presence of cosolvents such as 
alcohols or petroleum hydrocarbons decreases the adsorption of pentachlorophenol in soils by increasing 
its solubility in the soil solution (Christodoulatos et al. 1994).  This may also be important at spill, 
storage, and hazardous waste sites where a large amount of cosolvent would be expected.  Based on the 
results of a study of the mobility of pentachlorophenol, pentachlorodibenzodioxins, and 
pentachlorodibenzofurans in soils contaminated with wood-preserving oil, Jackson and Bisson (1990) 
indicated that decreased adsorption of the compounds in soil would result from the presence of a 
subsurface, contaminated oil phase.  They predicted that upon contact with groundwater, the compounds 
would be partitioned into the aqueous phase. In a study of desorption of chlorophenols in contaminated 
soils, pentachlorophenol was desorbed more readily in the presence of methanol and exhibited a positive 
correlation with increasing methanol concentration (You and Liu 1996). 
Decreased adsorption may also occur without the presence of a cosolvent/contaminant such as methanol 
or a petroleum hydrocarbon.  The release of soil organics and colloids in the presence of dissolved 
pentachlorophenol was investigated. When pentachlorophenol was added to soil at aqueous 
concentrations of 1,000–10,000 µg/L, surface organics (tentatively identified as fulvic acids) were 
solubilized and acted as a cosolvent, decreasing the adsorption of pentachlorophenol (Galil and Novak 
1995). Enhanced mobility of pentachlorophenol was also predicted from the observed increased stability 
of soil colloids that adsorbed 3–13% of the compound, but were released from soil particle surfaces into 
the soil solution. 
Pentachlorophenol can be leached from treated wood into surrounding soil.  For example, Arsenault 
(1976) reported that pentachlorophenol migrated from the surface of utility poles to the adjacent soil, 
which had an average pentachlorophenol concentration of 654 mg/L.  However, mobility in soil was 
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limited, as indicated by the average soil concentration of 3.4 mg/L pentachlorophenol at a distance of 
12 inches from the poles.  
In a review paper, McAllister et al. (1996) reported that available data on the plant uptake and 
transformation of pentachlorophenol are inconsistent among studies and are inconclusive with regard to 
the abilities of specific plants to take up the compound.  It was observed that the biodegradation of 
pentachlorophenol by microorganisms and its adsorption to soil limit the availability of the compound for 
plant uptake. Among the pentachlorophenol metabolites found in plants are tetrachlorophenols and 
anisoles (McAllister et al. 1996); additionally, oxidation products (tetrachlorobenzenes), conjugated 
forms of chlorinated phenols, and insoluble metabolites (lignin-incorporated residues) have been 
observed (Engelhardt et al. 1986). 
Veith et al. (1985) demonstrated that chemicals with a log Kow value greater than 4.0 are likely to 
bioaccumulate in organisms and food chains.  The log Kow presented in Chapter 4 is 5.01 for the 
un-ionized form, which suggests that pentachlorophenol will bioaccumulate.  However, the extent of 
bioaccumulation will depend on the pH of the medium and physiological pH, since at higher pH levels, 
pentachlorophenol converts to the more water-soluble pentachlorophenate anion.  Bluegill sunfish 
exposed to 100 µg/L pentachlorophenol accumulated the compound in various tissues (edible, nonedible, 
or whole fish) to levels of 10–350 times the ambient water concentration in a 16-day static/renewal 
bioassay.  Pentachlorophenol was rapidly eliminated upon transfer of the test organisms to clean water 
(Pruitt et al. 1977). Pentachlorophenol was reported to have a bioconcentration factor (BCF) of 
81–461 in the soft tissue of a freshwater mussel; however, the compound was rapidly cleared by the test 
organisms (52% loss within 12 hours) (Makela et al. 1991).  Other bioaccumulation tests with aquatic 
organisms include BCF values of 30–40 in carp muscle tissue and 300–400 in all other tissues (Gluth et 
al. 1985) and BCF values of 218 (whole fish) to 1,633 (fish lipid basis) for juvenile American flagfish 
(Smith et al. 1990).  In the latter test, which was a flow-through bioassay, the half-life of 
pentachlorophenol in the tissues was reported to be about 16 hours.  Bioaccumulation of pentachloro­
phenol in algae, aquatic invertebrates, and fish (with BCFs of up to 10,000) has been demonstrated. 
Representative BCFs are as follows: goldfish, 1,000; polychaete, 3,830; bluegill sunfish, 13; blue mussel, 
324; and eastern oyster, 78 (EPA 1986c).  
Biomagnification of pentachlorophenol in terrestrial or aquatic food chains has not been observed.  In a 
110-day study with rainbow trout, where pentachlorophenol was administered in the diet at a maximum 
concentration of 3,000 µg/kg, maximum concentrations of the compound in fish tissues were 40 µg/kg 
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after 50 days and 20 µg/kg at the end of the test period.  In a 28-day depuration test, tissue half-life of the 
compound was about 7 days.  According to the investigators, these results suggest that pentachlorophenol 
bioconcentration in fish occurs primarily through direct uptake from water rather than through ingestion 
of food. The similar pentachlorophenol tissue concentration levels of prey and predator salmonid fish 
from Lake Ontario were cited as additional evidence of the limited food chain bioaccumulation of the 
compound (Niimi and Cho 1983). 
Pentachlorophenol bioconcentration by earthworms has also been studied by several investigators.  In 
14-day exposure tests, BCFs of 3.4–13 were reported for uptake of pentachlorophenol adsorbed to soil 
particulates (Haque and Ebing 1988; van Gestel and Ma 1988).  However, when bioconcentration was 
calculated on the basis of concentration of test compound in soil solution, BCF values of 426–996 were 
obtained (van Gestel and Ma 1988). 
6.3.2 Transformation and Degradation 
6.3.2.1 Air 
Atmospheric pentachlorophenol is probably photolyzed in the absence of water, although mechanisms for 
this reaction are not well known (Crosby and Hamadad 1971; Gab et al. 1975).  Photolysis of sorbed or 
film-state pentachlorophenol in the presence of oxygen has also been observed (Gab et al. 1975).  The 
reaction products were similar to those found in aqueous photolysis.  Bunce and Nakai (1989) estimated 
the rate of photolysis in the atmosphere based on measured quantum yields (254 nm) in the laboratory, 
molar absorptivity values, and solar intensity values for midday in summer at 40 EN; the estimated loss of 
pentachlorophenol to vapor-phase photolysis was 6.2% per hour.  This rate represents the maximum rate 
at 40 EN; the average rate of photolysis for pentachlorophenol will be lower. 
No empirical data were found describing the reactivity of pentachlorophenol to free radical oxidation in 
the atmosphere.  Bunce and Nakai (1989) calculated the potential atmospheric degradation of 
pentachlorophenol due to hydroxyl radical attack.  The estimated loss rate was 1.5% per hour (half-life of 
66 hours) as calculated from an estimated rate constant of 4.7x10-13 cm3/molecule-sec, assuming a peak 
noon summer hydroxyl radical concentration of 6.2x106 radicals/cm3. Based on the estimated relative 
rates of photolysis and degradation by hydroxyl radicals, it was concluded that the former process would 
likely be the dominant of the two.  It is noted that the estimate by Bunce and Nakai did not take into 
account the adsorption of the compound to particulates in the atmosphere.  Using the method of Meylan 
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and Howard (1993), a half-life of 58 days for the vapor-phase reaction of pentachlorophenol with 
hydroxyl radicals can be obtained from an estimated rate constant of 5.5x10-12 cm3/molecule-sec and an 
average hydroxyl radical concentration of 5.5x105 molecule/cm3. Adsorption of pentachlorophenol to 
particulate matter, however, will attenuate the rate of this process in the atmosphere. 
6.3.2.2 Water 
Photolysis and biodegradation are believed to be the dominant transformation processes for pentachloro­
phenol in aquatic systems.  Hydrolysis and oxidation are not important mechanisms for removal of the 
compound from surface waters. 
The molecular structure of pentachlorophenol is indicative of its stability to hydrolysis or oxidation (EPA 
1979e). Wong and Crosby (1981) reported that pentachlorophenol did not hydrolyze in aqueous solutions 
(serving as dark controls in an aqueous photolysis study) at pH 3.3 or 7.3 when held at 26 EC for up to 
100 hours. 
Wong and Crosby (1981) reported that pentachlorophenol in aqueous solutions at 100 mg/L was 
photolyzed under laboratory ultraviolet (UV)-light irradiation with estimated half-lives of about 
100 hours at pH 3.3 and 3.5 hours at pH 7.3. Photolysis of pentachlorophenol in aqueous solution 
following exposure to sunlight was also rapid; in laboratory experiments, concentrations of pentachloro­
phenol in water were reduced from 9.3 to 0.4 mg/L in 24 hours, and approached zero at the end of 
48 hours (Arsenault 1976). Wong and Crosby (1981) also reported rapid photolysis in sunlight (July); 
pentachlorophenol in pH 7.3 aqueous solution at 100 mg/L photolyzed with a half-life of 48 hours (total 
elapsed time) and a total disappearance time of 10 days.  Degradates formed during photolysis included 
tetrachlorophenols, three tetrachlorodiols and their respective quinones, chloranilic acid, and eventually 
2,3-dichloromaleic acid, which also undergoes photolysis, but at a slightly slower rate than 
pentachlorophenol. The final products from the complete photolytic degradation of pentachlorophenol 
were carbon dioxide and chloride ions. In outdoor tests conducted with river water in manufactured 
channels, Pignatello et al. (1983) demonstrated that photolysis of pentachlorophenol (applied as the 
sodium salt) was rapid at the water surface (half-life of 0.70 hour at a depth of 0.5 cm).  However, 
photolysis was greatly attenuated with increasing depth of the water column (half-life of 9.63 hours at a 
depth of 13.8 cm).  Photolytic degradation accounted for a 5–28% decrease in the initial test 
concentration of the compound after 3 weeks. 
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Pentachlorophenol is biotransformed in aqueous systems by acclimated microorganisms.  In a 40-day 
study of sterile and nonsterile stream water samples that were not amended with acclimated microbial 
cultures, Baker et al. (1980) reported negligible biodegradation of pentachlorophenol at 0 and 20 EC. 
Pignatello et al. (1983) reported that microbial transformation became the primary removal mechanism of 
pentachlorophenol (applied as the sodium salt) added to river water in tests conducted in outdoor 
manufactured channels.  After about a 3-week acclimation period, microbial transformation accounted for 
a 26–46% decline in the initial test concentration of pentachlorophenol.  The majority of the microbes 
responsible for the mineralization of pentachlorophenol were associated with rock and macrophyte 
surfaces or surface sediments rather than existing in the water phase.  In a follow-up study utilizing the 
same type of outdoor tests, Pignatello et al. (1985) found that biotransformation accounted for a 55–74% 
decrease in concentration of applied pentachlorophenol after a 3–5-week adaptation period. 
Biotransformation in the water column above sediments occurred at a greater rate under aerobic than 
under anaerobic conditions. Ingerslev et al. (1998) reported that in a study utilizing a battery of shake 
flasks tests, pentachlorophenol at 1 and 100 mg/L biodegraded in 10–30 days under aerobic conditions in 
surface water from an unpolluted stream after an acclimation period of approximately 55 days.  The 
addition of either sterilized or unsterilized sediment to the samples resulted in reduced acclimation 
periods, but did not affect the postacclimation degradation rates in water. 
In a study using radiolabeled pentachlorophenol, Arsenault (1976) demonstrated that the compound was 
transformed to carbon dioxide, water, and hydrochloric acid in an activated sludge treatment plant.  On a 
pilot-plant scale, the same investigator also showed that a waste stream from a wood-preserving facility 
containing 23 mg/L of pentachlorophenol could be treated successfully to produce a final effluent 
concentration of 0.4 mg/L of pentachlorophenol. 
In a microcosm study of unfiltered aquifer samples (geologic material and groundwater) contaminated 
with polycyclic aromatic hydrocarbons and pentachlorophenol, a loss was observed.  Although reductions 
in the parent compound concentration occurred, only 1% of the applied radiolabeled pentachlorophenol 
had mineralized by 56 days (Mohammed et al. 1998).  Neither nutrient addition nor sample sterilization 
had a significant effect on mineralization.  The observed decreases in the pentachlorophenol 
concentrations were attributed to adsorption to particulate material and not to biodegradation. 
In four simulated lentic environments, Boyle et al. (1980) tested the effects of dissolved oxygen, light, 
pH, and the presence of a hydrosoil (i.e., pond soil/sediment) on the transformation of pentachlorophenol 
(applied as the sodium salt).  The persistence of pentachlorophenol was associated with three 
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environmental variables: absence of light and hydrosoil; pH near or below pKa; and low oxygen 
concentration. Major reaction products were pentachloroanisole, 2,3,4,5-tetrachlorophenol, 2,3,4,6-tetra­
chlorophenol, and 2,3,5,6-tetrachlorophenol; only pentachloroanisole was found in the water phase, and 
then only in the aerobic systems maintained in light.  
6.3.2.3 Sediment and Soil 
Photolysis of pentachlorophenol on soil surfaces is not a major transformation process.  Hebert and Miller 
(1990) reported that UV light was >90% attenuated in the surface 0.2 mm of soil.  However, while they 
will not approach rates of photolysis observed in aqueous solution, photolytic losses on the soil surface 
may be increased under certain conditions.  The effect of upward evaporative flux on the rates of 
photolytic loss of pentachlorophenol, applied at 1,500 µg/L, was examined in soils maintained at various 
moisture levels.  It was observed that the rates of photolysis on soil increased when near-saturated 
conditions were utilized, which increased the evaporative flux and translocated the compound to the 
surface 0.5 mm of the soil where photochemical degradation occurs (Donaldson and Miller 1997).  Under 
near-saturated flow conditions in loamy sand soil, up to 55% more degradation was observed in the 
irradiated samples than in the dark controls in 14 days. 
The rate of pentachlorophenol degradation from adsorption and metabolism in soil is not dependent on 
soil texture, clay content, free iron oxides, or the degree of base saturation; however, it is partially 
dependent on the ion exchange capacity of the soil (Engelhardt et al. 1986).  The rate of pentachloro­
phenol transformation in laboratory tests is more rapid in soils with high organic content than in those 
with low organic content, and greater when moisture content is high and soil temperature approaches the 
optimum for microbial activity (Young and Carroll 1951).  
Biodegradation is considered the major transformation mechanism for pentachlorophenol in soil.  Half-
lives are usually on the order of 2–4 weeks.  Pentachlorophenol is metabolized rapidly by most 
acclimated microorganisms (Kaufman 1978).  In a study by Edgehill and Finn (1983) inocula of a strain 
of pentachlorophenol-acclimated Arthrobacter bacteria was added to soils in laboratory and enclosed 
outdoor tests. The soils were amended with 120–150 mg pentachlorophenol/L and 34 kg pentachloro­
phenol/hectare, respectively.  In the laboratory test conducted in the dark at 30 EC, the half-life of 
pentachlorophenol in inoculated samples was about 1 day, whereas the half-life in uninoculated samples 
was 12–14 days.  Pentachlorophenol loss from uninoculated control plots in outdoor tests was 25% after 
12 days at ambient temperatures (8–16 EC), while losses from inoculated plots were 50–85%. 
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Pseudomonas biotransformed [14C]-pentachlorophenol rapidly and released radiolabeled carbon dioxide 
as well as the intermediate metabolites tetrachlorophenol and tetrachlorohydroquinone.  In another study, 
strains of Pseudomonas putida and Acinetobacter calcoaceticus sp. were found to be able to use 
pentachlorophenol as a sole carbon and energy source (Martins et al. 1997) 
An investigation was conducted by Frisbie and Nies (1997) to determine whether aged pentachlorophenol 
residues from contaminated soil at a former wood-treatment site would be biodegraded in the laboratory 
under aerobic and anaerobic conditions by indigenous microbes from that site.  Under aerobic conditions, 
both existing and newly added pentachlorophenol was biodegraded following a short acclimation period. 
The degradates 2-monochlorophenol and 4-monochlorophenol were rapidly degraded, but 3-monochloro­
phenol did not undergo significant degradation. Under anaerobic conditions, pentachlorophenol was 
degraded to 3-monochlorophenol, which accumulated and was then further degraded; however, 
approximately 30% of the initial pentachlorophenol was not degraded. 
Pentachlorophenol has been observed to degrade more rapidly in anaerobic environments than in aerobic 
ones. Pentachlorophenol degraded in a paddy soil at 28 EC with a half-life of about 3 weeks; reducing 
conditions increased the rate of reaction slightly (Ide et al. 1972).  These observations were confirmed by 
Kuwatsuka and Igarashi (1975) in 10 different soil types.  Pentachlorophenol biotransformation rates 
were higher under anaerobic (flooded) conditions than under aerobic (upland) conditions.  The half-life 
for pentachlorophenol under flooded conditions ranged from 10 to 70 days, while under upland 
conditions, the range was 20–120 days, and the rate of reaction increased with the organic matter content. 
Pentachlorophenol transformation was assumed to proceed by both chemical and microbial means, based 
on the effects of sterilization, soil temperature, and nature of the reaction products, which included 
pentachloroanisole; 2,3,4,5-, 2,3,4,6-, and 2,3,5,6-tetrachlorophenol; and 2,3,4-, 2,3,5-, 2,3,6-, 2,4,5-, 
2,4,6-, and 3,4,5-trichlorophenol. The major products were 2,3,4,5-tetrachlorophenol, and 2,3,6- and 
2,4,6-trichlorophenol. Tetrachloro-p-benzoquinone and 2,6-dichlorohydroquinone have also been 
implicated as metabolic intermediates for pentachlorophenol (Reiner et al. 1978). 
The degradates 3,4- and 3,5-dichlorophenol were also observed in biodegradation studies of 
pentachlorophenol (Engelhardt et al. 1986). These authors noted that pentachloroanisole was a major 
degradate in aerobic soils, but was present in minor amounts in anaerobic soils.  In anaerobic systems, 
pentachlorophenol is biodegraded only through reductive dechlorination, and the degradates 
3,5-dichlorophenol and 3-monochlorophenol may accumulate; complete dechlorination to phenol and its 
subsequent mineralization to methane and carbon dioxide have been observed (Frisbie and Nies 1997).  In 
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a review paper on microbial degradation of pentachlorophenol, McAllister et al. (1996) reported that the 
various intermediates found in numerous studies indicated that microbial degradation of the compound 
occurs by different mechanisms which are associated with specific microbial consortia.  
Pentachlorophenol is degraded under anaerobic conditions in sewage sludge and sediments.  After 
6 months of operation, about 60% of the initial concentration of pentachlorophenol added to laboratory-
scale, fixed-film reactors containing a digested municipal sewage sludge microbial inoculum was 
removed.  Removal from reactors supplemented with glucose attained 98% of the initial charge over the 
same time frame.  Trichlorophenol and tetrachlorophenol were observed as degradation products 
(Hendriksen et al. 1991). In other laboratory tests, reductive dechlorination of pentachlorophenol was 
found to be more rapid in freshwater sediments containing microbial communities adapted to dechlorinate 
2,4-dichlorophenol and 3,4-dichlorophenol than in nonadapted sediment microbial communities. 
Degradation products identified included 2,3,5,6-tetrachlorophenol, 2,3,5-trichlorophenol, 
3,5-dichlorophenol, 3-chlorophenol, and phenol (Bryant et al. 1991).  Ingerslev et al. (1998) also reported 
more rapid degradation and shorter or no acclimation periods in freshwater sediments amended with 
activated sludge which was preexposed to pentachlorophenol at various levels.  At concentrations ranging 
from 10 to 20,000 µg/L, the acclimation periods were reduced from 8.6–21.1 days to 0.1–3.2 days when 
sediments were amended with preexposed activated sludge compared with activated sludge which was not 
preexposed to pentachlorophenol; only at a toxic concentration of 74,000 µg/L was the acclimation period 
increased (15.5–59.4 days).  At concentrations of 10, 100–2,500, and 20,000 µg/L, preexposure reduced 
the respective postacclimation half-lives from 32, 3.7–5.6, and 108 days to #2.2 days; at 74,000 µg/L, the 
postacclimation half-life decreased from 80 days to >51.6 days. 
6.3.2.4 Other Media 
Laboratory studies were conducted to determine the effect of artificial light and sunlight on concentra­
tions of pentachlorophenol and chlorinated dibenzo-p-dioxins in wood treated with pentachlorophenol 
(Lamparski et al. 1980).  Although chlorinated dibenzo-p-dioxins are known to be present in pentachloro­
phenol products as impurities, formation of octachlorodibenzo-p-dioxin (OCDD) as well as heptachloro­
dibenzo-p-dioxin (HpCDD) and hexachlorodibenzo-p-dioxin (HxCDD) was observed even when purified 
pentachlorophenol was irradiated. Based on the relative levels of the isomers observed, HxCDD and 
HpCDD were presumed to be degradation products of OCDD, not condensation products of tetrachloro­
phenol and pentachlorophenol. The formation of OCDD was greatly reduced when hydrocarbon oil was 
utilized as the carrier solvent in place of methylene chloride. 
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6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Pentachlorophenol historically has been widely detected in environmental media as a result of its 
widespread past use by industry, the agricultural sector, and the general public, as a cooling-tower 
algicide and fungicide, herbicide, molluscicide, paint preservative, plywood and fiberboard waterproofing 
agent, and drilling mud and photographic solution biocide.  Pentachlorophenol is now regulated as a 
restricted-use pesticide. Therefore, it can only be purchased and used by certified applicators, and only 
for the applications covered by the applicator's certification.  Pentachlorophenol is no longer available to 
the general public. Although the compound has been detected in indoor air, surface waters, groundwater, 
drinking water, soils, rainwater, and a variety of foods in older monitoring studies, current contamination 
of these media by the compound is probably more limited given the restricted current usage of 
pentachlorophenol and its limited environmental persistence. 
6.4.1 Air 
Limited information is available on the levels of pentachlorophenol in ambient air.  EPA (1980f) 
estimated atmospheric concentrations of pentachlorophenol using air models.  A cumulative concentration 
estimate based on all emission sources was 0.15–136 ng/m3. The lower end of this range coincides with 
the upper end of the range of computed air concentration estimates based on pentachlorophenol 
concentrations in rainwater in Hawaii (0.002–0.063 ng/m3) where pentachlorophenol has been used 
extensively as an herbicide and wood preservative.  A Canadian study (Cessna et al. 1997) reported the 
amount of pentachlorophenol in air in Saskatchewan (Regina and Waskesiu) and Northwest Territories 
(Yellowknife). The concentrations of pentachlorophenol in the vicinity of Yellowknife ranged from 0.43 
to 3.68 ng/m3, with a mean concentration of 1.53 ng/m3. At both the Regina and Waskesiu sites, the 
concentrations ranged from 0.06 to 0.58 ng/m3 with a mean value of 0.30 ng/m3. 
6.4.2 Water 
Of 497 surface water observations in EPA's STORET database as of March 1979, 82% were at the 
detection limit; 84% of the remaining observations fell between 0.1 and 10 µg/L, with a total range of 
0.01–100 µg/L (EPA 1979b). These data imply that ambient levels of pentachlorophenol in surface water 
are usually below 1 µg/L, with much higher levels in more industrialized areas. 
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Pentachlorophenol levels monitored in surface water include the following: 0.1–0.7 µg/L in the 
Willamette River (Buhler et al. 1973); 9 µg/L in a river below a paper mill (Rudling 1970); 0.1–1 µg/L in 
the Great Lakes (EPA 1980f); <1 µg/L in a river at a sewage discharge site in Sacramento, California 
(Wong and Crosby 1978); 38–10,500 µg/L in a stream running through an industrial district in 
Pennsylvania (Fountaine et al. 1975); and 0.01–0.48 µg/L in streams in Hawaii (Young et al. 1976). 
Pentachlorophenol has also been detected in drinking waters at the following levels:  0.04–0.28 µg/L in 
Corvallis, Oregon (Buhler et al. 1973); a mean concentration of 0.07 µg/L in 108 samples surveyed by the 
National Organics Monitoring Survey (NOMS); and <1–800 µg/L (an average of 227 µg/L) in seven 
drinking water wells in Oroville, California (Wong and Crosby 1978). 
Pentachlorophenol was detected in raw effluent from a series of wood-treatment plants at levels ranging 
from 25,000 to 150,000 µg/L (Dust and Thompson 1972) and in influent (1–5 µg/L) and effluent 
(1–4 µg/L) at streams at a sewage plant in Corvallis, Oregon (Buhler et al. 1973).  The compound has also 
been detected (concentrations unspecified) in surface water and groundwater samples taken at a wood-
treatment facility in Arkansas (McChesney 1988), in the surface water (68 µg/L) at a wood-treatment 
facility in Louisiana (ATSDR 1995), in groundwater (up to 19,000 µg/L) at a wood-preserving  site in 
South Carolina (ATSDR 1993a), in groundwater (0.6 µg/L) at an inactive landfill in Florida (ATSDR 
1993b), and in groundwater (up to 4,300 µg/L) at Camilla Wood Preserving Company, Camilla, Georgia 
(Anonymous 1999). 
6.4.3 Sediment and Soil 
Although several investigators (Fountaine et al. 1975; Pierce and Victor 1978) refer to possible soil 
contamination as a source of pentachlorophenol levels in water samples, very little data are available on 
actual measurements of pentachlorophenol in soil.  Arsenault (1976) reported pentachlorophenol 
concentrations of 3.4–654 ppm in soil within 12 inches of treated utility poles.  Pentachlorophenol was 
detected in the soil samples taken from a depth of 0–3 inches at (320–2,300 µg/kg) and in subsurface soil 
(820–200,000 µg/kg) at a wood-treatment facility, a NPL site,  in Louisiana (ATSDR 1995). It was also 
found in soil at an inactive landfill in Florida, also a NPL site, at a maximum concentration of 
21,000 µg/kg (ATSDR 1993b). Pentachlorophenol was found in on-site (up to 13,000 µg/kg) and off-site 
(up to 1,300 µg/kg) soil samples from the Camilla Wood Preserving Company in Camilla, Georgia 
(Anonymous 1999) 
 164 PENTACHLOROPHENOL 
6. POTENTIAL FOR HUMAN EXPOSURE 
6.4.4 Other Environmental Media 
Levels of pentachlorophenol in food are examined as a part of FDA's ongoing food monitoring studies. 
In 1973–1974, 10 out of 360 composite food samples contained pentachlorophenol at 10–30 ppb:  1 in 
dairy products, 1 in cereals, 1 in vegetables, and 7 in sugar (Manske and Corneliussen 1976).  In the next 
year, 13 out of 240 composites contained pentachlorophenol (10–40 ppb), again mostly in sugars 
(Johnson and Manske 1977). Pentachlorophenol was detected in all of a series of random samples of 
Florida food at levels of 1–1,000 ppb, principally in grain products (Dougherty and Piotrowska 1976). 
Pentachlorophenol was also detected at low levels in peanut butter (1.8–62 µg/kg) and chicken 
(6–12 µg/kg) (Farrington and Munday 1976). 
Pentachlorophenol concentrations in fish tissue for the years 1976–1979, reported in EPA's STORET 
database, ranged from below the limit of detection to 50 mg/kg.  Mean concentrations by region were as 
follows: Lake Michigan, 0.002 mg/kg; lower Mississippi, 0.478 mg/kg; Pacific Northwest, 16.38 mg/kg; 
Alaska, 5.0 mg/kg; Western Gulf, not detected; and south central lower Mississippi, not detected (EPA 
1979b). 
Levels of pentachlorophenol ranging from 10 to 270 µg/L were reported in 9 out of 65 samples of 
children's paints in the Netherlands (Van Langeveld 1975). 
Another study (Thompson et al. 1997) estimated the amount of pentachlorophenol in the atmosphere by 
measuring the amount of pentachlorophenol in pine needles.  The lipid coating of pine needles has been 
shown to absorb contaminants from the atmosphere and, therefore, measurement of pollutants in pine 
needles provides an indirect way of estimating the atmospheric pollutants.  The pentachlorophenol 
concentrations in the vicinity of a utility pole storage site were found to range from 29 to 570 ng/g of the 
needles. In comparison, pentachlorophenol concentration in the pine needles from sites further away 
from the pole storage locations was found to be <0.5 ng/g.  
It should be noted that most of the data discussed above are 13–17 years old (more recent data are not 
available). Use of pentachlorophenol has decreased in the intervening years because of restrictions placed 
on its use. Therefore, levels of pentachlorophenol found in other environmental media have presumably 
decreased since the time these data were published. 
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Humans may be exposed to pentachlorophenol in occupational settings through inhalation of 
contaminated workplace air and dermal contact with the compound or with wood products treated with 
the compound.  General population exposure may occur through contact with contaminated 
environmental media, particularly in the vicinity of hazardous waste sites.  Important routes of exposure 
appear to be inhalation of contaminated air, ingestion of contaminated groundwater used as a source of 
drinking water, ingestion of contaminated food and soils, and dermal contact with contaminated soils or 
products treated with the compound.  
Before being regulated as a restricted-use pesticide, pentachlorophenol was used extensively in treating 
wood. Today, this use is restricted to the treatment of  utility poles, railroad ties, and wharf pilings where 
it is widely used.  Dermal exposure to pentachlorophenol by members of the general population may 
occur upon contact with these wood products. Since pentachlorophenol is readily absorbed through skin 
(Qiao et al. 1997; Wester et al. 1993), this represents a relevant route of low level exposure. 
Pentachlorophenol is known to volatilize from treated wood products (Bunce and Naki 1989) at a rate that 
is temperature-dependent (Ingram et al. 1986), and low level inhalation exposure may also occur with 
increased levels expected during the summer months.  In older residences constructed with treated wood 
products, inhalation of contaminated indoor air may also be an important source of exposure.  A reduction 
in volatilization of pentachlorophenol by coating the treated wood surfaces with varnishes and epoxy 
coatings was demonstrated by Ingram et al. (1986).  In past years, pentachlorophenol has been detected in 
human adipose tissue, blood, and urine. 
Data have been collected on pentachlorophenol levels in human urine, blood, adipose tissue, and 
cerebrospinal fluid for both occupational and nonoccupational groups.  While levels are much higher in 
occupationally exposed groups, tests on the general population consistently show evidence of low-level 
exposure. In an FDA study in Florida, Cranmer and Freal (1970) found an average pentachlorophenol 
urine level of 4.9 µg/L in the general population, compared with 119.9 µg/L in carpenters, boat builders, 
and spraymen.  A range of 1,100–5,910 µg/L in the urine of Japanese pest control operators exposed to 
pentachlorophenol, compared with 10–50 µg/L in nonexposed workers was cited by Bevenue and 
Beckman (1967).  A comparison of results from a study in Hawaii on pentachlorophenol in urine of three 
groups (occupational, nonoccupational, and a mixed population) was done by Bevenue et al. (1967).  The 
pentachlorophenol level of 1,802 µg/L in the occupationally exposed population was almost 50 times 
higher than the nonoccupational group level of 40 µg/L. Hill et al. (1989) detected pentachlorophenol in 
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100% of urine samples taken from 197 children in Arkansas at a median concentration of 14 µg/L. 

Ninety-seven of these children lived in the vicinity of a herbicide plant while the remaining one hundred
 
were part of a control group of children who lived elsewhere.  No difference was observed in the amount
 
of pentachlorophenol detected in the urine samples of these two groups.  Pentachlorophenol was also
 
found in 100% of urine samples taken from 50 members of the general population of Barcelona, Spain, at
 
a mean concentration of 25 µg/L (Gómez-Catalán et al. 1987).  

An analysis of the urine samples of 1,000 adults residing in the United States detected pentachlorophenol
 
in 64% of the samples (Hill et al. 1995).  The adults tested were a subset of those participating in the
 
National Health and Nutrition Examination Survey (NHANES III).  The median pentachlorophenol
 
concentration in urine was found to be 1.5 ng/mL.  A Canadian study compared results from urine
 
analysis studies of nonoccupationally exposed individuals residing in Saskatchewan, Canada, a region
 
with little lumber industry.  In the first study with normal healthy individuals, performed in September
 
1992, 100% of the samples analyzed were found to contain detectable amounts of pentachlorophenol with
 
a median concentration of 1.3 ng/mL (Thompson and Treble 1994).  A subsequent study, performed in
 
January 1995, also detected pentachlorophenol in 100% of the urine samples (Thompson and Treble
 
1996). The median concentration in this latter study was 0.5 ng/mL.  A third urinary analysis study of
 
nonoccupationally exposed individuals residing in Saskatchewan also detected pentachlorophenol in 94%
 
of the urine samples at a median concentration of 0.5 ng/mL (Treble and Thompson 1996). 

Among a group of 16 patients with neurological symptoms, pentachlorophenol was detected in blood
 
serum and cerebrospinal fluid using a gas chromatograph with electron capture detection technique. 

Mean concentrations in these media were 22 µg/L (range, 4–60 µg/L) and 0.75 µg/L (range,
 
0.24–2.03 µg/L), respectively.  Three people in the study group who reported contact with wood
 
preservative products had the highest serum levels of pentachlorophenol.  Cerebrospinal fluid levels were
 
not correlated with serum levels or cerebrospinal protein levels (Jorens et al. 1991). 

The National Health and Nutrition Examination Survey II (NHANES II) and the National Human
 
Adipose Tissue Monitoring Survey (NHATS) analyzed blood and urine specimens from approximately
 
6,000 persons between the ages of 12–74 years in 64 communities throughout the United States for the
 
presence of a number of compounds, including pentachlorophenol, during the period of 1976–1980.  The
 
initial results of the survey indicated that pentachlorophenol was detected in about 79% of urine samples
 
tested (Murphy et al. 1983), and that pentachlorophenol-related phenols were also detected at lower
 
frequencies. The mean pentachlorophenol value in urine samples tested during 1976–1979 was 6.3 µg/L
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with the maximum level of 193 µg/L(Kutz et al. 1978).  Pentachlorophenol measured in urine was 
considered to be the result of exposure to pentachlorophenol, lindane, and hexachlorobenzene.  More 
recent results of NHANES II indicate that pentachlorophenol was found in 71.6% of the urine samples 
collected from the general population at an estimated geometric mean concentration of 6.3 ng/mL.  These 
results suggest that, during 1976–1980, almost 119 million individuals from the general population were 
exposed to pentachlorophenol. Males were found to have higher percentage quantifiable levels of 
pentachlorophenol and higher geometric mean concentrations in urine than females (Kutz et al. 1992).  In 
a study of workers exposed to pentachlorophenol in the wood-preserving industry, Arsenault (1976) 
reported pentachlorophenol levels of 120–9,680 µg/L in urine, with a mean concentration of 1,683 µg/L. 
In another study, Ferreira et al. (1997) compared the concentration of pentachlorophenol in the urine and 
blood of a group of workers occupationally exposed to pentachlorophenol at a wood-transformation unit 
to those of a control group with no known exposure to pentachlorophenol.  The mean level of 
pentachlorophenol in the occupationally exposed group was found to be 1,197 and 1,273 µg/L in urine 
and blood, respectively.  The mean concentration of pentachlorophenol in the control group was 
considerably lower at 6.4 and 15.3 µg/L in urine and blood, respectively.  The urine samples of wood 
workers from a wood factory in northern Italy were monitored before work at 8 a.m. and after the work 
shift at 5 p.m (Colosio et al. 1993a).  The results indicated that a greater amount of pentachlorophenol 
was excreted in the morning (175 µg/L) than in the evening (106 µg/L).  A subsequent study by Barbieri 
et al. (1995) obtained similar results from which a half-life of about 10 days was estimated for 
pentachlorophenol excretion in urine. 
A mean pentachlorophenol blood serum level of 420 µg/L was reported for residents of log homes, 
whereas a mean level of 40 µg/L was reported for members of the general public with no known exposure 
to the compound.  For residents of the log homes, pentachlorophenol serum levels of children were found 
to average 1.8 times those of their parents.  Pentachlorophenol urine concentrations for residents of log 
homes averaged 69 µg/L, whereas urine levels for the general population were found to be 3.4 µg/L. 
Inhalation was believed to be the most likely route of exposure to pentachlorophenol in log homes (Cline 
et al. 1989). Pentachlorophenol was also found in serum samples taken from members of the general 
population of Barcelona, Spain, at a mean concentration of 21.9 µg/L (Gómez-Catalán et al. 1987).  In a 
separate study of 66 residents of log homes treated with pentachlorophenol in Kentucky, Hosenfeld et 
al. (1986) reported a geometric mean pentachlorophenol blood serum level of 47.6 µg/L and a geometric 
mean urine concentration of 21 µg per gram urinary creatinine.  Pentachlorophenol was detected in blood 
and urine of all 66 residents. 
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Mean pentachlorophenol blood serum levels in workers using pentachlorophenol or pentachlorophenol­
treated materials were found to range from 83 to 57,600 µg/L by Cline et al. (1989).  This upper limit is 
approximately 100 times the value expected from exposure to the threshold limit value (TLV) (Braun et 
al. 1979). Workers were involved in the construction of log homes, repair of telephone lines, custodial 
care of log cabin museums, and in various operations in wood-preservative and chemical-packaging 
facilities. One worker from a chemical-packaging facility, with a whole blood pentachlorophenol level of 
23,000 µg/L, died of pentachlorophenol poisoning (Cline et al. 1989). 
A mean level of 26.3 µg/kg was found in adipose tissue from the general U.S. population and it was 
concluded that humans are continuously exposed to low levels of pentachlorophenol from the 
environment, food supplies, and disinfectants (Shafik 1973).  The distribution and bioconcentration of 
pentachlorophenol in different tissues of humans was investigated by Geyer et al. (1987).  By comparing 
daily intake of pentachlorophenol with tissue concentrations, bioconcentration ratios of 5.7, 3.3, 1.4, 1.4, 
and 1.0 were obtained in liver, brain, blood, spleen, and adipose tissue, respectively.  Pentachlorophenol 
has also been found in human milk samples from West Germany at 0.03–2.8 µg/kg (Gebefugi and Korte 
1983). In a study of human tissues removed at autopsy, including testes, kidney, prostate glands, livers, 
and adipose tissue, pentachlorophenol was found in all tissues examined at a range of 7 ppb in 
subcutaneous fat to 4,140 ppb in testes (Wagner et al. 1991). 
Based on the pentachlorophenol levels in their 1977 food survey, FDA estimated an average dietary 
intake of 0.76 mg/day for a typical 15–20-year-old male, and EPA (1978a) calculated an average dietary 
intake of 1.5 mg/day and a maximum dietary intake of 18 mg/day.  However, the actual intake will be 
lower than estimates because average dietary intakes were based on mean concentration of positive 
samples.  Considering pentachlorophenol levels in fish, peanut butter, food packaging materials, jar lids, 
etc., the average intake of pentachlorophenol in food has been estimated to be 1.5 mg/day (EPA 1980f). 
Daily dietary intake of pentachlorophenol from contaminated food has been estimated by another source 
to be 0.1–6 µg/day (WHO 1987).  Using a six-compartment environmental partitioning model, Hattemen-
Frey and Travis (1989) reported that the food chain is the most important source of exposure to 
pentachlorophenol for the general population. They estimated average daily dietary intake of the 
compound to be 16 µg/day from ingestion of contaminated food, primarily root vegetables. 
Pentachlorophenol was detected in 15% of the foods collected in eight market basket surveys from 
different regions of the United States during the period of April 1982 to April 1984 (Gunderson 1988). 
Foods representative of the diets of eight different age/gender population groups were prepared for 
consumption prior to analysis in a revision to FDA's Total Diet Study methodology.  Estimated mean 
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daily intakes (ng/kg/day) of pentachlorophenol for these groups in 1982–1984 were as follows: 
(1) 6–11-month-old infants, 59.0; (2) 2-year-old children, 48.5; (3) 14–16-year-old females, 16.2; 
(4) 14–16-year-old males, 20.7; (5) 25–30-year-old females, 15.9; (6) 25–30-year-old males, 18.2; 
(7) 60–65-year-old females, 13.9; and (8) 60–65-year-old males, 15.5.  In a later survey of the Total Diet 
Study, Gunderson (1995a) estimated mean daily intakes (ng/kg/day) of pentachlorophenol for these same 
eight age/gender population groups during a 1986–1991 study as follows: (1) 6–11-month-old infants, 
0.9; (2) 2-year-old children, 1.4; (3) 14–16-year-old females, 0.5; (4) 14–16-year-old males, 0.5; 
(5) 25–30-year-old females, 0.8; (6) 25–30-year-old males, 0.7; (7) 60–65-year-old females, 0.8; and 
(8) 60–65-year-old males, 0.8.  A substantial reduction in the amount of pentachlorophenol in the 
estimated mean daily intake has been observed since the 1982–1984 study.  In a monitoring program 
conducted by the Danish National Pesticide Monitoring Program from 1995 to 1996, no pentachloro­
phenol was detected in the samples of fruits, vegetables, cereals, bran, fish, or animal products such as 
meats, butter, cheese, fat, and eggs. 
In earlier surveys of pentachlorophenol exposure, food was found to be the most important source of 
intake for members of the general population (Coad and Newhook 1992; Wild and Jones 1992).  In a 
multimedia analysis of pentachlorophenol exposure for the general population of Canada, food sources 
(mostly dairy products, grains, and cereals) accounted for an estimated 74–89% of the total daily intake of 
pentachlorophenol. Inhalation exposure, especially of indoor air, accounted for an estimated 10–25% of 
total daily intake, whereas water and soil/household dust were found to be negligible sources.  Daily 
exposure of recreational fishermen consuming about twice as much fish as members of the general 
population was estimated to be only about 2% higher than that of the general population.  However, 
lifetime dietary intakes of pentachlorophenol for aboriginal subsistence fishermen, relying on traditional 
diets of fish and fish products were estimated to be about twice those of members of the general Canadian 
population (Coad and Newhook 1992). In the United Kingdom, dietary sources are believed to account 
for greater than 90% of the estimated total daily intake of 5.7 µg pentachlorophenol/day by members of 
the general population. This value is considerably smaller than the 39 µg/day estimate for 
occupationally-exposed individuals.  Inhalation is believed to be the most important route of exposure in 
workplace settings (Wild and Jones 1992). In a study that used the clearance concept to estimate net daily 
intake (i.e., net daily intake=clearance times average steady state concentration in plasma), the net daily 
intake of pentachlorophenol for members of the general U.S. population not specifically exposed to the 
compound was estimated to be 12.3–135.9 µg/day.  For members of the general U.S. population residing 
in log homes, net intake was estimated to be 140–157 µg/day.  Daily intake estimates for occupationally­
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exposed individuals varied widely depending on the type of work involved; estimates ranged from 35 to 
24,000 µg/day (Reigner et al. 1992a). 
The National Organic Monitoring Survey conducted in 1976 found pentachlorophenol residues in 
86 of 108 drinking water samples, with a mean of 0.07 µg/L and a maximum of 0.7 µg/L (EPA 1978a); 
however, the median concentration was less than 0.01 µg/L, the minimum detectable limit.  In another 
survey, pentachlorophenol was detected at 1.3–12.0 µg/L in 8 out of 135 systems surveyed (EPA 1980a, 
1980c). Assuming an intake of 2 L of drinking water/day, exposure for most people would be less than 
0.02 µg/day, while the maximum exposure would be 24 µg/day. 
Inhalation of estimated ambient levels of pentachlorophenol in the atmosphere has an associated exposure 
level of 6 µg/day for the general population (EPA 1980f).  Subpopulations in the vicinity of pentachloro­
phenol sources and workers may be exposed to significantly higher levels.  For example, workers in the 
vicinity of a cooling tower may have been exposed to 14.4 mg pentachlorophenol/day, and those in wood-
treatment plants may have been exposed to 0.9–14 mg pentachlorophenol/day (EPA 1980f).  Pentachloro­
phenol levels in the air of an experimentally treated room varied greatly (1–160 µg/m3) with temperature 
and ventilation (Gebefugi et al. 1976). 
Pentachlorophenol was detected at a geometric mean concentration of 0.080 ng/L in 62 of 63 air samples 
taken in 21 log homes treated with the compound.  The homes, all located in Kentucky, were categorized 
into six treatment types:  (1) "never treated"; (2) external treatment; (3) manufacturer treated; (4) treated 
and sealed; (5) treated, sealed, and neutralized; and (6) treated and neutralized.  Concentrations in "never 
treated" homes, which were lower than those in treated homes, were believed to be the result of the 
application of pentachlorophenol to logs during storage to prevent fungal growth.  Treated logs were 
found to be the source of pentachlorophenol in indoor air; air concentrations were highly correlated with 
pentachlorophenol concentrations in wood cores (geometric mean, 15,900 ng/g wood) and log surface 
wipes (geometric means, 89.6 and 187 ng/100 cm2) (Hosenfeld et al. 1986). Concentrations of 
pentachlorophenol in older structures built with pressure-treated wood brushed with pentachlorophenol 
were reported to range from 0.5 to 10 µg/m3 (EPA 1984b). Use of sealers decreased this concentration by 
85%. Indoor air interiors of structures built with industrially dipped nonpressure-treated wood were 
reported to contain levels of pentachlorophenol that ranged from 34 to 104 µg/m3 (EPA 1984b). Logs 
used for home construction are no longer treated with pentachlorophenol.  Pentachlorophenol in air 
samples taken from 75 rooms in 30 buildings with suspected use of pentachlorophenol-containing wood 
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preservatives in Germany ranged from <0.03 to 576 ng/m3. Pentachlorophenol in the dust samples taken 
from the same sites ranged from 0.083 to 79 ng/kg (Schnelle-Kreis et al. 2000). 
Dermal absorption is another potential exposure pathway.  Pentachlorophenol is readily absorbed through 
skin (Qiao et al. 1997; Wester et al. 1993). EPA (1984) has assumed a dermal absorption efficiency in 
humans of 50% for pentachlorophenol in organic solvents and 10% for an aqueous solution of sodium 
pentachlorophenate. Dermal exposure is potentially an occupational problem; the general public is not 
expected to be exposed to pentachlorophenol via dermal contact.  Santodonato (1986) suggested that 
dermal contact is the most important route of occupational exposure to pentachlorophenol because of the 
manner in which the compound is used (i.e., manual handling of solutions and treated materials) and its 
low vapor pressure. Workers such as carpenters, lumberyard workers, and loading-dock laborers who 
handle treated materials could be exposed continually via this route as well as by inhalation.  The 
potential for dermal exposure to pentachlorophenol at hazardous waste sites is unknown. 
The National Occupational Hazard Survey (NOHS), conducted by the National Institute for Occupational 
Safety and Health (NIOSH), estimated that 179,243 workers in 22,347 plants were potentially exposed to 
pentachlorophenol in the workplace in 1970 (NIOSH 1976).  The largest numbers of exposed workers 
were employed in the following fields:  general building contractors; special trade contractors; chemicals 
and allied products industries; electric, gas, and sanitary services; and medical and other health services 
industries. 
Preliminary data from a second workplace survey, the National Occupational Exposure Survey (NOES) 
conducted by NIOSH from 1980 to 1983 indicated that 26,463 workers (including 3,916 women) in 
1,490 plants employed in lumber and wood products, business services, wholesale trade, general building 
contractors, and chemicals and allied products industries were potentially exposed to pentachlorophenol 
in the workplace in 1980 (NIOSH 1984a). Most of these workers were pest controllers, electrical power 
installers and repairers, laborers, assemblers, carpenters, miscellaneous precision workers, janitors, 
engineers, and engineering technicians. 
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6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in  3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults. 
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children are likely to be exposed to pentachlorophenol via the same routes that affect adults, such as 
inhalation of contaminated air, ingestion of contaminated groundwater used as a source of drinking water, 
ingestion of contaminated food, and dermal contact with contaminated soils or products treated with the 
compound.  In addition, small children are more likely than adults to come into intimate contact with yard 
dirt, lawns, and house (carpet) dust. Dislodgeable pesticide residues in carpets or on uncovered floors 
may present a relatively important exposure route for infants and toddlers through dermal contact and oral 
ingestion. The tendency of young children to ingest soil, either intentionally through pica or 
unintentionally through hand-to-mouth activity, is well documented.  These behavioral traits can result in 
ingestion of pentachlorophenol present in soil and dust.  Though pentachlorophenol is known to: 
(1) adsorb to soil, especially at lower pH (Chang and Choi 1974; Choi and Aomine 1974; Kuwatsuka and 
Igarashi 1975); (2) have an insignificant rate of volatilization from soil (Kilzer et al. 1979); and 
(3) biodegrade at a moderately rapid rate, very little data are available on the actual measurements of 
pentachlorophenol in soil. No studies are available that describe the dermal absorption of 
pentachlorophenol in children. Two studies are available, however, that show that absorption of 
pentachlorophenol occurs in both Rhesus monkeys and swine when dermally exposed to soil amended 
with pentachlorophenol (see Section 3.4.1.3). Therefore, it is possible that children may absorb 
pentachlorophenol dermally when exposed to soil contaminated with pentachlorophenol. 
Hill et al. (1989) compared the amounts of chlorinated phenols and phenoxy acids found in the urine of 
97 children living in the vicinity of a herbicide manufacturing plant to those found in the urine of a 
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control group of 100 children living away from the herbicide plant.  There was no significant difference 
in the amounts of pentachlorophenol or other herbicide residues detected in the two groups with the 
median pentachlorophenol concentration of 14 µg/L.  This insignificant difference in the amounts of 
pentachlorophenol between the two groups indicated that the children living in the vicinity of the 
herbicide plant were not at a greater risk of exposure.  Cline et al. (1989) measured the pentachlorophenol 
in the serum and urine of adults and children living in pentachlorophenol-treated log houses.  The 
pentachlorophenol serum levels of children were found to average 1.8 times those of their parents.  The 
mean concentrations were: (1) 2–5-year-old children, 600 µg/L; (2) 6–10-year-olds, 490 µg/L; 
(3) 11–15-year-olds, 370 µg/L; and (4) adults, 310 µg/L.  The higher concentration of pentachlorophenol 
detected in children was attributed to their greater body surface-to-weight ratio and a higher respiratory 
rate as compared to adults.  An East German study (Rehwagen et al. 1999), comparing urban versus rural 
exposure, detected a lower concentration of pentachlorophenol in the urine of children from the city of 
Leipzig than in the urine of children from the towns of Hettsdedt, Wippra, Roitzsch, and Greppin. 
Although the inhalation of house dust was a possible source of exposure to pentachlorophenol, no 
correlation could be established between the amount of pentachlorophenol detected in the urine and the 
amount of pentachlorophenol in the house dust. 
Pentachlorophenol was used extensively in treating wood.  Today, though no longer used in treatment of 
wood products in residences and agricultural buildings, pentachlorophenol is still widely used in the 
treatment of utility poles and railroad ties.  Playing near a utility pole such as a telephone or an electrical 
pole may pose a risk of dermal exposure.  Pentachlorophenol is also known to volatilize from treated 
wood (Bunce and Nakai 1989) with emissions expected to be highest in the hottest months of the summer 
(Ingram et al. 1986).  Therefore, low-level inhalation exposure may occur for children playing nearby. 
The soil samples, within a distance of 8 inches from the utility poles, were found to have a higher 
concentration of pentachlorophenol relative to those further away, indicating that leaching is occurring 
from their bases (Weinberg 1997).  This indicated a downward migration of pentachlorophenol down the 
poles, which would result in a higher concentration in the lower sections.  Higher than expected dermal 
exposure of children may, therefore, also occur since children may touch the lowest sections of utility 
poles while playing.  Old and unpainted playground equipment constructed with pentachlorophenol­
treated wood may be another mode of dermal exposure for children. 
Lewis et al. (1994) conducted a nine-home pilot study to monitor the potential exposure of small children 
to pesticides in the residential environment.  Pentachlorophenol was found to be one of the most 
frequently occurring pesticides and was detected in all of the samples in all nine houses irrespective of the 
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age of the house (year of construction ranged from 1930 to 1989).  The mean concentration of 
pentachlorophenol reported by the authors at various sites around a house is as follows: entryway soil, 
0.03 µg/g; walkway soil, 0.02 µg/g; and play area soil, 0.02 µg/g.  It was also detected in house dust, 
0.83 µg/g; child hand rinse, 0.02 µg; and air, 0.05 µg/m3. No attempts were made by the authors to 
estimate the amounts of carpet dust or soil that the children who participated in the study may have 
ingested. The authors concluded that dust ingestion could constitute a substantial portion of a child’s 
exposure to pesticides along with dermal absorption from house dust or yard soil. 
A potential source of exposure in infants is the presence of pentachlorophenol in breast milk or formula. 
No data were located on the presence of pentachlorophenol in breast milk in the United States.  However, 
in a study from Upper Bavaria, Gebefugi and Korte (1983) detected pentachlorophenol in 100% of  the 
samples of breast milk, with a median concentration of 1.43 µg/kg.  No significant sources of 
pentachlorophenol exposure were identified. In a more recent  study from Bratislava, Slovakia (a city 
with a highly concentrated chemical industry and intensive agriculture), human milk obtained from 
50 mothers was analyzed for the presence of chlorophenols (Veningerova et al. 1996).  The median 
concentration of pentachlorophenol was found to be 2.21 µg/kg.  The main source of pentachlorophenol 
exposure was through the ingestion of contaminated foods.  No pesticide residues (including 
pentachlorophenol) were detected in ready to serve milk-based infant formula, with and without iron 
(Gunderson 1995b; Yess et al. 1993). 
Van Langeveld (1975) reported levels of pentachlorophenol ranging from 10 to 270 µg/L in 9 out 
of 65 samples of children's paints in the Netherlands.  It is not known whether these paints are imported 
into the United States. No data were available about the presence of pentachlorophenol in children’s 
paints made in the United States. 
Percutaneous pentachlorophenol absorption from the pentachlorophenol used in the laundry can be a 
significant source of pentachlorophenol exposure in infants.  Smith et al. (1996) reported an occurrence of 
pentachlorophenol poisoning in newborn infants in St. Louis, Missouri during April–August 1967.  The 
infants were exposed to pentachlorophenol through the diapers, which were rinsed in the hospital laundry 
room with an anti-mildew agent containing 22.9% sodium pentachlorophenate.  Pentachlorophenol has, 
since then, been regulated as a restricted-use pesticide.  It is not likely to be used in the laundry today.
Foods representative of the diets of eight different age/gender population groups, including children 
(6–11-month-old infants, 2-year-old children, and 14–16-year-old males and females), were prepared for 
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consumption prior to analysis in a revision to the FDA's Total Diet Study methodology (Gunderson 
1988). Estimated mean daily intakes (ng/kg/day) of pentachlorophenol for children in 1982–1984 were 
as follows: (1) 6–11-month-old infants, 59.0; (2) 2-year-old children, 48.5; (3) 14–16-year-old females, 
16.2; and (4) 14–16-year-old males, 20.7.  In comparison, the intake for adults ranged from 15.5 to 
18.2 ng/kg/day.  In a later survey of the Total Diet Study during 1986–1991, Gunderson (1995a) 
estimated mean daily intakes (ng/kg/day) of pentachlorophenol for these population groups as follows: 
(1) 6–11-month-old infants, 0.9; (2) 2-year-old children, 1.4; (3) 14–16-year-old females, 0.5; 
(4) 14–16-year-old males, 0.5; and (5) 25–30-year-old females, 0.8.  In comparison, the intake for adults 
ranged from 0.7 to 0.8 ng/kg/day.  A substantial reduction in the amount of pentachlorophenol in the 
estimated mean daily intake has been observed since the 1982–1984 study.  No data are available for the 
exposure to and the effect of pentachlorophenol through specific food sources such as fish, animal 
products, cereals, etc. FDA also tested the presence of pesticide residues in a variety of infant and adult 
foods eaten by infants and children (Yess et al. 1993).  Since whole and unpeeled fruits and vegetables 
were tested, the results were not indicative of pesticide residues in foods as consumed.  Pentachloro­
phenol was found in plain milk (6.5% of the samples, maximum residue of 100 ppb), vitamin D milk (3% 
of the samples, maximum residue of 20 ppb), pork (7% of the samples, maximum residue of 6 ppb), grape 
jelly (4% of the samples, maximum residue of 4 ppb), raw pears  (4% of the samples, maximum residue 
of 7 ppb), and in canned, evaporated milk (7% of the samples, maximum residue of 7 ppb).  No data are 
available on children and their weight-adjusted intake of pentachlorophenol. 
The children of pesticide applicators who use pentachlorophenol may potentially be exposed to elevated 
levels from contact with their parents’ skin, hair, work clothes, and/or other workplace objects.  In 
addition, pentachlorophenol adsorbed onto the parent or the parent’s clothing may contaminate household 
objects when they come in contact with them, potentially exposing children to pentachlorophenol. 
Although pentachlorophenol is a restricted-use pesticide and is only supposed to be used by an EPA-
certified applicator for specified uses, there have been instances in which children were exposed to 
pesticides (methyl parathion) from the illegal application of pesticides.  No monitoring data are available 
on this route of exposure to pentachlorophenol. 
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6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Pentachlorophenol levels in human tissues are much higher in occupationally exposed groups than in the 
general public. Populations with potentially high exposure include individuals involved in the 
manufacture and use of the compound.  Residents near pentachlorophenol manufacturing plants and waste 
water treatment sludge disposal sites may also be exposed to the chemical at higher concentrations than 
the general public. Residents around the 313 NPL sites known to have pentachlorophenol contamination 
may also be exposed to the chemical at higher levels (>1,000 µg/kg) in contaminated environmental 
media. 
Pentachlorophenol is found as a residue in treated wood that has been preserved with this chemical. 
Examples of consumer items containing pentachlorophenol-treated wood have included boats, furniture, 
and log homes.  In fact, some families living in homes historically treated with pentachlorophenol have 
been reported to have symptoms of chronic exposure (Jagels 1985).  Since the compound is no longer 
used in the treatment of wood products for log homes, outdoor furniture, or playground equipment, 
human exposure from these sources is probably limited to contact with materials treated in the past. 
6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of pentachlorophenol is available.  Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is 
required to assure the initiation of a program of research designed to determine the health effects (and 
techniques for developing methods to determine such health effects) of pentachlorophenol. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical/chemical properties of pentachlorophenol are
 
well characterized and allow the prediction of the environmental fate of the compound (see Chapter 4). 

Estimates of the distribution of pentachlorophenol in the environment based on available constants (e.g.,
 
water solubility, Log Kow, Log Koc, vapor pressure) are generally in good agreement with experimentally
 
determined values.  No additional studies are required at this time.
 
Production, Import/Export, Use, Release, and Disposal. Pentachlorophenol is currently being
 
produced by only one manufacturer (SRI 1998).  Current production volume data are not available;
 
however, it is known that production volumes steadily decreased from 45 million pounds in
 
1983 (Mannsville 1987) to 9.1 million pounds in 1996 (IARC 1999).  No recent data are available on the
 
production, export, and use volumes of pentachlorophenol.  In the past, pentachlorophenol was one of the
 
most heavily used pesticides in the United States but is now regulated as a restricted use pesticide
 
(CELDS 1992; EPA 1984b). The compound is found in all environmental media (air, soil, and water) as
 
a result of its past widespread use. The only disposal method located in the literature is incineration,
 
which releases polychlorinated dibenzo-p-dioxins and dibenzofurans at unspecified levels (Karasek and
 
Dickson 1987). Disposal of pentachlorophenol is subject to EPA restrictions (EPA 1991, 1992). 

According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.
 
Section 11023, industries are required to submit chemical release and off-site transfer information to the
 
EPA. The TRI, which contains this information for 1999, became available in 2001.  This database will
 
be updated yearly and should provide a list of industrial production facilities and emissions.
 
Environmental Fate. Information on environmental fate of pentachlorophenol is sufficient to permit
 
a general idea of transport and transformation of the chemical in the environment.  Atmospheric or vapor-

phase pentachlorophenol is expected to photolyze at an estimated (midday in summer at 40 EN) maximum
 
rate of 6.2% per hour, and to degrade through reactions with hydroxyl radicals at an estimated (midday in
 
summer) loss rate of 1.5% per hour (Bunce and Nakai 1989).  Meylan and Howard (1993) estimated a
 
half-life of 58 days for the vapor-phase reaction of pentachlorophenol with hydroxyl radicals.  However,
 
the data need still exists for actual rates of vapor-phase photolysis and atmospheric degradation due to
 
hydroxyl radical attack.  Volatilized pentachlorophenol may also be lost from the atmosphere through
 
deposition. The compound is expected to partition to soils and sediment (Kuwatsuka and Igarashi 1975),
 
and to be transported in surface water and groundwater (Davis et al. 1994; Mohammed et al. 1998). 
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Pentachlorophenol is transformed by photolysis in water, with half-lives of 3.5 hours (pH 7.3) to 
100 hours (pH 3.3) under UV light and a half-life of 48 hours (pH 7.3) in sunlight (Wong and Crosby 
1981). Aqueous photolysis of the compound occurs more rapidly at the water surface (half-life of 
0.7 hours at 0.5-cm depth), with attenuated rates occurring at greater depths in the water column (half-life 
of 9.6 hours at 13.8-cm depth; Pignatello et al. 1983).  Pentachlorophenol does not photolyze to a 
significant extent in soils, but may be photolyzed at the soil surface (top 0.5 mm) when near-saturated 
conditions exist; total degradation in near-saturated irradiated soils was 55% greater than in the dark 
controls (Donaldson and Miller 1997).  Additional information on soil photolysis rates at various soil 
moisture contents may be helpful in determining the potential for degradation of the compound at sites 
with pentachlorophenol-contaminated areas which are flooded intermittently.  A more important 
mechanism for the transformation of pentachlorophenol in soils is the adsorption of the compound to soil 
mineral particles and soil organic matter.  Pentachlorophenol is a weakly acidic compound (pKa of 4.74) 
that is adsorbed to the largest extent under acidic soil conditions (where it is present in the unionized form 
which it is less soluble in water), and has greater mobility in neutral or alkaline soils where it is present as 
the phenolate anion (Kuwatsuka and Igarashi 1975). Maximum adsorption has been reported at soil pH 
values of 4.6–5.1, with no adsorption above pH 6.8; at a given pH, adsorption increases with increasing 
organic matter content (Choi and Aomine 1974).  In aquifers, the retardation or decreased mobility of the 
compound has been observed to be greater in areas of lower pentachlorophenol concentrations 
(<0.04 mg/L) than in areas of high concentrations (>1 or 10 mg/L; Davis et al. 1994).  Although it was 
determined in previously conducted studies of natural sediments and aquifer materials that the adsorption 
of pentachlorophenol was highly dependent on the organic matter content of the adsorbent, with an 
average Koc of 32,900 measured (Schellenberg et al. 1984), the use of normalized partition coefficients 
(Koc) do not accurately predict the adsorption of ionizable compounds such as pentachlorophenol since 
the adsorption of such does not increase linearly with the increasing concentration of the compound 
(Christodoulatos et al. 1994). For this reason, the need exists for a more accurate means of measuring 
and/or interpreting the potential mobility of pentachlorophenol in aquifers and in surface soils which are 
either intermittently subjected to flooding or are in contact with overland runoff.  Because the presence of 
alcohols and petroleum compounds such as oils and kerosene (all of which are utilized as cosolvents in 
the application of pentachlorophenol) may decrease the adsorption of pentachlorophenol in soils 
(Christodoulatos et al. 1994; Jackson and Bisson 1990), and because pentachlorophenol has also been 
observed to desorb more readily from contaminated soils in the presence of compounds such as methanol 
(You and Liu 1996), there is a need for data that indicate the potential mobility of pentachlorophenol 
when it is present in the soil or water in combination with such cosolvents.  Additionally, data are 
necessary on the adsorption of pentachlorophenol when it is present in combination with other 
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contaminants expected to occur in the same environment.  Biodegradation is another major mechanism 
for the transformation of pentachlorophenol in the environment (Englehardt et al. 1986; McAllister et al. 
1996; Pignatello et al. 1983). In water, pentachlorophenol may be biodegraded with observed first half-
lives of less than 1 month following acclimation periods of 5–7 weeks; the presence of sediment generally 
decreases the acclimation period (Ingerslev et al. 1998; Pignatello et al. 1985).  The biotransformation of 
pentachlorophenol in groundwater, and possibly in surface water may not be significant in the absence of 
nonacclimated microbial populations.  Decreases in the observed aqueous concentration of the compound 
may be attributed to adsorption to sediment or particulate material rather than to degradation of the 
compound (Mohammed et al. 1998).  Additional information, such as biodegradation half-lives in both 
surface water and groundwater, is necessary to evaluate the potential for the degradation of the compound 
in water that is not in contact with sediment, rock, or macrophyte surfaces and where acclimated 
microbial populations do not exist.  In soils, biodegradation of pentachlorophenol is generally rapid, with 
half-lives of 2–4 weeks. The metabolism of the compound is more rapid in soils with acclimated 
microbial populations (Kaufman 1978).  Biodegradation of pentachlorophenol and aged residues of the 
compound occurs in both aerobic and anaerobic soils, usually following an acclimation period, but may 
occur more completely and rapidly in aerobic soils (Frisbie and Nies 1997).  In other studies, 
biodegradation of the compound was observed to be more rapid in anaerobic environments (Ide et al. 
1972; Kuwatsuka and Igarashi 1975). McAllister et al. (1996) reported that there are multiple pathways 
for the biodegradation of pentachlorophenol, which differ according to the microbial populations present 
in the soil. While the biodegradation of pentachlorophenol has been studied extensively, there may still 
be a need for data that elucidate the effect of anaerobic environments (and alternating aerobic/anaerobic 
environments) on the rate and extent of the degradation of the compound and its metabolites. 
Additionally, information on the uptake and transformation of the compound in plants is necessary to 
improve the current understanding of pentachlorophenol's environmental fate; currently existing data on 
plant uptake and transformation are inconsistent between studies and are inconclusive with regard to the 
ability of specific plants to remove the compound from the soil (McAllister et al. 1996).  
Bioavailability from Environmental Media. Pentachlorophenol is readily and completely 
absorbed following inhalation (Casarett et al. 1969; Cline et al. 1989; Hosenfeld et al. 1986; Jones et al. 
1986), oral (Braun et al. 1979; Uhl et al. 1986), and dermal exposure (Hosenfeld et al. 1986; Qiao et al. 
1997; Wester et al. 1993). Using Rhesus monkeys, Wester et al. (1993) demonstrated the dermal 
absorption from pentachlorophenol-treated soil.  It was also shown that when [14C-UL]-pentachlorophenol 
in a soil-based mixture was applied occlusively or nonocclusively to a clipped 7.5-cm2 abdominal site of 
8 to 10-week-old female pigs, total radiolabel absorption was 29.08% under nonocclusive conditions and 
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100.72% under occlusive conditions 408 hours after dosing (Qiao et al. 1997).  Additional information on 
the bioavailability of pentachlorophenol adsorbed to soils would be helpful in assessing the relative 
importance of ingestion of contaminated soils as a potential route of human exposure.  Additional 
information is also necessary on the desorption of the compound from soils when the soil pH is altered or 
when pentachlorophenol-contaminated soil comes into contact with cosolvents (such as alcohols or 
petroleum compounds), which may enhance desorption and/or increase the solubility of 
pentachlorophenol. Cline et al. (1989) detected elevated levels of pentachlorophenol in the urine of log-
home residents.  They believed inhalation to be the most likely route of exposure.  Additional information 
is required to correlate the presence of pentachlorophenol in contaminated air and the exposure via 
inhalation. 
Food Chain Bioaccumulation. The log Kow of pentachlorophenol presented in Chapter 4 is 5.01, 
suggesting that pentachlorophenol is likely to bioaccumulate.  However, the extent of bioaccumulation 
will depend on the pH of the medium since pentachlorophenol converts at higher pH levels to the more 
water-soluble pentachlorophenate anion. Pentachlorophenol is bioconcentrated by terrestrial and aquatic 
organisms (EPA 1986c; Makela et al. 1991; Smith et al. 1990).  However, biomagnification of the 
compound in terrestrial and aquatic food chains has not been demonstrated as a result of the fairly rapid 
metabolism of the compound by exposed organisms (Niimi and Cho 1983).  BCF values of 218 (whole 
fish) to 1,633 (fish lipid basis) for juvenile American flagfish were demonstrated by Smith et al. (1990). 
The half-life of pentachlorophenol in the tissues was reported to be about 16 hours.  The food chain 
bioaccumulation potential of pentachlorophenol can currently be characterized without generating 
additional data. 
Exposure Levels in Environmental Media. Pentachlorophenol has been detected in ambient air, 
surface water, drinking water, soils, and foods. Estimates of dietary intake of the compound have been 
made by the World Health Organization (WHO 1987), EPA (EPA 1978a), and FDA (FDA 1989; 
Gunderson 1988). In a comparison of the 1986–1991 study to the 1982–1984 study, Gunderson (1995a) 
observed a substantial reduction in the amount of pentachlorophenol in the estimated mean daily intake. 
Lewis et al. (1994) detected low levels of pentachlorophenol in air, dust and soil in a nine-home (year of 
construction ranged from 1930 to 1989) pilot study to monitor the potential exposure of small children to 
pesticides in the residential environment.  Further monitoring is required to be able to evaluate the risk of 
exposure from pentachlorophenol-treated wood in homes.  Limited information is available regarding the 
levels of pentachlorophenol in air in the United States.  More ambient monitoring data of air is required to 
estimate the exposure of the general population via inhalation of pentachlorophenol in the 1990s. 
    
    
181 PENTACHLOROPHENOL 
6. POTENTIAL FOR HUMAN EXPOSURE 
Contemporary monitoring studies demonstrating the presence or absence of pentachlorophenol in various 
sources of surface and drinking water are also needed. 
Reliable monitoring data for the levels of pentachlorophenol in contaminated media at hazardous waste 
sites are needed so that the information obtained on levels of pentachlorophenol in the environment can 
be used in combination with the known body burden of pentachlorophenol to assess the potential risk of 
adverse health effects in populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans. Pentachlorophenol has been measured in blood (NHANES III) 
(Ferreira et al. 1997; NHANES II), urine (Barbieri et al. 1995; Bevenue et al. 1967; Colosio et al. 1993a; 
Ferreira et al. 1997; Hill et al. 1989, 1995; Thompson et al. 1994, 1996; Treble and Thompson 1996), 
cerebrospinal fluid (Jorens et al. 1991), and tissues of humans (Bevenue et al. 1967).  Quantitative data 
that correlate varying levels in the environment with levels in body fluids and health effects are not 
available. One study exists for residents of log homes treated with pentachlorophenol; levels in blood and 
urine were highly correlated with levels in indoor air ( Lewis et al. 1994).  Additional information on 
exposure levels for populations living near hazardous waste sites would be helpful.  Information 
regarding the exposure levels for populations near pentachlorophenol-treated utility poles would be 
useful. This information is necessary for assessing the need to conduct health studies on these 
populations. 
Exposures of Children. No monitoring studies have been performed to investigate the exposure to 
and the body burden of pentachlorophenol in children.  No studies are available on the dermal absorption 
of pentachlorophenol in infants and toddlers due to activities such as crawling, which will result in 
contact with the floor (carpet) and soil. Since pentachlorophenol is likely to be adsorbed to these 
materials, more information would allow the estimation of a child’s exposure to pentachlorophenol to be 
more rigorously determined.  A pilot study measured the amounts of pentachlorophenol in dust and soils 
that are found in areas where children may play, such as carpets and playgrounds (Lewis et al. 1994).  As 
part of the FDA total diet study, mean daily intake of pentachlorophenol by 6–11-month-old infants, 
2-year-old children, and 14–16-year-old males and females were determined (Gunderson 1995a).  Studies 
dealing with the weight-adjusted intake of pentachlorophenol by children would help in assessing the 
effects of pentachlorophenol in children. No studies are available on the amounts of pentachlorophenol 
present in the breast milk of women in the United States.  The estimation of the amounts of soil and house 
dust that are ingested by children needs to be determined.  No information is available on the exposure of 
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children to pentachlorophenol from the parent’s body, work clothes, and other objects from work. 
Studies are required to identify childhood-specific means of decreasing exposure to pentachlorophenol.  
Child health data needs relating to susceptibility are discussed in 3.12.2 Identification of Data Needs: 
Children’s Susceptibility. 
Exposure Registries. No exposure registries for pentachlorophenol were located.  This substance is 
not currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance. 
6.8.2 Ongoing Studies 
As part of the Third National Health and Nutrition Evaluation Survey (NHANES III), the Environment 
Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for 
Disease Control and Prevention, will be analyzing human urine samples for pentachlorophenol and other 
phenolic compounds.  These data will give an indication of the frequency of occurrence and background 
levels of these compounds in the general population. 
The U.S. Department of Agriculture is sponsoring several studies on the degradation, adsorption, and 
uptake of pentachlorophenol. At the Agricultural Research Service, Fargo, North Dakota, research is 
being conducted to identify and quantitate residues of chlorinated organics (congeners of dioxins, furans, 
and polychlorinated biphenyls) in beef, milk, and animal feeds, particularly forages.  In another study at 
Ohio Agricultural Research and Development Center, Wooster, Ohio, models for the transport of dioxins 
that are contained in feed and in other environmental matrices to beef that is intended for human 
consumption are being developed.  At Xenometrix, Inc., research is being focused on the microbial 
dehalogenation of pentachlorophenol by Flavobacterium. Researchers at University of Florida, 
Gainesville, Florida, are studying the soil processes that regulate the fate of chlorophenols in wetlands. 
Research is underway at Forest and Wildlife Research Center, Mississippi, to develop a rapid biological 
technique for cleanup of organic wood preservatives in groundwater using oxygen, surfactants, cofactors, 
and micronutrients; and to evaluate different commercial surfactants for enhancing the biodegradation of 
wood-preserving process water containing high concentrations of pentachlorophenol, polyaromatic 
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hydrocarbons, oil, and grease.  At Texas A&M University, College Station, Texas, research is being 
conducted to develop a method for dechlorinating pentachlorophenol from contaminated water and soil, 
and to refine the use of bioassays as monitoring tools to assess the changes in toxicity occurring as a 
result of remedial activities at Superfund waste sites.  At Oregon State University, Corvallis, Oregon, 
researchers are working on determining the effects of estrogenic environmental pollutants on chemical 
carcinogenesis using rainbow trout as a model system. 
In a study sponsored by the National Institute of General Medical Sciences, at University of Colorado, 
Boulder, Colorado, research is being performed to determine the mechanism of the enzyme, tetrachloro­
hydroquinone dehalogenase, that plays a critical role in biodegradation of pentachlorophenol.  A similar 
study, sponsored by National Science Foundation, investigating the role of tetrachloro-1,4-hydroquinone 
dehalogenase in the degradation of pentachlorophenol is underway at University of Colorado, Boulder, 
Colorado. The biochemistry of 2,4,5-trichlorophenoxyacetate and pentachlorophenol is being 
investigated in a National Science Foundation sponsored study at Washington State University, Richland, 
Washington. 
In addition, ongoing remedial investigations and feasibility studies at NPL sites known to be 
contaminated with pentachlorophenol should add to the available database for environmental levels, 
environmental fate, and human exposure. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 
measuring, and/or monitoring pentachlorophenol, its metabolites, and other biomarkers of exposure and 
effect to pentachlorophenol. The intent is not to provide an exhaustive list of analytical methods.  Rather, 
the intention is to identify well-established methods that are used as the standard methods of analysis. 
Many of the analytical methods used for environmental samples are the methods approved by federal 
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health 
(NIOSH). Other methods presented in this chapter are those that are approved by groups such as the 
Association of Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits, and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS 
Exposure to pentachlorophenol is most commonly evaluated by analysis of urine, blood, feces, or adipose 
or other tissues, using gas chromatography (GC) combined with electron capture detection (ECD) or 
high-performance liquid chromatography (HPLC) combined with ultraviolet (UV) detection.  Recovery is 
generally high and sensitivity using GC/ECD and HPLC/UV is in the parts per billion (ppb) range.  Some 
efforts are currently in development to detect pentachlorophenol metabolites in urine as a biological 
marker. 
Many purification schemes take advantage of the fact that pentachlorophenol is a weak organic acid. 
These methods involve extracting the compound into the organic phase under acidic conditions, and/or 
extracting into alkaline solution as phenolate salts (Chou and Bailey 1986; EPA 1986b).  Thus, the 
standard methods involve multiple extractions, with potential for sample loss; some of these methods 
derivatize pentachlorophenol prior to analysis (EPA 1980b; NIOSH 1984b).  Derivatization often 
involves diazomethane or diazoethane, which are toxic substances (Bevenue et al. 1968; Holler et al. 
1989; Morgade et al. 1980; Shafik 1973; Wagner et al. 1991).  Recent methods have tried to simplify the 
purification scheme and avoid using toxic chemicals for derivatization (Maris et al. 1988).  
In an effort to use less toxic materials, blood and urine samples were derivatized with acetic anhydride 
(Needham et al. 1981).  The detection limit was 1–2 ppb using GC/ECD.  Penta- and tetrachlorophenols 
were analyzed simultaneously in urine using HPLC (Pekari and Aito 1982).  This method was used for 
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3 years in Finland in the biological monitoring of workers exposed to chlorophenols.  It is more rapid 
than GC and does not involve the use of chemicals such as benzene, diazomethane, or pyridine, which 
pose health risks to the analyst.  A rapid extraction method followed by GC/ECD had a detection limit of 
0.5 ppb (Kalman 1984).  
Because pentachlorophenol exists in urine as both free pentachlorophenol and conjugated pentachloro­
phenol (glucuronide and sulfate), hydrolysis of urine is necessary to determine total  pentachlorophenol 
(Edgerton and Moseman 1979; Pekari et al. 1991).  Acid hydrolysis is preferable to enzymatic hydrolysis 
because the pentachlorophenol metabolite TCHQ is an inhibitor of β-glucuronidase (Drummond et al. 
1982). Although pentachlorophenol and other chlorinated phenols are stable in frozen urine samples, 
they are degraded by repeated thawing and refreezing (Edgerton 1981).  Acid hydrolysis followed by 
reverse phase HPLC/UV and GC/ECD have been used to measure total pentachlorophenol in urine of 
people occupationally exposed to pentachlorophenol (Drummond et al. 1982; Pekari et al. 1991).  The 
detection limits for HPLC/UV and GC/ECD were 0.20 and 0.01 ppm, respectively, which are sufficiently 
sensitive to detect occupational exposure. Using a simplified method without derivatization, total penta­
chlorophenol and free pentachlorophenol were measured in plasma and urine, with a detection limit of 
1.5 pg (Rick et al. 1982). This modification shortens analysis time and allows the use of GC/ECD, which 
increases sensitivity. 
The pentachlorophenol metabolites, TCHQ and tetrachloropyrocatechol, were identified in human urine 
samples using GC/MS (Edgerton et al. 1979).  The detection limit was 1 ppb and recovery was about 
95%.  Pentachlorophenol and TCHQ were also detected using a cheaper GC/ECD method following a 
simple extraction (Reigner et al. 1990), but the detection limit was at least 50 ppb. 
Negative chemical ionization (NCI) mass spectrometry (MS) was used to detect pentachlorophenol in 
human serum (Kuehl and Dougherty 1980).  The NCI mass spectrometer was reported to be uniquely 
suited for screening partially purified samples.  High sensitivity was obtained by dansylating purified 
compound and using HPLC/UV detection (de Ruiter et al. 1990). 
Hexane extraction, cleanup on thin layer chromatography (TLC) plates, and HPLC/UV detection were 
used to isolate and characterize pentachlorophenol in human fat, demonstrating that pentachlorophenol is 
present in human adipose tissue as an ester of palmitic acid (Ansari et al. 1985).  Fatty acid conjugates of  
pentachlorophenol and other chlorinated phenols could be separated by reverse-phase HPLC (Kaphalia 
1991). TLC followed by GC/ECD was used to analyze pentachlorophenol in adipose tissue (Ohe 1979). 
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GC/ECD has been used to quantify pentachlorophenol residues in tissues (Wagner et al. 1991).  The 
sensitivity of this method is in the sub-ppm range; >100% recoveries were obtained.  GC/MS (NCI) was 
then used to confirm the identity of the pentachlorophenol residues in the samples.  Precision data were 
not reported. 
Analytical methods for determining pentachlorophenol in biological fluids and tissues are shown in 
Table 7-1. 
7.2 ENVIRONMENTAL SAMPLES 
Concerns about contamination of environmental media, plants, and animals with pentachlorophenol have 
led to the need for more rapid, sensitive, and selective methods of analysis.  As with biological samples, 
the most common methods of analysis are GC/ECD, high resolution gas chromatography (HRGC)/ECD, 
and HPLC/UV detection. Under EPA's Contract Laboratory Program for semivolatiles such as penta­
chlorophenol, the Contract Required Quantitation Levels (CRQL) for water and low soil sediments are 
50 mg/L (50 ppm) and 160 mg/kg (160 ppm), respectively (EPA 1986a).  Methods are available that 
detect pentachlorophenol in water or sediment at the 1–10-ppb range. 
Pentachlorophenol could be detected in marine water at concentrations ranging from 0.2 to 200 ppb in 
volumes as small as 5 mL using a simplified monitoring procedure with HPLC/UV detection (Giam et al. 
1980). This method reduces costs and analysis time, and can also be used in other aquatic toxicity 
studies. Differential pulse polarography was used for direct determination of trace amounts of penta­
chlorophenol (Wade et al. 1979). It was demonstrated that pentachlorophenol is electrochemically 
reduced and direct determinations are possible at levels as low as 0.27 ppm.  HPLC/UV was used to 
distinguish among 10 different phenolic compounds at mg/L levels in water (Realini 1981).  HPLC/UV 
was also used to measure chlorinated phenols in surface-treated lumber and to distinguish between tetra-
and pentachlorophenol (Daniels and Swan 1979).  Automated HPLC is 10 times faster than wet chemical 
techniques. Once the method for analysis has been established and tested thoroughly, the HPLC method 
requires neither extensive pretreatment nor highly trained laboratory personnel (Ervin and McGinnis 
1980). 
For relatively clean water samples, HPLC offers a rapid and sensitive method, but its advantages are lost 
when a complex matrix such as municipal waste water has to be analyzed (Buisson et al. 1984).  The 
resolution possible with capillary gas chromatography and the selectivity of the ECD towards halogenated 
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Table 7-1. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Biological Samples
 
Analytical Sample detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Blood	 Add sulfuric acid. Extract with 
hexane, derivatize with 
diazomethane, elute 
pentachloroanisole from alumina with 
benzene/hexane 
Blood	 Extract with benzene and convert 
PCP to its methyl ether derivative 
Blood	 Add H2SO4 and benzene to the 
sample and stir while heating; 
centrifuge; collect benzene layer, 
evaporate and add diazomethane to 
make methyl ether derivative 
Blood	 Add benzene and conc H2SO4 to the 
sample and rotate. Transfer 
benzene layer and add methylating 
agent and vortex. Dilute with 
isooctane or hexane. 
Serum	 Acidify with phosphoric acid; elute 
from reverse phase column with 
dichloromethane; dansylate; 
concentrate 
Serum	 Acidify sample to pH 1 with 
hydrochloric acid; extract with 
dichloromethane; concentrate; 
derivatize with diazoethane; cleanup 
using silica gel 
GC/ECD 1 µg/L
 
GC/ECD 10 µg/L
 
GC/ECD 20 µg/L
 
GC/ECD No data
 
LC/UV 0.4 ppb
 
GC/ECD 30.0 µg/L
 
90% 
92% 
87–100% 
No data 
85% 
99% 
NIOSH 1984b 
(Method 8001) 
EPA 1980b 
Bevenue et al. 
1968 
EMMI 1997 
de Ruiter et al. 
1990 
Morgade et al. 
1980 
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Table 7-1. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Biological Samples (continued)
 
Analytical Sample detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Serum, urine	 Acidify to pH 2 with HCl, digest at 
100EC, extract with toluene 
Plasma, urine	 Sample collected into tubes 
containing EDTA and ascorbic acid; 
plasma mixed with citrate buffer, pH 
3, extracted with diethyl ether, and 
concentrated. Urine was buffered 
with phosphate buffer pH 7.4 and 
processed as above 
Urine	 ADD HCl and NaHSO4, extract with 
benzene, derivatize with 
diazomethane, add hexane; elute 
pentachloroanisole from alumina with 
benzene/hexane 
Urine	 Acidify urine; hydrolyze; extract with 
benzene; methylate phenolic group 
Urine	 Add HCl to sample; boil; extract with 
hexane/isopropanol; centrifuge; dry; 
collect residue in methanol/water 
Urine	 Add HCl to sample; boil; extract with 
hexane/isopropanol; centrifuge; back 
extract to basic borate buffer; 
derivatize with acetic acid anhydride 
and pyridine 
Urine	 Acidify with HCl; boil; add Na 
bisulfite; centrifuge; extract with 
benzene 
GC/ECD	 0.5 µg/L 
GC/ECD	 100 µg/L (urine); 
50 µg/L (plasma) 
GC/ECD	 1 µg/L 
GC/ECD 5 µg/L 
HPLC/UV 26 ppb 
GC/ECD	 10 µg/L 
GC/ECD	 <1 µg/L 
105% 
(urine); 80% 
(serum) 
89-93% 
94.7% 
90% 
84% 
No data 
91–97% 
Kalman 1984 
Reigner et al. 1990 
NIOSH 1984b 
(method 8303) 
EPA 1980b 
Pekari and Aitio 
1982 
Pekari et al. 1991 
Edgerton et al. 
1979 
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Table 7-1. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Biological Samples (continued)
 
Analytical Sample detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Urine 
Urine 
Urine 
Urine 
Urine 
Urine 
Body fluids 
Human semen and 
adipose tissue 
Add H2SO4; collect distillate and add 
NaCl and NaOH; acidify aqueous 
layer; extract with methylene chloride 
Add HCl to sample; extract twice with 
benzene; add hexane 
Add internal standard to sample; mix 
Acidify with H2SO4; extract with 
hexane 
Acid hydrolysis; extract with 
benzene; derivatize with 
diazoethane; column cleanup 
Add NaHSO4, acidify with HCl, boil, 
add more NaHSO4, extract with 
benzene, concentrate, column clean­
up 
Acidify sample and extract with 
hexane; add acetic anhydride; wash 
with boric acid / NaOH 
Macerate sample/tissue with sulfuric 
acid, complete steam distillation into 
2,2,4-trimethylpentane; concentrate 
organic layer 
RPHPLC/UV 
GC/ECD
 
HPLC/UV
 
GC/ECD
 
MS (NCI)
 
GC/ECD 
GC/ECD 
MS (NCI) 
200 ppb 
<10 pg 
250 µg/L 
1.5 pg 
1 µg/L 
No data 
1–2 µg/L 
low ng 
>85% 
88% 
89–96% 
102% 
-100% 
No data 
No data 
>90% 
Drummond et al. 
1982 
Siqueina and 
Fernicola 1981 
Chou and Bailey 
1986 
Rick et al. 1982 
Holler et al. 1989 
EMMI 1997 
Needham et al. 
1981 
Kuehl and 
Dougherty 1980 
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Table 7-1. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Biological Samples (continued)
 
Analytical Sample detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Adipose tissue	 Grind tissue; add hexane; add 
NaOH; extract with hexane; add 
concentrated HCl; extract with diethyl 
ether; mix; add diazoethane; 
concentrate; add hexane and 
anhydrous sodium sulfate; analyze 
hexane layer 
Adipose tissue	 Homogenize sample; rehomogenize 
in hexane; combine supernatants; 
separate extracted fat on TLC; 
scrape appropriate area and 
suspend in hexane; evaporate 
Adipose t issue	 Add hexane; homogenize; add 
aqueous sodium hydroxide; extract 
with hexane; add diethyl ether; 
extract; derivatize with diazoethane 
Feces	 Collect sample into tubes containing 
EDTA and ascorbic acid; acidify in 
warm sulfuric acid, extract with 
diethyl ether; concentrate 
Liver	 Homogenize, incubate with sulfuric 
acid at 100EC; extract with 
hexane/toluene 
GC/ECD 5 ppb 75%	 Shafik 1973 
GC/ECD 5 ppb 85–98%	 Ohe 1979 
GC/ECD 140 ppb 91%	 Morgade et al. 
1980 
GC/ECD 100 ppb No data	 Reigner et al. 1990 
LC/ECD 1.5 ppb 60–70%	 Maris et al. 1988 
PEN
TAC
H
LO
R
O
PH
EN
O
L 
7. AN
ALYTIC
AL M
ETH
O
D
S 
 192 
Table 7-1. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Biological Samples (continued)
 
Analytical Sample detection Percent 
Sample matrix Preparation method method limit recovery Reference 
Fat, liver muscle,	 Fat: homogenize with HCl; extract 
serum	 with ethyl acetate-hexane; elute from 
florisil chlorophenol with methanol-
chloroform 
Other tissues: homogenize; reflux 
with Na2SO4 and NaOH; add TBAH 
and ether extract; concentrate 
extract; elute from silica column with 
methanol chloroform 
Tissues (testes,	 Homogenize tissue sample, extract 
kidney, prostate, liver	 with hexane/propanol and centrifuge; 
and omentum fat)	 remove hexane layer; repeat 
extraction twice; partition into 
potassium hydroxide; acidify 
aqueous layer; extract with hexane; 
derivatize with diazomethane; 
cleanup on Florisil column; elute with 
hexane; additional clean up on 
activated silica gel column; elute with 
benzene in hexane 
RPHPLC/UV <100 ppb	 73–108% Mundy and Machin 
maximum 1981 
GC/ECD; GCMS 4 ppb 115% Wagner et al. 1991 
(NCI) 
ECD = electron capture detection; EDTA = ethylendiaminetetraacetic acid; GC = gas chromatography; HCl = hydrochloric acid; HPLC = high-performance liquid 
chromatography; H2SO4 = sulfuric acid; LC = liquid Chromatography; MS = mass spectrometry; Na = sodium; NaCl = sodium chloride; NaHSO4 = sodium bisulfite; 
NaOH = sodium hydroxide; Na2SO4 = sodium sulphate; NCl = negative chemical ionization; PCP =  pentachlorophenol; RPHPLC = reverse phase high 
performance liquid chromatography; TBAH = tetrabutylammonium hydroxide; TLC = thin layer chromatography 
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compounds make HRGC/ECD the method of choice for the detection and quantification of chlorinated 
phenols at trace levels in complex matrices.  Derivatization with a halogen-containing reagent enhances 
the ECD response. For measuring pentachlorophenol in waste water using HRGC/ECD, sensitivity is in 
the ppt range. Recoveries are adequate and precision is good. 
Similar results were obtained in a comparison of HPLC and GC techniques for determination of  penta­
chlorophenol in animal materials (Mundy and Machin 1981).  Pentachlorophenol could be separated from 
acidic pesticides and other organic acids possibly present in a mill effluent by extraction with an 
acetylating agent (Rudling 1970).  A similar single step extraction and acetylation procedure was used to 
determine several chlorinated phenolic compounds in paper mill effluent without interference (Lee et al. 
1989). GC/MS has been used to measure pentachlorophenol in honey (Muiño and Lozano 1991).  This 
method is simple, accurate, and rapid.  Sensitivity is in the low-ppb range.  Good recoveries (84–102%) 
and precision (2.8–6.3% relative standard deviation ([RSD]) were obtained. 
A study comparing several methods for rapidly extracting pentachlorophenol from water or soil reported 
high recovery from all methods using HPLC/UV (Wall and Stratton 1991).  A method combining 
extraction with derivatization by acetic anhydride had a detection limit of about 0.1 ppb for GC/ECD (Xie 
1983). 
Immunochemical personal exposure monitors (PEMs) are currently being developed for assaying penta­
chlorophenol sampled from ambient air (Hall et al. 1992).  This method is highly selective and involves 
direct, antibody-based sampling of analytes from air with subsequent quantitation of the analyte by 
enzyme immunoassay.  The lower limit of detection for measuring pentachlorophenol in the assay is 
approximately 0.5 ng/mL.  Recovery and precision data were not reported. 
Methods for analyzing pentachlorophenol in environmental samples are shown in Table 7-2. 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of pentachlorophenol is available.  Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a 
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Table 7-2. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Environmental Samples
 
Sample matrix Preparation method Analytical method 
Sample 
detection limit 
Percent 
recovery Reference 
Stack samples Extract sample with hexane; 
derivatize with acetic anhydride, 
collect organic layer; concentrate 
GC/MS No data 80–104% Cuiu et al. 1986 
Air Air samples collected in PEMs; 
analyte diffuses across 
semipermeable membrane into 
antibody reservoir; analyte is bound 
by antibody in PEM; antibody is 
removed from PEM device and 
ELISA 0.5 ng/mL No data Hall et al. 1992 
quantified by enzyme 
immunoassay 
Air Air samples collected in ethylene 
glycol contained in bubbler using 
sampler pump, add methanol 
GC/UV 8 µg/sample No data NIOSH 1994 
Waste water Acidify waste water sample with 
H2SO4; extract with chloroform 
HPLC/UV 11 µg/L No data Ervin and McGinnis 
1980 
Water Acidify sample with HCl extract with 
methylene chloride 
HPLC/UV 1 µg/L 90% Realini 1981 
Water, mill effluent Acidify sample with H2SO4; extract 
with hexane; extract organic phase 
with borax; add hexane, acetylate, 
and analyze the organic phase 
GC/ECD 0.1 µg/L 84–93% Rudling 1970 
Pulp mill effluent Extract onto solid phase sorbents; 
elute with acetonitrile 
LC-ED No data >100% Butler and Dal Pont 
1992 
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Table 7-2. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Environmental Samples (continued)
 
Sample Percent 
Sample matrix Preparation method Analytical method detection limit recovery Reference 
Marine water 
Drinking water 
Waste water 
Water and waste 
water 
Effluent 
Sludge/soil 
Take 5 mL water and acidify with 
H2SO4; extract with petroleum 
ether/diethyl ether; evaporate 
solvent; dissolve residue in CH3CN; 
measure at 254 nm 
Acidify water sample; extract with 
dichloromethane and hexane; 
derivatize with diazoethane; 
cleanup on silica gel 
Acidify to pH <2; extract with 
methylene chloride; exchange into 
2-propanol. For ECD, derivatize 
with pentafluorobenzyl bromide 
Homogenize with dichloromethane; 
cleanup by sample concentration; 
back extract with alkali; derivatize 
by extractive alkylation with 
pentafluorobenzoyl chloride 
Mix sample with potassium 
carbonate, acetic anhydride, and 
petroleum ether; dry organic layer 
and concentrate 
Add Na2SO4; soxhlet extract using 
toluene/methanol or 
acetone/hexane; acid-base 
partition cleanup. For ECD 
derivatize with 
pentafluorobenzylbromide 
HPLC/UV 0.2 µg/L 
GC/ECD 300 ng/L 
GC/FID 7.4 µg/L
 
GC/ECD 0.59 µg/L
 
HRGC/ECD 5 ng/L 
GC/ECD #0.6 µg/L
 
GC/FID 7.4 µg/L
 
GC/ECD 0.59 µg/L
 
84% 
64% 
36–134% 
36–134% 
64–80% 
92–104% 
36–134% 
36–134% 
Giam et al. 1980 
Morgade et al. 1980 
EPA 1986b (Method 
8040) 
Buisson et al. 1984 
Lee et al. 1989 
EPA 1986b (Method 
8040) 
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Table 7-2. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Environmental Samples (continued)
 
Sample matrix Preparation method Analytical method 
Sample 
detection limit 
Percent 
recovery Reference 
Sediment Mix with sodium carbonate with or 
without hexane (“pretreatment”); 
discard organic phase if present; 
derivatize by adding acetic 
anhydride in hexane; centrifuge 
GC/ECD -0.1 ng/g 96–99% 
(without 
pretreatment); 
89% (with 
pretreatment) 
Xie 1983 
Soil (1) Soxhlet extract in 
ethanol/toluene; (2) extract with 
hexane/acetone acidified to pH 2 
with HCl centrifuge; (3) add water 
to sample and acidify with HCl 
ultrasonically extract with 
hexane/acetone; centrifuge; 
(4) vortex extract with acetonitrile; 
centrifuge; dry extracts and 
dissolve in acetonitrile 
HPLC/UV No data (1) 94.3–98% 
(2) 
94.8–97.8% 
(3) 
94.4–98.5% 
(4) 
96.1–100% 
Wall and Stratton 
1991 
Soil/sediment Add Na2SO4 and methanol, 
centrifuge. To 2 mL of extract, add 
pentafluorobenzyl bromide, 
hexacyclooctadecane, Na2SO4 
GC/ECD No data No data EMMI 1997 
(AOB 
Method 0-001-1) 
Soil Add acidified water, MTBE, and 
centrifuge. Derivatize with 
N-nitrosomethyl urea, concentrate 
GC/ECD No data No data EMMI 1997 
(AOB (0-008-1)) 
Surface-treated 
lumber 
Grind dried lumber sample; extract 
with acetonitrile containing p­
bromophenacyl derivative of ßß­
dimethylahyic acid 
HPLC/UV 0.1 mg/cm3 No data Daniels and Swan 
1979 
 Table 7-2. Analytical Methods for Determining Pentachlorophenol and 

Metabolites in Environmental Samples (continued)
 
Sample matrix Preparation method Analytical method 
Sample 
detection limit 
Percent 
recovery Reference 
Egg Homogenize sample; extract with 
ethyl acetate-hexane; elute 
chlorophenol with methanol 
chloroform 
RPHPLC/ UV <100 µg/kg 73–108% 
maximum 
Mundy and Machin 
1981 
Fish tissue Homogenize in water; acidify to pH 
2 with HCl extract with methylene 
chloride; extract with 0.1 N NaOH; 
acidify; extract with toluene, dry 
GC/ECD 0.5 ppb 86% Kalman 1984 
Honey Dissolve sample in acidified water; 
extract onto Sep-Pak C18 cartridge; 
elute with hexane/diethyl ether 
GC/MS 7.6 µg/kg 84–102% Muiño and Lozano 
1991 
Gelatin Add 12 N H2SO4, extract with 
hexane-isopropanol, partition into 
1 N KOH, acidify with 
12 NH2SO4, extract with hexane 
GC/ECD 10 ppb No data Helrich 1990 
(AOAC 
Method 985.24) 
General Add internal standard, sonnicate 
and separate 
HPLC/UV No data No data EMMI 1997 
(EPA Method B) 
General Add internal standard and acetone GC/FID-IS No data No data EMMI 1997 
(EPA Method B) 
CH3CN = acetonitrile; ECD = electron capture detection; FID = flame ionization; GC = gas chromatography; HCl = hydrochloric acid; HPLC = high-performance 
liquid chromatography; H2SO4 = sulfuric acid; MS = mass spectrometry; MTBE = methyl-tertiary-butyl ether; NaOH = sodium hydroxide; Na2SO4 = sodium sulphate; 
RPHPLC = reverse phase high performance liquid chromatography; UV = ultra-violet detection 
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program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of pentachlorophenol.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Methods are available to 
detect and quantify pentachlorophenol in blood (Bevenue et al. 1968; EMMI 1997; EPA 1980b; NIOSH 
1984b), serum (Kalman 1984; Morgade et al. 1980), urine (Chou and Bailey 1986; Edgerton et al. 1979; 
EMMI 1997; EPA 1980b; Holler et al. 1989; Kalman 1984; NIOSH 1984b; Rick et al. 1982; Siqueina 
and Fernicola 1981), adipose tissue (Kuehl and Dougherty 1980; Morgade et al. 1980; Ohe 1979; Shafik 
1973), feces (Reigner et al. 1990), liver (Maris et al. 1988) and tissue including the liver, muscle, testes, 
prostrate, and omentum fat (Wagner et al. 1991).  Chromatographic techniques, such as GC and HPLC 
were used to isolate the pentachlorophenol, its derivatives, and its degradation products.  ECD and MS 
were coupled with the separation techniques to detect these compounds.  Sensitivity was high (blood: 
1–20 ppb; serum: 0.4–30 ppb; urine: 0.5–250 ppb; adipose tissue: low ng–140 ppb; feces: 100 ppb; and 
other tissues: 1.5–<100 ppb) and recovery was good (blood: 87–100%; serum: 80–99%; urine: 84–105%; 
adipose tissue: 75–98%; and other tissues: 60–115%). These methods can accurately detect pentachloro­
phenol at background concentrations in blood, urine, and adipose tissue.  Only limited data exist on 
methods for metabolite characterization.  TCHQ, tetrachloropyrocatechol, and palmitoyl-pentachloro­
phenol are the known metabolites of pentachlorophenol.  These compounds can be monitored using 
GC/ECD (Reigner et al. 1990) or MS (Edgerton et al. 1979).  GC/ECD is more economical than MS, but 
using GC/ECD for metabolite detection has been reported in only one study (Reigner et al. 1990). 
However, since the majority of pentachlorophenol is excreted unchanged, monitoring of metabolites 
might not provide useful additional information on exposure concentrations.  In general, no attempts have 
been made to correlate levels of pentachlorophenol in the body with levels absorbed through skin or via 
inhalation. However, data from a study in log homes demonstrate a positive correlation between serum 
and urine concentrations of pentachlorophenol and indoor air concentrations of this compound (Hosenfeld 
et al. 1986; Hill et al. 1989). 
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No identified biomarkers of effect (e.g., increased SGOT or SGPT enzyme levels in serum, increased 
blood urea nitrogen, or neurological symptoms) are specific for pentachlorophenol.  The identification of 
specific biomarkers of effect may be useful. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods are available to measure pentachlorophenol in stack samples (Cuiu et al. 1986), air 
(Cuiu et al. 1986; Hall et al. 1992; NIOSH 1994), water (Giam et al. 1980; Morgade et al. 1980; Realini 
1981), waste water and effluent (Buisson et al. 1984; Butler and Dal Pont 1992; EPA 1986b; Ervin and 
McGinnis 1980; Lee et al. 1989; Rudling 1970), soil, sludge and sediment (EMMI 1997; EPA 1986b; 
Wall and Stratton 1991; Xie 1983), surface-treated lumber (Daniels and Swan 1979), fish tissue (Kalman 
1984), honey (Muiño and Lozano 1991), and gelatin (Helrich 1990).  Sensitivity of detection is as 
follows: air: 5 ppb; water: 0.1–30 ppb; waste water: 0.1 ppb–7.4 ppm; soil/sludge: 0.1 ppb–7.4 ppm; and 
foods: 0.5–100 ppb. The recovery of pentachlorophenol varies depending on the method of isolation and 
detection, and the source of the sample (water: 64–102%; waste water: 36–134%; and soil/sludge: 
36–134%). The available methods are, in general, sensitive enough to measure both the background 
levels and the higher levels of acute exposure.  However, even though inhalation is considered to be a 
major route of human exposure, only limited data concerning methods for determining pentachlorophenol 
in air were located (Cuiu et al. 1986; Hall et al. 1992), and recovery data were not reported for these 
methods.  Although both occupational exposure and exposure from sources such as log cabins are known 
to occur, methods for measuring ambient concentrations of pentachlorophenol in air are lacking.  An 
additional source of pentachlorophenol exposure is food; methods are available for analyzing penta­
chlorophenol in animal tissue and honey (Kalman 1984; Muiño and Lozano 1991), though the recovery is 
not very good.  More methods are required to accurately measure the levels of pentachlorophenol (low 
ppb levels or lower) in foods. 
7.3.2 Ongoing Studies 
L.L. Ingram, Jr., of the Forest Products Utilization Laboratory at Mississippi State University, is 
conducting research on the development of mass spectrometric methods for analysis of creosote and 
pentachlorophenol (CRISP 1992). 
The Environmental Health Laboratory Sciences Division of the National Center for Environmental Health 
and Injury Control, Centers for Disease Control, is developing methods for the analysis of pentachloro­
phenol and other phenolic compounds in urine.  These methods use high resolution gas chromatography 
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and magnetic sector mass spectrometry, which gives detection limits in the low parts per trillion (ppt) 
range. 
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The international, national, and state regulations and guidelines regarding pentachlorophenol in air, water, 
and other media are summarized in Table 8-1. 
An acute-duration oral MRL of 0.005 mg/kg/day has been derived for pentachlorophenol.  This MRL is 
based on a LOAEL of 5 mg/kg/day for developmental effects (increased occurrence of delayed 
ossification of the skull) in the offspring of rats (Schwetz et al. 1974).  The MRL was derived by dividing 
the LOAEL by an uncertainty factor of 1,000 (10 to account for the use of a LOAEL, 10 for interspecies 
extrapolation, and 10 for human variability).  
An intermediate-duration oral MRL of 0.001 mg/kg/day has been derived for pentachlorophenol.  This 
MRL is based on a LOAEL of 1 mg/kg/day for reproductive effects (increased severity of cystic uterine 
glands and decreased proportions of mink accepting a second mating and number of mink whelping) in 
mink (Beard et al. 1997).  The MRL was derived by dividing the LOAEL by an uncertainty factor of 
1,000 (10 to account for the use of a LOAEL, 10 for interspecies extrapolation, and 10 for human 
variability).  
An MRL of 0.001 mg/kg/day has been derived for chronic-duration oral exposure to pentachlorophenol. 
The MRL is based on a LOAEL of 1 mg/kg/day for decreased serum thyroxine concentrations and 
decreased relative thyroid weight in mink (Beard and Rawlings 1998).  The LOAEL was divided by an 
uncertainty factor of 1,000  (10 to account for the use of a LOAEL, 10 for interspecies extrapolation, and 
10 for human variability) to derive the MRL.     
EPA (IRIS 2001) derived an oral reference dose (RfD) of 0.03 mg/kg/day for pentachlorophenol.  The 
RfD was based on a NOAEL of 3 mg/kg/day for liver and kidney pathology in rats (Schwetz et al. 1978). 
The MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 for interspecies 
extrapolation and 10 for human variability). 
EPA (IRIS 2001) has assigned pentachlorophenol a weight-of-evidence classification of B2, probable 
human carcinogen. 
The International Agency for Research on Cancer (IARC 2001) assigned pentachlorophenol a group 2B 
cancer classification, possibly carcinogenic to humans. 
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EPA has restricted the sale and use of pesticide products containing pentachlorophenol (EPA 1987d). 
This was effective July 13, 1984 (EPA 1984a). 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
Agency Description	 Information References 
INTERNATIONAL 
Guidelines: 
IARC Carcinogenicity classification Group 2Ba IARC 2001 
WHO Drinking water quality 9 µg/L WHO 2001 
NATIONAL 
Regulations and 
Guidelines: 
a. Air 
ACGIH TLV–TWAb 0.5 mg/m3	 ACGIH 2000 
EPA RAC 30 µg/m3	 EPA 2001k
 
40CFR266
 
Appendix IV
 
NIOSH REL (TWA)b 0.5 mg/m3	 NIOSH 2001a 
IDLH	 2.5 mg/m3 NIOSH 2001b 
OSHA PEL (8-hour TWA)b OSHA 2001b 
General industry 0.5 mg/m3 29CFR1910.1000 
Table Z-1 
PEL (8-hour TWA)b OSHA 2001c 
Construction industry 0.5 mg/m3 29CFR1926.55 
Appendix A 
PEL (8-hour TWA)b OSHA 2001a 
Shipyard construction 0.5 mg/m3 29CFR1915.100 
Table Z 
USC	 HAP USC 2001
 
42USC7412
 
b. Water 
DOT	 Marine pollutant— DOT 2001b 
pentachlorophenol and sodium 49CFR172.101 
pentachlorophenate Appendix B 
EPA Drinking water standard 1x10-3 ppm	 EPA 2001j 
40CFR141.32 
Groundwater monitoring	 EPA 2001l 
list—standards for TSD	 40CFR264 
Suggested method 8040 8270 Appendix IX 
PQL 5 µg/L 50 µg/L 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description	 Information References 
NATIONAL (cont.) 
EPA 
c. Food 
FDA 
MCL—applies to community and 
non-transient, non-community 
water systems 
MCLG 
Effluent guidelines—toxic pollutant 
1-Day health advisory (10-kg child) 
10-Day health advisory 
(10-kg child) 
DWEL 
Concentration at cancer risk of 10-4 
Organoleptic effect criteria 
Toxic criteria for those states not 
complying with Clean Water Act 
section 303(c)(2)(B) 
Freshwater 
Maximum concentration 
Continuous concentration 
Saltwater 
Maximum concentration 
Continuous concentration 
Water pollution—designation of 
hazardous substance 
Water programs—determination of 
reportable quantities of hazardous 
substances 
Bottled water—allowable level 
Indirect food additives— adhesives 
and components of coatings 
Indirect food additives—animal glue 
Sodium pentachlorophenate 
1x10-3 mg/L	 EPA 2001h 
40CFR141.61 
0 mg/L	 EPA 2001i 
40CFR141.50 
EPA 2001a 
40CFR401.15 
1.0 mg/L	 EPA 2000d 
0.3 mg/L 
1.0 mg/L 
0.03 mg/L 
30 µg/L	 EPA 1999b 
EPA 2001o 
40CFR131.36 
20 µg/L 
13 µg/L 
13 µg/L 
7 µg/L 
EPA 2001p 
40CFR116.4 
10 pounds	 EPA 2001q 
40CFR177.3 
1x10-3 mg/L	 FDA 2000a 
21CFR165.110 
FDA 2000b 
21CFR175.105 
FDA 2000c 
21CFR178.3120 
(d)(3) 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description	 Information References 
NATIONAL (cont.) 
FDA Indirect food additives—rubber 
articles intended for repeated use 
Sodium pentachlorophenate 
Indirect food additives—textiles and 
textile fibers 
Sodium pentachlorophenate 
Indirect food additives— 
preservatives for wood 
Pentachlorophenol and sodium 
pentachlorophenate 
d. Other 
ACGIH BEI 
Total pentachlorophenol in urine 
Free pentachlorophenol in 
plasma 
Carcinogenicity classification 
DOT	 Hazardous material— 
pentachlorophenol and sodium 
pentachlorophenate 
Use of tank cars—hazardous 
substance 
EPA	 Carcinogenicity classification 
Oral slope factor 
RfD 
General pretreatment regulations 
for existing and new sources of 
pollution—pollutants eligible for a 
removal credit (land application) 
Identification and listing of 
hazardous waste—comparable/ 
Syngas fuel exclusion 
Minimum required detection limit 
for comparable fuel specification 
Not to exceed 
50 ppm in the 
treated wood 
2 mg/g creatinine 
5 mg/L 
A3c 
B2d 
12 (mg/kg/day)-1 
3x10-2 mg/kg/day 
30 mg/kg 
2,400 mg/kg 
FDA 2000e 
21CFR177.2600 
(c)(4) 
FDA 2000f 
21CFR177.2800 
(d)(5) 
FDA 2000d 
21CFR177.3800 
(b) 
ACGIH 2000 
DOT 2001a 
49CFR172.101 
DOT 2001c 
49CFR173.31 
(f)(2) 
IRIS 2001 
EPA 2001b 
40CFR403 
Appendix G 
EPA 2001f 
40CFR261.38 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description	 Information References 
NATIONAL (cont.) 
EPA	 Identification and listing of
 
hazardous waste—hazardous
 
constituent
 
Identification and listing of 
hazardous waste—maximum 
concentration of contaminant for 
the toxicity characteristic 
Hazardous waste—concentration 
limits for health based limits for 
exclusion of waste-derived residues 
Health and environmental 
protection standards for uranium 
and thorium mill tailings 
Superfund—reportable quantity 
Toxic chemical release reporting; 
Community Right-to-Know 
—effective date 
STATE 
Regulations and 
Guidelines: 
a. Air: 
Arkansas	 RAC 
California	 RAC 
Toxic air contaminant 
Colorado Hazardous air pollutant
 
8 hour
 
30 minute
 
Delaware	 RAC 
Idaho Toxic air pollutant
 
OEL
 
EL
 
AAC
 
Illinois	 RAC 
Toxic air contaminant 
EPA 2001e 
40CFR261 
Appendix VIII 
100 mg/L	 EPA 2001g 
40CFR261.24 
1 mg/kg	 EPA 2001c 
40CFR266 
Appendix VII 
Listed constituent	 EPA 2001d 
40CFR192 
Appendix I 
10 pounds	 EPA 2001m 
40CFR302.4 
01/01/87	 EPA 2001n 
40CRF372.65 
30 µg/m3	 BNA 2001 
30 µg/m3	 BNA 2001 
BNA 2001 
10 µg/m3 
50 µg/m3 
30 µg/m3	 BNA 2001 
BNA 2001 
0.5 mg/m3 
0.033 pounds/hour 
0.025 mg/m3 
30 µg/m3	 BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description	 Information References 
STATE (cont.)
 
Kansas HAP BNA 2001
 
Maximum air emissions allowed 0.7 tons/year CDC 1999a
 
Kentucky RAC 30 µg/m3 BNA 2001
 
Minnesota HAP threshold 0.7 tons/year BNA 2001
 
New Hampshire Regulated toxic air pollutant BNA 2001
 
OEL 0.5 mg/m3
 
North Carolina Emission rates requiring a permit BNA 2001
 
Chronic toxicants 0.063 pounds/day
 
Acute systemic toxicants 0.0064 pounds/day
 
Chronic toxicants (24 hour) 0.003 mg/m3
 
Acute systemic toxicants 0.025 mg/m3
 
(1 hour)
 
allowable concentration
 
Annual average 1.19 µg/m3
 
Action level 0.10 µg/m3
 
Wisconsin Proposed thresholds Wisconsin DNR
 
24 hour $25 ft <75 ft 0.104 pounds/hour
 
24 hour $75 ft 0.811 pounds/hour
 
Toxic air pollutants BNA 2001
 
Rhode Island HAP BNA 2001
 
South Carolina RAC 30 µg/m3 BNA 2001
 
Toxic air emissions—maximum 5 µg/m3 BNA 2001
 
Tennessee RAC 30 µg/m3 BNA 2001
 
Vermont Hazardous ambient air standard BNA 2001
 
Washington Threshold for HAPs 0.35 tons/year BNA 2001
 
24 hour <25 ft 0.0269 pounds/hour 2001
 
Proposed standard—AAC 12 µg/m3
 
Wyoming RAC 30 µg/m3 BNA 2001
 
b. Water: 
Alabama MCL	 1 ppb BNA 2001
 
Toxic pollutant criteria	 BNA 2001
 
Marine acute 13 µg/L
 
Marine chronic 7.9 µg/L
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description Information References 
STATE (cont.) 
Alaska MCL 0.001 mg/L BNA 2001
 
Freshwater 2.1 µg/L
 
Costal and marine estuarine 7.9 µg/L
 
waters
 
Hawaii MCL—community, non-transient, 1x10-3 mg/L CDC 1999b
 
and non-community water systems
 
groundwater monitoring
 
concentrations
 
Michigan MCL 0.001 mg/L BNA 2001
 
Minnesota Drinking water guideline 3 µg/L HSDB 2001
 
Groundwater clean-up level 0.001 mg/L BNA 2001
 
Arizona MCL 0.001 mg/L BNA 2001
 
Aquifer water quality standard 0.001 mg/L BNA 2001
 
Drinking water guideline 220 µg/L HSDB 2001
 
Arkansas Groundwater monitoring (PQL) 5 mg/L BNA 2001
 
Colorado MCL 0.001 mg/L BNA 2001
 
Florida MCL 0.001 mg/L BNA 2001
 
Georgia MCL 0.001 mg/L BNA 2001
 
Instream concentrations BNA 2001
 
Idaho Groundwater quality standard 0.001 mg/L BNA 2001
 
Illinois MCL 0.001 mg/L BNA 2001
 
Groundwater monitoring 5 µg/L BNA 2001
 
Indiana MCL 0.001 mg/L BNA 2001
 
Iowa MCL 0.001 mg/L BNA 2001
 
Kansas MCL 0.001 mg/L BNA 2001
 
Kentucky MCL 0.001 mg/L BNA 2001
 
Hazardous constituent for BNA 2001
 
Maximum allowable instream 0.28 mg/L BNA 2001
 
Maine Drinking water guideline 1 µg/L HSDB 2001
 
Maryland MCL 0.001 mg/L BNA 2001
 
Massachusetts Groundwater monitoring (PQL) 5 µg/L BNA 2001
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description	 Information References 
STATE (cont.) 
Mississippi Groundwater standard
 
Freshwater
 
Acute
 
Chronic
 
Salt water
 
Acute
 
Chronic
 
Missouri MCL
 
Montana MCL
 
Nebraska MCL
 
Drinking water standard 
Nevada Standards for toxic materials 
applicable to municipal or domestic 
supply 
New Hampshire	 MCL
 
MCLG
 
Ambient groundwater quality
 
standard 
New Hampshire Water quality criteria 
Fresh acute 
Fresh chronic 
Marine acute 
Marine chronic 
Water and fish ingestion 
Fish consumption only 
New Jersey Groundwater quality criteria 
PQL 
New Mexico MCL 
Groundwater parameters (PQL) 
New York MCL 
Groundwater monitoring (PQL) 
North Dakota MCL
 
Ohio MCL
 
Oklahoma MCL
 
Water column criteria to protect for 
the consumption of fish flesh 
1 ppb	 BNA 2001 
BNA 2001 
3.32 µg/L 
2.1 µg/L 
13 µg/L 
7.9 µg/L 
0.001 mg/L	 BNA 2001 
0.001 mg/L	 BNA 2001 
0.001 mg/L	 BNA 2001 
0.001 mg/L BNA 2001 
1,010 µg/L BNA 2001 
0.001 mg/L BNA 2001 
0 
1 µg/L	 BNA 2001 
BNA 2001 
5.28 µg/L 
4.05 µg/L 
13.0 µg/L 
7.9 µg/L 
0.28 µg/L 
8.2 µg/L 
0.3 µg/L 	 BNA 2001 
1.0 µg/L 
0.001 mg/L	 BNA 2001 
0.005 mg/L	 BNA 2001 
0.001 mg/L BNA 2001 
5 µg/L BNA 2001 
0.001 mg/L	 BNA 2001 
0.001 mg/L	 BNA 2001 
0.001 mg/L BNA 2001 
29,370 µg/L BNA 2001 
 210 PENTACHLOROPHENOL 
8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description Information References 
STATE (cont.) 
Oklahoma Hazardous constituent (PQL) 5 µg/L BNA 2001 
Rhode Island MCLG 0 BNA 2001 
MCL 0.001 mg/L 
Groundwater quality standard 
Preventive action limit 
0.001 mg/L 
0.0005 mg/L 
BNA 2001 
South Carolina Groundwater monitoring (PQL) 5 µg/L BNA 2001 
Water quality criteria 
MCL 
Organism consumption 
1.0 µg/L 
82 µg/L 
BNA 2001 
South Dakota MCL 0.001 mg/L BNA 2001 
Groundwater standard 1x10-3 mg/L FSTRAC 1999b 
Tennessee Toxic substance criteria 
Maximum concentration 
Continuous concentration 
Water and organism 
Organism only 
1.0 µg/L 
20 µg/L 
13 µg/L 
2.8 µg/L 
82 µg/L 
BNA 2001 
Texas MCL 0.001 mg/L BNA 2001 
Utah MCL 0.001 mg/L BNA 2001 
Groundwater quality standard 0.001 mg/L BNA 2001 
Vermont MCL 0.001 mg/L BNA 2001 
MCLG 0 BNA 2001 
Vermont Consumption of water and 
organism 
Consumption of organism only 
0.28 µg/L 
8.2 µg/L 
BNA 2001 
Enforcement standard 
Preventive action level 
1.0 µg/L 
0.3 µg/L 
BNA 2001 
Virginia Hazardous constituent (PQL) 5 µg/L BNA 2001 
Public water supplies 
All other surface waters 
2.8 µg/L 
82 µg/L 
BNA 2001 
Washington MCL 0.001 mg/L BNA 2001 
West Virginia Groundwater standard 0.001 mg/L BNA 2001 
Wisconsin MCLG 0.003 mg/L BNA 2001 
c. Food 
Nebraska Standards for bottled water 0.001 mg/L BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Pentachlorophenol 
(continued) 
Agency Description Information References 
STATE (cont.) 
d. Other 
Arizona Soil remedial level BNA 2001 
Residential 
Non-residential 
25.0 mg/kg 
79.0 mg/kg 
Connecticut Direct exposure criteria for soil 
Residential 
Industrial/commercial 
5.1 ppm 
48 ppm 
BNA 2001 
Hawaii Restricted use pesticide Restricted 
concentration 
BNA 2001 
above 5% 
Massachusetts RfD 
Oral slope factor 
3x10-2 mg/kg/day 
12 (mg/kg/day)-1 
BNA 2001 
Toxic pollutant 
Minnesota Slope factor 
Health risk limit 
0.12 (mg/kg/day)-1 
3 µg/L 
BNA 2001 
Missouri Hazardous constituent BNA 2001 
New Hampshire Restricted use pesticide All concentrations BNA 2001 
New Jersey Restricted use pesticide All concentrations 
above 5% 
BNA 2001 
New York Restricted use pesticide All concentrations 
above 5% 
BNA 2001 
aGroup2B: possibly carcinogenic to humans

bSkin notation: danger of cutaneous absorption 

cA3: confirmed animal carcinogen with unknown relevance to humans

dGroup B2: probable human carcinogen
 
AAC = acceptable ambient concentrations; ACGIH = American Conference of Governmental Industrial Hygienists;
 
BEI = biological exposure index; BNA = Bureau of National Affairs; CDC = Center for Disease Control; CFR = Code of
 
Federal Regulations; DNR = Department of Natural Resources; DOT = Department of Transportation;
 
DWEL = drinking water equivalent level; EL = emissions level; EPA = Environmental Protection Agency; FDA = Food
 
and Drug Administration; FSTRAC = Federal–State Toxicology Risk Analysis Committee; HAP = hazardous air
 
pollutant; HSDB = Hazardous Substances Data Bank; IARC = International Agency for Research on Cancer;
 
IDLH = immediately dangerous to life and health; IRIS = Integrated Risk Information System; MCL = maximum
 
contaminant level; MCLG = maximum contaminant level goal; NIOSH = National Institute of Occupational Safety and
 
Health; OEL = occupational exposure level; OSHA = Occupational Safety and Health Administration;
 
PEL = permissible exposure limit; PQL = practical quantitation limit; RAC = reference air concentration;
 
REL = recommended exposure release; RfD = reference dose; TLV = threshold limit value; TSD = treatment, storage,
 
and disposal; TWA = time-weighted average; USC = United States Code; WHO = World Health Organization
 

_______________ 
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10. GLOSSARY 
Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of organic 
carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at 
a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research but are not actual research studies. 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Clastogenic–An agent capable of causing breakage of chromosomes. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a 
chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Endocrine System–A system of ductless hormone-secreting glands that includes the hypothalamus, 
pituitary gland, adrenal glands, thyroid glands, parathyroid glands, and pancreatic islets. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.  
FEFR25–75—Forced expiratory flowrate between 25 and 75%. 
FEV1.0—Forced expiratory volume in 1.0 seconds. 
FVC—Forced vital capacity. 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
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Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immune System–A cellular complex that forms the basis of the body’s defenses to both biological and 
chemical exogenous substances. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total number 
of individuals in that population who could have developed that condition in a specified time period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air which has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical is 
expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or 
group of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
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Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a minimal risk 
level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical in 
n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor). An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Organophosphate or Organophosphorus Compound—A phosphorus containing organic compound and 
especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40 hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism. Utilizing computational techniques, it provides the means of studying the 
absorption, distribution, metabolism and excretion of chemicals by the body. 
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Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereby the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical information 
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called 
biologically based tissue dosimetry models. 
ppbv—Parts per billion by volume. 
ppmv—Parts per million by volume. 
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Proportionate Mortality Ratio (PMR)—The ratio of a cause-specific mortality proportion in an exposed 
group to the mortality proportion in an unexposed group; mortality proportions may be adjusted for 
confounding variables such as age. Cause-specific mortality proportions can be calculated when the 
cohort (the population at risk) cannot be defined due to inadequate records, but the number of deaths and 
the causes of deaths are known. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) 
of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely 
to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  The inhalation 
reference concentration is for continuous inhalation exposures and is appropriately expressed in units of 
mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
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effects during a lifetime.  The RfD is operationally derived from the No-Observed-Adverse-Effect Level 
(NOAEL- from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Relative Risk (RR)—The risk expressed as a ratio of the incidence of diseased subjects exposed to a 
particular risk factor to the incidence of diseased subjects in a non-exposed referent group. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the 
Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at 
some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic, that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial Hygienists 
(ACGIH) maximum concentration to which workers can be exposed for up to 15 min continually.  No 
more than four excursions are allowed per day, and there must be at least 60 min between exposure 
periods. The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may not be exceeded. 
Standardized Mortality Ratio (SMR)—The ratio of a cause-specific mortality rate in an exposed cohort 
during a given period to the mortality rate of an unexposed cohort; mortality rates are often adjusted for 
age or other confounding variables. 
Standardized Proportionate Incidence Ratio (SPIR)—Similar to a Proportionate Mortality Ratio (PMR) 
in that it is a ratio of a proportion of a specific disease in an exposed group compared with the proportion 
in an unexposed group. 
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Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. 
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The study of the absorption, distribution and elimination of toxic compounds in the 
living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using Lowest­
Observed-Adverse-Effect Level (LOAEL) data rather than No-Observed-Adverse-Effect Level (NOAEL) 
data. A default for each individual UF is 10; if complete certainty in data exists, a value of one can be 
used; however a reduced UF of three may be used on a case-by-case basis, three being the approximate 
logarithmic average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
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ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 
99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly 
with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically  compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as a hundredfold below levels 
that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Pentachlorophenol 
CAS Number: 87-86-5 
Date: June 22, 2001 
Profile Status: Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute  [  ] Intermediate  [  ] Chronic 
Key to Figure: 14 
Species: Rats 
Minimal Risk Level: 0.005 [X] mg/kg/day  [  ] mg/m3 
Reference: Schwetz BA, Keeler PA, Gehring PJ. 1974.  The effect of purified and commercial grade 
pentachlorophenol on rat embryonal and fetal development.  Toxicol Appl Pharmacol 28:151-161.  
Experimental design (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details):  Purified (98%+) and commercial-grade (88.4%) pentachlorophenol were 
administered by gavage in corn oil to groups of 20–40 pregnant Sprague-Dawley rats on days 6–15 of 
gestation at doses of 0 (corn oil control), 5, 15, 30, and 50 mg/kg/day.  At the 5 and 30 mg/kg/day dose 
levels, the actual amount of pentachlorophenol administered was 5.8 and 34.7 mg/kg/day, which was 
equivalent to 5 and 30 mg/kg/day pure pentachlorophenol. 
Effects noted in study and corresponding concentrations: Maternal body weight gain was significantly 
decreased at 30 and 50 mg/kg/day with both pure and commercial-grade pentachlorophenol.  Otherwise, 
no signs of maternal toxicity were noted.  Significant increases in incidences of resorptions were seen at 
15, 30, and 50 mg/kg/day commercial-grade pentachlorophenol and at 30 and 50 mg/kg/day with the pure 
pentachlorophenol. There was 100% resorption of implantations at the 50 mg/kg/day pure 
pentachlorophenol dose level. The sex ratio was significantly altered at 30 mg/kg/day pure 
pentachlorophenol and 50 mg/kg/day of the commercial-grade pentachlorophenol, with the majority of 
the survivors being male offspring.  
Significant decreases in fetal body weight were observed at 30 and 50 mg/kg/day of commercial-grade 
pentachlorophenol and significant decreases in fetal body weight and crown-rump length were seen with 
30 mg/kg/day of pure pentachlorophenol.  Fetal malformations and/or variations were observed at 
15 mg/kg/day and higher for the commercial-grade pentachlorophenol and 5 mg/kg/day and higher for the 
pure pentachlorophenol. The observed effects for the commercial-grade groups included subcutaneous 
edema and lumbar spurs at $15 mg/kg/day, rib, sternebrae, and vertebrae anomalies at $30 mg/kg/day.  In 
the pure pentachlorophenol offspring, the incidence of delayed ossification of the skull was significantly 
increased at $5 mg/kg/day, and significant increases in the occurrence of subcutaneous edema, lumbar 
spurs, and skeletal anomalies in the ribs, sternebrae, and vertebrae were observed at $15 mg/kg/day.
Concentration and end point used for MRL derivation: This MRL is based on a LOAEL of 5 mg/kg/day 
for delayed ossification of the skull in rat pups when the dams were given pure pentachlorophenol by 
corn oil gavage on gestation days 6 through 15. 
[ ] NOAEL  [X] LOAEL 
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Uncertainty Factors used in MRL derivation: 
[X] 10 for use of a LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  NA 
Was a conversion used from intermittent to continuous exposure?  NA 
Other additional studies or pertinent information that lend support to this MRL:  Similar developmental 
effects have been observed in another developmental toxicity study (Argus 1993b/Bernard et al. 2001b). 
In this study, significant increases in the occurrence of resorptions, soft tissue and skeletal malformations 
and variations and decreases in fetal body weight were observed in the offspring of rats were administered 
by gavage 80 mg/kg/day technical grade (89% pure) pentachlorophenol on gestational days 6–15.  This 
study identified a NOAEL of 30 mg/kg/day.  Intermediate-duration oral developmental toxicity studies in 
rats have also reported increased fetal/neonatal mortality, malformations, and/or variations, and decreased 
growth (Argus 1997/Bernard et al. 2001c; Courtney et al. 1976; Exon and Koller 1982; Schwetz et al. 
1978; Welsh et al. 1987). 
Agency Contact (Chemical Manager):  Lori L. Miller, M.P.H. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Pentachlorophenol 
CAS Number: 87-86-5 
Date: June 22, 2001 
Profile Status: Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate  [  ] Chronic 
Key to Figure: 47 
Species: Mink 
Minimal Risk Level: 0.001 [X] mg/kg/day  [  ] mg/m3 
Reference: Beard AP, McRae AC, Rawlings NC. 1997. Reproductive efficiency in mink (Mustela 
vison) treated with the pesticides lindane, carbofuran, and pentachlorophenol.  J Reprod Fertil 111:21-28. 
Experimental design (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details):  Groups of 10 female mink were exposed to 1 mg/kg/day pentachlorophenol 
in the diet for 3 weeks prior to mating with unexposed males and throughout pregnancy and lactation. 
The females were mated twice at 7–8 day intervals.  The purity of the pentachlorophenol was not 
reported. 
Effects noted in study and corresponding concentrations: A decrease in the proportion of mated females 
accepting a second mating and the proportion of mink that whelped were observed.  No effect on the 
proportion of mink accepting the first mating or the proportion of mink with visible implantation sites 
were found. An increase in the severity cystic uterine glands was also observed in the pentachlorophenol­
exposed mink. 
Concentration and end point used for MRL derivation: This MRL is based on a LOAEL of 1 mg/kg/day 
for reproductive effects in mink exposed to pentachlorophenol (purity not reported) in the diet. 
[ ] NOAEL  [X] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 10 for use of a LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Dose was calculated 
by the study authors. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  NA 
Was a conversion used from intermittent to continuous exposure?  NA 
Other additional studies or pertinent information that lend support to this MRL:  Several other studies 
have examined the reproductive toxicity of pentachlorophenol.  Decreased fertility has been observed in 
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the first generation of rats exposed to 60 mg/kg/day, but not in the parental or second generations; the 
NOAEL for this effect is 30 mg/kg/day (Argus 1997/Bernard et al. 2001c).  A significant decrease in 
testicular spermatid count, decreases in absolute testes weight and the ratio of testes weight to brain 
weight, and focal/multifocal mononuclear cell infiltrate in the epididymis were observed in the F1 rats 
administered 30 or 60 mg/kg/day.  However, no alterations in the average number of motile or nonmotile 
sperm, epididymal or testicular sperm counts, or sperm morphology were observed in either generation 
(Argus 1997/Bernard et al. 2001c). No alterations in reproductive tissues were observed in the female 
rats. Significant increases in the average day of preputial separation and vaginal patency were observed 
in the F1 generation, suggesting that in utero exposure to pentachlorophenol disrupted the normal 
development of the reproductive system.  No adverse reproductive effects were observed in another mink 
study in which the animals were also fed a diet containing 1 mg/kg/day pentachlorophenol (purity not 
reported) (Beard and Rawlings 1998).  Additionally, no significant alterations in mating response, 
ovulation rate, follicle and corpus luteum size, gestation length, pregnancy rate, lambing rate, and lamb 
birth rate were observed in sheep exposed to 1 mg/kg/day pentachlorophenol in the diet for 5 weeks 
premating and throughout the gestation and lactation periods (Beard et al. 1999b).  No effect on fertility 
was observed in the offspring of these sheep, later mated to unexposed males (Beard and Rawlings 1999). 
Several reproductive toxicity and nonreproductive toxicity studies have reported histological alterations 
in reproductive tissues. The observed effects include focal degeneration of the seminiferous tubules and 
decreased sperm density in the epididymis body (but not in caput or cauda epididymis) in sheep exposed 
to 1 mg/kg/day pentachlorophenol (purity not reported) in the diet during gestation, lactation, and for 
20 weeks postnatally (Beard et al. 1999a), minimal to marked germinal epithelial degeneration and lack 
of spermatozoa in the seminiferous tubules of rats exposed to 270 mg/kg/day pure pentachlorophenol in 
the diet for 28 days (effects may have been secondary to poor condition of animals) (Chhabra et al. 1999; 
NTP 1999), increased severity of oviductal intraepithelial cysts in sheep administered 2 mg/kg/day pure 
pentachlorophenol by gavage twice weekly for 43 days (Rawlings et al. 1998), and lymphocyte 
infiltration into the endometrium in sheep exposed to 1 mg/kg/day pentachlorophenol (purity not 
reported) in the diet for 5 weeks premating and during the gestation and lactation periods (Beard et al. 
1999b). No histological alterations in reproductive tissues were observed in male or female rats 
chronically exposed to 30 mg/kg/day pure pentachlorophenol in the diet for 2 years (Chhabra et al. 1999; 
NTP 1999). Additionally, no alterations in reproductive hormones (estradiol, testosterone, progesterone, 
follicle stimulating hormone, and/or luteinizing hormone levels) have been observed in mink (Beard et al. 
1997) or sheep (Beard et al. 1999a). 
Liver and developmental effects also appear to be sensitive end points of pentachlorophenol following 
intermediate-duration oral exposure; the lowest adverse effect levels for these effects are 10-fold higher 
than the reproductive effects reported in mink.  Significant increases in relative liver weight and the 
occurrence of centrilobular hepatocellular hypertrophy have been reported in rats and mice exposed to 
<10 mg/kg/day pure or technical-grade pentachlorophenol (Blakley et al. 1998; Kerkvliet et al. 1982; 
Kimbrough and Linder 1978; Knudsen et al. 1974).  At higher doses, hepatocyte degeneration and 
necrosis have been observed (Kerkvliet et al. 1982; NTP 1989, 1999).  Developmental effects (decreased 
pup body weight) have also been observed in rat offspring at 10–15 mg/kg/day (Argus 1997/Bernard et 
al. 2001c; Welsh et al. 1987). 
Agency Contact (Chemical Manager):  Lori L. Miller, M.P.H. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Pentachlorophenol 
CAS Number: 87-86-5 
Date: June 22, 2001 
Profile Status: Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [  ] Acute  [  ] Intermediate  [X] Chronic 
Key to Figure: 54 
Species: Mink 
Minimal Risk Level: 0.001 [X] mg/kg/day  [  ] mg/m3 
Reference: Beard AP, Rawlings NC. 1998. Reproductive effects in mink (mustela vison) exposed to the 
pesticides lindane, carbofuran and pentachlorophenol in a multigeneration study.  J Reprod Fertil 113:95­
104. 
Experimental design (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details):  Pentachlorophenol (Sigma, St. Louis, Missouri; purity not indicated) was 
administered at a dose of 1 mg/kg/day in the diet to parental-generation female mink from 3 weeks prior 
to mating (with untreated males) until weaning of first-generation offspring.  Male and female offspring 
in the first and second generations were continued on the pentachlorophenol diet effectively from 
conception until sexual maturity.  As with the parental generation, females of the first generation were 
mated with untreated males.  The number of control and treated females in the parental generation was 
not indicated. Ten control and 8 pentachlorophenol-treated females of the first generation, continued on 
the pentachlorophenol diet throughout growth, mating, pregnancy, lactation, and for 3 months after the 
end of lactation, were mated to produce the second generation.  Ten control and 6 pentachlorophenol 
males of the first generation were killed when their testis development was maximal at about 42 weeks of 
age. The study group in the second generation consisted of 8 males and 10 females given control diet and 
8 males and 10 females continued on the pentachlorophenol diet.  At necropsy of the first-generation 
males, weights of the testes, epididymides, and penis were recorded, and these organs and samples of the 
pancreas, liver, and pituitary gland were fixed for microscopic examination; dimensions of the testes and 
penis were also recorded. At necropsy of the first-generation females, weights of the ovaries, oviduct, 
uterus, pituitary, thyroid, parathyroid, and adrenals were recorded, and samples of these and the pancreas 
were fixed for microscopic examination.  Weights of the heart, brain, liver, and kidney were also 
recorded. In the second-generation animals, the same tissues were weighed and measured, but no tissues 
were examined histologically in the females and only endocrine and reproductive tissues were examined 
histologically in the males.  Serum from blood samples collected at necropsy of first and second 
generation males and females was analyzed for estradiol and thyroxine.  Serum cortisol was also 
measured in first-generation females and serum testosterone was measured in first- and second-generation 
males. 
Effects noted in study and corresponding concentrations: No overt signs of toxicity were seen and no 
reproductive effect end points were altered in the  pentachlorophenol-treated groups compared with 
controls. The only effects noted in the pentachlorophenol-treated groups were significantly-decreased 
serum thyroxine concentrations in males of the first generation and in males and females of the second 
generation, and significantly-decreased relative thyroid weight in females of the second generation. 
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Concentration and end point used for MRL derivation: This MRL is based on a LOAEL of 1 mg/kg/day 
(only dose tested) for significantly-decreased serum thyroxine concentrations in males of the first 
generation and males and females of the second generation and decreased relative thyroid weight in 
females of the second generation when mink were administered pentachlorophenol of unspecified purity 
continuously in the diet in a multigeneration reproduction study. 
[ ] NOAEL  [X] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 10 for use of a LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. The dose of 
1 mg/kg/day was estimated by the study authors.  Details of the method of dose estimation were not 
provided. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  NA 
Was a conversion used from intermittent to continuous exposure?  NA 
Other additional studies or pertinent information that lend support to this MRL:  Single intraperitoneal 
injections of pentachlorophenol of unspecified purity at doses up to 28 mg/kg caused marked, statistically 
significant, dose-related decreases in the serum total thyroxine level in male rats (van Raaij et al. 1991a). 
The decreases were maximal at 6–24 hours after administration, and thyroxine levels slowly returned to 
control values within 96 hours after administration.  Further in vitro studies by these investigators 
revealed that the likely mechanism of action for this anti-thyroid effect was competition for serum protein 
thyroxine binding sites (van Raaij et al. 1991b).  A decrease in maternal serum thyroxine (T4) 
concentration throughout pregnancy and lactation and a significant increase in maternal thyroid gland 
follicle size were found in female sheep administered 1 mg/kg/day pentachlorophenol (purity not 
indicated) in the diet 5 weeks prior to mating and throughout pregnancy and lactation until 2 weeks after 
weaning of the lambs (Beard et al. 1999b).  Additionally, increased thyroxine levels were observed in 
their ewe and ram lambs that also received postnatal exposure to pentachlorophenol (Beard and Rawling 
1999; Beard et al. 1999a). Oral gavage administration of pure pentachlorophenol to young adult female 
rats over a 28-day period at doses of 3 or 30 mg/kg produced decreases in circulating and free 
concentrations of the thyroid hormones triiodothyronine (T3) and T4 in serum, a decrease in serum 
thyroid stimulating hormone, decreases in intrathyroidal levels of T3 and T4, a decrease in the T4:T3 
ratio in serum, and a reduction in thyroidal hormone stores.  Technical-grade pentachlorophenol, tested 
only at a dose of 3 mg/kg, produced the same effects except the reduction in free T3 in serum (data for 
free serum T4 were not reported) (Jekat et al. 1994).  Single intraperitoneal injections of pentachloro­
phenol of unspecified purity into adult male rats at doses of 7, 14, or 28 mg/kg also caused marked, 
statistically significant, dose-related decreases in the uptake of radiolabeled T4 into cerebrospinal fluid 
compared with control (van Raaij et al. 1994).   
Agency Contact (Chemical Manager):  Lori L. Miller, M.P.H. 
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USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, 
weight-of-evidence discussions for human health end points by addressing the following questions. 
1.	 What effects are known to occur in humans? 
2.	 What effects observed in animals are likely to be of concern to humans? 
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order they appear within the Discussion of Health Effects by 
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are 
presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered 
in this chapter. If data are located in the scientific literature, a table of genotoxicity information is 
included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal risk levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
 B-2 PENTACHLOROPHENOL 
APPENDIX B 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure 
levels at which adverse health effects are not expected to occur in humans.  They should help physicians 
and public health officials determine the safety of a community living near a chemical emission, given the 
concentration of a contaminant in air or the estimated daily dose in water.  MRLs are based largely on 
toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest NOAEL that does not 
exceed any adverse effect levels.  When a NOAEL is not available, a lowest-observed-adverse-effect 
level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. 
Additional uncertainty factors of 10 must be used both for human variability to protect sensitive 
subpopulations (people who are most susceptible to the health effects caused by the substance) and for 
interspecies variability (extrapolation from animals to humans).  In deriving an MRL, these individual 
uncertainty factors are multiplied together.  The product is then divided into the inhalation concentration 
or oral dosage selected from the study.  Uncertainty factors used in developing a substance-specific MRL 
are provided in the footnotes of the LSE Tables. 
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (3-1, 3-2, and 3-3) and figures (3-1 and 3-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects.  These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper- bound 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a 
quick review of the health effects and to locate data for a specific exposure scenario.  The LSE tables and 
figures should always be used in conjunction with the text.  All entries in these tables and figures 
represent studies that provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels 
(NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
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The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 3-1 
(1)	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance using 
these tables and figures should be the relevant and appropriate route of exposure.  When sufficient 
data exists, three LSE tables and two LSE figures are presented in the document.  The three LSE 
tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE 
Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation (LSE Figure 3-1) 
and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and 
will not therefore have all five of the tables and figures. 
(2)	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15–364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure.  In this 
example, an inhalation study of intermediate exposure duration is reported.  For quick reference to 
health effects occurring from a known length of exposure, locate the applicable exposure period 
within the LSE table and figure. 
(3)	 Health Effect The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are 
further defined in the "System" column of the LSE table (see key number 18). 
(4)	 Key to Figure Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study represented 
by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 
2 "18r" data points in Figure 3-1). 
(5)	 Species The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via 
inhalation for 6 hours per day, 5 days per week, for 3 weeks.  For a more complete review of the 
dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., 
Nitschke et al. 1981. 
(7)	 System This column further defines the systemic effects.  These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
"Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. 
In the example of key number 18, 1 systemic effect (respiratory) was investigated. 
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(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied.  Key number 18 reports a NOAEL of 3 ppm 
for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 
0.005 ppm (see footnote "b"). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect.  LOAELs have been classified into "Less Serious" and 
"Serious" effects. These distinctions help readers identify the levels of exposure at which adverse 
health effects first appear and the gradation of effects with increasing dose.  A brief description of 
the specific end point used to quantify the adverse effect accompanies the LOAEL.  The respiratory 
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm.  MRLs are not 
derived from Serious LOAELs. 
(10)	 Reference The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in 
the footnotes. Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive an 
MRL of 0.005 ppm. 
LEGEND 
See Figure 3-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14)	 Health Effect These are the categories of health effects for which reliable quantitative data exists. 
The same health effects appear in the LSE table. 
(15)	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are graphically 
displayed in the LSE figures.  Exposure concentration or dose is measured on the log scale "y" axis. 
Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16)	 NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates 
to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the LSE table. 
The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see 
entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived.  The diamond 
symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 corresponds to 
the entry in the LSE table. 
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are 
derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of 
the cancer dose response curve at low dose levels (q1*). 
(19)	 Key to LSE Figure The Key explains the abbreviations and symbols used in the figure. 
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SAMPLE 
6	 Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation1 
3 
4 
Key to 
figurea Species 
Exposure 
frequency/ 
duration System 
NOAEL 
(ppm) 
6 INTERMEDIATE EXPOSURE 
5 6 7 8 
6 Systemic 9 9 9 9 
6 18 Rat 13 wk 
5 d/wk 
6 hr/d 
Resp 3b 
CHRONIC EXPOSURE 
Cancer 
38 Rat 18 mo 
5 d/wk 
7 hr/d 
39 Rat 89–104 wk 
5 d/wk 
6 hr/d 
40 Mouse 79–103 wk 
5 d/wk 
6 hr/d 
a The number corresponds to entries in Figure 3-1. 
LOAEL (effect) 
Less serious (ppm) Serious (ppm) Reference 
9  10  
9	 9 
10 (hyperplasia)	 Nitschke et al. 
1981 
11 
9 
20 (CEL, multiple Wong et al. 1982 
organs) 
10 (CEL, lung tumors, NTP 1982 
nasal tumors) 
10 (CEL, lung tumors, NTP 1982 
hemangiosarcomas) 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5 x 10-3 ppm; dose adjusted for intermittent exposure and divided by 
an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability). 12 
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ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ADI Acceptable Daily Intake 
ADME Absorption, Distribution, Metabolism, and Excretion 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT Best Available Technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BSC Board of Scientific Counselors 
C Centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL Cancer Effect Level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CNS central nervous system 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
d  day  
Derm dermal 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO North America/International Maritime Dangerous Goods Code 
DWEL Drinking Water Exposure Level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
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EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
ft foot 
FR Federal Register 
g  gram  
GC gas chromatography 
Gd gestational day 
gen generation 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
hr hour 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank 
IDLH Immediately Dangerous to Life and Health 
IARC International Agency for Research on Cancer 
ILO International Labor Organization 
in inch 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LCLo lethal concentration, low 
LC50 lethal concentration, 50% kill 
LDLo lethal dose, low 
LD50 lethal dose, 50% kill 
LT50 lethal time, 50% kill 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
m meter 
MA trans,trans-muconic acid 
MAL Maximum Allowable Level 
mCi millicurie 
MCL Maximum Contaminant Level 
MCLG Maximum Contaminant Level Goal 
mg milligram 
min minute 
mL milliliter 
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mm millimeter 
mm Hg millimeters of mercury 
mmol millimole 
mo month 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCI National Cancer Institute 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NFPA National Fire Protection Association 
ng nanogram 
NLM National Library of Medicine 
nm nanometer 
NHANES National Health and Nutrition Examination Survey 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH Polycyclic Aromatic Hydrocarbon 
PBPD Physiologically Based Pharmacodynamic 
PBPK Physiologically Based Pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
PID photo ionization detector 
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pg picogram 
pmol picomole 
PHS Public Health Service 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS Pretreatment Standards for New Sources 
REL recommended exposure level/limit 
RfC Reference Concentration 
RfD Reference Dose 
RNA ribonucleic acid 
RTECS Registry of Toxic Effects of Chemical Substances 
RQ Reportable Quantity 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
sec second 
SIC Standard Industrial Classification 
SIM selected ion monitoring 
SMCL Secondary Maximum Contaminant Level 
SMR standard mortality ratio 
SNARL Suggested No Adverse Response Level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC Total Organic Compound 
TPQ Threshold Planning Quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TRI Toxics Release Inventory 
TWA time-weighted average 
U.S. United States 
UF uncertainty factor 
VOC Volatile Organic Compound 
yr year 
WHO World Health Organization 
wk week 
> greater than 
> greater than or equal to 
= equal to 
< less than 
< less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
µm micrometer 
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µg microgram 
q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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Restricted-use pesticide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13, 141, 143, 145, 147, 162, 165, 174, 175
 
RfD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  201, 205, 211
 
sediment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153, 158, 159, 161, 163, 177, 179, 187, 196, 199
 
selenium  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  112 
  
soil  . . . . . . . . . . . . . . . . . . . .  2, 3, 6-9, 13, 84, 98, 131, 133, 145, 151-156, 158-160, 163, 169, 172-174, 177-183, 187, 193, 195,
 
196, 199, 211
 
solubility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13, 32, 96, 139, 154, 177, 180
 
Superfund  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  183 
  
surface water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2, 3, 151, 152, 158, 162, 163, 177, 179, 180
 
T3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56 
  
T4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56, 88, 101, 104
 
TCHQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  75, 80, 89-93, 105, 110, 113, 115, 130-132, 186, 198
 
tetrachlorohydroquinone (see TCHQ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  79, 80, 160, 183
 
thyroid  . . . . . . . . . . . . . . . . . . . . . . . . . .  14, 15, 19, 25, 31, 51, 56, 74, 80, 104, 107, 117, 124, 125, 127, 128, 130, 134, 135, 201
 
thyroid stimulating hormone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19, 25, 56, 107 
  
thyroxine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 19, 56, 61, 74, 80, 104, 107, 110, 117, 124, 125, 128, 131, 134, 201
 
time-weighted average  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  211 
  
toxicokinetic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21, 101, 133
 
Toxics Release Inventory (see TRI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  141, 147
 
tremors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60 
  
TRI  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65, 90, 95, 141, 147, 148, 150-152, 177
 
triiodothyronine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15, 19, 25, 56, 107, 110
 
 tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14, 51, 52, 58, 59, 66, 67, 74, 105, 130
 
TWA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  203, 211
 
U.S. Department of Agriculture  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  182 
  
vapor pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  139, 171, 177
 
volatilization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  147, 148, 152, 153, 165, 172
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